{
    "source_url": "https://priyalifescience.com/clinical-trials-europe",
    "retrieved_at": "2026-09-17T15:07:09+00:00",
    "count": 2500,
    "rows": [
        {
            "ct_number": "2026-525182-53-00",
            "title": "Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Atherosclerotic cardiovascular disease and either overweight or obesity",
            "member_states": "Czechia",
            "decision_date": "16/09/2026",
            "enrolled": "320",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525182-53-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526654-14-01",
            "title": "A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator\u2019s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Newly Diagnosed Multiple Myeloma",
            "member_states": "Netherlands; Czechia",
            "decision_date": "16/09/2026",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526654-14-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524439-38-00",
            "title": "A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)",
            "phase": "Phase II",
            "lead_sponsor": "Oslo Universitetssykehus HF",
            "conditions": "Non Small Cell Lung Cancer (NSCLC)",
            "member_states": "Sweden",
            "decision_date": "16/09/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524439-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522393-37-00",
            "title": "A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Autoimmune Hepatitis (AIH)",
            "member_states": "Belgium; Netherlands; Portugal",
            "decision_date": "16/09/2026",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522393-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523274-17-00",
            "title": "A Phase 3a, observer blind, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational combined measles, mumps, rubella, and varicella vaccine compared with intramuscular administration of ProQuad when administered as a second dose to healthy children aged 15 months to 6 years of age",
            "phase": "Phase III",
            "lead_sponsor": "GlaxoSmithKline Biologicals",
            "conditions": "Measles, mumps, rubella, varicella",
            "member_states": "Germany",
            "decision_date": "16/09/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523274-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526788-39-00",
            "title": "A single-centre, Phase 2, open-label study to investigate ovulation inhibition after the administration of different dosages of dienogest tablets in combination with different dosages of drospirenone tablets with regular intake and after intentional intake errors in healthy premenopausal female participants",
            "phase": "Phase II",
            "lead_sponsor": "Gedeon Richter Plc.",
            "conditions": "Contraception/Pregnancy prevention in healthy subjects",
            "member_states": "Germany",
            "decision_date": "16/09/2026",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526788-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519897-38-01",
            "title": "Randomized double-blinded placebo-controlled study of the efficacy of fluoxetine in add-on treatment of drug-resistant, complex and rare epilepsy in children aged 8 years and older: use of a design evaluating the time to reach a defined number of seizures for each child during the prospective observational phase (FLUOXEPIL)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional De Marseille",
            "conditions": "complex and rare epilepsy in children aged 8 years and older",
            "member_states": "France",
            "decision_date": "15/09/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519897-38-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522707-26-00",
            "title": "A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Advanced HR+/HER- breast cancer",
            "member_states": "Germany; Italy",
            "decision_date": "15/09/2026",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522707-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525244-14-00",
            "title": "Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer",
            "phase": "Phase I",
            "lead_sponsor": "Fondazione IRCCS Istituto Nazionale Dei Tumori",
            "conditions": "Metastatic prostate cancer",
            "member_states": "Italy",
            "decision_date": "15/09/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525244-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525122-35-00",
            "title": "Attachment Development and Learning in ADHD: The Role of Dopamine.",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Attention-Deficit/Hyperactivity Disorder (ADHD)",
            "member_states": "Belgium",
            "decision_date": "15/09/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525122-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526207-30-00",
            "title": "A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)",
            "phase": "Phase II",
            "lead_sponsor": "Aplagon Oy",
            "conditions": "End stage kindey disease",
            "member_states": "Sweden; Finland",
            "decision_date": "15/09/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526207-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525964-17-00",
            "title": "Multicenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation",
            "phase": "Phase II",
            "lead_sponsor": "Fundacion PETHEMA",
            "conditions": "Acute lymphoblastic leukaemia",
            "member_states": "Spain",
            "decision_date": "15/09/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525964-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525480-41-00",
            "title": "J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Pulmonary Disease, Chronic Obstructive",
            "member_states": "Denmark; France; Czechia; Poland; Germany",
            "decision_date": "15/09/2026",
            "enrolled": "174",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525480-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524829-40-00",
            "title": "Effects of General Anaesthetic Agents on the Efficacy of Electroconvulsive Therapy and EEG Changes in Patients with Depression",
            "phase": "Phase IV",
            "lead_sponsor": "Varsinais-Suomen hyvinvointialue",
            "conditions": "Severe unipolar depression treated with electroconvulsive therapy",
            "member_states": "Finland",
            "decision_date": "15/09/2026",
            "enrolled": "174",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524829-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526941-91-00",
            "title": "REconsidering Long-TErm ASpirin in the Elderly in Secondary Prevention of Coronary Artery Disease (RELEASE) Norway: A Randomised, Registry-based Trial",
            "phase": "Phase IV",
            "lead_sponsor": "Vestre Viken HF",
            "conditions": "Chronic coronary syndrome",
            "member_states": "Norway",
            "decision_date": "15/09/2026",
            "enrolled": "7000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526941-91-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526613-29-01",
            "title": "Detection of rEPO using Dried Blood Spot (DBS)",
            "phase": "Phase I",
            "lead_sponsor": "Consorci Mar Parc De Salut De Barcelona",
            "conditions": "healthy participants",
            "member_states": "Spain",
            "decision_date": "15/09/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526613-29-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524655-30-00",
            "title": "Interventional, randomized, double-blind, parallel-group, placebo-controlled, \nflexible-dose trial of Lu AF28996 in adults with Parkinson\u2019s disease experiencing motor fluctuations.",
            "phase": "Phase II",
            "lead_sponsor": "H. Lundbeck A/S",
            "conditions": "Parkinson\u2019s disease",
            "member_states": "Czechia; Spain; Italy; Germany; Sweden",
            "decision_date": "15/09/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524655-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527524-27-00",
            "title": "Optimization of De-EscalatiON strategies in early breast cancer",
            "phase": "Phase II",
            "lead_sponsor": "Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS",
            "conditions": "breast cancer",
            "member_states": "Italy",
            "decision_date": "14/09/2026",
            "enrolled": "1",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527524-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527015-42-00",
            "title": "Study of the distribution of linezolid in the prostate in patients who underwent endoscopic prostate enucleation \u2013 DiProLine",
            "phase": "Phase I",
            "lead_sponsor": "Centre Hospitalier Le Mans",
            "conditions": "A Study of the Distribution of Linezolid in the Prostate in Patients Who Underwent Endoscopic Prostatectomy.",
            "member_states": "France",
            "decision_date": "14/09/2026",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527015-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524657-14-00",
            "title": "Comparative bioavailability study of Colistin Cyclops\u00ae administered as 3 different doses",
            "phase": "Phase I",
            "lead_sponsor": "CCDRD Cooperative Clinical Drug Research and Development AG, PureIMS B.V.",
            "conditions": "No therapeutic indication in the current bioavailability trial with healthy adult participants.",
            "member_states": "Bulgaria",
            "decision_date": "14/09/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524657-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526803-31-00",
            "title": "An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex\u00ae-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).",
            "phase": "Phase III",
            "lead_sponsor": "Grifols Therapeutics LLC",
            "conditions": "Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma",
            "member_states": "Italy; Poland; Czechia; Spain",
            "decision_date": "14/09/2026",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526803-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526797-16-00",
            "title": "A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity",
            "phase": "Phase I/II",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Obesity and overweight",
            "member_states": "Netherlands",
            "decision_date": "14/09/2026",
            "enrolled": "170",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526797-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526215-10-00",
            "title": "A Study to Evaluate the Safety, Tolerability, and Activity of a Novel Oral Anticancer Drug (FLC\u2011436) in Patients With Refractory or Relapsed Solid Malignancies",
            "phase": "Phase I",
            "lead_sponsor": "Fileclo Sp. z o.o.",
            "conditions": "Refractory or Relapsed Solid Malignancies",
            "member_states": "Poland",
            "decision_date": "14/09/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526215-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527465-30-00",
            "title": "A study to evaluate how well linaprazan glurate is absorbed and how it controls stomach acid (Part I) and investigation of the influence of a meal on the blood levels of linaprazan glurate (Part II) in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Cinclus Pharma Holding AB (publ)",
            "conditions": "Healthy volunteer",
            "member_states": "Germany",
            "decision_date": "14/09/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527465-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524496-23-00",
            "title": "A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Papulopustular Rosacea (PPR)",
            "member_states": "Bulgaria; France; Germany",
            "decision_date": "14/09/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524496-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524215-36-00",
            "title": "COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus\nFOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild\ntype (wt) advanced colorectal cancer (mCRC) without liver metastases",
            "phase": "Phase II",
            "lead_sponsor": "Unicancer",
            "conditions": "Patients with non resectable pMMR/MSS BRAF wt mCRC, without liver metastasis in the secondline setting after first-line FOLFOX-based chemotherapy",
            "member_states": "France",
            "decision_date": "11/09/2026",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524215-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526359-75-00",
            "title": "A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants From Study BL013",
            "phase": "Phase IV",
            "lead_sponsor": "Urogen Pharma Ltd.",
            "conditions": "Non-Muscle Invasive Bladder Cancer",
            "member_states": "Estonia; Romania; Spain; Bulgaria; Latvia",
            "decision_date": "11/09/2026",
            "enrolled": "33",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526359-75-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525680-41-00",
            "title": "Attenuating Calciprotein particles Transformation and Inhibiting Vascular calcification Evolution by Sodium ThioSulphate trial",
            "phase": "Phase II",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Vascular Calcification",
            "member_states": "Netherlands",
            "decision_date": "11/09/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525680-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521143-20-00",
            "title": "Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)",
            "phase": "Phase I",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Bone Morphogenic Protein Receptor type 2 mutation carriers\nChronic Kidney Disease\nIdiopathic Pulmonary Fibrosis\nMetabolic dysfunction-associated Steatotic Liver Disease\nPulmonary Arterial Hypertension\nPrimary Sclerosing Cholangitis",
            "member_states": "Netherlands",
            "decision_date": "10/09/2026",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521143-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526282-25-00",
            "title": "A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sj\u00f6gren's Disease (SjD)",
            "phase": "Phase I",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Systemic lupus erythematosus, sj\u00f6gren's disease and rheumatoid arthritis",
            "member_states": "Germany",
            "decision_date": "10/09/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526282-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520498-38-00",
            "title": "Evaluation of the bioequivalence of two intravaginal gel preparations containing 90 mg progesterone",
            "phase": "Phase I",
            "lead_sponsor": "CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.",
            "conditions": "No therapeutic indication in the current trial with healthy volunteers.",
            "member_states": "Bulgaria",
            "decision_date": "10/09/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520498-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526184-38-00",
            "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Enveda Therapeutics Inc.",
            "conditions": "Atopic Dermatitis",
            "member_states": "Germany",
            "decision_date": "10/09/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526184-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526075-35-00",
            "title": "SCARP-DIAL (SGLT2i for CARdiovascular Protection in DIALysis)",
            "phase": "Phase III",
            "lead_sponsor": "Karolinska University Hospital",
            "conditions": "Chronic dialysis, Cardiovascular disease",
            "member_states": "Sweden",
            "decision_date": "10/09/2026",
            "enrolled": "1000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526075-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525888-40-00",
            "title": "A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDYTO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS",
            "phase": "Phase I",
            "lead_sponsor": "Nextcure Inc.",
            "conditions": "Advanced solid tumors",
            "member_states": "Italy; Poland; France; Spain",
            "decision_date": "09/09/2026",
            "enrolled": "95",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525888-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524916-13-00",
            "title": "AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma",
            "phase": "Phase IV",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Asthma",
            "member_states": "France; Spain; Germany",
            "decision_date": "09/09/2026",
            "enrolled": "640",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524916-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525318-75-00",
            "title": "C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Overweight or Obesity",
            "member_states": "Spain; France; Germany; Italy",
            "decision_date": "09/09/2026",
            "enrolled": "140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525318-75-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525445-73-00",
            "title": "Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high",
            "phase": "Phase II",
            "lead_sponsor": "UZ Brussel",
            "conditions": "TMB-high advanced neoplasms",
            "member_states": "Belgium",
            "decision_date": "09/09/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525445-73-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526293-16-00",
            "title": "GRT-2U101: A randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-002 in healthy volunteers and patients with chronic spontaneous urticaria after single or multiple intravenous or subcutaneous dosing of GRT-002 (BASALT trial).",
            "phase": "Phase I",
            "lead_sponsor": "Granite Bio AG",
            "conditions": "Chronic Spontaneous Urticaria",
            "member_states": "Germany",
            "decision_date": "09/09/2026",
            "enrolled": "73",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526293-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526951-79-00",
            "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Semaglutide Subcutaneous Depot (CAM2056) in People with Obesity or Overweight",
            "phase": "Phase II",
            "lead_sponsor": "Camurus AB",
            "conditions": "Body weight management",
            "member_states": "Germany",
            "decision_date": "09/09/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526951-79-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526241-98-00",
            "title": "A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study",
            "phase": "Phase II",
            "lead_sponsor": "Kymera Therapeutics Inc.",
            "conditions": "Uncontrolled Moderate to Severe Eosinophilic Asthma",
            "member_states": "Germany; Romania; Italy; Slovakia; Spain",
            "decision_date": "09/09/2026",
            "enrolled": "39",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526241-98-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523610-83-00",
            "title": "Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG",
            "phase": "Phase IV",
            "lead_sponsor": "Institut Gustave Roussy",
            "conditions": "Elderly patients (>70 years old) presenting with cancer and treated with oral therapy in cohorts:\n\u2022\tBreast cohort: Abemaciclib, Ribociclib, Palbociclib, Everolimus\n\u2022\tLung cohort: Alectinib, Brigatinib, Osimertinib\n\u2022\tProstate cohort: Abiraterone, Enzalutamide, Olaparib\n\u2022\tColon Cohort: Trifluridine+Tipiracil, Capecitabine\n\u2022\tKidney cohort: Axitinib, Cabozantinib, Lenvatinib\n\u2022\tSarcoma/ GIST cohort: Sunitinib, Regorafenib, Pazopanib",
            "member_states": "France",
            "decision_date": "08/09/2026",
            "enrolled": "794",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523610-83-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524715-37-00",
            "title": "A study of IDE892 as monotherapy and combination in MTAP-deleted Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Ideaya Biosciences Inc.",
            "conditions": "MTAP-Deleted Advanced Solid Tumors",
            "member_states": "Spain; France",
            "decision_date": "08/09/2026",
            "enrolled": "73",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524715-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523601-16-00",
            "title": "A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Follicular Lymphoma",
            "member_states": "Spain; Poland; Italy; France; Germany",
            "decision_date": "08/09/2026",
            "enrolled": "188",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523601-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525489-23-00",
            "title": "A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Relapsed Extensive-Stage Small Cell Lung Cancer After \nPlatinum-based First-line chemotherapy",
            "member_states": "Poland; Germany; Greece; Netherlands; Hungary; Portugal; France; Belgium; Italy; Spain",
            "decision_date": "08/09/2026",
            "enrolled": "159",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525489-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524649-28-00",
            "title": "A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by hypercortisolaemia due to Cushing\u2019s Syndrome",
            "phase": "Phase IV",
            "lead_sponsor": "Recordati AG",
            "conditions": "Cushing's syndrome",
            "member_states": "Germany; Bulgaria; France; Romania; Italy; Poland; Spain",
            "decision_date": "08/09/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524649-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526730-73-00",
            "title": "A Phase Ia/II Randomized Controlled Trial of Daratumumab Alone Versus \nDaratumumab Plus Abatacept for resistant active Antibody-Mediated \nRejection in Kidney Transplant Recipients",
            "phase": "Phase I/II",
            "lead_sponsor": "Fundacio Hospital Universitari Vall D\u2019Hebron Institut De Recerca",
            "conditions": "active Antibody-Mediated \nRejection in Kidney Transplant Recipients",
            "member_states": "Spain",
            "decision_date": "08/09/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526730-73-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520765-50-00",
            "title": "A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1",
            "phase": "Phase III",
            "lead_sponsor": "Spur Therapeutics Limited",
            "conditions": "Gaucher Disease Type 1",
            "member_states": "Spain",
            "decision_date": "08/09/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520765-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519111-34-00",
            "title": "A clinical trial to learn about the effects of 225Ac-ETN029 in people with advanced solid tumors",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Large Cell Neuroendocrine Carcinoma (LCNEC) of the lung",
            "member_states": "France; Spain; Italy; Germany",
            "decision_date": "08/09/2026",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519111-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526218-10-00",
            "title": "A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren\u2019s Disease-Associated Sensorimotor or Sensory Polyneuropathy",
            "phase": "Phase II",
            "lead_sponsor": "Argenx",
            "conditions": "Sjogren\u2019s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)",
            "member_states": "Germany; Estonia; Lithuania; Portugal; Slovakia; Hungary; Romania; Poland; Spain; Austria; Belgium; France; Bulgaria",
            "decision_date": "08/09/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526218-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525374-19-00",
            "title": "EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Immune system diseases",
            "member_states": "Hungary; Italy; France; Finland; Germany; Spain",
            "decision_date": "08/09/2026",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525374-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526719-13-00",
            "title": "POISON \u2013 Perioperative Safety and Effective Opioid Dosing in Chronic Opioid Use \u2013 a Randomized Clinical Study",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Opioid dependent chronic pain",
            "member_states": "Denmark",
            "decision_date": "08/09/2026",
            "enrolled": "318",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526719-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527538-29-00",
            "title": "SemenGlutide: A randomized double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men",
            "phase": "Phase II",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Infertility, overweight",
            "member_states": "Denmark",
            "decision_date": "08/09/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527538-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523414-89-00",
            "title": "Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY \u2013 A Steno MODERN-MODY project (MM-SEMA)",
            "phase": "Phase II",
            "lead_sponsor": "Steno Diabetes Center Copenhagen",
            "conditions": "Maturity-onset diabetes of the young type 3 (HNF1A-MODY), Maturity-onset diabetes of the young type 1 (HNF4A-MODY)",
            "member_states": "Denmark",
            "decision_date": "08/09/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523414-89-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527363-16-00",
            "title": "A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX\u00ae\u202fXFG.1.1 against SARS-CoV-2 Omicron XFG.1.1 variant.",
            "phase": "Phase IV",
            "lead_sponsor": "Hipra Scientific S.L.",
            "conditions": "COVID-19",
            "member_states": "Spain",
            "decision_date": "07/09/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527363-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525170-19-00",
            "title": "A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",
            "phase": "Phase II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",
            "member_states": "Italy; Spain; Romania; Germany; France",
            "decision_date": "07/09/2026",
            "enrolled": "77",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525170-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526083-20-00",
            "title": "A research study looking into how a high dose of s.c. semaglutide works with emptying of the stomach in people with excess body weight",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Participants with obesity",
            "member_states": "Austria",
            "decision_date": "07/09/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526083-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526530-13-00",
            "title": "\"Evaluation of the impact of the dose of heparin on the occurrence of DWI ischemic lesions after embolization of unruptured intracranial aneurysm\" \"HARMONI\"",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Bordeaux",
            "conditions": "Intracranial aneurysms",
            "member_states": "France",
            "decision_date": "07/09/2026",
            "enrolled": "124",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526530-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526888-37-00",
            "title": "A Long-Term Follow-Up Study to Assess the Safety and Efficacy of B-Cell-Directed Therapy in Patients with Systemic Autoimmune Disease (B-CARE)",
            "phase": "Phase I/II",
            "lead_sponsor": "Universitaetsklinikum Erlangen A\u00f6R",
            "conditions": "systemic autoimmune diseases",
            "member_states": "Germany",
            "decision_date": "07/09/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526888-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526171-32-00",
            "title": "A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Systemic Lupus Erythematosus",
            "member_states": "Poland; Hungary",
            "decision_date": "07/09/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526171-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527220-27-00",
            "title": "Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma",
            "phase": "Phase III",
            "lead_sponsor": "Region Nordjylland",
            "conditions": "Large B-cell lymphomas, transformations of indolent B-cell lymphomas, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma and T-cell lymphomas (The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms), Glucocorticoid induced osteoporosis",
            "member_states": "Denmark",
            "decision_date": "07/09/2026",
            "enrolled": "132",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527220-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511410-20-01",
            "title": "A Study to Learn How Different Manufactured Products of the Study Medicine Called Osivelotor (PF-07940367) Taste and Are Taken Up Into the Blood When Mixed With Soft Foods or Liquids Given on an Empty Stomach or Given With Food or an Acid Reducing Agent in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Sickle Cell Disease",
            "member_states": "Belgium",
            "decision_date": "07/09/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511410-20-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525990-38-00",
            "title": "Phase 2, randomized, blinded, non-treatment-controlled study assessing the efficacy and safety of dimethyl fumarate in patients with NBIA, a neurodegeneration associated with brain iron accumulation.",
            "phase": "Phase II",
            "lead_sponsor": "Instytut Psychiatrii I Neurologii",
            "conditions": "Neurodegeneration with brain iron accumulation (NBIA), including pantothenate kinase-associated neurodegeneration (PKAN) and mitochondrial membrane protein-associated neurodegeneration (MPAN).",
            "member_states": "Poland",
            "decision_date": "07/09/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525990-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523980-39-00",
            "title": "A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Rheumatoid arthritis (RA)",
            "member_states": "Germany",
            "decision_date": "07/09/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523980-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526264-20-00",
            "title": "Study of GS-2426 in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Gilead Sciences Inc.",
            "conditions": "MTAP-Deleted Advanced Solid Tumors",
            "member_states": "Spain",
            "decision_date": "07/09/2026",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526264-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525215-13-00",
            "title": "A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Spain; Poland; Romania; Hungary; Germany; Italy; Belgium; Netherlands; Denmark; France",
            "decision_date": "07/09/2026",
            "enrolled": "142",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525215-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524104-30-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia",
            "phase": "Phase II",
            "lead_sponsor": "Neurocrine Biosciences Inc.",
            "conditions": "Tardive Dyskinesia",
            "member_states": "Bulgaria; Croatia; Romania; Slovakia; Czechia",
            "decision_date": "07/09/2026",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524104-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526939-19-00",
            "title": "Phase 1/2, first-in-human, randomized, double-blind, reference-controlled study to evaluate the safety and immunogenicity of an extemporaneously mixed Combo Inactivated Influenza Vaccine (Green Cross [GC]-IIV; 15\u00b5g of each hemagglutinin [HA])/OVX836 (480\u00b5g), in comparison to GC-IIV (15\u00b5g of each HA) concomitantly administered with OVX836 (480\u00b5g),  GC-IIV alone (15 \u00b5g each HA), OVX836 alone (480\u00b5g), and a licensed reference trivalent IIV (Vaxigrip\u00ae; 15\u00b5g of each HA), administered intramuscularly (IM) in healthy participants",
            "phase": "Phase I/II",
            "lead_sponsor": "Osivax",
            "conditions": "Influenza disease",
            "member_states": "Belgium",
            "decision_date": "04/09/2026",
            "enrolled": "250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526939-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521863-11-00",
            "title": "A Phase 1 study of a novel sublingual insulin formulation",
            "phase": "Phase I",
            "lead_sponsor": "Sublin B.V.",
            "conditions": "Type 1 diabetes mellitus",
            "member_states": "Netherlands",
            "decision_date": "04/09/2026",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521863-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525027-27-00",
            "title": "A Multicenter, Open-Label, Single-Group Clinical Study to Assess the\nPharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric \nSubjects (aged 6 to 23 months) with Moderate-to-Severe Atopic Dermatitis\nNot Adequately Controlled with Topical Therapy",
            "phase": "Phase II",
            "lead_sponsor": "Galderma S.A.",
            "conditions": "Atopic Dermatitis",
            "member_states": "Poland",
            "decision_date": "04/09/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525027-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525479-15-00",
            "title": "Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)",
            "phase": "Phase II",
            "lead_sponsor": "Ribocure Pharmaceuticals AB",
            "conditions": "Venous Thromboembolism",
            "member_states": "Poland; Romania; France; Bulgaria",
            "decision_date": "04/09/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525479-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526756-31-00",
            "title": "A Study to See How a New Compound, Trontinemab Affects the Body and Whether Immune Signals Triggered by it Affect How Other Medicines are Processed",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Not Applicable",
            "member_states": "Germany",
            "decision_date": "04/09/2026",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526756-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526406-32-00",
            "title": "An Open-Label, Phase 1 Dose-finding Study to Define the Maximum Tolerated Dose and Schedule of TRP-001 as Neoadjuvant Therapy in Treatment-na\u00efve Very High-Risk Prostate Cancer Patients Eligible for Radical Prostatectomy with Extended Pelvic Lymph Node Dissection",
            "phase": "Phase I",
            "lead_sponsor": "Torpedo Pharmaceuticals AG",
            "conditions": "Prostate cancer",
            "member_states": "Germany",
            "decision_date": "04/09/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526406-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525209-11-00",
            "title": "Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1\u20133 oral glucose-lowering medications (AMBITION 7)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Type 2 diabetes (T2D) and increased cardiovascular (CV) risk not in adequate glycaemic control on 1\u20133 marketed oral glucose lowering medications.",
            "member_states": "Greece; Germany; Italy; Czechia; Poland; Bulgaria; Spain",
            "decision_date": "04/09/2026",
            "enrolled": "477",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525209-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526119-12-00",
            "title": "A Phase I dose escalation study of intrapleural administration of Oncofid-P-M in patients with unresectable recurrent/progressive pleural mesothelioma after first-line treatment",
            "phase": "Phase I",
            "lead_sponsor": "Fidia Farmaceutici S.p.A.",
            "conditions": "unresectable recurrent/progressive pleural mesothelioma",
            "member_states": "Italy",
            "decision_date": "03/09/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526119-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523903-31-00",
            "title": "Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.",
            "phase": "Phase III",
            "lead_sponsor": "Fondazione IRCCS Istituto Nazionale Dei Tumori",
            "conditions": "Metastatic renal cell carcinoma",
            "member_states": "Italy",
            "decision_date": "03/09/2026",
            "enrolled": "500",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523903-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520895-24-00",
            "title": "BiFAST : A phase II trial evaluating fixed dose and faster ramp-up of epcoritamab with lenalidomide for 3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line",
            "phase": "Phase II",
            "lead_sponsor": "LYSARC",
            "conditions": "3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line",
            "member_states": "France",
            "decision_date": "02/09/2026",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520895-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527107-22-00",
            "title": "ACTOR \u2013 AUC Control of Tacrolimus in Organ Recipients",
            "phase": "Phase IV",
            "lead_sponsor": "Oslo Universitetssykehus HF",
            "conditions": "Kidney transplantation",
            "member_states": "Norway",
            "decision_date": "02/09/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527107-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525406-36-00",
            "title": "Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia",
            "conditions": "Adrenocortical Carcinoma",
            "member_states": "Italy",
            "decision_date": "02/09/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525406-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526545-95-00",
            "title": "Propranolol Dosefinding Assessment in Reactive Aggression Treatment (PRO-DART)",
            "phase": "Phase II",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Reactive aggression",
            "member_states": "Netherlands",
            "decision_date": "02/09/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526545-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526848-13-00",
            "title": "First-in-human evaluation of [11C]UCB-1A as imaging marker for synaptic vesicle glycoprotein 2C (SV2C): a PET study in healthy volunteers and participants with Parkinson\u2019s disease",
            "phase": "Phase I",
            "lead_sponsor": "Karolinska Institutet",
            "conditions": "Parkinson's disease",
            "member_states": "Sweden",
            "decision_date": "02/09/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526848-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515904-37-00",
            "title": "Reduced-dose versus full-dose systemic thrombolysis for high-risk pulmonary embolism: a multicentre, randomised, open-label, blinded-endpoint trial",
            "phase": "Phase IV",
            "lead_sponsor": "Vaestra Goetalandsregionen, University Of Gothenburg",
            "conditions": "Pulmonary embolism",
            "member_states": "Denmark; Sweden; Norway",
            "decision_date": "02/09/2026",
            "enrolled": "280",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515904-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525913-30-00",
            "title": "A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Immune system diseases",
            "member_states": "Belgium; Czechia; Hungary; Sweden; Lithuania; Croatia; Netherlands; Slovakia; Poland; Austria; Norway; France; Italy; Bulgaria; Spain; Germany; Romania; Slovenia; Estonia; Portugal; Greece; Denmark",
            "decision_date": "02/09/2026",
            "enrolled": "338",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525913-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524606-15-00",
            "title": "A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).",
            "phase": "Phase III",
            "lead_sponsor": "Tecnimede-Sociedade Tecnico-Medicinal S.A.",
            "conditions": "Type 2 Diabetes mellitus",
            "member_states": "Poland; Germany; Portugal; Italy; Spain",
            "decision_date": "02/09/2026",
            "enrolled": "760",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524606-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526995-22-00",
            "title": "Antibiotikapenetration og v\u00e6vsrespons ved infektion og rekonstruktiv kirurgi i hoved-hals regionen",
            "phase": "Phase III",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Treatment and prevention of post operative infections",
            "member_states": "Denmark",
            "decision_date": "02/09/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526995-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524034-26-02",
            "title": "A randomized, placebo-controlled trial, to evaluate the safety, immunogenicity and the optimal dose of MOPEVAC-Las vaccine candidate against Lassa Fever, in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase (FIRST-IN-MOP)",
            "phase": "Phase I",
            "lead_sponsor": "Institut Pasteur",
            "conditions": "Lassa fever",
            "member_states": "France",
            "decision_date": "01/09/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524034-26-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525187-18-00",
            "title": "A study to test how well different doses of BI 4060107 are tolerated by people with advanced cancer (solid tumours)",
            "phase": "Phase I",
            "lead_sponsor": "Aimed Bio lnc.",
            "conditions": "solid tumours",
            "member_states": "France",
            "decision_date": "01/09/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525187-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525526-38-00",
            "title": "PRadR 2 - A single center, open-label, Phase I study evaluating 161Tb-PSMA therapy in adult patients with metastatic clear cell renal cell carcinoma",
            "phase": "Phase I",
            "lead_sponsor": "Centre Leon Berard",
            "conditions": "Metastatic clear cell renal cell carcinoma",
            "member_states": "France",
            "decision_date": "01/09/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525526-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526884-39-00",
            "title": "Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "Stroke",
            "member_states": "France",
            "decision_date": "01/09/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526884-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523055-55-00",
            "title": "A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP)",
            "phase": "Phase II",
            "lead_sponsor": "Universitaetsklinikum Heidelberg A\u00f6R",
            "conditions": "Neoplasm",
            "member_states": "Germany",
            "decision_date": "01/09/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523055-55-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524748-37-00",
            "title": "Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)",
            "phase": "Phase II",
            "lead_sponsor": "Dompe' Farmaceutici S.p.A.",
            "conditions": "Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)",
            "member_states": "Denmark; Italy; Germany; Hungary; Netherlands; Spain; Belgium; France; Portugal",
            "decision_date": "01/09/2026",
            "enrolled": "171",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524748-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524451-31-00",
            "title": "Randomized, controlled, multi-center trial to evaluate the efficacy, tolerability, and safety of an (S)-ibuprofen gel vs. placebo in the local symptomatic and short-term treatment of pain in acute contusions of the soft tissues following blunt trauma",
            "phase": "Phase III",
            "lead_sponsor": "Aponia Laboratories Inc.",
            "conditions": "acute contusions of soft tissues",
            "member_states": "Germany",
            "decision_date": "01/09/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524451-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526070-16-00",
            "title": "A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)",
            "phase": "Phase II",
            "lead_sponsor": "Mediwound Ltd.",
            "conditions": "Venous Leg Ulcer (VLU)",
            "member_states": "Czechia; Slovakia",
            "decision_date": "01/09/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526070-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524014-29-00",
            "title": "A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Newly Diagnosed Multiple Myeloma",
            "member_states": "Poland; Italy; Denmark; France; Sweden; Germany; Spain",
            "decision_date": "01/09/2026",
            "enrolled": "234",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524014-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525848-15-00",
            "title": "A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson\u2019s disease carrying a heterozygous mutation of GBA1",
            "phase": "Phase II",
            "lead_sponsor": "Vanqua Bio Inc.",
            "conditions": "GBA1-associated Parkinson\u2019s disease",
            "member_states": "Netherlands; France; Spain; Germany",
            "decision_date": "01/09/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525848-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526348-11-01",
            "title": "Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A\nPhase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study",
            "phase": "Phase IV",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Eosinophilic Esophagitis",
            "member_states": "Netherlands",
            "decision_date": "01/09/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526348-11-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524490-17-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo\u2011controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)",
            "phase": "Phase III",
            "lead_sponsor": "Vaderis Therapeutics AG",
            "conditions": "Hereditary Hemorrhagic Telangiectasia (HHT)",
            "member_states": "Hungary; Netherlands; Germany; Bulgaria; France; Italy; Lithuania; Spain; Belgium",
            "decision_date": "31/08/2026",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524490-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525820-76-00",
            "title": "Clinical Study of Local and Systemic biological Impact of GLP1/GIP-Receptor Agonists in patients with Breast Cancer: The CLARA trial",
            "phase": "Phase II",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Hormone Receptor positive postmenopausal breast cancer",
            "member_states": "Belgium",
            "decision_date": "31/08/2026",
            "enrolled": "168",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525820-76-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523483-20-00",
            "title": "\u200b\u200bPerioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial\u200b",
            "phase": "Phase I/II",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Gastroesophageal adenocarcinoma (GEA)",
            "member_states": "Belgium",
            "decision_date": "31/08/2026",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523483-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525698-38-00",
            "title": "An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability.",
            "phase": "Phase I/II",
            "lead_sponsor": "Sensorion",
            "conditions": "Hearing Loss Related to biallelic pathogenic variation (s) of the GJB2 Gene.",
            "member_states": "France",
            "decision_date": "31/08/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525698-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523857-32-00",
            "title": "A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy",
            "phase": "Phase III",
            "lead_sponsor": "Biogen Idec Research Limited",
            "conditions": "Spinal Muscular Atrophy",
            "member_states": "Portugal; Italy; Belgium; Croatia; Hungary; Germany; Ireland; France; Norway; Poland",
            "decision_date": "31/08/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523857-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524345-28-00",
            "title": "A Phase II, single-arm trial on the addition of the DLL3xCD3 bispecific T-cell engager obrixtamig (BI 764532) to standard-of-care platinum-based first-line treatment of advanced large-cell neuroendocrine carcinoma of the lung (ALPINE 2)",
            "phase": "Phase II",
            "lead_sponsor": "Technische Universitaet Dresden",
            "conditions": "Male and female adult patients with locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung not eligible for curative treatment",
            "member_states": "Germany",
            "decision_date": "31/08/2026",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524345-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524917-96-00",
            "title": "Evaluation of the Impact of a Strategy of Perioperative NSAID Suppression in Patients Undergoing Video-assisted Thoracic Surgery (VATS) on the Presence of Chronic Postoperative Pain (CPOP): a Randomised Clinical Trial (EVADRAINS)",
            "phase": "Phase III",
            "lead_sponsor": "Les Hopitaux Universitaires De Strasbourg",
            "conditions": "Thoracic surgery",
            "member_states": "France",
            "decision_date": "31/08/2026",
            "enrolled": "318",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524917-96-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521383-35-00",
            "title": "A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "overweight/obesity",
            "member_states": "Germany",
            "decision_date": "31/08/2026",
            "enrolled": "320",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521383-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523453-34-00",
            "title": "Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial",
            "phase": "Phase III",
            "lead_sponsor": "Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico",
            "conditions": "Patients colonized with CPE undergoing liver transplantation (LT)",
            "member_states": "Italy",
            "decision_date": "31/08/2026",
            "enrolled": "168",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523453-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526251-60-00",
            "title": "In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Unresectable stage III non-small cell lung cancer",
            "member_states": "Netherlands",
            "decision_date": "31/08/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526251-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524230-25-00",
            "title": "HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma",
            "phase": "Phase II",
            "lead_sponsor": "Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting",
            "conditions": "Diffuse large B-cell lymphoma (DLBCL)",
            "member_states": "Czechia; Denmark; Croatia; Spain; Sweden; Finland; Portugal; Ireland; Netherlands; Belgium; Norway",
            "decision_date": "31/08/2026",
            "enrolled": "276",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524230-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523070-16-00",
            "title": "Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "Postoperative delirium",
            "member_states": "Spain",
            "decision_date": "31/08/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523070-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524780-20-00",
            "title": "REGN9220 in Combination with Odronextamab in Adult Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "B-cell Non-Hodgkins Lymphoma (B-NHL)",
            "member_states": "Belgium",
            "decision_date": "31/08/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524780-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525685-22-00",
            "title": "Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab",
            "phase": "Phase II",
            "lead_sponsor": "Region Midtjylland, Region Sjaelland",
            "conditions": "Bullous pemphigoid",
            "member_states": "Denmark",
            "decision_date": "31/08/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525685-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525465-42-00",
            "title": "Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes \u2013 a dose-finding study",
            "phase": "Phase II",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Type 2 diabetes (T2D)",
            "member_states": "Spain; Hungary; Romania; Slovakia; Poland; Germany",
            "decision_date": "31/08/2026",
            "enrolled": "175",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525465-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526837-24-00",
            "title": "A prospective, randomized, double-blinded, placebo-controlled, cross-over study investigating the effects of metyrapone treatment on cardio-metabolic outcome parameters and chronobiology in patients with mild autonomous cortisol secretion",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "Mild autonomous cortisol secretion",
            "member_states": "Austria",
            "decision_date": "29/08/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526837-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524874-41-00",
            "title": "Paediatric sarcoma, hybrid imaging & FAPI \u2013 Raising the diagnostic standard for paediatric sarcoma patients combining novel radiotracer FAPI and whole-body PET/MRI",
            "phase": "Phase II",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Paediatric sarcoma",
            "member_states": "Denmark",
            "decision_date": "28/08/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524874-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526299-21-00",
            "title": "An Open-Label Study of IDE034 in Adult Participants with Locally \nAdvanced/Metastatic Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Ideaya Biosciences Inc.",
            "conditions": "Locally Advanced/Metastatic Solid\nTumors  -non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), endometrial cancer, high-grade serous ovarian cancer (HGSOC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), and castration-resistant prostate cancer (CRPC)",
            "member_states": "Spain",
            "decision_date": "28/08/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526299-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526668-19-00",
            "title": "A prospective, exploratory, parallel-group, low-intervention, phase IV,\nrandomized, double-blind, placebo-controlled, multi-center, national,\n2-arm trial to investigate efficacy and safety of Amara-Tropfen (Amara\ndrops) in patients with irritable bowel syndrome (IBS)",
            "phase": "Phase IV",
            "lead_sponsor": "Weleda AG",
            "conditions": "Irritable Bowel Syndrome",
            "member_states": "Germany",
            "decision_date": "28/08/2026",
            "enrolled": "106",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526668-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525128-88-00",
            "title": "A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies",
            "phase": "Phase I/II",
            "lead_sponsor": "Institut De Recherches Internationales Servier IRIS",
            "conditions": "Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome /Acute Myeloid Leukemia (MDS/AML) or Chronic Myelomonocytic Leukemia (CMML)",
            "member_states": "Netherlands; Spain; Germany; Italy; France; Finland",
            "decision_date": "27/08/2026",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525128-88-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525588-41-00",
            "title": "S-KETamine vs. propofol for prehospital sedation of patients with severe Acute Brain Injury: The KETABI randomised trial",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "traumatic brain injury, subarachnoid haemorrhage, intracerebral haemorrhage",
            "member_states": "Denmark",
            "decision_date": "27/08/2026",
            "enrolled": "284",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525588-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526416-37-00",
            "title": "Relative oral bioavailability and tolerability of hydrocortisone from 2-dimensionally printed orodispersible films in children and adolescents with primary adrenal insufficiency (REPLACE trial)",
            "phase": "Phase I",
            "lead_sponsor": "Universitaetsklinikum Heidelberg A\u00f6R",
            "conditions": "adrenal insufficiency",
            "member_states": "Germany",
            "decision_date": "27/08/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526416-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525207-27-00",
            "title": "A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-na\u00efve/pseudo-na\u00efve adult male participants with Fabry disease",
            "phase": "Phase III",
            "lead_sponsor": "Idorsia Pharmaceuticals Ltd.",
            "conditions": "Fabry disease",
            "member_states": "Germany; France",
            "decision_date": "27/08/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525207-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515184-65-01",
            "title": "MDMA-assisted therapy for adolescents with treatment-resistant PTSD",
            "phase": "Phase II",
            "lead_sponsor": "Stichting Amsterdam UMC",
            "conditions": "Post-traumatic stress disorder",
            "member_states": "Netherlands",
            "decision_date": "26/08/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515184-65-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521901-42-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis",
            "phase": "Phase II",
            "lead_sponsor": "Contineum Therapeutics Inc.",
            "conditions": "Idiopathic Pulmonary Fibrosis (IPF)",
            "member_states": "Italy; Belgium; Denmark; Austria; Greece; Germany; France; Netherlands; Portugal; Poland; Spain",
            "decision_date": "26/08/2026",
            "enrolled": "156",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521901-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524825-42-00",
            "title": "C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer",
            "member_states": "Spain; France; Italy; Ireland; Germany; Poland",
            "decision_date": "26/08/2026",
            "enrolled": "33",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524825-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524130-26-00",
            "title": "A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers",
            "phase": "Phase II",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Gastrointestinal Cancers",
            "member_states": "Italy; Belgium; France; Spain; Denmark; Netherlands; Germany",
            "decision_date": "26/08/2026",
            "enrolled": "67",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524130-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524253-14-00",
            "title": "Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly",
            "phase": "Phase II",
            "lead_sponsor": "Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol",
            "conditions": "Acromegaly",
            "member_states": "Spain",
            "decision_date": "26/08/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524253-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524865-25-00",
            "title": "A Phase 2a, proof-of-concept, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy and safety of ACT-777991 in adults with non-segmental vitiligo",
            "phase": "Phase II",
            "lead_sponsor": "Idorsia Pharmaceuticals Ltd.",
            "conditions": "Non-segmental vitiligo",
            "member_states": "Czechia; Poland",
            "decision_date": "26/08/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524865-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527325-35-00",
            "title": "Bioequivalence clinical trial of two formulations of empagliflozin/metformin",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Normon S.A.",
            "conditions": "Healthy volunteers",
            "member_states": "Spain",
            "decision_date": "26/08/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527325-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525351-81-00",
            "title": "DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "chronic thromboembolic pulmonary hypertension",
            "member_states": "France",
            "decision_date": "25/08/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525351-81-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525646-29-00",
            "title": "A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)",
            "phase": "Phase II",
            "lead_sponsor": "Nefro Avillion Clinical Development LLC",
            "conditions": "Renal Transplantation",
            "member_states": "Czechia; Spain; Portugal; Austria",
            "decision_date": "25/08/2026",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525646-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525280-40-00",
            "title": "Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Fondation A De Rothschild",
            "conditions": "Acute ischemic stroke",
            "member_states": "France",
            "decision_date": "25/08/2026",
            "enrolled": "592",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525280-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524897-40-00",
            "title": "[68]GA-FAPI-46 PET/CT for the diagnosis of metastatic lesions in patients with lobular breast cancer (ICL). FAPICL",
            "phase": "Phase II",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "invasive lobular carcinomas of the breast",
            "member_states": "France",
            "decision_date": "25/08/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524897-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527078-35-00",
            "title": "A single and multiple ascending dose study of DFL23693 in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Dompe' Farmaceutici S.p.A.",
            "conditions": "Osteoarthritis",
            "member_states": "France",
            "decision_date": "25/08/2026",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527078-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523968-20-00",
            "title": "A Phase 1 Study of CTIM-76 in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Context Therapeutics Inc.",
            "conditions": "Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors (Testicular and Endometrial Cancer)",
            "member_states": "France; Spain",
            "decision_date": "25/08/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523968-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524757-14-00",
            "title": "A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis",
            "phase": "Phase III",
            "lead_sponsor": "UCB Biopharma",
            "conditions": "Ocular Myasthenia Gravis",
            "member_states": "Hungary; France; Greece; Poland; Spain; Italy; Germany",
            "decision_date": "25/08/2026",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524757-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523821-17-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension",
            "phase": "Phase III",
            "lead_sponsor": "Harmony Biosciences Management Inc.",
            "conditions": "narcolepsy",
            "member_states": "Belgium; Italy; Germany; France; Spain; Poland",
            "decision_date": "25/08/2026",
            "enrolled": "92",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523821-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526764-21-00",
            "title": "A Phase 1 Trial to Evaluate the Safety, PK, and PD of AX-0811 in Healthy Participants",
            "phase": "Phase I",
            "lead_sponsor": "ProQR Therapeutics VIII B.V.",
            "conditions": "Cholestatic disease",
            "member_states": "Belgium",
            "decision_date": "25/08/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526764-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527468-34-00",
            "title": "The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used for lowering levels of cholesterol in the blood.",
            "phase": "Phase I",
            "lead_sponsor": "Adamed Pharma S.A.",
            "conditions": "No medical condition",
            "member_states": "Czechia",
            "decision_date": "25/08/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527468-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525673-39-00",
            "title": "A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Apollo Therapeutics Limited",
            "conditions": "Atopic Dermatitis (AD)",
            "member_states": "Hungary; Czechia; Germany; Bulgaria; Poland; Spain",
            "decision_date": "25/08/2026",
            "enrolled": "138",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525673-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527569-31-00",
            "title": "Bioavailability Comparison of Valsartan 320 mg Tablets (Test vs. Reference Product)",
            "phase": "Phase I",
            "lead_sponsor": "ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.",
            "conditions": "Not applicable (submitted trial is a BE study in healthy participants)",
            "member_states": "Czechia",
            "decision_date": "25/08/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527569-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524793-42-00",
            "title": "Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of\nTocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in\nParticipants With Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase II",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Relapsed/Refractory Multiple Myeloma",
            "member_states": "Sweden; Spain; Greece; Portugal; France; Hungary",
            "decision_date": "25/08/2026",
            "enrolled": "123",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524793-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524905-34-00",
            "title": "Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)",
            "phase": "Phase II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Solid tumor",
            "member_states": "Greece; Hungary; Poland; Belgium; Spain; Netherlands; Germany; France; Portugal; Italy; Romania",
            "decision_date": "25/08/2026",
            "enrolled": "116",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524905-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526131-20-00",
            "title": "Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Urosepsis, Infection of unknown origin, Pyelonephritis, Cystitis, Urinary tract infection, Pneumonia, Sepsis",
            "member_states": "Denmark",
            "decision_date": "25/08/2026",
            "enrolled": "2162",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526131-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523536-39-00",
            "title": "A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide\nand Dexamethasone in Participants with Multiple Myeloma",
            "phase": "Phase I",
            "lead_sponsor": "TOLREMO therapeutics AG",
            "conditions": "Relapsed and Refractory Multiple Myeloma",
            "member_states": "Italy; Spain",
            "decision_date": "24/08/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523536-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511586-10-01",
            "title": "A combined phase I/IIa trial to investigate the safety and pharmacokinetics of StaphAcute in healthy participants and patients with Staphylococcus aureus bacteremia - StaphAcute",
            "phase": "Phase I/II",
            "lead_sponsor": "University Of Cologne",
            "conditions": "Phase IIa: patients with methicillin susceptible (MSSA) or methicillin resistant (MRSA) Staphylococcus aureus bacteremia (SAB)., Phase I: first in human application in healthy particpants, dose escalation study.",
            "member_states": "Germany",
            "decision_date": "24/08/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511586-10-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524539-38-01",
            "title": "Proof of cOncept Study demonStrating the potential substitutIon of suBcutaneous Injection of recombinant human insulin by subLIngual administration of S.L.I.M\u00ae-Formulations in TYpe-I DIABEtic PaTiEntS",
            "phase": "Phase I",
            "lead_sponsor": "Sublin B.V.",
            "conditions": "Patients with diabete type 1 under pump",
            "member_states": "France",
            "decision_date": "24/08/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524539-38-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524287-38-00",
            "title": "A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Etifoxine Monotherapy in The Treatment of Adjustment Disorder with Anxiety (ADWA)",
            "phase": "Phase III",
            "lead_sponsor": "Biocodex",
            "conditions": "Treatment of adjustment disorder with anxiety (ADWA).",
            "member_states": "Bulgaria; France",
            "decision_date": "24/08/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524287-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524928-21-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)",
            "phase": "Phase III",
            "lead_sponsor": "Revolution Medicines Inc.",
            "conditions": "Pancreatic Adenocarcinoma",
            "member_states": "Sweden; Spain; France; Poland; Italy; Norway; Belgium; Germany; Czechia; Austria; Netherlands; Denmark",
            "decision_date": "24/08/2026",
            "enrolled": "281",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524928-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522505-37-00",
            "title": "Adalimumab Treatment for Patients with Hidradenitis Suppurativa at high risk of Progressing to Severe Disease: An Unblinded Randomized, Controlled Trial",
            "phase": "Phase IV",
            "lead_sponsor": "Gentofte Hospital",
            "conditions": "Hidradenitis suppurativa",
            "member_states": "Denmark",
            "decision_date": "24/08/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522505-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526655-59-00",
            "title": "A Prospective Diagnostic Trial of Al[\u00b9\u2078F]F-NOTA-folate PET in Patients with Suspected Cardiac Sarcoidosis or Infective Endocarditis and Healthy Volunteers (FOL-CARD)",
            "phase": "Phase I/II",
            "lead_sponsor": "Turku University Hospital",
            "conditions": "Cardiac Sarcoidosis, Infective endocarditis",
            "member_states": "Finland",
            "decision_date": "24/08/2026",
            "enrolled": "143",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526655-59-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526649-85-00",
            "title": "Evaluation of the efficacy and safety of photodynamic therapy with BF-200 ALA (Ameluz\u00ae) in immunosuppressed patients with actinic keratoses and superficial basal cell carcinoma at any location.",
            "phase": "Phase III",
            "lead_sponsor": "Dra. Elena Gonz\u00e1lez Guerra",
            "conditions": "Immunosuppressed patients with premalignant and malignant skin lesions, such as actinic keratosis (AK), cutaneous squamous cell carcinoma (cSCC), and basal cell carcinoma (BCC), due to chronic immunosuppression.",
            "member_states": "Spain",
            "decision_date": "24/08/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526649-85-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525896-23-00",
            "title": "A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy",
            "phase": "Phase II",
            "lead_sponsor": "Ovid Therapeutics Inc.",
            "conditions": "Focal epilepsy",
            "member_states": "Netherlands",
            "decision_date": "21/08/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525896-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521663-13-00",
            "title": "FOSFOLD - Fosfomycin trometamol compared with another active antibiotic relay therapy for the treatment of acute Escherichia coli pyelonephritis in elderly women: a randomized, multicenter, non-inferiority trial",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Women aged 75 years or older presenting with E. coli pyelonephritis",
            "member_states": "France",
            "decision_date": "21/08/2026",
            "enrolled": "312",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521663-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521374-34-00",
            "title": "Surgery versus intra-lesional sclerosis with polidocanol (Aetoxisclerol) in labial venous malformations in children and adults: a randomized controlled trial - SASOV",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire De Tours",
            "conditions": "superficial labial venous malformation",
            "member_states": "France",
            "decision_date": "21/08/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521374-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524846-85-00",
            "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara\u00ae (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)",
            "phase": "Phase III",
            "lead_sponsor": "Laboratorios Farmaceuticos Rovi S.A.",
            "conditions": "\u200b\u200bHR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer\u200b",
            "member_states": "Romania; Spain; Bulgaria; Czechia; Latvia; Poland; Croatia; Slovakia",
            "decision_date": "21/08/2026",
            "enrolled": "97",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524846-85-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524669-25-00",
            "title": "A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera",
            "phase": "Phase III",
            "lead_sponsor": "Deciphera Pharmaceuticals Inc.",
            "conditions": "Polycythemia Vera",
            "member_states": "Austria; Czechia; Italy; Portugal; Germany; France; Hungary; Spain; Poland",
            "decision_date": "21/08/2026",
            "enrolled": "106",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524669-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524934-24-00",
            "title": "A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Neoplasms, Gastrointestinal Stromal",
            "member_states": "Italy; Portugal; Germany; Sweden; Poland; Romania; Finland; Greece; Norway; Spain; Netherlands; France; Hungary",
            "decision_date": "21/08/2026",
            "enrolled": "302",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524934-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525093-11-00",
            "title": "A Multicenter, Randomized, Double-Blind, 2-Treatment Arm Study to Assess Comparative Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Intravenous AVT32-DRL_PB and Keytruda\u00ae as an Adjuvant Treatment in Participants with Stage IIB/C-III Melanoma Following Complete Resection",
            "phase": "Phase III",
            "lead_sponsor": "Alvotech Swiss AG",
            "conditions": "Stage IIB/C-III Melanoma",
            "member_states": "Romania; Spain",
            "decision_date": "21/08/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525093-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526089-26-00",
            "title": "A randomized, double-blind, placebo-controlled clinical trial to investigate the human monoclonal antibody NG004 in acute, incomplete cervical spinal cord injury (SCI) patients",
            "phase": "Phase I",
            "lead_sponsor": "NovaGo Therapeutics AG",
            "conditions": "Acute Incomplete Cervical Spinal Cord Injury",
            "member_states": "Germany",
            "decision_date": "21/08/2026",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526089-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525827-25-00",
            "title": "A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Immatics US Inc.",
            "conditions": "Solid tumors",
            "member_states": "Germany",
            "decision_date": "21/08/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525827-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524706-15-00",
            "title": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With \u03b1- or \u03b2-Non\u2013Transfusion-Dependent Thalassemia (ENERGIZEKids)",
            "phase": "Phase III",
            "lead_sponsor": "Agios Pharmaceuticals Inc.",
            "conditions": "Non-Transfusion-Dependent Alpha- or Beta-Thalassemia",
            "member_states": "Italy; Greece",
            "decision_date": "21/08/2026",
            "enrolled": "3",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524706-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526903-31-00",
            "title": "\u00c8n dosis intraven\u00f8s penicillin som till\u00e6g til peroral penicillin i behandlingen af akut tonsillitis, peritonsill\u00e6r phlegmone og peritonsill\u00e6r absces \u2013 et randomiseret, dobbeltblindet, placebo-kontrolleret studie",
            "phase": "Phase II",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Tonsillitis",
            "member_states": "Denmark",
            "decision_date": "21/08/2026",
            "enrolled": "154",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526903-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524641-27-00",
            "title": "A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator\u2019s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression",
            "phase": "Phase III",
            "lead_sponsor": "K-Group Beta Inc.",
            "conditions": "High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "member_states": "Germany; Spain; Italy; Belgium; Poland; France; Ireland",
            "decision_date": "21/08/2026",
            "enrolled": "197",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524641-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526205-15-00",
            "title": "A study to see how safe a new medicine (NNC0705-0002) is in healthy people",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Cardiometabolic",
            "member_states": "Netherlands",
            "decision_date": "21/08/2026",
            "enrolled": "112",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526205-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524555-31-00",
            "title": "A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)",
            "phase": "Phase I",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Recurrent Glioblastoma",
            "member_states": "Netherlands",
            "decision_date": "21/08/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524555-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525418-67-00",
            "title": "A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing  Autologous  Hematopoietic Stem Cell Transplantation",
            "phase": "Phase II",
            "lead_sponsor": "Instytut Hematologii I Transfuzjologii",
            "conditions": "Multiple Myeloma",
            "member_states": "Poland",
            "decision_date": "21/08/2026",
            "enrolled": "418",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525418-67-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527136-13-00",
            "title": "A 52-week multicenter, randomized, parallel-group trial in overweight people investigating lifestyle changes, mushroom supplementation and bupropion to reduce adiposity and cardiometabolic risk",
            "phase": "Phase III",
            "lead_sponsor": "Uppsala University",
            "conditions": "Overweight or class I obesity (BMI 25.0\u201334.9 kg/m\u00b2), with or without cardiometabolic risk factors (hypertension, hyperlipidemia, and/or prediabetes).",
            "member_states": "Sweden",
            "decision_date": "21/08/2026",
            "enrolled": "250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527136-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524707-71-00",
            "title": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With \u03b1- or \u03b2-Transfusion-Dependent Thalassemia (ENERGIZEKids-T)",
            "phase": "Phase III",
            "lead_sponsor": "Agios Pharmaceuticals Inc.",
            "conditions": "Transfusion-Dependent Alpha- or Beta-Thalassemia",
            "member_states": "Italy; Greece",
            "decision_date": "20/08/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524707-71-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523252-31-00",
            "title": "A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering\nMultiple Myeloma at High Risk of Developing Multiple Myeloma",
            "phase": "Phase III",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "High Risk Smoldering Multiple Myeloma (HR-SMM)",
            "member_states": "Italy; Spain; Poland; France; Norway; Greece; Germany",
            "decision_date": "20/08/2026",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523252-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520342-28-00",
            "title": "Multicenter, open-label single arm phase I study evaluating the safety and efficacy of combined MB-CART19.1-IBK cells and the 2nd generation BTK-inhibitor Zanubrutinib in relapsed or refractory PCNSL\n\n\"Zanubrutinib and CAR T cells in R/R PCNSL: Z-CARP-Study\"\nA prospective non-randomized multicenter phase I study",
            "phase": "Phase I",
            "lead_sponsor": "Medizinische Universitaet Innsbruck",
            "conditions": "relapsed/ refractory Primary central nervous system lymphoma (r/r PCNSL)",
            "member_states": "Germany; Austria",
            "decision_date": "20/08/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520342-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525397-19-00",
            "title": "Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity",
            "phase": "Phase I",
            "lead_sponsor": "Heinrich-Heine-Universitaet Duesseldorf",
            "conditions": "Recurrent Glioblastoma",
            "member_states": "Germany",
            "decision_date": "20/08/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525397-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525296-60-00",
            "title": "A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR",
            "phase": "Phase III",
            "lead_sponsor": "Alkeus Pharmaceuticals Inc.",
            "conditions": "Stargardt Disease (STGD1)",
            "member_states": "Belgium; France; Spain; Italy; Germany",
            "decision_date": "20/08/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525296-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525463-40-00",
            "title": "Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA",
            "phase": "Phase I/II",
            "lead_sponsor": "Les Hopitaux Universitaires De Strasbourg",
            "conditions": "osteosarcomas, chondrosarcomas, Ewing sarcomas, Ewing-like tumors with rare fusions, CIC-DUX4 bone sarcomas",
            "member_states": "France",
            "decision_date": "20/08/2026",
            "enrolled": "89",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525463-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526442-28-00",
            "title": "Effects of Menopausal Hormone Therapy on QTc in Genetically Confirmed Long QT Syndrome: A Prospective Randomized Sequential Crossover Study with Long-Term Observational Follow-Up (LQTS-HER)",
            "phase": "Phase IV",
            "lead_sponsor": "Oslo Universitetssykehus HF",
            "conditions": "Long QT syndrome",
            "member_states": "Norway",
            "decision_date": "20/08/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526442-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524171-22-00",
            "title": "A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Solid Tumors",
            "member_states": "Spain",
            "decision_date": "20/08/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524171-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526068-19-00",
            "title": "An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",
            "phase": "Phase IV",
            "lead_sponsor": "Eidos Therapeutics Inc.",
            "conditions": "Transthyretin Amyloidosis",
            "member_states": "Spain; Denmark",
            "decision_date": "20/08/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526068-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526109-13-00",
            "title": "Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) and Pleurectomy in the local treatment of pleural tumors. A Prospective Randomized Study The Tic-Tac Trial",
            "phase": "Phase III",
            "lead_sponsor": "Universita' Degli Studi Di Torino",
            "conditions": "malignant pleural effusion",
            "member_states": "Italy",
            "decision_date": "20/08/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526109-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524973-17-00",
            "title": "J2S-MC-GZMS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-D",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Irritable Bowel Syndrome\nDiarrhea",
            "member_states": "Germany; Poland; Spain; Belgium",
            "decision_date": "20/08/2026",
            "enrolled": "186",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524973-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525826-39-00",
            "title": "Treatment of post-traumatic stress disorder with medical nitrous oxide combined with exposure to a personal traumatic script: a multicenter randomized controlled trial (POTESTA)",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire De Tours",
            "conditions": "Post-Traumatic Stress Disorder",
            "member_states": "France",
            "decision_date": "19/08/2026",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525826-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527022-13-00",
            "title": "A clinical trial of MK-8210 in healthy participants (MK-8210-001)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "HIV-1 (Human Immunodeficiency Virus Type 1)",
            "member_states": "Belgium",
            "decision_date": "19/08/2026",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527022-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522310-24-00",
            "title": "JS2-MC-GZMI: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEW-MDD- 2)",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Depressive Disorder, Major",
            "member_states": "Poland; Greece; Spain; Germany",
            "decision_date": "19/08/2026",
            "enrolled": "228",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522310-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526777-42-00",
            "title": "A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Janux Therapeutics Inc.",
            "conditions": "Metastatic Castration-Resistant Prostate Cancer",
            "member_states": "Spain",
            "decision_date": "19/08/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526777-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525036-34-00",
            "title": "A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations",
            "phase": "Phase I/II",
            "lead_sponsor": "Terremoto Biosciences Inc.",
            "conditions": "Solid Tumours",
            "member_states": "Spain; Ireland; Hungary; Romania; France; Portugal; Belgium; Poland",
            "decision_date": "18/08/2026",
            "enrolled": "228",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525036-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525159-20-00",
            "title": "Evaluation of an asPirin-free strategy with ticAgrelor in patieNTs witH a myocardial infarction treatEd medically alONe (PANTHEON)",
            "phase": "Phase III",
            "lead_sponsor": "Montreal Heart Institute",
            "conditions": "myocardial infarction",
            "member_states": "France",
            "decision_date": "18/08/2026",
            "enrolled": "600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525159-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524756-54-00",
            "title": "A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis",
            "phase": "Phase III",
            "lead_sponsor": "UCB Biopharma",
            "conditions": "Ocular Myasthenia Gravis",
            "member_states": "Hungary; Greece; Italy; Spain; Germany; Poland; France",
            "decision_date": "18/08/2026",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524756-54-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525901-10-00",
            "title": "A Randomized, Double-Blind, Placebo-Controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants with CAD",
            "phase": "Phase II",
            "lead_sponsor": "Ribocure Pharmaceuticals AB",
            "conditions": "Coronary artery disease",
            "member_states": "Sweden; Poland",
            "decision_date": "18/08/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525901-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524591-30-00",
            "title": "A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab",
            "phase": "Phase II",
            "lead_sponsor": "Akeso Biopharma Co. Ltd.",
            "conditions": "Hepatocellular Carcinoma",
            "member_states": "Poland; France; Spain; Italy",
            "decision_date": "18/08/2026",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524591-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526090-42-00",
            "title": "A study to test how well different and multiple doses of BI 3034701 are tolerated in people living with overweight or obesity",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "overweight, obesity",
            "member_states": "Germany",
            "decision_date": "18/08/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526090-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526916-35-00",
            "title": "A clinical research study investigating how the body processes the new compound \nafabicin in people with kidney problems and people with normal kidney function",
            "phase": "Phase I",
            "lead_sponsor": "Debiopharm International S.A.",
            "conditions": "Renal Impairment",
            "member_states": "Germany",
            "decision_date": "18/08/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526916-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525102-38-00",
            "title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Elevated lipoprotein(a)",
            "member_states": "Netherlands; Denmark; Germany; Spain",
            "decision_date": "18/08/2026",
            "enrolled": "295",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525102-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524581-14-00",
            "title": "A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer\u2019s disease.",
            "phase": "Phase II",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Dementia Alzheimer's type",
            "member_states": "Spain; Germany",
            "decision_date": "18/08/2026",
            "enrolled": "266",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524581-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523682-24-00",
            "title": "Evaluation of the efficacy of intravenous lidocaine on chronic postoperative pain in patients requiring emergency abdominal surgery. Randomized, double-blind, controlled, multicenter study \u2013 LIDOC-POPEYE.",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "emergency abdominal surgery",
            "member_states": "France",
            "decision_date": "17/08/2026",
            "enrolled": "266",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523682-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523632-39-00",
            "title": "FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML",
            "phase": "Phase II",
            "lead_sponsor": "Institut Paoli Calmettes",
            "conditions": "acute myeloid lymphoma",
            "member_states": "France",
            "decision_date": "17/08/2026",
            "enrolled": "77",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523632-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523500-72-00",
            "title": "A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA\u00ae HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Neovascular Age-related Macular Degeneration (nAMD)",
            "member_states": "Slovakia; Latvia; Czechia; Poland; Spain; Hungary; Lithuania",
            "decision_date": "17/08/2026",
            "enrolled": "255",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523500-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525394-39-00",
            "title": "Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPAC",
            "phase": "Phase II",
            "lead_sponsor": "Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience",
            "conditions": "Patients with primary angiitis of the central nervous system",
            "member_states": "France",
            "decision_date": "17/08/2026",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525394-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524080-20-00",
            "title": "A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Metastatic castration resistant prostate cancer",
            "member_states": "France; Italy; Spain; Germany",
            "decision_date": "17/08/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524080-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525513-31-00",
            "title": "Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer \u2013 an open label, randomized phase III trial (DAHRTS)",
            "phase": "Phase III",
            "lead_sponsor": "Norges Teknisk-Naturvitenskapelige Universitet NTNU",
            "conditions": "Small-cell lung cancer, limited stage",
            "member_states": "Denmark; Finland; Estonia; Germany; Lithuania; Sweden; Norway; Netherlands",
            "decision_date": "17/08/2026",
            "enrolled": "426",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525513-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521693-33-00",
            "title": "Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke",
            "phase": "Phase II",
            "lead_sponsor": "Sinfatin S.L.",
            "conditions": "Stroke",
            "member_states": "Spain",
            "decision_date": "17/08/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521693-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523447-35-02",
            "title": "C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Pneumoccoccal Immunisation",
            "member_states": "Spain; Finland; Poland; Germany; Greece; Hungary; Italy",
            "decision_date": "17/08/2026",
            "enrolled": "1345",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523447-35-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524915-36-00",
            "title": "A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)",
            "phase": "Phase I/II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Lymphoma, Non-Hodgkin",
            "member_states": "Italy; Germany; Spain; Finland; France",
            "decision_date": "17/08/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524915-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524445-27-00",
            "title": "A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer",
            "phase": "Phase III",
            "lead_sponsor": "BioNTech SE",
            "conditions": "Metastatic castration-resistant prostate cancer (mCRPC)",
            "member_states": "Belgium; Spain; Italy; Poland; Germany; Hungary",
            "decision_date": "17/08/2026",
            "enrolled": "183",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524445-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524324-22-00",
            "title": "A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non\u2011cystic fibrosis bronchiectasis (NCFB) (Part 2)",
            "phase": "Phase I",
            "lead_sponsor": "Zambon S.p.A.",
            "conditions": "Non-cystic fibrosis bronchiectasis",
            "member_states": "Belgium; Poland; Bulgaria",
            "decision_date": "17/08/2026",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524324-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526258-15-00",
            "title": "A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared with Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolaemia.",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Hypercholesterolaemia",
            "member_states": "Germany",
            "decision_date": "17/08/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526258-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523346-27-00",
            "title": "A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression",
            "phase": "Phase II",
            "lead_sponsor": "Universita' Degli Studi G. D'Annunzio Di Chieti",
            "conditions": "Treatment-Resistant Depression",
            "member_states": "Italy",
            "decision_date": "14/08/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523346-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525898-39-00",
            "title": "The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI",
            "phase": "Phase III",
            "lead_sponsor": "Azienda Sanitaria Locale Napoli 1 Centro",
            "conditions": "Advanced hepatocellular carcinoma",
            "member_states": "Italy",
            "decision_date": "14/08/2026",
            "enrolled": "1700",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525898-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526828-41-00",
            "title": "Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Ospedaliera Universitaria Integrata Verona",
            "conditions": "Erosive hand osteoarthritis (EHOA)",
            "member_states": "Italy",
            "decision_date": "14/08/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526828-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525033-31-00",
            "title": "A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF)\n(CALIBRATE-HF)",
            "phase": "Phase II",
            "lead_sponsor": "Cardurion Pharmaceuticals Inc.",
            "conditions": "heart failure",
            "member_states": "Latvia; Slovakia; Lithuania; Hungary; Italy; Netherlands; Spain; Poland; Bulgaria; Czechia",
            "decision_date": "14/08/2026",
            "enrolled": "369",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525033-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525825-19-00",
            "title": "A study to test how BI 3034701 is taken up and processed by the body in healthy men with normal weight or overweight",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy",
            "member_states": "Hungary",
            "decision_date": "14/08/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525825-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526477-42-00",
            "title": "Bioequivalence of Estradiol 10 mcg Vaginal Tablets in Healthy Women Participants.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Leon Farma S.A.",
            "conditions": "Not applicable (submitted trial is a bioavailability trial in healthy participants).",
            "member_states": "Czechia",
            "decision_date": "14/08/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526477-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509125-41-00",
            "title": "A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)",
            "phase": "Phase II",
            "lead_sponsor": "Kinaset Therapeutics Inc.",
            "conditions": "Severe asthma",
            "member_states": "Czechia; Bulgaria; Romania; Hungary; Germany; Poland; Greece",
            "decision_date": "14/08/2026",
            "enrolled": "350",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509125-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525539-18-00",
            "title": "An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer\u2019s Disease",
            "phase": "Phase II",
            "lead_sponsor": "Merry Life Biomedical Co. Ltd.",
            "conditions": "Early Alzheimer\u2019s Disease",
            "member_states": "Sweden",
            "decision_date": "14/08/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525539-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519491-60-00",
            "title": "An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases",
            "phase": "Phase I/II",
            "lead_sponsor": "Universitaetsklinikum Tuebingen A\u00f6R",
            "conditions": "ANCA associated vasculitis (AAV), Immune thrombocytopenic purpura (ITP), Multiple sclerosis (MS), Rheumatoid arthritis (RA), Pemphigus vulgaris (PV), Systemic sclerosis (SSc), Inflammatory idiopathic Myositis (IIM)",
            "member_states": "Germany",
            "decision_date": "14/08/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519491-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525454-11-00",
            "title": "A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of\nAdults With Previously Untreated Primary Immune Thrombocytopenia (ITP)",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Diagnosis of primary ITP according to the 2019 International Consensus Report that is previously untreated and requires treatment",
            "member_states": "Spain; Hungary; Germany",
            "decision_date": "14/08/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525454-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525336-41-00",
            "title": "TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Interstitial Lung Disease",
            "member_states": "France",
            "decision_date": "14/08/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525336-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521324-29-00",
            "title": "[\u2076\u2078Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)",
            "phase": "Phase II",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Primary breast cancer",
            "member_states": "Denmark",
            "decision_date": "14/08/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521324-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525550-11-00",
            "title": "Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial",
            "phase": "Phase II",
            "lead_sponsor": "Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard",
            "conditions": "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
            "member_states": "Spain",
            "decision_date": "14/08/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525550-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527080-15-00",
            "title": "Phase IV Low Intervention Clinical Trial to Study Biomarkers of \"inflammageing\" and Senescence in Pre-diabetic Patients Treated with Metformin: A Study nested within the project \u201cNLRP3 Inflammasome at the Crossroad of Vascular Inflammageing: A Novel Target for Senomorphic Drugs\u201d.",
            "phase": "Phase IV",
            "lead_sponsor": "Universidad Autonoma De Madrid",
            "conditions": "Pre-diabetic Patients",
            "member_states": "Spain",
            "decision_date": "14/08/2026",
            "enrolled": "105",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527080-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524131-39-00",
            "title": "Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]",
            "phase": "Phase III",
            "lead_sponsor": "Charite Universitaetsmedizin Berlin K\u00f6R",
            "conditions": "locally advanced or metastatic small bowel adenocarcinoma",
            "member_states": "Germany",
            "decision_date": "13/08/2026",
            "enrolled": "112",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524131-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524868-38-00",
            "title": "A Phase 1b Study of ZN-c3 in Combination with Chemotherapy or Bevacizumab in Subjects with Ovarian, Peritoneal, or Fallopian Tube Cancer",
            "phase": "Phase I",
            "lead_sponsor": "K-Group Beta Inc.",
            "conditions": "Ovarian, Peritoneal, or Fallopian Tube Cancer",
            "member_states": "France",
            "decision_date": "13/08/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524868-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518027-30-00",
            "title": "Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)",
            "phase": "Phase II",
            "lead_sponsor": "CHU De Martinique",
            "conditions": "leptospirosis",
            "member_states": "France",
            "decision_date": "13/08/2026",
            "enrolled": "304",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518027-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525328-10-00",
            "title": "A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)",
            "phase": "Phase II",
            "lead_sponsor": "Medica Scientia Innovation Research S.L.",
            "conditions": "HR-positive/HER2-negative advanced breast cancer",
            "member_states": "Spain; Italy; Germany",
            "decision_date": "13/08/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525328-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525869-42-00",
            "title": "A two-part, randomised, double-blind, placebo-controlled, parallel-group, 12week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants",
            "phase": "Phase I/II",
            "lead_sponsor": "Pila Pharma AB",
            "conditions": "Obesity",
            "member_states": "Sweden",
            "decision_date": "13/08/2026",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525869-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523444-12-00",
            "title": "SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st  line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Breast Cancer",
            "member_states": "Poland; Spain; France; Germany; Italy",
            "decision_date": "13/08/2026",
            "enrolled": "79",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523444-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524392-23-00",
            "title": "A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation",
            "phase": "Phase IV",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Chronic obstructive pulmonary disease (COPD)",
            "member_states": "Belgium; Italy; Spain",
            "decision_date": "13/08/2026",
            "enrolled": "190",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524392-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524747-13-00",
            "title": "AN OPEN LABEL, SINGLE ARM, EXPLORATIVE TRIAL TO EVALUATE EFFICACY AND SAFETY OF BEROTRALSTAT IN PREVENTING ANGIOEDEMA ATTACKS IN SUBJECTS WITH ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE)",
            "phase": "Phase II",
            "lead_sponsor": "Policlinico San Donato S.p.A.",
            "conditions": "Acquired angioedema due to C1 inhibitor deficiency",
            "member_states": "Italy",
            "decision_date": "12/08/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524747-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524676-32-00",
            "title": "International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies",
            "phase": "Phase III",
            "lead_sponsor": "ROXALL Medizin GmbH",
            "conditions": "Patients suffering from rhinitis / rhinoconjunctivitis, with well-controlled mild-to-moderate asthma or without asthma, due to the exposure to any of the allergen sources under investigation, for at least 2 years in case of seasonal allergenic sources or for at least 1 year in case of perennial allergenic sources.",
            "member_states": "Germany; Spain",
            "decision_date": "12/08/2026",
            "enrolled": "140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524676-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526460-20-00",
            "title": "A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Ospedaliero Universitaria Di Modena",
            "conditions": "AMYOTROPHIC LATERAL SCLEROSIS",
            "member_states": "Italy",
            "decision_date": "12/08/2026",
            "enrolled": "87",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526460-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527382-30-00",
            "title": "Bioavailability Comparison of Finerenone 20 mg Tablets (Test vs. Comparator Product).",
            "phase": "Phase I",
            "lead_sponsor": "ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.",
            "conditions": "Comparative bioavailability study under fasting conditions.",
            "member_states": "Czechia",
            "decision_date": "12/08/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527382-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527110-23-00",
            "title": "A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer",
            "phase": "Phase II",
            "lead_sponsor": "Region Uppsala",
            "conditions": "Prostate cancer",
            "member_states": "Sweden",
            "decision_date": "12/08/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527110-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525110-29-01",
            "title": "Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified to radical therapy",
            "phase": "Phase III",
            "lead_sponsor": "Narodowe Centrum Badan Jadrowych",
            "conditions": "triple-negative breast cancer",
            "member_states": "Poland",
            "decision_date": "12/08/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525110-29-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525776-26-00",
            "title": "Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial",
            "phase": "Phase II",
            "lead_sponsor": "Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy",
            "conditions": "adenoid cystic carcinoma of the salivary glands",
            "member_states": "Poland",
            "decision_date": "12/08/2026",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525776-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524046-10-00",
            "title": "Preventive Dendritic Cell vaccination for Lynch Syndrome (PREVENT-Lynch)",
            "phase": "Phase I/II",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Lynch Syndrome",
            "member_states": "Netherlands",
            "decision_date": "12/08/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524046-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526403-30-00",
            "title": "A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and its Metabolites in Healthy Participants",
            "phase": "Phase I",
            "lead_sponsor": "Merck Healthcare KGaA",
            "conditions": "This clinical trial is performed in healthy participants; the planned indication is: Neurofibromatosis Type I",
            "member_states": "Germany",
            "decision_date": "12/08/2026",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526403-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521798-15-00",
            "title": "Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan",
            "phase": "Phase III",
            "lead_sponsor": "Istituto Di Ricerche Farmacologiche Mario Negri",
            "conditions": "Breast Cancer",
            "member_states": "Italy",
            "decision_date": "11/08/2026",
            "enrolled": "244",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521798-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524805-34-00",
            "title": "A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors",
            "phase": "Phase I",
            "lead_sponsor": "Exelixis Inc.",
            "conditions": "Locally Advanced or Metastatic Solid Tumors",
            "member_states": "Italy; Netherlands; France; Spain",
            "decision_date": "11/08/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524805-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522532-14-00",
            "title": "Phase 1 Study of PF-08046033 in Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Advanced solid tumors",
            "member_states": "Netherlands; France; Spain",
            "decision_date": "11/08/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522532-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524859-31-00",
            "title": "Patient-Controlled Anesthesia for endoscopic Procedural Sedation \u2013 PCAPS study",
            "phase": "Phase IV",
            "lead_sponsor": "Karolinska Institutet",
            "conditions": "Adenoma",
            "member_states": "Sweden",
            "decision_date": "11/08/2026",
            "enrolled": "175",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524859-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527162-72-00",
            "title": "Bioequivalence clinical trial of two formulations of quetiapine.",
            "phase": "Phase I/II",
            "lead_sponsor": "Laboratorios Alter S.A.",
            "conditions": "Healthy participants",
            "member_states": "Spain",
            "decision_date": "11/08/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527162-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520387-34-01",
            "title": "A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study",
            "phase": "Phase III",
            "lead_sponsor": "Fondazione IRCCS Policlinico San Matteo",
            "conditions": "electrical storm",
            "member_states": "Italy",
            "decision_date": "11/08/2026",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520387-34-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525733-24-00",
            "title": "Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia",
            "conditions": "Recurrent and/or Metastatic Adenoid Cystic Carcinom",
            "member_states": "Italy",
            "decision_date": "11/08/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525733-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524974-41-00",
            "title": "J2S-MC-GZMT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-C",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Irritable Bowel Syndrome - Constipation",
            "member_states": "Belgium; Spain",
            "decision_date": "11/08/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524974-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-506001-19-00",
            "title": "SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "paraganglioma or pheochromocytoma with surgical indication",
            "member_states": "France",
            "decision_date": "10/08/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-506001-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524584-20-00",
            "title": "AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Premature ventricular contractions (PVC)",
            "member_states": "France",
            "decision_date": "10/08/2026",
            "enrolled": "158",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524584-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526775-27-00",
            "title": "A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study",
            "phase": "Phase II",
            "lead_sponsor": "Laboratoires Kol",
            "conditions": "Wet Age-Related Macular Degeneration (wAMD) Patients",
            "member_states": "France",
            "decision_date": "10/08/2026",
            "enrolled": "162",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526775-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525217-31-00",
            "title": "A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms",
            "phase": "Phase I",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Myeloproliferative Neoplasms",
            "member_states": "Italy; Belgium; Germany; France; Spain",
            "decision_date": "10/08/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525217-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525353-37-00",
            "title": "Evaluation of Interference and Synergy of Anti-Circumsporozoite Antibodies on GA2-induced Immunity",
            "phase": "Phase I/II",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Plasmodium falciparum malaria",
            "member_states": "Netherlands",
            "decision_date": "10/08/2026",
            "enrolled": "33",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525353-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525271-57-00",
            "title": "A research study looking into how a single dose of the medicine NNC0537-1482 moves through the body of participants with normal or reduced kidney function",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Heart failure with preserved ejection fraction",
            "member_states": "Germany",
            "decision_date": "10/08/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525271-57-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521689-86-00",
            "title": "Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.",
            "phase": "Phase II",
            "lead_sponsor": "Sinfatin S.L.",
            "conditions": "Stroke",
            "member_states": "Spain",
            "decision_date": "10/08/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521689-86-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525610-62-00",
            "title": "A Phase 1 Trial of GEN1119 in Participants with Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Solid Tumors",
            "member_states": "Spain; France",
            "decision_date": "10/08/2026",
            "enrolled": "66",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525610-62-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522824-29-00",
            "title": "A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Primary IgAN",
            "member_states": "France; Spain",
            "decision_date": "10/08/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522824-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525450-11-00",
            "title": "Bioequivalence study 3 to compare pharmacokinetics of Parkinson\u00b4s disease drugs in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Orion Corporation",
            "conditions": "Parkinson's desease",
            "member_states": "Czechia",
            "decision_date": "10/08/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525450-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524993-41-00",
            "title": "A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)",
            "phase": "Phase II",
            "lead_sponsor": "Celgene Corp.",
            "conditions": "Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)",
            "member_states": "Germany; Denmark",
            "decision_date": "10/08/2026",
            "enrolled": "3",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524993-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525925-19-00",
            "title": "A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects with Schizophrenia, Followed by a 40-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications",
            "phase": "Phase III",
            "lead_sponsor": "Minerva Neurosciences Inc.",
            "conditions": "Schizophrenia with negative symptoms",
            "member_states": "Bulgaria; Romania",
            "decision_date": "10/08/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525925-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524626-18-00",
            "title": "Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Overweight and obesity",
            "member_states": "Netherlands; Belgium; Greece; Poland; Spain; Denmark; France; Bulgaria; Sweden",
            "decision_date": "10/08/2026",
            "enrolled": "315",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524626-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527032-14-00",
            "title": "The RHINOME study",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Severe asthma",
            "member_states": "Denmark",
            "decision_date": "10/08/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527032-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523472-23-01",
            "title": "An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma",
            "phase": "Phase II",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Cutaneous T-cell lymphoma (CTCL)\nMycosis fungoides",
            "member_states": "Denmark",
            "decision_date": "10/08/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523472-23-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523333-26-00",
            "title": "A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves\u2019 Disease Inadequately Controlled With Antithyroid Drugs",
            "phase": "Phase III",
            "lead_sponsor": "Argenx",
            "conditions": "Graves' Disease (GD)",
            "member_states": "Italy; Czechia; Spain; Denmark; Belgium; Romania; Latvia; France; Germany; Greece; Sweden; Poland; Lithuania; Bulgaria",
            "decision_date": "07/08/2026",
            "enrolled": "145",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523333-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520678-20-00",
            "title": "Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.",
            "member_states": "France",
            "decision_date": "07/08/2026",
            "enrolled": "187",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520678-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524845-28-00",
            "title": "HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire Vaudois",
            "conditions": "Cytomegalovirus infection in solid-organ transplant recipients.",
            "member_states": "France; Spain",
            "decision_date": "07/08/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524845-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526720-49-00",
            "title": "A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults \u2265 65 Years (DAN-COMBO)",
            "phase": "Phase IV",
            "lead_sponsor": "Gentofte Hospital, Moderna Inc.",
            "conditions": "SARS-CoV-2 infection, Influenza infection",
            "member_states": "Denmark; Spain",
            "decision_date": "07/08/2026",
            "enrolled": "410000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526720-49-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525821-19-00",
            "title": "A study in healthy men to test whether carbamazepine influences the amount of verducatib in the blood",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy",
            "member_states": "Germany",
            "decision_date": "07/08/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525821-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525696-77-00",
            "title": "A study in healthy people to test how Zongertinib is taken up in the body when given as tablets made by two different manufacturers with or without food",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy",
            "member_states": "Germany",
            "decision_date": "07/08/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525696-77-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526395-23-00",
            "title": "CLINIC-CURE, a pilot exploratory clinical trial of analytical treatment interruption in people with HIV with a highly favorable profile",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "HIV",
            "member_states": "Spain",
            "decision_date": "06/08/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526395-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522819-42-01",
            "title": "BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Rennes",
            "conditions": "sepsis",
            "member_states": "France",
            "decision_date": "06/08/2026",
            "enrolled": "672",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522819-42-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523807-31-00",
            "title": "[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.",
            "phase": "Phase II",
            "lead_sponsor": "Bayer AG",
            "conditions": "Atrial fibrillation",
            "member_states": "Belgium; Netherlands; Germany; Poland; Italy; Hungary; Bulgaria",
            "decision_date": "06/08/2026",
            "enrolled": "105",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523807-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524663-20-00",
            "title": "A Randomized, Open label, Single Center, Single Oral Dose, Four Treatment, Four Period, Four Sequence, Crossover Bioavailability Study of Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) vs. Panadol Advance Tablets 2X (paracetamol 500 mg), Naprosyn Tablets 1X (naproxen 250 mg), administered individually in fasted conditions and Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) in fed conditions in Healthy Adult Participants",
            "phase": "Phase I",
            "lead_sponsor": "Haleon CH SARL",
            "conditions": "Healthy volunteers, therapeutic indication not studied",
            "member_states": "Germany",
            "decision_date": "06/08/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524663-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524783-38-00",
            "title": "Spironolactone and SGLT2 inhibitor to Address Fontan circulatory failure and Enhance Resilience: The SAFER-Fontan trial",
            "phase": "Phase III",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Fontan circulation",
            "member_states": "Belgium",
            "decision_date": "06/08/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524783-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524773-16-00",
            "title": "A study in healthy people to compare how 2 different formulations of vicadrostat / empagliflozin tablets are taken up in the body",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy",
            "member_states": "Germany",
            "decision_date": "06/08/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524773-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525150-19-01",
            "title": "Influence of Doxycycline Use as Prophylaxis for Sexually Transmitted Infections on Bacterial Resistance and Gut Microbiota: MiDoxyR-PEP Study",
            "phase": "Phase IV",
            "lead_sponsor": "Instituto De Investigacion Marques De Valdecilla",
            "conditions": "Colonization by methicillin-resistant S. aureus and gut microbiota in users of pre-exposure prophylaxis (PrEP) and people living with HIV (PLHIV) with STIs.",
            "member_states": "Spain",
            "decision_date": "06/08/2026",
            "enrolled": "392",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525150-19-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525864-17-00",
            "title": "Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Orion Corporation",
            "conditions": "Advanced solid tumours",
            "member_states": "Spain",
            "decision_date": "06/08/2026",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525864-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524318-27-00",
            "title": "VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "People with stage 1 or stage 2 T1D between the ages of 7 and 45",
            "member_states": "France",
            "decision_date": "05/08/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524318-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518511-19-00",
            "title": "A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART",
            "phase": "Phase III",
            "lead_sponsor": "Viiv Healthcare UK Limited",
            "conditions": "HIV Infections",
            "member_states": "Spain",
            "decision_date": "05/08/2026",
            "enrolled": "81",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518511-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526397-17-00",
            "title": "An open label, randomized, single-dose, two-treatment, two-sequence, two-period, cross-over pilot comparative bioavailability study comparing Empagliflozin and Metformin f.c. tabs (12.5+1000) mg, VIANEX S.A., Greece versus Synjardy 12.5 mg/1,000 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Vianex S.A.",
            "conditions": "treatment of diabetes",
            "member_states": "Czechia",
            "decision_date": "05/08/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526397-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525974-21-00",
            "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Chronic Kidney Disease, Heart Failure, Coronary Artery disease",
            "member_states": "Germany",
            "decision_date": "05/08/2026",
            "enrolled": "43",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525974-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523307-29-00",
            "title": "ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES), Asthma",
            "member_states": "Denmark; Belgium; France; Italy; Netherlands; Austria; Poland",
            "decision_date": "04/08/2026",
            "enrolled": "94",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523307-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526200-69-00",
            "title": "A Phase IV, Randomized Controlled Trial to Evaluate the Effects of Resistance Training Versus Usual Care on Thigh Muscle Volume During Treatment with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Adults with Obesity",
            "phase": "Phase IV",
            "lead_sponsor": "Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)",
            "conditions": "Obesity",
            "member_states": "Germany",
            "decision_date": "04/08/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526200-69-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525016-41-00",
            "title": "A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Idiopathic Pulmonary Fibrosis",
            "member_states": "Poland; Hungary; Netherlands; Germany; Spain; Greece; Bulgaria; Italy; France; Denmark",
            "decision_date": "04/08/2026",
            "enrolled": "139",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525016-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523935-20-00",
            "title": "A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "type 2 diabetes mellitus",
            "member_states": "Poland; Germany; Bulgaria; Czechia",
            "decision_date": "04/08/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523935-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525953-35-00",
            "title": "Study in healthy volunteers to evaluate how the body processes Iadademstat and if food affects it",
            "phase": "Phase I",
            "lead_sponsor": "Oryzon Genomics S.A.",
            "conditions": "Healthy Volunteers",
            "member_states": "Spain",
            "decision_date": "04/08/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525953-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524652-63-00",
            "title": "A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer",
            "phase": "Phase I",
            "lead_sponsor": "Sumitomo Pharma America Inc.",
            "conditions": "Advanced Cancer",
            "member_states": "Spain; Bulgaria; Poland; Romania",
            "decision_date": "04/08/2026",
            "enrolled": "43",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524652-63-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523940-12-00",
            "title": "A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "type 2 diabetes mellitus",
            "member_states": "Germany; Bulgaria; Spain; Denmark",
            "decision_date": "03/08/2026",
            "enrolled": "183",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523940-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523941-81-00",
            "title": "A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "type 2 diabetes mellitus",
            "member_states": "Slovakia; Poland; Czechia; Germany; Hungary; Greece; Denmark",
            "decision_date": "03/08/2026",
            "enrolled": "360",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523941-81-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526179-49-00",
            "title": "Non-inferiority of surgical treatment of cartilage defects of the knee with autologous minced cartilage implantation (AMCI) and matrix-asscociated autologous chondrocyte implantation with respect to KOOS at 24 months (M ACI) - MinCaRCT",
            "phase": "Phase IV",
            "lead_sponsor": "Medical Center - University Of Freiburg",
            "conditions": "Full-thickness cartilage defects of the knee",
            "member_states": "Germany",
            "decision_date": "03/08/2026",
            "enrolled": "166",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526179-49-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521591-64-00",
            "title": "RUBY study \u00ab Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.\u00bb",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Adult patients with a diagnosis of fibrotic Hypersensitivity Pneumonitis (HP) (\u201cdefinite\u201d or \u201chigh confidence\u201d) after multi-disciplinary discussion (MDD) with a mild to moderate disease severity, and never treated for fibrotic HP.",
            "member_states": "France",
            "decision_date": "03/08/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521591-64-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523724-47-00",
            "title": "A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Acute Myeloid Leukemia",
            "member_states": "France; Austria; Spain",
            "decision_date": "03/08/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523724-47-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525360-18-00",
            "title": "A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms",
            "phase": "Phase I",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Myeloproliferative Neoplasms",
            "member_states": "Italy; Belgium; Germany",
            "decision_date": "03/08/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525360-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523884-39-00",
            "title": "A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Systemic sclerosis",
            "member_states": "Denmark; Hungary; Sweden; Netherlands; Germany; Belgium; France; Greece; Norway; Finland; Czechia; Portugal; Bulgaria; Spain; Austria; Romania; Croatia; Poland; Estonia; Italy; Lithuania",
            "decision_date": "03/08/2026",
            "enrolled": "179",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523884-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522006-21-00",
            "title": "Feasibility clinical trial of the sequential combination of AloCelyvir and activated tumor-infiltrating lymphocytes (TILs) for the treatment of children and young adults with advanced neuroblastoma",
            "phase": "Phase I",
            "lead_sponsor": "Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa",
            "conditions": "High-risk relapsed/refractory (R/R) neuroblastoma (NB).",
            "member_states": "Spain",
            "decision_date": "03/08/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522006-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527114-23-00",
            "title": "Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.",
            "phase": "Phase II",
            "lead_sponsor": "Ovid Therapeutics Inc.",
            "conditions": "Epilepsy",
            "member_states": "Netherlands",
            "decision_date": "03/08/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527114-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519592-26-00",
            "title": "Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)",
            "phase": "Phase I",
            "lead_sponsor": "Universitaetsklinikum Heidelberg A\u00f6R",
            "conditions": "Therapy-resistant and progressing lung fibrosis in the course of an autoantibody-positive autoimmune\ndisease like Systemic Sclerosis, ANCA-associated Vasculitis, seropositive Rheumatoid\nArthritis, Sj\u00f6gren\u2019s disease, anti-Synthetase Syndrome or other autoimmune diseases",
            "member_states": "Germany",
            "decision_date": "03/08/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519592-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525922-39-00",
            "title": "A Phase 3, Randomized, Double-blind, and Active\u2011controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ\u201178934804 in Participants With Moderately to Severely Active Crohn\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Moderately to Severely Active Crohn\u2019s Disease",
            "member_states": "Norway; Romania; Austria; Italy; Slovakia; Germany; Hungary; Netherlands; Belgium; France; Portugal; Czechia; Poland; Spain; Greece",
            "decision_date": "03/08/2026",
            "enrolled": "194",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525922-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525923-26-00",
            "title": "A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Moderately to Severely Active Ulcerative Colitis",
            "member_states": "France; Bulgaria; Romania; Slovakia; Norway; Denmark; Greece; Italy; Austria; Poland; Netherlands; Czechia; Germany; Belgium; Spain; Hungary; Portugal",
            "decision_date": "03/08/2026",
            "enrolled": "302",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525923-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524911-34-00",
            "title": "A Phase I Study to Evaluate ELA822",
            "phase": "Phase I",
            "lead_sponsor": "Electra Therapeutics Inc.",
            "conditions": "Healthy Volunteers",
            "member_states": "Austria",
            "decision_date": "02/08/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524911-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525669-33-00",
            "title": "Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study",
            "phase": "Phase II",
            "lead_sponsor": "Aalborg University Hospital",
            "conditions": "Chronic postsurgical pain (CPSP)",
            "member_states": "Denmark",
            "decision_date": "01/08/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525669-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524939-39-02",
            "title": "The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.",
            "phase": "Phase II",
            "lead_sponsor": "Slagelse Hospital",
            "conditions": "Anorexia nervosa",
            "member_states": "Denmark",
            "decision_date": "01/08/2026",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524939-39-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526859-54-00",
            "title": "A Randomised, Placebo\u2011Controlled Trial to Assess Effect of IMU\u2011838 on QT/QTc",
            "phase": "Phase I",
            "lead_sponsor": "Immunic AG",
            "conditions": "Multiple sclerosis",
            "member_states": "Belgium",
            "decision_date": "31/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526859-54-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525785-22-00",
            "title": "A study to test how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumours)",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "solid tumours",
            "member_states": "Spain",
            "decision_date": "31/07/2026",
            "enrolled": "39",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525785-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526531-18-00",
            "title": "Perioperative Intravenous Metamizole in Laparoscopic Cholecystectomy: A rondomized, double blind, clinical trial.",
            "phase": "Phase III",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Post operative pain relief in Patients undergoing laparoscopic cystectomy in day-surgery clinic",
            "member_states": "Belgium",
            "decision_date": "31/07/2026",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526531-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523222-40-00",
            "title": "An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates",
            "phase": "Phase II",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "End stage renal failure",
            "member_states": "Austria",
            "decision_date": "31/07/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523222-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525161-40-00",
            "title": "A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients \u2265 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.",
            "phase": "Phase II",
            "lead_sponsor": "PannTheraPi",
            "conditions": "Drug resistant focal epilepsy related to focal cortical dysplasia",
            "member_states": "France",
            "decision_date": "31/07/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525161-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525568-17-00",
            "title": "Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer",
            "phase": "Phase I",
            "lead_sponsor": "Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting",
            "conditions": "HER2 mutation positive NSCLC",
            "member_states": "Netherlands",
            "decision_date": "30/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525568-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525111-17-00",
            "title": "A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3",
            "phase": "Phase I/II",
            "lead_sponsor": "Institut De Recherches Internationales Servier IRIS",
            "conditions": "Spinocerebellar ataxia type 3",
            "member_states": "France; Denmark; Spain; Portugal",
            "decision_date": "30/07/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525111-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526867-39-00",
            "title": "Nav 1.8 and 1.7 combo trial",
            "phase": "Phase I",
            "lead_sponsor": "Niroda Therapeutics Inc.",
            "conditions": "Pain",
            "member_states": "Netherlands",
            "decision_date": "30/07/2026",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526867-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525836-41-00",
            "title": "Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "Not applicable (submitted trial is a bioavailability trial in healthy participants).",
            "member_states": "Czechia",
            "decision_date": "30/07/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525836-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524858-34-00",
            "title": "J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases",
            "member_states": "Hungary; Czechia; Spain; Netherlands",
            "decision_date": "30/07/2026",
            "enrolled": "145",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524858-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525707-27-00",
            "title": "Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function",
            "phase": "Phase I",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Renal Impairment",
            "member_states": "Germany",
            "decision_date": "30/07/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525707-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-510098-33-01",
            "title": "A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Follicular Lymphoma",
            "member_states": "Denmark",
            "decision_date": "29/07/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-510098-33-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526116-36-00",
            "title": "A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy",
            "phase": "Phase I",
            "lead_sponsor": "Pliant Therapeutics Inc.",
            "conditions": "Advanced or metastatic solid tumours",
            "member_states": "Spain",
            "decision_date": "29/07/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526116-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526383-20-00",
            "title": "B-HAPPI: Bipolar disorder and high-dose adjunctive pramipexole for anhedonic depression \u2013 a phase III, double-blind, randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Region Skane",
            "conditions": "Bipolar disorder",
            "member_states": "Sweden",
            "decision_date": "29/07/2026",
            "enrolled": "186",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526383-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521740-38-00",
            "title": "A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the \nsafety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age",
            "phase": "Phase I/II",
            "lead_sponsor": "Sanofi Pasteur Inc.",
            "conditions": "Acne",
            "member_states": "Spain; Germany; Poland",
            "decision_date": "29/07/2026",
            "enrolled": "189",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521740-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523267-38-00",
            "title": "Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study",
            "phase": "Phase IV",
            "lead_sponsor": "Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.",
            "conditions": "Major depressive disorder (MDD)",
            "member_states": "Bulgaria; Poland; Hungary",
            "decision_date": "29/07/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523267-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526304-79-00",
            "title": "A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF);\non background SGLT2i.",
            "member_states": "Spain; Hungary; Germany; Poland; Italy; Bulgaria; Netherlands; Austria; Romania; Sweden; France; Greece; Slovakia; Czechia",
            "decision_date": "29/07/2026",
            "enrolled": "2343",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526304-79-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526311-11-00",
            "title": "An Open-label Phase 1 Study in Healthy Adult Participants to Investigate the Effect of Itraconazole on the Blood Levels of Engasertib",
            "phase": "Phase I",
            "lead_sponsor": "Vaderis Therapeutics AG",
            "conditions": "This clinical trial is performed in healthy participants; the planned indication: Treatment of Hereditary hemorrhagic telangiectasia (HHT)",
            "member_states": "Germany",
            "decision_date": "29/07/2026",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526311-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525382-47-00",
            "title": "A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Puma Biotechnology Inc.",
            "conditions": "Small Cell Lung Cancer (SCLC)",
            "member_states": "France; Poland; Spain",
            "decision_date": "28/07/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525382-47-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526821-16-00",
            "title": "Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma",
            "phase": "Phase I/II",
            "lead_sponsor": "Karolinska University Hospital",
            "conditions": "Unresectable Stage III or Stage IV Cutaneous Melanoma",
            "member_states": "Sweden",
            "decision_date": "28/07/2026",
            "enrolled": "105",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526821-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525106-37-00",
            "title": "Comparative study of two vaccination schedules for the subunit Herpes Zoster vaccine in Multiple Sclerosis and Neuromyelitis optica spectrum disease patients treated with anti-CD20 therapy: an open-label randomised controlled trial.",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "Multiple Sclerosis and Neuromyelitis optica spectrum",
            "member_states": "France",
            "decision_date": "28/07/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525106-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524003-68-00",
            "title": "OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Patients with newly or active diffuse Systemic sclerosis at the time of screening.",
            "member_states": "France",
            "decision_date": "28/07/2026",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524003-68-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525933-22-00",
            "title": "STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)",
            "phase": "Phase IV",
            "lead_sponsor": "Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz",
            "conditions": "ischemic heart disease",
            "member_states": "Spain; Norway",
            "decision_date": "28/07/2026",
            "enrolled": "3500",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525933-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522209-40-00",
            "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer",
            "phase": "Phase I",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Ovarian Cancer",
            "member_states": "Portugal; Denmark; Spain; France",
            "decision_date": "27/07/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522209-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525484-40-00",
            "title": "A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms",
            "phase": "Phase I",
            "lead_sponsor": "Prelude Therapeutics Inc.",
            "conditions": "Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Intermediate-1, Intermediate-2, or High-Risk Primary Myelofibrosis, High-risk Polycythemia Vera",
            "member_states": "Italy; France; Spain",
            "decision_date": "27/07/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525484-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526368-18-00",
            "title": "A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial",
            "phase": "Phase III",
            "lead_sponsor": "Azienda Ospedaliera Universitaria Gaetano Martino Messina",
            "conditions": "Chronic Coronary Syndrome in patients undergoing percutaneous coronary intervention (PCI)",
            "member_states": "Italy",
            "decision_date": "27/07/2026",
            "enrolled": "500",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526368-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524233-45-00",
            "title": "A first-in-human, randomized, double-blind, placebo-controlled, 3-part study assessing the safety, tolerability, pharmacodynamics and pharmacokinetics of GL0071 after single and repeated ascending subcutaneous doses in healthy normal weight, overweight and obese participants, as well as a 12-week treatment randomized, double blind, placebo-controlled exploratory Proof-of-Concept study in overweight and obese participants.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "Type 2 diabetes mellitus, Overweight",
            "member_states": "Belgium",
            "decision_date": "27/07/2026",
            "enrolled": "124",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524233-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522757-19-00",
            "title": "A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)",
            "phase": "Phase II",
            "lead_sponsor": "Cancer Research UK",
            "conditions": "LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA",
            "member_states": "Spain; France; Germany; Norway",
            "decision_date": "27/07/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522757-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524816-13-00",
            "title": "A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Non-small Cell Lung Cancer",
            "member_states": "Spain",
            "decision_date": "27/07/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524816-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522488-14-00",
            "title": "A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Participants with obesity with or without type 2 diabetes",
            "member_states": "Greece; Portugal; France; Slovakia; Bulgaria; Netherlands; Romania; Italy; Austria; Poland; Hungary; Spain; Czechia; Belgium",
            "decision_date": "27/07/2026",
            "enrolled": "1140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522488-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523837-25-00",
            "title": "4TAZPower:  A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome",
            "phase": "Phase III",
            "lead_sponsor": "Stealth Biotherapeutics Inc.",
            "conditions": "Barth Syndrome",
            "member_states": "Ireland; Netherlands; France; Italy",
            "decision_date": "27/07/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523837-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524977-18-00",
            "title": "Phase I/II Trial to Determine Safety and Efficacy of non-Viral Allogeneic Dual CD123/33-Chimeric Antigen Receptor CIK (CARCIK-CD123/33) Cells in Adult and Pediatric Patients with Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",
            "phase": "Phase I/II",
            "lead_sponsor": "Fondazione Tettamanti, Fondazione IRCCS San Gerardo Dei Tintori",
            "conditions": "Acute myeloid leukemia and Blastic plasmacytoid dendritic cell neoplasm",
            "member_states": "Italy",
            "decision_date": "27/07/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524977-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526674-17-00",
            "title": "A clinical trial of MK-3868 in healthy participants (MK-3868-001)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Malaria",
            "member_states": "Belgium",
            "decision_date": "27/07/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526674-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523819-11-00",
            "title": "A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Small Cell Lung Cancer",
            "member_states": "Italy; Greece; Spain; Belgium; France; Austria; Germany",
            "decision_date": "27/07/2026",
            "enrolled": "125",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523819-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516251-40-01",
            "title": "Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.",
            "phase": "Phase III",
            "lead_sponsor": "Milestone Pharmaceuticals Inc.",
            "conditions": "Atrial Fibrillation",
            "member_states": "Netherlands",
            "decision_date": "27/07/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516251-40-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526526-41-01",
            "title": "Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",
            "member_states": "Austria",
            "decision_date": "27/07/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526526-41-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518861-90-00",
            "title": "Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer",
            "phase": "Phase IV",
            "lead_sponsor": "HUS-Yhtymae",
            "conditions": "Venous thromboembolism (in bladder cancer patients)",
            "member_states": "Finland",
            "decision_date": "27/07/2026",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518861-90-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525813-30-00",
            "title": "A study in healthy people to measure how different doses of verducatib affect the heart",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "27/07/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525813-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524688-19-00",
            "title": "A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Participants Living with Obesity or Overweight with at least 1 comorbidity with or without Type 2 Diabetes Mellitus",
            "member_states": "Spain; Germany; Italy; Poland",
            "decision_date": "27/07/2026",
            "enrolled": "1010",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524688-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523960-19-00",
            "title": "An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease",
            "phase": "Phase III",
            "lead_sponsor": "BeOne Medicines I GmbH",
            "conditions": "Advanced or Metastatic HR+/HER2- Breast Cancer",
            "member_states": "Poland; Italy; Germany; France; Spain",
            "decision_date": "27/07/2026",
            "enrolled": "233",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523960-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525862-23-00",
            "title": "Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "parkinson disease",
            "member_states": "France",
            "decision_date": "24/07/2026",
            "enrolled": "39",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525862-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525040-18-00",
            "title": "DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer",
            "phase": "Phase II",
            "lead_sponsor": "Institut Paoli Calmettes",
            "conditions": "triple\u2011negative breast cancer",
            "member_states": "France",
            "decision_date": "24/07/2026",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525040-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523650-14-00",
            "title": "functional imaging of digital osteoarthritis and  rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase  II clinical study",
            "phase": "Phase II",
            "lead_sponsor": "Centre Jean Perrin",
            "conditions": "Arthritis  rheumatoid and  finger  osteoarthritis",
            "member_states": "France",
            "decision_date": "24/07/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523650-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526289-25-00",
            "title": "VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)",
            "phase": "Phase IV",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Parapneumonic pleural infection/pleural empyema",
            "member_states": "Netherlands",
            "decision_date": "24/07/2026",
            "enrolled": "164",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526289-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522409-39-00",
            "title": "Immune Cell Therapy for People with Early, Active Multiple Sclerosis",
            "phase": "Phase I",
            "lead_sponsor": "Medizinische Hochschule Hannover",
            "conditions": "Newly diagnosed highly-active Multiple Sclerosis",
            "member_states": "Germany",
            "decision_date": "24/07/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522409-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524054-34-00",
            "title": "An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Na\u00efve or Have Previously Been Treated With Risdiplam",
            "phase": "Phase III",
            "lead_sponsor": "Biogen Idec Research Limited",
            "conditions": "Spinal Muscular Atrophy",
            "member_states": "Finland; Spain; Italy; Poland; Ireland; Germany; France",
            "decision_date": "24/07/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524054-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525417-31-00",
            "title": "A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation",
            "phase": "Phase II",
            "lead_sponsor": "Ribocure Pharmaceuticals AB",
            "conditions": "non-valvular atrial fibrillation",
            "member_states": "Norway; Denmark; Poland; Sweden",
            "decision_date": "24/07/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525417-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524951-30-00",
            "title": "161Tb-labeled Gastrin Analogue - A Novel Tool for Precision Treatment of Advanced Medullary Thyroid Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Uniwersytet Jagiellonski Collegium Medicum",
            "conditions": "Thyroid cancer",
            "member_states": "Poland",
            "decision_date": "24/07/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524951-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523994-41-00",
            "title": "A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Chronic kidney disease (CKD) in adults, with specified ranges of eGFR and albuminuria (UACR), irrespective of T2DM status; background SGLT2i dapagliflozin 10 mg as GDMT.",
            "member_states": "Czechia; Italy; Hungary; Romania; Bulgaria; Sweden; Denmark; Poland; Spain; Norway; Finland; Greece; France; Germany",
            "decision_date": "24/07/2026",
            "enrolled": "1600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523994-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525097-11-00",
            "title": "Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)",
            "phase": "Phase III",
            "lead_sponsor": "Polish Myeloma Consortium",
            "conditions": "Multiple myeloma",
            "member_states": "Poland",
            "decision_date": "23/07/2026",
            "enrolled": "248",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525097-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525042-22-00",
            "title": "A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD",
            "phase": "Phase I",
            "lead_sponsor": "Genentech Inc.",
            "conditions": "Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis",
            "member_states": "Germany",
            "decision_date": "23/07/2026",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525042-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524125-40-01",
            "title": "Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors",
            "phase": "Phase II",
            "lead_sponsor": "Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets",
            "conditions": "Metastatic solid tumors, with the following specific indications:\n\nNon\u2013Small Cell Lung Cancer (NSCLC), metastatic, PD-(L)1\u2013refractory/resistant\nGastric adenocarcinoma, metastatic, PD-(L)1\u2013refractory/resistant\nColorectal cancer (microsatellite stable, MSS), metastatic, immunotherapy\u2011na\u00efve\nPancreatic adenocarcinoma, metastatic, immunotherapy\u2011na\u00efve",
            "member_states": "Italy",
            "decision_date": "23/07/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524125-40-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524918-28-00",
            "title": "A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)",
            "phase": "Phase II",
            "lead_sponsor": "Sironax USA Inc.",
            "conditions": "VEXAS Syndrome",
            "member_states": "Italy",
            "decision_date": "23/07/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524918-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525185-21-00",
            "title": "IKF-099/D-FLOT-TNT\nTotal Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma",
            "phase": "Phase II",
            "lead_sponsor": "Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH",
            "conditions": "Gastroesophageal Adenocarcinoma",
            "member_states": "Germany; Spain",
            "decision_date": "23/07/2026",
            "enrolled": "91",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525185-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524282-24-00",
            "title": "A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia",
            "phase": "Phase III",
            "lead_sponsor": "Neurocrine Biosciences Inc.",
            "conditions": "Classic Congenital Adrenal Hyperplasia (CAH)",
            "member_states": "Czechia; Germany; Sweden; Portugal; Romania; Bulgaria; Italy; Austria; Spain",
            "decision_date": "23/07/2026",
            "enrolled": "71",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524282-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525727-24-00",
            "title": "Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.",
            "phase": "Phase III",
            "lead_sponsor": "Chemo Research S.L.",
            "conditions": "No medical condition",
            "member_states": "Sweden; Czechia; Spain; Hungary; Poland; Finland; Romania",
            "decision_date": "23/07/2026",
            "enrolled": "1550",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525727-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522263-14-00",
            "title": "A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "Skyhawk Therapeutics Inc.",
            "conditions": "Huntington\u2019s Disease",
            "member_states": "Germany; Spain",
            "decision_date": "23/07/2026",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522263-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524418-27-00",
            "title": "A  Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC",
            "phase": "Phase I/II",
            "lead_sponsor": "Triana Biomedicines Inc.",
            "conditions": "Advanced ALK-positive NSCLC",
            "member_states": "France; Italy; Germany; Spain",
            "decision_date": "22/07/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524418-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526294-42-00",
            "title": "An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy",
            "phase": "Phase I",
            "lead_sponsor": "Tridem Bioscience FlexCo",
            "conditions": "Parkinson's disease",
            "member_states": "Austria",
            "decision_date": "22/07/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526294-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526804-59-00",
            "title": "Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults \u226560 Years: A Pragmatic Randomized Trial (BronquiVal)",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana",
            "conditions": "Respiratory syncytial virus infection\u2013related respiratory disease",
            "member_states": "Spain",
            "decision_date": "22/07/2026",
            "enrolled": "100000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526804-59-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523435-18-00",
            "title": "Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)",
            "phase": "Phase III",
            "lead_sponsor": "Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International",
            "conditions": "Major cardiovascular events (MACE), spontaneous intracerebral hemorrhage",
            "member_states": "Spain; Belgium",
            "decision_date": "22/07/2026",
            "enrolled": "312",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523435-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525909-13-00",
            "title": "Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?",
            "phase": "Phase IV",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Diabetes",
            "member_states": "Netherlands",
            "decision_date": "22/07/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525909-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525620-23-00",
            "title": "Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)",
            "phase": "Phase II",
            "lead_sponsor": "Vall D Hebron Institute Of Oncology",
            "conditions": "advanced gastric cancer",
            "member_states": "Spain",
            "decision_date": "22/07/2026",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525620-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524359-30-00",
            "title": "Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "lead_sponsor": "Vall D Hebron Institute Of Oncology",
            "conditions": "surgically resectable recurrent high-grade glioma",
            "member_states": "Spain",
            "decision_date": "22/07/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524359-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520666-22-00",
            "title": "A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis",
            "phase": "Phase I/II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Refractory, difficult-to-treat Rheumatoid Arthritis",
            "member_states": "Poland; Italy; Spain; Germany",
            "decision_date": "22/07/2026",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520666-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523933-24-00",
            "title": "A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "type 2 diabetes mellitus",
            "member_states": "Poland; Hungary; Italy; Bulgaria; Germany",
            "decision_date": "22/07/2026",
            "enrolled": "335",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523933-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523390-42-00",
            "title": "A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer\u2019s Disease (DS-AD)",
            "phase": "Phase II",
            "lead_sponsor": "Alnylam Pharmaceuticals Inc.",
            "conditions": "Early-Stage Down Syndrome-Associated Alzheimer\u2019s Disease (DS-AD)",
            "member_states": "Italy; Netherlands; Spain; Germany; Ireland",
            "decision_date": "22/07/2026",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523390-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523067-38-01",
            "title": "Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Advanced Malignant Tumors; High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)",
            "member_states": "Spain; France; Italy",
            "decision_date": "21/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523067-38-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525242-29-00",
            "title": "A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis",
            "phase": "Phase III",
            "lead_sponsor": "Ipsen Bioscience Inc.",
            "conditions": "Primary Sclerosing Cholangitis",
            "member_states": "Spain; Sweden; Germany; Romania; Finland; Portugal; Austria; Italy; Denmark; Czechia; France; Netherlands; Poland; Belgium; Norway",
            "decision_date": "21/07/2026",
            "enrolled": "127",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525242-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525632-41-00",
            "title": "Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) \u2013 VRE-ex",
            "phase": "Phase II",
            "lead_sponsor": "Fraunhofer Institute For Translational Medicine And Pharmacology ITMP",
            "conditions": "Intestinal colonization with vancomycin-resistant enterococci (VRE)",
            "member_states": "Germany",
            "decision_date": "21/07/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525632-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523874-17-00",
            "title": "A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).",
            "phase": "Phase I/II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Neoplasms, Prostate",
            "member_states": "Netherlands; France; Spain",
            "decision_date": "21/07/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523874-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526209-13-00",
            "title": "A more sustainable perioperative treatment regimen for gastroesophageal cancer \u2014replacing 5-FU with capecitabine within the FLOT regimen",
            "phase": "Phase I",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Gastric Cancer, Esophageal cancer",
            "member_states": "Netherlands",
            "decision_date": "21/07/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526209-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522803-60-00",
            "title": "A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)",
            "phase": "Phase II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "newly diagnosed amyloid light chain amyloidosis",
            "member_states": "Italy; Greece; Spain",
            "decision_date": "21/07/2026",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522803-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524336-19-00",
            "title": "A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing \nAntibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens",
            "phase": "Phase III",
            "lead_sponsor": "Gilead Sciences Inc.",
            "conditions": "HIV-1",
            "member_states": "Poland; Italy; France; Spain; Germany; Netherlands",
            "decision_date": "21/07/2026",
            "enrolled": "183",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524336-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524335-39-00",
            "title": "A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Gilead Sciences Inc.",
            "conditions": "HIV-1",
            "member_states": "Netherlands; Poland; Germany; France; Spain; Italy",
            "decision_date": "21/07/2026",
            "enrolled": "183",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524335-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524873-17-00",
            "title": "A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period",
            "phase": "Phase III",
            "lead_sponsor": "Leo Pharma A/S",
            "conditions": "Lichen Sclerosus",
            "member_states": "Italy; France; Spain; Poland; Germany",
            "decision_date": "21/07/2026",
            "enrolled": "205",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524873-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523258-15-00",
            "title": "J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Breast Neoplasms",
            "member_states": "Belgium; France; Italy; Germany",
            "decision_date": "21/07/2026",
            "enrolled": "361",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523258-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524744-36-00",
            "title": "DOXYCYCLINE PENETRATION INTO BONE AND JOINT.",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Caen Normandie",
            "conditions": "Patients requiring total hip arthroplasty for coxofemoral osteoarthritis",
            "member_states": "France",
            "decision_date": "20/07/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524744-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524929-41-00",
            "title": "Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3",
            "phase": "Phase I",
            "lead_sponsor": "Myricx Pharma Limited",
            "conditions": "Advanced Solid Tumor Types Known to Express B7-H3",
            "member_states": "Spain",
            "decision_date": "20/07/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524929-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522144-41-00",
            "title": "Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer",
            "phase": "Phase II",
            "lead_sponsor": "Universitaetsklinikum Tuebingen A\u00f6R",
            "conditions": "biochemical relapse of prostate cancer",
            "member_states": "Germany",
            "decision_date": "20/07/2026",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522144-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524842-89-00",
            "title": "HOVON 180 CLL:   Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)",
            "phase": "Phase II",
            "lead_sponsor": "Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting",
            "conditions": "chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)",
            "member_states": "Netherlands",
            "decision_date": "20/07/2026",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524842-89-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525736-42-00",
            "title": "A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Multiple Myeloma (MM)",
            "member_states": "Germany",
            "decision_date": "20/07/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525736-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523908-75-00",
            "title": "A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)",
            "member_states": "Germany; Italy; Spain; France; Sweden",
            "decision_date": "20/07/2026",
            "enrolled": "158",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523908-75-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524249-29-00",
            "title": "A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Participants with overweight or obesity",
            "member_states": "Sweden; Greece; Hungary; Portugal",
            "decision_date": "20/07/2026",
            "enrolled": "171",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524249-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522227-99-00",
            "title": "A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Huntington\u2019s Disease",
            "member_states": "Norway; Poland; Spain; Sweden; Bulgaria; Netherlands; Finland; Portugal; Austria; Italy; Greece; Ireland; Czechia; France; Romania; Belgium; Germany; Denmark; Slovakia; Hungary",
            "decision_date": "20/07/2026",
            "enrolled": "368",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522227-99-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524711-36-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1",
            "phase": "Phase III",
            "lead_sponsor": "Alkermes Inc.",
            "conditions": "Narcolepsy Type 1",
            "member_states": "Sweden; Finland; Belgium; Spain; Austria; Netherlands; France; Norway; Germany; Italy; Poland",
            "decision_date": "20/07/2026",
            "enrolled": "116",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524711-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525162-21-00",
            "title": "A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.",
            "phase": "Phase II",
            "lead_sponsor": "PannTheraPi",
            "conditions": "Drug resistant seizures associated to Focal Cortical Dysplasia",
            "member_states": "France",
            "decision_date": "20/07/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525162-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523662-24-00",
            "title": "Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)",
            "phase": "Phase III",
            "lead_sponsor": "Arrowhead Pharmaceuticals Inc.",
            "conditions": "Homozygous Familial Hypercholesterolemia (HoFH)",
            "member_states": "Netherlands; Denmark; Norway; Sweden; Poland",
            "decision_date": "20/07/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523662-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524936-20-00",
            "title": "A study comparing the new drugs PG511/PG521/PG531 produced by Celon Pharma SA with the drug PG203 in healthy volunteers.",
            "phase": "Phase I",
            "lead_sponsor": "Celon Pharma S.A.",
            "conditions": "Treatment of psychotic disorders like schizophrenia\nTreatment of levodopa-induced dyskinesia in Parkinson's disease",
            "member_states": "Poland",
            "decision_date": "20/07/2026",
            "enrolled": "68",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524936-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524169-26-00",
            "title": "An open label multicenter phase II study to investigate the efficacy, safety and\ntolerability of the Obe-cel in patients with minimal residual disease (MRD) of\nPhiladelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL",
            "phase": "Phase II",
            "lead_sponsor": "Goethe University Frankfurt",
            "conditions": "Ph-negative CD19 positive B-precursor ALL patients in CR1 with\nmolecular failure defined as MRD of 10-4 or greater after induction II of\nfront-line therapy",
            "member_states": "Germany",
            "decision_date": "20/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524169-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526225-18-00",
            "title": "A phase I/IIa safety, dose finding and feasibility trial of CD30/CEA CART in patients with liver metastases from CEA positive colorectal adenocarcinoma",
            "phase": "Phase I/II",
            "lead_sponsor": "Universitaetsklinikum Regensburg A\u00f6R",
            "conditions": "Colorectal Adenocarcinoma",
            "member_states": "Germany",
            "decision_date": "20/07/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526225-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524576-28-00",
            "title": "Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)",
            "phase": "Phase III",
            "lead_sponsor": "Elpida Therapeutics SPC",
            "conditions": "Hereditary Spastic Paraplegia Type 50 (SPG50)",
            "member_states": "Spain",
            "decision_date": "17/07/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524576-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523840-11-00",
            "title": "SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms",
            "phase": "Phase II",
            "lead_sponsor": "Centre Leon Berard",
            "conditions": "Children with refractory symptoms",
            "member_states": "France",
            "decision_date": "17/07/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523840-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525740-15-00",
            "title": "Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with acute coronary syndrome",
            "phase": "Phase III",
            "lead_sponsor": "Fondazione Per Il Tuo Cuore Onlus Denominabile Anche Fondazione Italiana Per La Lotta Alle Malattie Cardiovascolari Onlus Ed Anche Heart Care Foundation Hcf Onlus",
            "conditions": "Acute Coronary Syndrome",
            "member_states": "Italy",
            "decision_date": "17/07/2026",
            "enrolled": "600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525740-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526224-48-02",
            "title": "Bioequivalence study of Vitamin D3 Pharma Patent 20,000 IU and the Vigantol 20,000 IU oral drops solutions and assessment of bioavailability in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Pharma Patent Kft.",
            "conditions": "Healthy volunteers",
            "member_states": "Hungary",
            "decision_date": "17/07/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526224-48-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526078-18-00",
            "title": "A single center, randomized, controlled trial in healthy volunteers using dermal open flow microperfusion to assess cutaneous BE of two doxepin hydrochloride creams",
            "phase": "Phase I",
            "lead_sponsor": "Medical University Of Graz",
            "conditions": "No medical condition is being investigated in this clinical trial.",
            "member_states": "Austria",
            "decision_date": "17/07/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526078-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524449-28-00",
            "title": "A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes",
            "phase": "Phase I",
            "lead_sponsor": "Immunocore Limited",
            "conditions": "Type 1 Diabetes",
            "member_states": "Austria",
            "decision_date": "17/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524449-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525810-80-00",
            "title": "An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease",
            "phase": "Phase II",
            "lead_sponsor": "Tectonic Operating Company Inc.",
            "conditions": "Pulmonary hypertension secondary to interstitial lung disease",
            "member_states": "Poland; Romania; Spain",
            "decision_date": "17/07/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525810-80-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-527164-32-00",
            "title": "Bioequivalence clinical trial of two formulations of dapagliflozin/metformin",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Alter S.A.",
            "conditions": "Healthy participants",
            "member_states": "Spain",
            "decision_date": "17/07/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-527164-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523617-29-01",
            "title": "Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Oral cavity squamous cell carcinoma",
            "member_states": "Netherlands",
            "decision_date": "17/07/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523617-29-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524599-52-03",
            "title": "Paracervical block with ropivacaine for pain relief in second trimester medical abortion - a double blind placebo controlled randomized trial",
            "phase": "Phase III",
            "lead_sponsor": "Karolinska Institutet",
            "conditions": "abortion",
            "member_states": "Sweden",
            "decision_date": "17/07/2026",
            "enrolled": "132",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524599-52-03",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525972-25-00",
            "title": "FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Febrile male urinary tract infections caused by Escherichia coli",
            "member_states": "France",
            "decision_date": "16/07/2026",
            "enrolled": "312",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525972-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523482-23-00",
            "title": "PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy",
            "phase": "Phase II",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "neoplastic pleural effusion",
            "member_states": "France",
            "decision_date": "16/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523482-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525020-99-00",
            "title": "PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin",
            "phase": "Phase III",
            "lead_sponsor": "University Hospital Of Clermont-Ferrand",
            "conditions": "Breast Cancer",
            "member_states": "France",
            "decision_date": "16/07/2026",
            "enrolled": "1600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525020-99-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524682-24-00",
            "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid",
            "phase": "Phase II",
            "lead_sponsor": "Microbial Resource Management Health",
            "conditions": "Ulcerative Colitis",
            "member_states": "Czechia; Poland; Italy",
            "decision_date": "16/07/2026",
            "enrolled": "109",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524682-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526343-35-00",
            "title": "A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis",
            "phase": "Phase I",
            "lead_sponsor": "Pharmability AB",
            "conditions": "Atopic dermatitis",
            "member_states": "Sweden",
            "decision_date": "16/07/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526343-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525419-16-00",
            "title": "Randomized, observer-blind, placebo-controlled, four Parallel Group, Clinical Trial for exploring the Efficacy and Tolerability of two different strengths ketotifen nasal spray (Ketotifen 0.025 mcg/ml and 0.050 mcg/ml) vs sodium cromoglicate nasal spray 2% in Patients with Rhinitis",
            "phase": "Phase II",
            "lead_sponsor": "Eudemus Pharmaceuticals Limited",
            "conditions": "Rhinitis",
            "member_states": "Greece",
            "decision_date": "16/07/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525419-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519985-35-00",
            "title": "Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial\n(OBLUMEN)",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "systemic lupus erythematosus pure membranous nephropathy",
            "member_states": "France",
            "decision_date": "15/07/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519985-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526122-41-00",
            "title": "COLOVERT \u2013 Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II \u201cpick-the-winner\u201d open-label randomized trial",
            "phase": "Phase II",
            "lead_sponsor": "Uppsala University Hospital",
            "conditions": "Colorectal cancer with peritoneal metastases",
            "member_states": "Sweden",
            "decision_date": "15/07/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526122-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525876-24-00",
            "title": "Phase I/II clinical trial on the use of central nervous system administrations of CART-NKG2D or NKIL15 cells in children, adolescent and young adults with recurrent/refractory high grade Central Nervous System tumours (CINK-CAR)",
            "phase": "Phase I/II",
            "lead_sponsor": "Hospital Universitario La Paz",
            "conditions": "Central nervous system tumours",
            "member_states": "Spain",
            "decision_date": "15/07/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525876-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524463-20-00",
            "title": "The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Asthma",
            "member_states": "Ireland; Spain; Germany; Czechia; Bulgaria; France; Belgium; Romania; Italy",
            "decision_date": "14/07/2026",
            "enrolled": "229",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524463-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522734-31-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke",
            "phase": "Phase II",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Acute Ischemic Stroke",
            "member_states": "Greece; Belgium; France; Germany",
            "decision_date": "14/07/2026",
            "enrolled": "67",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522734-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525917-29-00",
            "title": "Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation - \nThe randomized, controlled, open-label, parallel group TRIPLE-LIPID-OUT trial",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Graz",
            "conditions": "Peripheral arterial disease, Coronary artery atherosclerotic heart disease, Hypercholesterolaemia",
            "member_states": "Germany; Austria",
            "decision_date": "14/07/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525917-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524648-37-00",
            "title": "A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Healthcare KGaA",
            "conditions": "Metastatic colorectal cancer",
            "member_states": "Belgium; Germany; France; Denmark; Poland; Spain; Netherlands; Italy; Austria",
            "decision_date": "14/07/2026",
            "enrolled": "323",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524648-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526961-76-00",
            "title": "FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia",
            "phase": "Phase I/II",
            "lead_sponsor": "Karolinska University Hospital",
            "conditions": "Adults (\u2265 18 years of age) with relapsed or refractory acute myeloid leukemia (R/R AML)",
            "member_states": "Sweden",
            "decision_date": "14/07/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526961-76-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523633-25-00",
            "title": "A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione GONO Plus",
            "conditions": "cutaneous squamous cell carcinoma",
            "member_states": "Italy",
            "decision_date": "14/07/2026",
            "enrolled": "33",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523633-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524448-36-00",
            "title": "A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis",
            "phase": "Phase III",
            "lead_sponsor": "Apellis Pharmaceuticals Inc.",
            "conditions": "Focal segmental glomerulosclerosis (FSGS)",
            "member_states": "France; Portugal; Spain; Slovakia; Italy; Germany; Poland",
            "decision_date": "14/07/2026",
            "enrolled": "97",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524448-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525088-34-00",
            "title": "RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma",
            "phase": "Phase III",
            "lead_sponsor": "Revolution Medicines Inc.",
            "conditions": "Metastatic Pancreatic Adenocarcinoma",
            "member_states": "Poland; Belgium; Norway; Sweden; Austria; Germany; Denmark; Netherlands; France; Italy; Spain",
            "decision_date": "14/07/2026",
            "enrolled": "337",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525088-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524027-49-00",
            "title": "An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (\u00b9\u2077\u2077Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)",
            "phase": "Phase I",
            "lead_sponsor": "Universitaetsklinikum Aachen A\u00f6R",
            "conditions": "Metastatic triple negative breast cancer",
            "member_states": "Germany",
            "decision_date": "14/07/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524027-49-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525682-45-00",
            "title": "Efficacy of oral bicarbonate versus placebo on the risk of assisted delivery in nulliparous women with prolonged labour (ProLabour): protocol fora randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Prolonged labour",
            "member_states": "Denmark",
            "decision_date": "14/07/2026",
            "enrolled": "1520",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525682-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524139-38-00",
            "title": "A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Antibody-mediated Kidney Disease",
            "member_states": "France; Germany; Italy; Belgium; Poland; Spain",
            "decision_date": "13/07/2026",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524139-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517888-23-00",
            "title": "Model-informed precision dosing for linezolid: a randomized clinical trial",
            "phase": "Phase III",
            "lead_sponsor": "University Medical Center Hamburg-Eppendorf",
            "conditions": "Bacterial infection (pneumonia, skin or soft tissue infection) requiring treatment with linezolid in patients in intensive care unit",
            "member_states": "Germany",
            "decision_date": "13/07/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517888-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525096-83-00",
            "title": "Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy with Reduced versus Standard Dose of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (REBEL)",
            "phase": "Phase II",
            "lead_sponsor": "Polish Myeloma Consortium",
            "conditions": "Relapsed/refractory Multiple myeloma",
            "member_states": "Poland",
            "decision_date": "13/07/2026",
            "enrolled": "228",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525096-83-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525105-20-00",
            "title": "A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma",
            "phase": "Phase I/II",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Multiple Myeloma (MM), Multiple Myeloma (MM)",
            "member_states": "Germany; Poland; Czechia; Belgium; France; Greece; Sweden; Portugal; Italy",
            "decision_date": "13/07/2026",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525105-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523725-17-00",
            "title": "Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 \u2013 a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)",
            "phase": "Phase II",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "HIV-1 disease",
            "member_states": "Sweden; Norway; Denmark; Iceland",
            "decision_date": "13/07/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523725-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525282-50-00",
            "title": "A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)",
            "phase": "Phase II",
            "lead_sponsor": "Recursion Pharmaceuticals Inc.",
            "conditions": "Familial Adenomatous Polyposis",
            "member_states": "Netherlands; Germany; Spain",
            "decision_date": "13/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525282-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523293-17-00",
            "title": "SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study",
            "phase": "Phase II",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Cluster headache",
            "member_states": "Netherlands",
            "decision_date": "13/07/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523293-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526292-37-01",
            "title": "Phase IV randomized, single-blind clinical trial with three parallel arms to compare ovulation triggering strategies in IVF cycles with fresh embryo transfer.",
            "phase": "Phase IV",
            "lead_sponsor": "Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA",
            "conditions": "Women with infertility and low ovarian reserve.",
            "member_states": "Spain",
            "decision_date": "13/07/2026",
            "enrolled": "126",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526292-37-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525234-39-00",
            "title": "A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies",
            "phase": "Phase I",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Relapsed or Refractory acute myeloid leukemia, Relapsed or Refractory chronic lymphocytic leukemia, Relapsed or Refractory higher-risk myelodysplastic syndromes, Relapsed or Refractory small lymphocytic lymphoma",
            "member_states": "France; Spain; Germany; Denmark; Belgium",
            "decision_date": "13/07/2026",
            "enrolled": "175",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525234-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524442-10-00",
            "title": "Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)",
            "phase": "Phase II",
            "lead_sponsor": "Goethe University Frankfurt",
            "conditions": "Long-term persistence of SARS-CoV-2",
            "member_states": "Germany; Spain",
            "decision_date": "13/07/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524442-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523092-33-00",
            "title": "Effect of Vitamin D supplementation on MyocardIal Fibrosis in PaTients with Acute Myocarditis (EDIT-AM): a multicenter, open-label, randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Spanish Society Of Cardiology",
            "conditions": "Myocardial fibrosis, Acute myocarditis",
            "member_states": "Spain",
            "decision_date": "10/07/2026",
            "enrolled": "152",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523092-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519123-14-00",
            "title": "A Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 1b Study to Assess the Safety, Immunogenicity and Pharmacodynamics of TRB-001 in Early Idiopathic Parkinson\u2019s Disease Patients",
            "phase": "Phase I",
            "lead_sponsor": "Tridem Bioscience FlexCo",
            "conditions": "Parkinson's disease",
            "member_states": "Austria",
            "decision_date": "10/07/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519123-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525272-25-00",
            "title": "Prospective trial of [18F]AlF-FAPI-74 for PET imaging of fibroblast activation protein in patients with endometriosis",
            "phase": "Phase II",
            "lead_sponsor": "UZ Leuven",
            "conditions": "endometriosis",
            "member_states": "Belgium",
            "decision_date": "10/07/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525272-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526708-56-00",
            "title": "A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Dose-Ranging Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTX611 in Healthy Adult Participants",
            "phase": "Phase I",
            "lead_sponsor": "CRISPR Therapeutics AG",
            "conditions": "Thromboembolic disorders",
            "member_states": "Hungary",
            "decision_date": "10/07/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526708-56-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525808-94-00",
            "title": "EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma",
            "phase": "Phase I/II",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Oncology",
            "member_states": "Denmark",
            "decision_date": "10/07/2026",
            "enrolled": "39",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525808-94-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525569-30-00",
            "title": "A study to learn how a high-fat meal affects the way elinzanetant is taken up by the body in healthy women",
            "phase": "Phase I",
            "lead_sponsor": "Bayer AG",
            "conditions": "Vasomotor symptoms as a sex hormone-dependent disorder in women and men",
            "member_states": "Germany",
            "decision_date": "10/07/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525569-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526444-13-01",
            "title": "Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNissle randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Pohjois-Pohjanmaan hyvinvointialue",
            "conditions": "Urinary tract infection or Pyelonephritis",
            "member_states": "Finland",
            "decision_date": "10/07/2026",
            "enrolled": "250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526444-13-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523923-22-00",
            "title": "A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement",
            "phase": "Phase II",
            "lead_sponsor": "Elevar Therapeutics Inc.",
            "conditions": "Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement",
            "member_states": "France; Spain",
            "decision_date": "09/07/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523923-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522190-11-01",
            "title": "AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia",
            "phase": "Phase III",
            "lead_sponsor": "Universitaetsklinikum Schleswig-Holstein A\u00f6R",
            "conditions": "acute lymphoblastic leukemia in children and adolescents",
            "member_states": "Germany",
            "decision_date": "09/07/2026",
            "enrolled": "2250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522190-11-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526036-38-00",
            "title": "Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma",
            "phase": "Phase II",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Pleural mesothelioma",
            "member_states": "Netherlands",
            "decision_date": "09/07/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526036-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526270-17-00",
            "title": "Early switch to oral antibiotic therapy in vertebral osteomyelitis: a multicentre, open-label, randomised, active control, parallel group, non-inferiority trial (sWITCH-VO)",
            "phase": "Phase IV",
            "lead_sponsor": "University Of Cologne",
            "conditions": "bone and joint infections",
            "member_states": "Germany",
            "decision_date": "09/07/2026",
            "enrolled": "280",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526270-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522939-33-00",
            "title": "Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis.\n\nISA 2 to Master Protocol ARGX-999-2-MG-2000 \u2013 an Exploratory, Phase\u202f2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis",
            "phase": "Phase II",
            "lead_sponsor": "Argenx",
            "conditions": "AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG",
            "member_states": "Greece; Italy; Germany; Belgium; Netherlands; Spain; Poland",
            "decision_date": "08/07/2026",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522939-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525260-18-00",
            "title": "Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Multiple Sclerosis",
            "member_states": "Netherlands",
            "decision_date": "08/07/2026",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525260-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526105-15-00",
            "title": "A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac\u00ae) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.",
            "phase": "Phase III",
            "lead_sponsor": "Probelte Pharma S.L.",
            "conditions": "Allergic rhinitis/rhinoconjunctivitis due to house dust mites exposure",
            "member_states": "Spain",
            "decision_date": "08/07/2026",
            "enrolled": "174",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526105-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514894-22-01",
            "title": "Nasal application of Staphylococcus lugdunensis for decolonization of Staphylococcus aureus \u2013 a first-in-human proof-of-concept microbiome intervention study",
            "phase": "Phase I",
            "lead_sponsor": "Universitaetsklinikum Tuebingen A\u00f6R",
            "conditions": "Persistent or intermitting colonization of the nose with Staphylococcus aureus",
            "member_states": "Germany",
            "decision_date": "08/07/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514894-22-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-505575-69-01",
            "title": "Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)",
            "phase": "Phase III",
            "lead_sponsor": "Institut Gustave Roussy",
            "conditions": "Osteosarcoma",
            "member_states": "Sweden; Poland; Denmark; Finland; Netherlands; Italy; France; Spain",
            "decision_date": "08/07/2026",
            "enrolled": "508",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-505575-69-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523503-30-00",
            "title": "A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy",
            "phase": "Phase II",
            "lead_sponsor": "Eisai Limited",
            "conditions": "Narcolepsy",
            "member_states": "Belgium; Italy; Spain; Germany",
            "decision_date": "08/07/2026",
            "enrolled": "51",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523503-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524967-19-00",
            "title": "HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)",
            "phase": "Phase II",
            "lead_sponsor": "Alnylam Pharmaceuticals Inc.",
            "conditions": "Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)",
            "member_states": "Netherlands; Sweden; Germany",
            "decision_date": "08/07/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524967-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526307-30-00",
            "title": "A study to compare how 2 different formulations of survodutide are taken up in the body when given by injection in healthy men and women with and without overweight or obesity",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy",
            "member_states": "Germany",
            "decision_date": "08/07/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526307-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526237-26-00",
            "title": "A Trial to Evaluate the Safety and Drug Levels of Single and Multiple Oral Doses of AT-587 in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Atea Pharmaceuticals Inc.",
            "conditions": "Chronic hepatitis E virus (HEV) infection",
            "member_states": "Belgium",
            "decision_date": "07/07/2026",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526237-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522686-29-00",
            "title": "A clinical trial comparing how the body takes up budesonide from different forms of medicine when taken by mouth with or without food.",
            "phase": "Phase I",
            "lead_sponsor": "Dr. Falk Pharma GmbH",
            "conditions": "Acute eosinophilic esophagitis",
            "member_states": "Sweden",
            "decision_date": "07/07/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522686-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526168-19-00",
            "title": "Phase I Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine",
            "phase": "Phase I",
            "lead_sponsor": "LimmaTech Biologics AG",
            "conditions": "Gonorrhea",
            "member_states": "Germany",
            "decision_date": "07/07/2026",
            "enrolled": "142",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526168-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524285-18-00",
            "title": "A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion",
            "phase": "Phase II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion",
            "member_states": "Belgium; Ireland; Germany; Norway; Italy; France; Spain",
            "decision_date": "07/07/2026",
            "enrolled": "123",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524285-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522165-30-00",
            "title": "An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C\u202fin Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",
            "phase": "Phase III",
            "lead_sponsor": "Grifols Therapeutics LLC",
            "conditions": "Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)",
            "member_states": "Romania; Czechia; Poland",
            "decision_date": "07/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522165-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525594-39-00",
            "title": "Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa\u00ae (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults.\n(FAST 7)",
            "phase": "Phase III",
            "lead_sponsor": "Ntc S.r.l.",
            "conditions": "Cataract",
            "member_states": "Spain; Poland; Greece; Sweden; Italy",
            "decision_date": "07/07/2026",
            "enrolled": "536",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525594-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521887-37-00",
            "title": "A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Ovarian Neoplasms\nBreast Neoplasms\nPancreatic Intraductal Neoplasms\nColorectal Neoplasms\nEsophageal Neoplasms\nStomach Neoplasms\nCholangiocarcinoma",
            "member_states": "Germany; Netherlands",
            "decision_date": "07/07/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521887-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509074-31-00",
            "title": "A PHASE 1/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFECTS ON CLINICAL OUTCOMES OF PEGTIBATINASE\u202f(TVT-058) ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH CYSTATHIONINE BETASYNTHASE-DEFICIENT HOMOCYSTINURIA (COMPOSE)",
            "phase": "Phase I/II",
            "lead_sponsor": "Travere Therapeutics Switzerland GmbH, Travere Therapeutics Inc.",
            "conditions": "Classical Homocystinuria",
            "member_states": "France",
            "decision_date": "07/07/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509074-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524717-86-00",
            "title": "C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NA\u00cfVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA",
            "member_states": "France; Spain; Italy",
            "decision_date": "07/07/2026",
            "enrolled": "91",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524717-86-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523369-32-00",
            "title": "A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Fibrosing interstitial lung disease",
            "member_states": "Belgium; Greece; Germany; France; Finland; Spain; Czechia; Poland; Italy; Netherlands; Denmark; Portugal",
            "decision_date": "07/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523369-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524028-23-00",
            "title": "A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Multiple Myeloma",
            "member_states": "France; Germany; Italy; Greece; Denmark; Czechia; Spain; Poland",
            "decision_date": "07/07/2026",
            "enrolled": "133",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524028-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522563-15-00",
            "title": "Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Metastatic Pancreatic Ductal Adenocarcinoma; PDAC",
            "member_states": "Portugal; Spain; France; Italy; Germany; Austria",
            "decision_date": "06/07/2026",
            "enrolled": "194",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522563-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524213-84-00",
            "title": "TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer",
            "phase": "Phase III",
            "lead_sponsor": "Unicancer",
            "conditions": "Patients with advanced or metastatic ER+ HER2- breast cancer",
            "member_states": "France",
            "decision_date": "06/07/2026",
            "enrolled": "526",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524213-84-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521493-33-00",
            "title": "Macroleave: Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Intercommunal Creteil",
            "conditions": "bronchiectasis unrelated to cystic fibrosis",
            "member_states": "France",
            "decision_date": "06/07/2026",
            "enrolled": "185",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521493-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524374-42-00",
            "title": "Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial\nRSVaxID",
            "phase": "Phase II",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "allogeneic haematopoietic stem cell transplant recipient, lung transplant",
            "member_states": "France",
            "decision_date": "06/07/2026",
            "enrolled": "400",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524374-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520783-17-01",
            "title": "Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 \u2014 ALACARTE trial)",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Adult patients diagnosed with uncomplicated acute appendicitis",
            "member_states": "France",
            "decision_date": "06/07/2026",
            "enrolled": "560",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520783-17-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-510793-24-00",
            "title": "Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "suspected malignant pulmonary disease (lung lesions and/or lymph nodes suspicious for lung cancer)",
            "member_states": "Netherlands",
            "decision_date": "06/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-510793-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525790-39-00",
            "title": "A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.",
            "phase": "Phase I",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Tuberculosis",
            "member_states": "Spain",
            "decision_date": "06/07/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525790-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526581-24-01",
            "title": "Oral versus Intravenous Tranexamic Acid for Blood Loss Prevention in Off-Pump Coronary Artery Bypass Surgery: A\nRandomised Non-Inferiority Trial (TRANSCAB Study)",
            "phase": "Phase IV",
            "lead_sponsor": "Sante et Prevoyance",
            "conditions": "Coronary artery disease requiring off-pump coronary artery bypass surgery (OPCAB)",
            "member_states": "Belgium",
            "decision_date": "06/07/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526581-24-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518016-39-00",
            "title": "A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Respiratory tract diseases",
            "member_states": "Denmark; Sweden; Poland; Estonia; Portugal; Latvia; Spain; Hungary; Germany; Finland; Italy; Belgium; France",
            "decision_date": "06/07/2026",
            "enrolled": "613",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518016-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518213-25-00",
            "title": "A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Respiratory tract diseases",
            "member_states": "Germany; Romania; Greece; Norway; Netherlands; Poland; Lithuania; Czechia; Slovakia; Spain",
            "decision_date": "06/07/2026",
            "enrolled": "550",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518213-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517189-40-00",
            "title": "A Phase 1 Study of TORL-1-23 in Advanced Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Torl Biotherapeutics LLC",
            "conditions": "Advanced Cancer",
            "member_states": "Ireland",
            "decision_date": "06/07/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517189-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521506-17-01",
            "title": "iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Medisch Centrum Utrecht",
            "conditions": "Hypoxic-ischemic brain injury (HIBI) because of Perinatal Asphyxia (PA) or Perinatal arterial ischemic stroke (PAIS)",
            "member_states": "Netherlands",
            "decision_date": "06/07/2026",
            "enrolled": "162",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521506-17-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525809-13-00",
            "title": "Efficacy, Safety, and Patient Satisfaction of Patient-Controlled Remimazolam Sedation in Outpatient Colonoscopy: A randomized controlled trial.",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "The trial will study sedation related to colonoscopy, therefore the trial is not concerned with the underlaying medical condition leading to the colonoscopy.",
            "member_states": "Denmark",
            "decision_date": "06/07/2026",
            "enrolled": "1",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525809-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525442-30-00",
            "title": "The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease",
            "phase": "Phase III",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Ischemic heart disease/Chronic coronary syndrome (Myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting)",
            "member_states": "Denmark",
            "decision_date": "06/07/2026",
            "enrolled": "7000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525442-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525221-21-01",
            "title": "Optimising Arthritis Strategies in Elderly patients (\u226570 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference",
            "phase": "Phase IV",
            "lead_sponsor": "Aalborg University Hospital, Aalborg University Hospital",
            "conditions": "Rheumatoid arthritis",
            "member_states": "Denmark",
            "decision_date": "06/07/2026",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525221-21-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525629-20-00",
            "title": "A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Larkspur Biosciences Inc.",
            "conditions": "Solid tumors",
            "member_states": "France",
            "decision_date": "03/07/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525629-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525844-14-00",
            "title": "Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "End-Stage Kidney Disease (ESKD)",
            "member_states": "Belgium",
            "decision_date": "03/07/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525844-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522961-31-01",
            "title": "The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)",
            "phase": "Phase II",
            "lead_sponsor": "Kobenhavns Universitet, Koebenhavns Universitet",
            "conditions": "Depression",
            "member_states": "Denmark",
            "decision_date": "03/07/2026",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522961-31-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522453-20-00",
            "title": "Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients",
            "phase": "Phase II",
            "lead_sponsor": "Oslo University Hospital HF",
            "conditions": "Acute lymphoblastic leukemia and lymphoma",
            "member_states": "Norway",
            "decision_date": "03/07/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522453-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524755-31-00",
            "title": "Dual-agent fluorescence-guided surgery for colorectal liver metastases",
            "phase": "Phase III",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Colorectal liver metastases",
            "member_states": "Netherlands",
            "decision_date": "03/07/2026",
            "enrolled": "39",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524755-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520319-42-01",
            "title": "A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder",
            "phase": "Phase II",
            "lead_sponsor": "Ostfold Hospital Trust",
            "conditions": "Major Depressive Disorder",
            "member_states": "Norway",
            "decision_date": "03/07/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520319-42-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526388-39-00",
            "title": "Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial",
            "phase": "Phase I",
            "lead_sponsor": "Region Sjaelland",
            "conditions": "Bladder cancer, Bladder tumors, Urothelial cancer, Urothelial tumors",
            "member_states": "Denmark",
            "decision_date": "03/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526388-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517799-40-00",
            "title": "A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024",
            "phase": "Phase II",
            "lead_sponsor": "G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica",
            "conditions": "Advanced squamous non-small cell lung cancer",
            "member_states": "Italy",
            "decision_date": "03/07/2026",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517799-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523921-17-00",
            "title": "Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Regional Et Universitaire De Brest",
            "conditions": "myeloproliferative neoplasms",
            "member_states": "France",
            "decision_date": "02/07/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523921-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523829-17-00",
            "title": "18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Lille",
            "conditions": "Patients (male or female) \u226518 years old with Suspected functional pituitary adenoma (prolactinoma, Cushing's disease, acromegaly, thyrotropic adenoma), de novo or recurrence/persistence, With indeterminate pituitary MRI.",
            "member_states": "France",
            "decision_date": "02/07/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523829-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526840-10-00",
            "title": "Bioequivalence Study of Dapagliflozin 10 mg",
            "phase": "Phase I",
            "lead_sponsor": "Vipharm S.A.",
            "conditions": "Not applicable (submitted trial is a BE study in healthy participants)",
            "member_states": "Czechia",
            "decision_date": "02/07/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526840-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522801-39-00",
            "title": "IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer",
            "phase": "Phase II",
            "lead_sponsor": "Intergroupe Francophone De Cancerologie Thoracique",
            "conditions": "Stage III Non Small Cell Lung Cancer",
            "member_states": "France",
            "decision_date": "02/07/2026",
            "enrolled": "177",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522801-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-507214-28-00",
            "title": "Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial",
            "phase": "Phase I",
            "lead_sponsor": "Stichting Radboud University Medical Center",
            "conditions": "Advanced thyroid cancer",
            "member_states": "Netherlands",
            "decision_date": "02/07/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-507214-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521929-32-01",
            "title": "AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)",
            "phase": "Phase III",
            "lead_sponsor": "University Of Oxford",
            "conditions": "First Episode Psychosis (FEP)",
            "member_states": "Netherlands; Greece; Germany; Italy; Austria; Spain",
            "decision_date": "01/07/2026",
            "enrolled": "156",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521929-32-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523438-24-00",
            "title": "A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Ideaya Biosciences Inc.",
            "conditions": "DLL3 Expressing Tumors Including Small Cell Lung Cancer",
            "member_states": "France; Spain",
            "decision_date": "01/07/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523438-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523815-12-00",
            "title": "\"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with\nRelapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an\nAnti-CD38 Antibody and Lenalidomide\"",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Relapsed or Refractory Multiple Myeloma",
            "member_states": "Poland; Spain; Czechia; France; Italy; Germany; Greece",
            "decision_date": "01/07/2026",
            "enrolled": "206",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523815-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523858-13-01",
            "title": "High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.",
            "phase": "Phase II",
            "lead_sponsor": "Oslo Universitetssykehus HF",
            "conditions": "Non-toxic acute cardiogenic shock",
            "member_states": "Norway",
            "decision_date": "01/07/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523858-13-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525220-15-00",
            "title": "A phase 1b trial to study the safety and effect of ZP9830 in patients with plaque psoriasis",
            "phase": "Phase I",
            "lead_sponsor": "Zealand Pharma A/S",
            "conditions": "Plaque Psoriasis",
            "member_states": "Netherlands",
            "decision_date": "01/07/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525220-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525421-20-00",
            "title": "An open label, balanced, randomized, single dose, two-treatment, two period, two-sequence, crossover, bioequivalence study comparing Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablet 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D\u00ae 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fed conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "Seasonal allergic rhinitis",
            "member_states": "Romania",
            "decision_date": "01/07/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525421-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525420-22-00",
            "title": "An open label, balanced, randomized, single dose, two-treatment, four period, two-sequence, crossover, fully replicate, bioequivalence study comparing Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablet USP 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D\u00ae 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "Seasonal allergic rhinitis",
            "member_states": "Romania",
            "decision_date": "01/07/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525420-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525987-16-00",
            "title": "The headache- and migraine-inducing effects of apremilast in women with migraine without aura",
            "phase": "Phase I/II",
            "lead_sponsor": "Syddansk Universitet (University of Southern Denmark)",
            "conditions": "Migraine without aura",
            "member_states": "Denmark",
            "decision_date": "01/07/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525987-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524914-26-00",
            "title": "A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose\u2011ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Asthma",
            "member_states": "Czechia; Poland; Hungary",
            "decision_date": "01/07/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524914-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523127-21-00",
            "title": "A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis",
            "phase": "Phase I",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Rheumatoid Arthritis",
            "member_states": "Belgium; Netherlands; Spain; Germany; Italy",
            "decision_date": "01/07/2026",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523127-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525549-60-00",
            "title": "A study in healthy men to find out how blocking certain transport proteins affects the amount of BI 3000202 in the blood",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy",
            "member_states": "Germany",
            "decision_date": "01/07/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525549-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522167-15-00",
            "title": "A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)",
            "phase": "Phase III",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)",
            "member_states": "Finland; Belgium; Hungary; France; Denmark; Austria; Germany; Italy; Spain; Czechia; Norway; Poland",
            "decision_date": "01/07/2026",
            "enrolled": "257",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522167-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526334-67-00",
            "title": "C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "chronic weight management and other weight-related co-morbidities",
            "member_states": "Belgium",
            "decision_date": "01/07/2026",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526334-67-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523949-10-00",
            "title": "A study in healthy men to test how BI 1815368 is processed in the body",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteers trial",
            "member_states": "Netherlands",
            "decision_date": "30/06/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523949-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525747-33-00",
            "title": "Progesterone Luteal Support in Unexplained Infertility Management (PLUIM study)",
            "phase": "Phase IV",
            "lead_sponsor": "Universitair Medisch Centrum Utrecht",
            "conditions": "unexplained subfertillity, infertillity",
            "member_states": "Netherlands",
            "decision_date": "30/06/2026",
            "enrolled": "640",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525747-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524775-23-00",
            "title": "Evaluation of bioequivalence of two products containing estradiol: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA 0.1% gel (Comparator). An open, randomized, single-dose, four-period, full-replicative trial in healthy postmenopausal women",
            "phase": "Phase I",
            "lead_sponsor": "CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.",
            "conditions": "No therapeutic indication in the current trial with healthy volunteers.",
            "member_states": "Bulgaria",
            "decision_date": "30/06/2026",
            "enrolled": "140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524775-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522723-98-00",
            "title": "A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs",
            "phase": "Phase I/II",
            "lead_sponsor": "Krystal Biotech Inc.",
            "conditions": "solid tumor",
            "member_states": "France; Spain",
            "decision_date": "30/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522723-98-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508533-14-00",
            "title": "Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Eosinophilic Disease",
            "member_states": "Poland; Netherlands; France",
            "decision_date": "30/06/2026",
            "enrolled": "7",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508533-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525566-21-00",
            "title": "A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)",
            "phase": "Phase II",
            "lead_sponsor": "Theriva Biologics S.L.",
            "conditions": "metastatic pancreatic adecarcinoma",
            "member_states": "Spain",
            "decision_date": "30/06/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525566-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521971-29-00",
            "title": "A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection",
            "phase": "Phase III",
            "lead_sponsor": "Nuvation Bio Inc.",
            "conditions": "Non Small Cell Lung Cancer (NSCLC)",
            "member_states": "Spain; Belgium; France; Italy; Germany",
            "decision_date": "30/06/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521971-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521769-29-00",
            "title": "A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease",
            "phase": "Phase III",
            "lead_sponsor": "Insmed Inc.",
            "conditions": "Pulmonary Hypertension Associated with Interstitial Lung Disease",
            "member_states": "Greece; France; Italy; Belgium; Denmark; Germany; Poland; Czechia; Portugal; Austria; Spain; Romania",
            "decision_date": "30/06/2026",
            "enrolled": "165",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521769-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523835-20-00",
            "title": "Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome",
            "phase": "Phase I/II",
            "lead_sponsor": "Ionis Pharmaceuticals Inc.",
            "conditions": "Dravet Syndrome",
            "member_states": "Spain; France; Belgium; Portugal; Germany",
            "decision_date": "30/06/2026",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523835-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526022-41-00",
            "title": "A double-blind, prospective, randomised, placebo-controlled, single-centre, proof-of-principle trial in healthy volunteers to investigate safety, local tolerability, pharmacokinetics, and pharmacodynamics of Asacaine after topical administration on skin exposed to ultraviolet B radiation",
            "phase": "Phase I",
            "lead_sponsor": "Auxesis Pharma Holding AB (publ)",
            "conditions": "Topical pain",
            "member_states": "Sweden",
            "decision_date": "30/06/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526022-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526149-91-00",
            "title": "Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci",
            "phase": "Phase III",
            "lead_sponsor": "Friedrich-Schiller-Universitaet Jena",
            "conditions": "Infectious endocarditis caused by Gram-positive cocci (staphylococci,\nenterococci, streptococci)",
            "member_states": "Germany",
            "decision_date": "30/06/2026",
            "enrolled": "166",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526149-91-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524397-42-00",
            "title": "A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma",
            "phase": "Phase III",
            "lead_sponsor": "Renaissance Pharma Limited",
            "conditions": "Participants with relapsed HRNB and participants \nwith HRNB refractory to treatment\n\nThe clinical trial will recruit participants aged \u226518 months to <18 years, and therefore all participants will be minors at the time of consent.",
            "member_states": "France; Spain; Denmark; Ireland; Germany",
            "decision_date": "30/06/2026",
            "enrolled": "111",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524397-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523778-17-00",
            "title": "A study to compare how the body absorbs 4 different forms of norucholic acid medicine (tablets, granules, and capsules) when taken with or without food in healthy adults",
            "phase": "Phase I",
            "lead_sponsor": "Dr. Falk Pharma GmbH",
            "conditions": "Not applicable, healthy volunteers",
            "member_states": "Germany",
            "decision_date": "30/06/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523778-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525830-49-00",
            "title": "A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Allinky Biopharma S.L.",
            "conditions": "Treatment of several inflammatory diseases, including inflammation-related fibrosis and autoinflammatory diseases",
            "member_states": "Spain",
            "decision_date": "29/06/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525830-49-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524855-30-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care",
            "phase": "Phase III",
            "lead_sponsor": "Merck Healthcare KGaA",
            "conditions": "Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease",
            "member_states": "Germany; Romania; France; Bulgaria; Belgium; Spain; Poland; Greece; Italy; Czechia",
            "decision_date": "29/06/2026",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524855-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523871-44-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care",
            "phase": "Phase III",
            "lead_sponsor": "Merck Healthcare KGaA",
            "conditions": "Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease",
            "member_states": "Spain; Belgium; France; Germany; Slovakia; Romania; Bulgaria; Italy; Poland; Greece",
            "decision_date": "29/06/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523871-44-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521712-19-00",
            "title": "AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Colorectal Cancer",
            "member_states": "Greece; Portugal; Germany; Belgium; Spain",
            "decision_date": "29/06/2026",
            "enrolled": "243",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521712-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525001-21-00",
            "title": "Methoxyflurane versus Standard Care for Non-Traumatic Pain in the Emergency Department (PAIN-THROX) : A Multicenter, Randomized, Controlled, Superiority Trial",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire De Tours",
            "conditions": "Non-traumatic pain",
            "member_states": "France",
            "decision_date": "29/06/2026",
            "enrolled": "164",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525001-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524686-24-00",
            "title": "C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Small Cell Lung Cancer",
            "member_states": "France; Italy; Spain",
            "decision_date": "29/06/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524686-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524148-36-00",
            "title": "Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA",
            "phase": "Phase II",
            "lead_sponsor": "Institut National De La Sante Et De La Recherche Medicale",
            "conditions": "Alcoholism",
            "member_states": "France",
            "decision_date": "29/06/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524148-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525500-10-00",
            "title": "ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)",
            "phase": "Phase IV",
            "lead_sponsor": "Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre",
            "conditions": "Obstructive sleep apnea syndrome, Obesity",
            "member_states": "Spain",
            "decision_date": "29/06/2026",
            "enrolled": "345",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525500-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523599-21-00",
            "title": "A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Non-small Cell Lung Cancer",
            "member_states": "Spain; Germany",
            "decision_date": "29/06/2026",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523599-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524791-30-00",
            "title": "PET imaging\u202fFor eaRly predictiOn of respoNse to neoadjuvanT\u202ftReatment in lUNg caNcER",
            "phase": "Phase I/II",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Non small cell lung cancer",
            "member_states": "Netherlands; Germany",
            "decision_date": "29/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524791-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524623-50-00",
            "title": "A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Revolution Medicines Inc.",
            "conditions": "Solid Tumors",
            "member_states": "France; Poland; Ireland; Spain; Greece; Germany; Italy; Sweden; Belgium",
            "decision_date": "29/06/2026",
            "enrolled": "252",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524623-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525058-20-00",
            "title": "CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL",
            "phase": "Phase III",
            "lead_sponsor": "Elliniko Institouto Meletis Tis Sipsis",
            "conditions": "Community- acquired pneumonia related sepsis with evidence of Sepsis Induced Immunoparalysis SII",
            "member_states": "Greece",
            "decision_date": "29/06/2026",
            "enrolled": "252",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525058-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525834-45-00",
            "title": "LAFOV-Lung PET",
            "phase": "Phase I",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "Investigation in healthy volunteers",
            "member_states": "Austria",
            "decision_date": "29/06/2026",
            "enrolled": "41",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525834-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523288-39-00",
            "title": "A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)",
            "phase": "Phase II",
            "lead_sponsor": "Mediar Therapeutics Inc.",
            "conditions": "Diffuse Cutaneous Systemic Sclerosis (dcSSc)",
            "member_states": "Netherlands; Romania; Poland; France; Italy; Spain",
            "decision_date": "29/06/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523288-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524299-44-00",
            "title": "First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor",
            "phase": "Phase I",
            "lead_sponsor": "Ygion Biomedical GmbH",
            "conditions": "Glioblastoma",
            "member_states": "Austria",
            "decision_date": "29/06/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524299-44-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525531-16-00",
            "title": "A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Hamlet BioPharma AB",
            "conditions": "Non-Muscle Invasive Papillary Bladder Cancer",
            "member_states": "Czechia",
            "decision_date": "29/06/2026",
            "enrolled": "169",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525531-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526314-90-00",
            "title": "Unprescribing the Pill to Reassess Symptom and Cognitive Recovery in Depression (UNPRESCRIB-D)",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Major Depressive Disorder",
            "member_states": "Denmark",
            "decision_date": "29/06/2026",
            "enrolled": "106",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526314-90-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524955-30-01",
            "title": "Self-Assessment Method for Statin side-effects Or Nocebo 2",
            "phase": "Phase III",
            "lead_sponsor": "Copenhagen University Hospital, Region Hovedstaden",
            "conditions": "Cardiovascular diseases",
            "member_states": "Denmark",
            "decision_date": "28/06/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524955-30-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525009-18-00",
            "title": "A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)",
            "phase": "Phase III",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Pancreatic Ductal Adenocarcinoma",
            "member_states": "Poland; Italy; Netherlands; Sweden; Denmark; Finland; Spain; France; Germany; Belgium; Norway; Austria",
            "decision_date": "26/06/2026",
            "enrolled": "239",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525009-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513987-24-00",
            "title": "A Phase 1 Study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Metastatic Castration-resistant Prostate Cancer",
            "member_states": "France",
            "decision_date": "26/06/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513987-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525121-13-00",
            "title": "Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF).",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Coronary artery disease, Atrial fibrillation",
            "member_states": "Belgium",
            "decision_date": "26/06/2026",
            "enrolled": "988",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525121-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526113-28-00",
            "title": "Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.",
            "phase": "Phase IV",
            "lead_sponsor": "Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.",
            "conditions": "Advanced thyroid carcinoma.\nPost-thyroidectomy hypothyroidism.",
            "member_states": "Italy",
            "decision_date": "26/06/2026",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526113-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524019-35-00",
            "title": "Three-part PK and PD study of AXN-027",
            "phase": "Phase I",
            "lead_sponsor": "Axonis Therapeutics Inc.",
            "conditions": "Chronic pain, refractory epilepsy, and other neurological disorders of excitation/inhibition (E/I) imbalance within neuronal circuits.",
            "member_states": "Netherlands",
            "decision_date": "26/06/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524019-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524722-17-00",
            "title": "Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy",
            "phase": "Phase IV",
            "lead_sponsor": "Region Skane",
            "conditions": "Obstructive Hypertrophic Cardiomyopathy",
            "member_states": "Sweden",
            "decision_date": "26/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524722-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525628-13-00",
            "title": "\u201cIn vivo\u201d biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.",
            "phase": "Phase II",
            "lead_sponsor": "Probelte Pharma S.L.",
            "conditions": "IgE-mediated respiratory allergic disease due to the allergen whose extract is to be standardized, DPT and DF.",
            "member_states": "Spain",
            "decision_date": "26/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525628-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519299-16-00",
            "title": "A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants with Solid and Hematologic Cancers (ROXI-CAT-II)",
            "phase": "Phase III",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Cancer Associated Thrombosis",
            "member_states": "Bulgaria; Romania",
            "decision_date": "26/06/2026",
            "enrolled": "164",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519299-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525269-34-00",
            "title": "Skin irritation and sensitization trial",
            "phase": "Phase I",
            "lead_sponsor": "CCDRD Cooperative Clinical Drug Research and Development AG, Corium Innovations Inc.",
            "conditions": "The intended indication is for the treatment of major depressive disorder.",
            "member_states": "Bulgaria",
            "decision_date": "26/06/2026",
            "enrolled": "230",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525269-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516033-12-00",
            "title": "Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial",
            "phase": "Phase III",
            "lead_sponsor": "Universitaetsspital Basel",
            "conditions": "Atrial Fibrillation",
            "member_states": "Germany",
            "decision_date": "26/06/2026",
            "enrolled": "1",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516033-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524795-35-00",
            "title": "Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice",
            "phase": "Phase IV",
            "lead_sponsor": "Uniwersytet Medyczny W Lublinie",
            "conditions": "Adult with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)",
            "member_states": "Poland",
            "decision_date": "26/06/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524795-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524312-11-00",
            "title": "Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) \u2013 a randomized, prospective, multicenter, open-label, controlled phase III trial",
            "phase": "Phase III",
            "lead_sponsor": "Medizinische Hochschule Hannover",
            "conditions": "Patients after the first year following liver transplantation",
            "member_states": "Germany",
            "decision_date": "26/06/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524312-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525658-13-00",
            "title": "A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Haematological diseases; any disorder that primarily affects the blood, bone marrow, the lymphatic system and/or blood-forming organs.",
            "member_states": "Denmark",
            "decision_date": "25/06/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525658-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526465-18-00",
            "title": "Evaluating the effect of inhaled levodopa (Inbrija\u00ae) for early morning off in Parkinson\u2019s disease",
            "phase": "Phase III",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "parkinson's disease",
            "member_states": "Denmark",
            "decision_date": "25/06/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526465-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525621-20-00",
            "title": "A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease",
            "phase": "Phase I",
            "lead_sponsor": "Oblenio Bio Inc.",
            "conditions": "B-cell\u2013mediated autoimmune diseases",
            "member_states": "Germany; Romania",
            "decision_date": "25/06/2026",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525621-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524746-96-00",
            "title": "Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis",
            "phase": "Phase I",
            "lead_sponsor": "Jade Biosciences Inc.",
            "conditions": "Rheumatoid Arthritis",
            "member_states": "Romania; Bulgaria; Germany",
            "decision_date": "25/06/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524746-96-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525008-12-00",
            "title": "An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration",
            "phase": "Phase II",
            "lead_sponsor": "PulseSight Therapeutics",
            "conditions": "Geographic atrophy secondary to age-related macular degeneration",
            "member_states": "France",
            "decision_date": "25/06/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525008-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525181-22-00",
            "title": "ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "prostate cancer",
            "member_states": "France",
            "decision_date": "25/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525181-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523726-40-00",
            "title": "A PHASE III, OPEN-LABEL, SINGLE-ARM,  MULTI-CENTER STUDY TO EVALUATE THE  SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME  ADMINISTRATION OF OCRELIZUMAB IN  PATIENTS WITH MULTIPLE SCLEROSIS",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Multiple Sclerosis",
            "member_states": "Spain; France; Poland; Italy",
            "decision_date": "24/06/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523726-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525838-32-00",
            "title": "Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial",
            "phase": "Phase IV",
            "lead_sponsor": "Region Skane",
            "conditions": "Serious, chronic, life-limiting disease",
            "member_states": "Sweden",
            "decision_date": "24/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525838-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523107-30-01",
            "title": "Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "Post-traumatic stress disorder (PTSD)",
            "member_states": "France",
            "decision_date": "24/06/2026",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523107-30-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525978-19-00",
            "title": "A single and multiple dose trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of ZP6590",
            "phase": "Phase I",
            "lead_sponsor": "Zealand Pharma A/S",
            "conditions": "Weight management",
            "member_states": "Germany",
            "decision_date": "24/06/2026",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525978-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526434-21-00",
            "title": "Systemic Bioavailability and Bioequivalence of Topical Diclofenac Fysioline 23.2 mg/g gel compared with Diclofenac Diethylamine - Voltaren Forte 2.32% gel",
            "phase": "Phase I",
            "lead_sponsor": "Fysioline Oy",
            "conditions": "Bioequivalence, musculoskeletal pain pain",
            "member_states": "Finland",
            "decision_date": "24/06/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526434-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523305-15-00",
            "title": "THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom",
            "phase": "Phase I",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Patients  affected by IPEX syndrome, proven by molecular\ndiagnosis, with any active autoimmune complications or controlled under\nimmunosuppressive therapy can be enrolled in this trial., IPEX syndrome is a primary immunodeficiency caused by hemizygous mutations in the gene FOXP3, which encodes an essential transcription factor required to maintain immunological tolerance by thymus-derived regulatory T (Treg) cells.",
            "member_states": "France",
            "decision_date": "24/06/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523305-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526167-38-00",
            "title": "ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis",
            "phase": "Phase III",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "liver cirrhosis",
            "member_states": "Netherlands",
            "decision_date": "23/06/2026",
            "enrolled": "634",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526167-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524761-25-00",
            "title": "The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Santiago Dexeus Font Fundacio Privada",
            "conditions": "infertility",
            "member_states": "Spain",
            "decision_date": "23/06/2026",
            "enrolled": "240",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524761-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523403-29-00",
            "title": "A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).",
            "phase": "Phase II",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Non-cystic fibrosis bronchiectasis",
            "member_states": "Poland; Spain; France; Netherlands; Germany",
            "decision_date": "23/06/2026",
            "enrolled": "41",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523403-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523832-38-00",
            "title": "Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone",
            "phase": "Phase III",
            "lead_sponsor": "Schneider Children's Medical Center Of Israel",
            "conditions": "Small for gestational age (SGA) and idiopathic short stature (ISS)",
            "member_states": "Greece; Poland; France; Czechia",
            "decision_date": "23/06/2026",
            "enrolled": "95",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523832-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525766-21-01",
            "title": "USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.",
            "phase": "Phase IV",
            "lead_sponsor": "Hospital Universitario Rio Hortega",
            "conditions": "Hypoxemic episodes in patients undergoing gastroscopy, colonoscopy, or oral endoscopic ultrasound under deep sedation with oxygen therapy administration.",
            "member_states": "Spain",
            "decision_date": "23/06/2026",
            "enrolled": "326",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525766-21-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524976-40-00",
            "title": "ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospital Region Metz Thionville",
            "conditions": "patients with influenza-induced acute hypoxemic respiratory failure",
            "member_states": "France",
            "decision_date": "23/06/2026",
            "enrolled": "544",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524976-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524164-37-00",
            "title": "An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Relapsing-Remitting Multiple Sclerosis (RRMS)",
            "member_states": "Poland; Germany; France",
            "decision_date": "23/06/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524164-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524481-15-00",
            "title": "A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).",
            "phase": "Phase II",
            "lead_sponsor": "Rigshospitalet, Elpida Therapeutics SPC",
            "conditions": "Heriditary spastic paraplegia (SPG50)",
            "member_states": "Denmark",
            "decision_date": "23/06/2026",
            "enrolled": "2",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524481-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525611-13-00",
            "title": "Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial",
            "phase": "Phase IV",
            "lead_sponsor": "Oslo Universitetssykehus HF",
            "conditions": "Juvenil Idiopatic Arthritis",
            "member_states": "Norway",
            "decision_date": "23/06/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525611-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525123-27-00",
            "title": "SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon\u00ae",
            "phase": "Phase III",
            "lead_sponsor": "Azienda Ospedaliero Universitaria Careggi, University Of Florence",
            "conditions": "Benign prostatic hypertrophy",
            "member_states": "Italy",
            "decision_date": "23/06/2026",
            "enrolled": "410",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525123-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525157-39-00",
            "title": "A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Silexion Therapeutics Ltd.",
            "conditions": "Non-Resectable Locally Advanced Pancreatic Cancer (LAPC)",
            "member_states": "Germany",
            "decision_date": "23/06/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525157-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523491-23-00",
            "title": "Efficacy of asciminib in chronic phase CML patients with T315l mutations",
            "phase": "Phase II",
            "lead_sponsor": "Friedrich-Schiller-Universitaet Jena",
            "conditions": "Chronic Myeloid Leukemia",
            "member_states": "Germany",
            "decision_date": "23/06/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523491-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521353-16-00",
            "title": "A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema",
            "phase": "Phase III",
            "lead_sponsor": "Adarx Pharmaceuticals Inc.",
            "conditions": "Hereditary Angioedema",
            "member_states": "Poland; Italy; Hungary; France; Austria; Czechia; Belgium; Spain; Bulgaria; Germany; Croatia",
            "decision_date": "22/06/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521353-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526324-48-00",
            "title": "Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy",
            "phase": "Phase I/II",
            "lead_sponsor": "Centr Georges Francois Leclerc",
            "conditions": "HCC \u2013 Hepatocellular Carcinoma",
            "member_states": "France",
            "decision_date": "22/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526324-48-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524322-18-00",
            "title": "A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis",
            "phase": "Phase III",
            "lead_sponsor": "Zenas Biopharma (USA) LLC",
            "conditions": "Non-active Secondary Progressive Multiple Sclerosis (SPMS)",
            "member_states": "Germany; Bulgaria; Netherlands; Sweden; Portugal; Croatia; Italy; Austria; Spain; Poland; France; Denmark; Hungary; Romania; Estonia; Slovakia; Belgium; Czechia; Norway; Lithuania; Greece",
            "decision_date": "22/06/2026",
            "enrolled": "486",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524322-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524488-18-00",
            "title": "An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).",
            "phase": "Phase II",
            "lead_sponsor": "Astellas Pharma Global Development Inc.",
            "conditions": "Muscle-invasive Bladder Cancer",
            "member_states": "Germany; France; Poland; Italy; Spain",
            "decision_date": "22/06/2026",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524488-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523479-49-00",
            "title": "A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Colitis ulcerative",
            "member_states": "Italy; Greece; Netherlands; Poland; Germany; France",
            "decision_date": "22/06/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523479-49-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524713-88-00",
            "title": "Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)",
            "phase": "Phase II",
            "lead_sponsor": "Verastem Inc.",
            "conditions": "Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)",
            "member_states": "France",
            "decision_date": "22/06/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524713-88-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523111-11-00",
            "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis",
            "phase": "Phase I/II",
            "lead_sponsor": "Trace Neuroscience Inc.",
            "conditions": "Amyotrophic lateral sclerosis",
            "member_states": "Germany; Netherlands",
            "decision_date": "22/06/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523111-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522275-28-00",
            "title": "Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program",
            "phase": "Phase IV",
            "lead_sponsor": "Orchard Therapeutics (Europe) Limited",
            "conditions": "Metachromatic leukodystrophy",
            "member_states": "Netherlands; Germany; Italy; Sweden; France",
            "decision_date": "22/06/2026",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522275-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525464-18-00",
            "title": "Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Clonal Cytopenia of Undetermined Significance with SF3B1 mutation, Low-Risk Myelodysplastic Syndrome with SF3B1 mutation",
            "member_states": "Belgium",
            "decision_date": "22/06/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525464-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521488-11-00",
            "title": "Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study",
            "phase": "Phase II",
            "lead_sponsor": "ARQ National Psychotrauma Centrum",
            "conditions": "Posttraumatic stress disorder",
            "member_states": "Netherlands",
            "decision_date": "22/06/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521488-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525871-24-00",
            "title": "Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Fracture-Related Infection",
            "member_states": "Netherlands",
            "decision_date": "22/06/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525871-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522587-33-00",
            "title": "A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)",
            "phase": "Phase II",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Narcolepsy with Cataplexy (NT1)",
            "member_states": "Spain; Italy; France",
            "decision_date": "22/06/2026",
            "enrolled": "69",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522587-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-507975-23-01",
            "title": "Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study",
            "phase": "Phase II",
            "lead_sponsor": "St. Olavs Hospital HF",
            "conditions": "Retinopathy of prematurity",
            "member_states": "Norway",
            "decision_date": "22/06/2026",
            "enrolled": "33",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-507975-23-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524625-41-00",
            "title": "Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events",
            "phase": "Phase III",
            "lead_sponsor": "Daiichi Sankyo Europe GmbH",
            "conditions": "Coronary atherosclerosis",
            "member_states": "Italy; Spain; Germany",
            "decision_date": "22/06/2026",
            "enrolled": "103",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524625-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522951-24-00",
            "title": "A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)",
            "phase": "Phase II",
            "lead_sponsor": "Angitia Inc. Ltd.",
            "conditions": "Osteogenesis Imperfecta",
            "member_states": "Netherlands; France; Denmark",
            "decision_date": "22/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522951-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525158-20-00",
            "title": "Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo\u00ae as adjuvant monotherapy in patients with melanoma",
            "phase": "Phase I",
            "lead_sponsor": "Biocon Biologics UK PLC",
            "conditions": "Stage IIB/C, Stage III, or Stage IV Melanoma",
            "member_states": "Spain; Romania",
            "decision_date": "22/06/2026",
            "enrolled": "43",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525158-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525966-22-00",
            "title": "A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee",
            "phase": "Phase II",
            "lead_sponsor": "Latigo Biotherapeutics Inc.",
            "conditions": "Osteoarthritis of the knee",
            "member_states": "Denmark",
            "decision_date": "22/06/2026",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525966-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524337-11-00",
            "title": "A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)",
            "phase": "Phase III",
            "lead_sponsor": "Celgene Corp.",
            "conditions": "Systemic Sclerosis",
            "member_states": "Spain; Germany; France; Italy; Belgium",
            "decision_date": "19/06/2026",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524337-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526014-87-00",
            "title": "A Phase 1 first-in-human study to evaluate SAR448272 in adult participants",
            "phase": "Phase I",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "healthy volunteers, immunological diseases",
            "member_states": "Germany",
            "decision_date": "19/06/2026",
            "enrolled": "147",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526014-87-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523374-17-03",
            "title": "Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio Hospital Universitari Vall D\u2019Hebron Institut De Recerca",
            "conditions": "Type 2 diabetes",
            "member_states": "Spain",
            "decision_date": "19/06/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523374-17-03",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524879-23-00",
            "title": "Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)",
            "phase": "Phase II",
            "lead_sponsor": "Universitaetsklinikum Ulm A\u00f6R",
            "conditions": "Marginal Zone Lymphoma",
            "member_states": "Germany",
            "decision_date": "19/06/2026",
            "enrolled": "53",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524879-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522900-26-00",
            "title": "Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study.",
            "phase": "Phase IV",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Post-ERCP Pancreatitis",
            "member_states": "Netherlands",
            "decision_date": "19/06/2026",
            "enrolled": "520",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522900-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525179-26-00",
            "title": "A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Cardiometabolic",
            "member_states": "Netherlands",
            "decision_date": "19/06/2026",
            "enrolled": "128",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525179-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514190-21-00",
            "title": "Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product",
            "phase": "Phase I/II",
            "lead_sponsor": "Iecure Inc.",
            "conditions": "Ornithine Transcarbamylase Deficiency (OTC)",
            "member_states": "Spain; France",
            "decision_date": "18/06/2026",
            "enrolled": "3",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514190-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525085-29-00",
            "title": "A first study in healthy volunteers to examine the safety and tolerability of convalescent plasma given through the nose,\u00a0 as well as the duration of its presence in the nose",
            "phase": "Phase I",
            "lead_sponsor": "Rode Kruis-Vlaanderen",
            "conditions": "Healthy volunteers",
            "member_states": "Belgium",
            "decision_date": "18/06/2026",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525085-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524150-34-00",
            "title": "A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and Patients",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Atopic Dermatitis",
            "member_states": "Poland",
            "decision_date": "18/06/2026",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524150-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525897-20-00",
            "title": "A study to check whether adding RUTI\u00ae to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body\u2019s defenses, with participants randomly receiving RUTI\u00ae or a look-alike treatment.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorio Reig Jofre S.A.",
            "conditions": "High-risk non-muscle invasive bladder cancer (NMIBC)",
            "member_states": "Spain",
            "decision_date": "18/06/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525897-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524048-36-00",
            "title": "Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO",
            "phase": "Phase III",
            "lead_sponsor": "Fondazione GONO G.I.",
            "conditions": "Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma",
            "member_states": "Spain; Germany; Italy",
            "decision_date": "18/06/2026",
            "enrolled": "212",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524048-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513496-40-00",
            "title": "A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)",
            "phase": "Phase II",
            "lead_sponsor": "Universitaetsklinikum Tuebingen A\u00f6R",
            "conditions": "PARKINSON\u2019S DISEASE",
            "member_states": "Spain; Germany; Italy; Sweden; France; Luxembourg",
            "decision_date": "18/06/2026",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513496-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523654-13-00",
            "title": "A  multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system",
            "phase": "Phase III",
            "lead_sponsor": "Medizinische Hochschule Hannover",
            "conditions": "Demyelinating diseases",
            "member_states": "Germany; Austria",
            "decision_date": "17/06/2026",
            "enrolled": "116",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523654-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524889-25-00",
            "title": "Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial",
            "phase": "Phase II",
            "lead_sponsor": "University Hospital Of Clermont-Ferrand",
            "conditions": "Osteoporotic Fracture",
            "member_states": "France",
            "decision_date": "17/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524889-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525643-32-00",
            "title": "STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Regional De Marseille",
            "conditions": "ulcerative colitis",
            "member_states": "France",
            "decision_date": "17/06/2026",
            "enrolled": "224",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525643-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526038-26-00",
            "title": "A Study to Learn About How Different Forms of Study Medicine Prifetrastat are Taken Up Into the Blood in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Locally advanced or metastatic ER+/HER2- breast cancer",
            "member_states": "Belgium",
            "decision_date": "17/06/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526038-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524687-38-00",
            "title": "Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Rondo Therapeutics Inc.",
            "conditions": "Other Solid Tumors Associated with Nectin-4 Expression, Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer",
            "member_states": "Spain",
            "decision_date": "17/06/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524687-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519121-38-01",
            "title": "A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients",
            "phase": "Phase I",
            "lead_sponsor": "Mipsalus ApS",
            "conditions": "Phenylketonuria",
            "member_states": "Denmark",
            "decision_date": "17/06/2026",
            "enrolled": "7",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519121-38-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522373-10-00",
            "title": "IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis",
            "member_states": "Finland; Portugal; Hungary; Ireland; Poland; Greece; France; Belgium; Denmark; Italy; Spain; Netherlands; Austria; Germany",
            "decision_date": "17/06/2026",
            "enrolled": "318",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522373-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522294-11-00",
            "title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period",
            "phase": "Phase II",
            "lead_sponsor": "Galderma S.A.",
            "conditions": "Systemic sclerosis",
            "member_states": "Poland; Italy; Bulgaria; France; Greece; Spain; Croatia",
            "decision_date": "17/06/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522294-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526279-52-00",
            "title": "A First\u2011in\u2011Human Phase 1 Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants",
            "phase": "Phase I",
            "lead_sponsor": "Arcus Biosciences Inc.",
            "conditions": "Healthy volunteers",
            "member_states": "Netherlands",
            "decision_date": "16/06/2026",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526279-52-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524305-32-00",
            "title": "RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer",
            "phase": "Phase II",
            "lead_sponsor": "Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting",
            "conditions": "Stage I non-small cell lung cancer",
            "member_states": "Netherlands",
            "decision_date": "16/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524305-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524690-16-00",
            "title": "Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer",
            "phase": "Phase I",
            "lead_sponsor": "Theras Inc.",
            "conditions": "Solid Tumors",
            "member_states": "Spain; Italy; France",
            "decision_date": "16/06/2026",
            "enrolled": "2999997",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524690-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525124-10-00",
            "title": "A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)",
            "phase": "Phase II",
            "lead_sponsor": "Entrada Therapeutics Inc.",
            "conditions": "Duchenne Muscular Dystrophy",
            "member_states": "Belgium; Italy; Netherlands; Spain",
            "decision_date": "16/06/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525124-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523130-11-00",
            "title": "A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",
            "phase": "Phase I",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Hematological malignancies, Advanced solid tumors",
            "member_states": "Italy; Belgium; Denmark",
            "decision_date": "16/06/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523130-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519787-40-00",
            "title": "A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2",
            "member_states": "France; Italy; Spain; Hungary; Poland; Belgium; Germany; Netherlands",
            "decision_date": "16/06/2026",
            "enrolled": "516",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519787-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520626-37-00",
            "title": "A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Metastatic Prostate Cancer",
            "member_states": "Belgium; Spain; Poland; Italy; Netherlands",
            "decision_date": "16/06/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520626-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522643-18-00",
            "title": "A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Stage I NSCLC",
            "member_states": "Greece; Poland; Italy; Hungary; Germany; Netherlands; France; Spain",
            "decision_date": "16/06/2026",
            "enrolled": "283",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522643-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524640-35-00",
            "title": "A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease",
            "phase": "Phase II",
            "lead_sponsor": "Spyre Therapeutics Inc.",
            "conditions": "Ulcerative colitis (Inflammatory Bowel Disease)",
            "member_states": "Croatia; Poland; Austria; Czechia; Italy; Slovakia; Bulgaria; Greece; Belgium; Spain; Hungary; Germany; Lithuania; France; Romania",
            "decision_date": "16/06/2026",
            "enrolled": "228",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524640-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524344-35-00",
            "title": "Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Montpellier",
            "conditions": "Heart failure",
            "member_states": "France",
            "decision_date": "15/06/2026",
            "enrolled": "1050",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524344-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511296-15-00",
            "title": "A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Musculoskeletal diseases",
            "member_states": "France; Netherlands; Germany; Czechia; Belgium; Austria; Hungary; Greece; Spain",
            "decision_date": "15/06/2026",
            "enrolled": "177",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511296-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524371-23-00",
            "title": "An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)",
            "phase": "Phase III",
            "lead_sponsor": "ML Bio Solutions Inc.",
            "conditions": "Limb Girdle Muscular Dystrophy (LGMD) Type 2I",
            "member_states": "Germany; Denmark; Netherlands; Italy; Norway",
            "decision_date": "15/06/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524371-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511937-37-01",
            "title": "A single arm single center exploratory observational phase II study, aimed to detect long term changes in volume of port-wine macrocheilia and color of port-wine stain in patients undergoing surgery and laser therapy during sirolimus treatment. Quality of life and efficacy and safety of sirolimus will be assessed.",
            "phase": "Phase II",
            "lead_sponsor": "Oslo University Hospital HF",
            "conditions": "Vascular malfomation",
            "member_states": "Norway",
            "decision_date": "15/06/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511937-37-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522114-23-00",
            "title": "A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy",
            "phase": "Phase II",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Multiple myeloma (RRMM)",
            "member_states": "Finland; Denmark; Estonia; Norway",
            "decision_date": "15/06/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522114-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524487-37-00",
            "title": "Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)",
            "phase": "Phase IV",
            "lead_sponsor": "Swedish Orphan Biovitrum AB (publ)",
            "conditions": "C3 Glomerulopathy (C3G), Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)",
            "member_states": "France; Italy; Spain; Germany; Belgium",
            "decision_date": "15/06/2026",
            "enrolled": "82",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524487-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523616-36-00",
            "title": "Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "Transthyretin cardiac amyloidosis",
            "member_states": "France",
            "decision_date": "13/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523616-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522038-29-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation\u200b",
            "member_states": "Italy; Netherlands; France; Germany; Spain; Poland; Greece",
            "decision_date": "12/06/2026",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522038-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526411-11-00",
            "title": "A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.",
            "phase": "Phase I",
            "lead_sponsor": "Antabio",
            "conditions": "Not applicable for phase I study",
            "member_states": "France",
            "decision_date": "12/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526411-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522267-15-00",
            "title": "A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "\u200bRelapsed/refractory B-cell Acute Lymphoblastic Leukemia\u200b",
            "member_states": "Greece; Netherlands; Sweden; France; Italy; Spain; Denmark",
            "decision_date": "12/06/2026",
            "enrolled": "109",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522267-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523674-16-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Metabolic Dysfunction-Associated Steatohepatitis (MASH)",
            "member_states": "Greece; Germany; Belgium; Netherlands; Poland; Italy; France; Spain; Bulgaria; Austria",
            "decision_date": "12/06/2026",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523674-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519268-41-00",
            "title": "BEAT Fatigue \u2013 Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Fatigue in rheumatoid arthritis patients",
            "member_states": "Denmark",
            "decision_date": "12/06/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519268-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524871-22-00",
            "title": "Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.",
            "phase": "Phase I",
            "lead_sponsor": "Pevisal Group Farmaceutici S.r.l.",
            "conditions": "Healthy subjects",
            "member_states": "Czechia",
            "decision_date": "12/06/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524871-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521608-23-00",
            "title": "A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2",
            "phase": "Phase II",
            "lead_sponsor": "IRCCS Istituto Nazionale Tumori Fondazione Pascale",
            "conditions": "patients with unrestectable hepatocellular carcinoma (SLIDE-HCC)",
            "member_states": "Italy",
            "decision_date": "12/06/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521608-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524112-11-00",
            "title": "J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn\u2019s Disease \nJ6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn\u2019s Disease",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "J6Z-MC-IIBD - Colitis, Ulcerative  Crohn Disease \nJ6Z-MC-CD01 - Crohn Disease",
            "member_states": "Italy; Germany; Hungary; Poland; Belgium",
            "decision_date": "11/06/2026",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524112-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522449-23-00",
            "title": "Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.",
            "phase": "Phase I/II",
            "lead_sponsor": "Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz",
            "conditions": "Refractory Lupus Nephritis",
            "member_states": "Spain",
            "decision_date": "11/06/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522449-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525540-15-00",
            "title": "Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) \u2013 Protocol OMCOS",
            "phase": "Phase III",
            "lead_sponsor": "Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre",
            "conditions": "chronic suppurative otitis media (CSOM)",
            "member_states": "Spain",
            "decision_date": "11/06/2026",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525540-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524095-27-00",
            "title": "A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas",
            "phase": "Phase II",
            "lead_sponsor": "Gilead Sciences Inc.",
            "conditions": "HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ, and esophageal adenocarcinomas",
            "member_states": "Spain; France",
            "decision_date": "11/06/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524095-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525191-26-00",
            "title": "Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed, moderate-to-severe Crohn\u2019s disease: A 52-week, multicenter, open-label, randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Universitaetsklinikum Schleswig-Holstein A\u00f6R",
            "conditions": "Crohn\u2019s disease",
            "member_states": "Germany",
            "decision_date": "11/06/2026",
            "enrolled": "320",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525191-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525518-70-00",
            "title": "Clinical trial to evaluate the correlation between variation in intestinal lactase activity measured with LacTEST 0.45g and alteration of intestinal barrier integrity and/or intestinal permeability in patients with celiac disease",
            "phase": "Phase IV",
            "lead_sponsor": "Venter Pharma S.L.",
            "conditions": "Patients with celiac disease",
            "member_states": "Spain",
            "decision_date": "11/06/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525518-70-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524728-22-01",
            "title": "ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)",
            "phase": "Phase I/II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)",
            "member_states": "France",
            "decision_date": "10/06/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524728-22-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523593-16-00",
            "title": "First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)",
            "phase": "Phase III",
            "lead_sponsor": "Institut Gustave Roussy",
            "conditions": "Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III well differentiated R0 resected",
            "member_states": "France",
            "decision_date": "10/06/2026",
            "enrolled": "504",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523593-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524092-23-00",
            "title": "A Phase 3 prospective, randomized, multicenter, active-controlled study to evaluate the efficacy and safety of BV100 plus low-dose polymyxin B compared with colistin plus high-dose ampicillin/sulbactam in the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex",
            "phase": "Phase III",
            "lead_sponsor": "Bioversys S.A.S.",
            "conditions": "Hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex",
            "member_states": "Greece; Croatia",
            "decision_date": "10/06/2026",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524092-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524404-29-00",
            "title": "J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate",
            "member_states": "Latvia; Portugal; Greece; France; Czechia; Italy; Poland; Slovakia; Hungary; Croatia; Lithuania",
            "decision_date": "10/06/2026",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524404-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523665-24-00",
            "title": "A clinical trial to learn about the effects of  JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Patients with metastatic PDAC, NSCLC, HR+/HER2- ductal and lobular BC, TNBC, CRC or STS.",
            "member_states": "Denmark",
            "decision_date": "10/06/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523665-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526212-37-00",
            "title": "Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)",
            "phase": "Phase III",
            "lead_sponsor": "Institut De Recherches Internationales Servier IRIS",
            "conditions": "Advanced lymphoid leukemia",
            "member_states": "France",
            "decision_date": "09/06/2026",
            "enrolled": "1",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526212-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522777-10-00",
            "title": "A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Follicular Lymphoma",
            "member_states": "France; Spain; Germany; Greece; Italy; Poland",
            "decision_date": "09/06/2026",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522777-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526263-38-00",
            "title": "A trial in healthy participants to find out how long JNJ-101556143 stays in and acts on the body when administered as different formulations and under different food conditions",
            "phase": "Phase I",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Prostate Cancer",
            "member_states": "Belgium",
            "decision_date": "09/06/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526263-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525316-33-00",
            "title": "DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial",
            "phase": "Phase IV",
            "lead_sponsor": "Sint Maartenskliniek Stichting",
            "conditions": "Rheumatoid arthritis",
            "member_states": "Netherlands",
            "decision_date": "09/06/2026",
            "enrolled": "202",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525316-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523990-40-00",
            "title": "Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent)",
            "phase": "Phase III",
            "lead_sponsor": "Universitaetsklinikum Heidelberg A\u00f6R",
            "conditions": "Newly diagnosed Multiple Myeloma in patients eligible for stem cell transplantation",
            "member_states": "Germany",
            "decision_date": "09/06/2026",
            "enrolled": "399",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523990-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523432-39-01",
            "title": "A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Verastem Inc.",
            "conditions": "Advanced KRAS G12D-Mutant Solid Tumors",
            "member_states": "Italy; France; Germany; Belgium; Spain; Netherlands",
            "decision_date": "09/06/2026",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523432-39-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524454-34-00",
            "title": "Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis",
            "phase": "Phase III",
            "lead_sponsor": "Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau",
            "conditions": "Bronchiectasis",
            "member_states": "Spain",
            "decision_date": "09/06/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524454-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523896-44-00",
            "title": "Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial",
            "phase": "Phase III",
            "lead_sponsor": "GWT-Tud GmbH",
            "conditions": "Congenital hemophilia A (HA), Synovitis",
            "member_states": "Austria; Germany",
            "decision_date": "08/06/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523896-44-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522176-86-01",
            "title": "A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis\n(KATALYST-AV)",
            "phase": "Phase III",
            "lead_sponsor": "Kardigan Inc.",
            "conditions": "Moderate Calcific Aortic Valve Stenosis (CAVS)",
            "member_states": "Norway; Czechia; Portugal; Austria; Poland; France; Spain",
            "decision_date": "08/06/2026",
            "enrolled": "496",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522176-86-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521032-11-00",
            "title": "A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Small cell lung cancer extensive stage",
            "member_states": "Germany; Poland; Greece; Italy; France; Spain",
            "decision_date": "08/06/2026",
            "enrolled": "79",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521032-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525700-10-00",
            "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST\u2011905\u2011AG1 in Healthy Volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Syremis Therapeutics Ltd.",
            "conditions": "Schizophrenia",
            "member_states": "France",
            "decision_date": "08/06/2026",
            "enrolled": "280",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525700-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524283-38-00",
            "title": "HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia\nRED RIVER CLL study: Reduced Duration Rituximab VEnetoclax in Relapsed/refractory CLL",
            "phase": "Phase III",
            "lead_sponsor": "Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting",
            "conditions": "Relapsed or refractory small lymphocytic lymphoma, Relapsed or refractory chronic lymphocytic leukemia",
            "member_states": "Netherlands",
            "decision_date": "08/06/2026",
            "enrolled": "456",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524283-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526016-36-00",
            "title": "A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Leuven",
            "conditions": "obesity",
            "member_states": "Belgium",
            "decision_date": "08/06/2026",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526016-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522301-37-00",
            "title": "A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Nonsegmental vitiligo",
            "member_states": "Germany; Spain; Netherlands; France; Italy",
            "decision_date": "08/06/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522301-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524727-41-00",
            "title": "J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Alopecia Areata",
            "member_states": "Poland; Netherlands",
            "decision_date": "08/06/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524727-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525355-93-00",
            "title": "PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP \u2013 TRIAL)",
            "phase": "Phase III",
            "lead_sponsor": "Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus",
            "conditions": "ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS",
            "member_states": "Spain",
            "decision_date": "08/06/2026",
            "enrolled": "500",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525355-93-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523984-39-00",
            "title": "A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With  Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).",
            "phase": "Phase II",
            "lead_sponsor": "Gilead Sciences Inc.",
            "conditions": "Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)",
            "member_states": "Spain; Italy; France",
            "decision_date": "08/06/2026",
            "enrolled": "94",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523984-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525783-18-00",
            "title": "Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?",
            "phase": "Phase III",
            "lead_sponsor": "Fundacion Biomedica Galicia Sur",
            "conditions": "Laparoscopic cholecystectomy",
            "member_states": "Spain",
            "decision_date": "08/06/2026",
            "enrolled": "66",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525783-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523497-16-00",
            "title": "TSRA196-AAT-201:  A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency",
            "phase": "Phase I/II",
            "lead_sponsor": "Tessera Therapeutics Inc.",
            "conditions": "Lung and/or Liver Disease Associated with Alpha-1 Antitrypsin Deficiency (AATD)",
            "member_states": "Ireland; Sweden; Netherlands",
            "decision_date": "08/06/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523497-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525144-18-00",
            "title": "A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA\n(BEXAR Study)",
            "phase": "Phase I/II",
            "lead_sponsor": "Medica Scientia Innovation Research S.L.",
            "conditions": "Advanced or metastatic histologically confirmed soft tissue sarcoma (STS) in adult patients who are not candidates for curative treatment.",
            "member_states": "Spain",
            "decision_date": "08/06/2026",
            "enrolled": "278",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525144-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522818-23-00",
            "title": "A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator\u2019s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Zai Lab (US) LLC",
            "conditions": "Small Cell Lung Cancer (SCLC)",
            "member_states": "Belgium; Czechia; Germany; Denmark; Greece; Netherlands; Poland; Spain; Austria; Italy; France",
            "decision_date": "08/06/2026",
            "enrolled": "234",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522818-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526084-38-00",
            "title": "REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM)",
            "phase": "Phase II",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Immune Aging, Chronic inflammation",
            "member_states": "Netherlands",
            "decision_date": "08/06/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526084-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524208-31-00",
            "title": "Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone",
            "conditions": "Symptomatic bone metastases from breast cancer",
            "member_states": "Italy",
            "decision_date": "08/06/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524208-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525701-12-00",
            "title": "Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.",
            "phase": "Phase II",
            "lead_sponsor": "Universidad Rey Juan Carlos",
            "conditions": "Parkinson's disease",
            "member_states": "Spain",
            "decision_date": "08/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525701-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523109-14-00",
            "title": "A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease",
            "phase": "Phase III",
            "lead_sponsor": "Chiesi Farmaceutici S.p.A.",
            "conditions": "Congenital Heart Disease",
            "member_states": "Netherlands; Germany; Portugal; Austria",
            "decision_date": "08/06/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523109-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518587-12-00",
            "title": "C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)",
            "member_states": "Spain; Germany; Poland; Czechia; Greece; Italy; Bulgaria; France; Hungary",
            "decision_date": "08/06/2026",
            "enrolled": "318",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518587-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525478-21-00",
            "title": "A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy",
            "phase": "Phase I",
            "lead_sponsor": "Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.",
            "conditions": "Drug resistant epilepsy",
            "member_states": "Sweden",
            "decision_date": "08/06/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525478-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522555-26-00",
            "title": "OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab",
            "phase": "Phase IV",
            "lead_sponsor": "Alexion Pharmaceuticals Inc.",
            "conditions": "Generalized Myasthenia Gravis",
            "member_states": "Italy; Germany",
            "decision_date": "08/06/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522555-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522049-23-00",
            "title": "PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)",
            "phase": "Phase IV",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "granulomatosis with polyangiitis and microscopic polyangiitis",
            "member_states": "France",
            "decision_date": "08/06/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522049-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522845-23-00",
            "title": "An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases",
            "phase": "Phase II",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Oral Squamous Cell Carcinoma with neck metastases, Oropharyngeal Squamous Cell Carcinoma",
            "member_states": "Denmark",
            "decision_date": "08/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522845-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526160-21-00",
            "title": "Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up",
            "phase": "Phase IV",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Prevention of measles, mumps, and rubella by vaccination",
            "member_states": "Denmark",
            "decision_date": "08/06/2026",
            "enrolled": "1000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526160-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523648-11-00",
            "title": "A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation",
            "phase": "Phase I",
            "lead_sponsor": "Bayer Consumer Care AG",
            "conditions": "adenocarcinoma of the colon or rectum",
            "member_states": "Finland; Spain; Sweden; Italy; Denmark; Netherlands; Belgium",
            "decision_date": "08/06/2026",
            "enrolled": "49",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523648-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523537-26-00",
            "title": "KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments",
            "phase": "Phase I/II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer; advanced solid tumors harboring the KRAS G12C mutation.",
            "member_states": "Spain; Italy; France; Denmark; Belgium",
            "decision_date": "08/06/2026",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523537-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524363-20-01",
            "title": "Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.",
            "phase": "Phase II",
            "lead_sponsor": "Instituto De Salud Carlos III",
            "conditions": "HIV-1 infection",
            "member_states": "Spain",
            "decision_date": "08/06/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524363-20-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523675-39-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Metabolic Dysfunction-Associated Steatohepatitis (MASH)",
            "member_states": "Belgium; Greece; Poland; France; Spain; Bulgaria; Italy; Germany; Austria; Netherlands",
            "decision_date": "08/06/2026",
            "enrolled": "173",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523675-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-504439-42-03",
            "title": "Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)",
            "phase": "Phase II",
            "lead_sponsor": "Hospital Universitario 12 De Octubre",
            "conditions": "alcohol dependence",
            "member_states": "Spain",
            "decision_date": "08/06/2026",
            "enrolled": "118",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-504439-42-03",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524240-35-00",
            "title": "OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Rennes",
            "conditions": "indication for pulmonary resection surgery (segmentectomy or lobectomy), video-assisted thoracoscopy or scheduled robot-assisted surgery.",
            "member_states": "France",
            "decision_date": "05/06/2026",
            "enrolled": "176",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524240-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525069-65-00",
            "title": "ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nimes",
            "conditions": "Alcohol use disorder, depressive symptoms",
            "member_states": "France",
            "decision_date": "05/06/2026",
            "enrolled": "172",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525069-65-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523913-27-00",
            "title": "PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence",
            "phase": "Phase III",
            "lead_sponsor": "Unicancer",
            "conditions": "Participants with R0/R1 resected liver metastases from colorectal cancer (CRLM).",
            "member_states": "France",
            "decision_date": "05/06/2026",
            "enrolled": "272",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523913-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521988-13-00",
            "title": "ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis",
            "phase": "Phase IV",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Infection prophylaxis",
            "member_states": "France",
            "decision_date": "05/06/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521988-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523397-16-00",
            "title": "Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy",
            "phase": "Phase II",
            "lead_sponsor": "Les Hopitaux Universitaires De Strasbourg",
            "conditions": "Septic Coagulopathy",
            "member_states": "France",
            "decision_date": "05/06/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523397-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524741-28-00",
            "title": "BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)",
            "phase": "Phase IV",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Severe Asthma",
            "member_states": "Netherlands",
            "decision_date": "05/06/2026",
            "enrolled": "142",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524741-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525324-26-00",
            "title": "Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders \u2013 RITS-LONG",
            "phase": "Phase II",
            "lead_sponsor": "Region Oerebro Laen",
            "conditions": "Schizophrenia spectrum disorder (SSD)",
            "member_states": "Sweden",
            "decision_date": "05/06/2026",
            "enrolled": "122",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525324-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524894-17-00",
            "title": "A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)",
            "phase": "Phase III",
            "lead_sponsor": "Eyebiotech Limited",
            "conditions": "Neovascular age-related macular degeneration (NVAMD)",
            "member_states": "Austria; Slovakia; Portugal; Czechia; Hungary; Spain; France; Denmark; Italy; Croatia",
            "decision_date": "05/06/2026",
            "enrolled": "250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524894-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521570-34-00",
            "title": "A randomised, double-blind, three parallel-group, placebo controlled superiority trial assessing the effect of intravenous versus oral iron supplementation on physical performance, quality of life and cognitive function in iron deficient FRAIL elderly IndiviDuals with cardiovascular disease (FRAIL-ID trial)",
            "phase": "Phase IV",
            "lead_sponsor": "Wroclaw Medical University",
            "conditions": "Frailty with Iron Deficiency in Elderly Patients with Cardiovascular Disease",
            "member_states": "Poland",
            "decision_date": "05/06/2026",
            "enrolled": "396",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521570-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526494-42-00",
            "title": "Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Varsinais-Suomen hyvinvointialue",
            "conditions": "Gastric cancer",
            "member_states": "Finland",
            "decision_date": "05/06/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526494-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525817-29-00",
            "title": "A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)",
            "phase": "Phase II",
            "lead_sponsor": "Sundance Biosciences Inc.",
            "conditions": "Multiple Sclerosis; Primary Progressive Multiple Sclerosis; non-active Secondary Progressive Multiple Sclerosis",
            "member_states": "Finland",
            "decision_date": "05/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525817-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523912-35-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2",
            "phase": "Phase III",
            "lead_sponsor": "Alkermes Inc.",
            "conditions": "Narcolepsy Type 2",
            "member_states": "Spain; Netherlands; Belgium; Italy; France; Austria; Czechia; Germany; Sweden; Poland",
            "decision_date": "04/06/2026",
            "enrolled": "132",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523912-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524110-28-00",
            "title": "Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Incidental Subsegmental Pulmonary Embolism in cancer patients",
            "member_states": "Denmark",
            "decision_date": "04/06/2026",
            "enrolled": "234",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524110-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509795-42-00",
            "title": "TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study TALISCHER - SAH",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "Aneurysmal subarachnoid hemorrhage",
            "member_states": "France",
            "decision_date": "04/06/2026",
            "enrolled": "274",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509795-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524232-20-00",
            "title": "REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.",
            "phase": "Phase I/II",
            "lead_sponsor": "Asso De Recherche Cancers Gynecologiques",
            "conditions": "Patients with poor prognostic ovarian cancers based on the tumor primary chemonsensitivity and incomplete debulking surgery.",
            "member_states": "France",
            "decision_date": "04/06/2026",
            "enrolled": "43",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524232-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525780-41-00",
            "title": "Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Subjects Under Fed Conditions",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "Not applicable (submitted trial is a bioavailability trial in healthy participants).",
            "member_states": "Czechia",
            "decision_date": "04/06/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525780-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522490-11-00",
            "title": "T cell imaging in kidney transplantation (TIK)",
            "phase": "Phase I",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Renal allograft rejection",
            "member_states": "Netherlands",
            "decision_date": "04/06/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522490-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524456-58-00",
            "title": "A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults",
            "phase": "Phase I/II",
            "lead_sponsor": "GlaxoSmithKline Biologicals",
            "conditions": "Respiratory Syncytial Virus Infections+Metapneumovirus",
            "member_states": "Belgium",
            "decision_date": "04/06/2026",
            "enrolled": "464",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524456-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525554-11-00",
            "title": "Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries",
            "phase": "Phase II",
            "lead_sponsor": "Astrocyte Pharmaceuticals Inc.",
            "conditions": "Traumatic brain injury",
            "member_states": "Netherlands",
            "decision_date": "04/06/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525554-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518706-41-01",
            "title": "Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial",
            "phase": "Phase III",
            "lead_sponsor": "Vaestra Goetalandsregionen",
            "conditions": "Cardiovascular disease",
            "member_states": "Sweden",
            "decision_date": "03/06/2026",
            "enrolled": "40000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518706-41-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523939-18-00",
            "title": "A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.",
            "phase": "Phase I/II",
            "lead_sponsor": "Nura Bio Inc.",
            "conditions": "Amyotrofic Lateral Sclerosis (ALS)",
            "member_states": "Poland; Netherlands; Italy; Spain",
            "decision_date": "03/06/2026",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523939-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525906-37-00",
            "title": "Montelukast as disease modifying treatment in mild-moderate Parkinson\u2019s disease, an open-label, phase II extension trial (MONTPARK_OLE)",
            "phase": "Phase III",
            "lead_sponsor": "Karolinska University Hospital",
            "conditions": "Parkinson's Disease",
            "member_states": "Sweden",
            "decision_date": "03/06/2026",
            "enrolled": "98",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525906-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524575-22-00",
            "title": "A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)",
            "phase": "Phase III",
            "lead_sponsor": "Eyebiotech Limited",
            "conditions": "Neovascular age-related macular degeneration (NVAMD)",
            "member_states": "Spain; Poland; Estonia; Latvia; Germany",
            "decision_date": "03/06/2026",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524575-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523590-42-00",
            "title": "A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.",
            "phase": "Phase I/II",
            "lead_sponsor": "Crescent Biopharma Inc.",
            "conditions": "Locally Advanced or Metastatic Solid Tumors",
            "member_states": "Spain; Ireland; Italy; France; Romania",
            "decision_date": "02/06/2026",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523590-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523892-50-00",
            "title": "A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)",
            "phase": "Phase III",
            "lead_sponsor": "Region Stockholm \u2013 SLSO",
            "conditions": "Multiple Sclerosis",
            "member_states": "Sweden",
            "decision_date": "02/06/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523892-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524720-22-00",
            "title": "Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers",
            "phase": "Phase II",
            "lead_sponsor": "Fakultni Nemocnice Kralovske Vinohrady",
            "conditions": "patients with head and neck squamous cell carcinoma (HNSCC)",
            "member_states": "Czechia",
            "decision_date": "02/06/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524720-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526556-31-00",
            "title": "Randomized, open-label, multiple dose, two-period, two-treatment, cross-over pharmacodynamic study in healthy male and female participants under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Adamed Pharma S.A.",
            "conditions": "Pharmacodynamic study under fasting condition.",
            "member_states": "Czechia",
            "decision_date": "02/06/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526556-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523911-13-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1",
            "phase": "Phase III",
            "lead_sponsor": "Alkermes Inc.",
            "conditions": "Narcolepsy Type 1",
            "member_states": "Italy; France; Netherlands; Spain; Belgium; Austria; Czechia; Finland; Germany; Sweden; Poland",
            "decision_date": "02/06/2026",
            "enrolled": "113",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523911-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523670-17-00",
            "title": "Multinational, Interventional, 52-week, Open-label, Single-arm \nStudy to Evaluate the Treatment Outcomes of Anifrolumab 120 mg\nSubcutaneous Once Weekly in Immunosuppressant-na\u00efve and\nBiologic-na\u00efve Systemic Lupus Erythematosus (SUNFLOWER)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Systemic lupus erythematosus",
            "member_states": "Poland; Germany; Italy; France; Spain",
            "decision_date": "02/06/2026",
            "enrolled": "113",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523670-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524219-35-00",
            "title": "An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon\u00ae retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Vianex S.A.",
            "conditions": "treatment of myasthenia gravis",
            "member_states": "Czechia",
            "decision_date": "02/06/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524219-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523570-17-00",
            "title": "A randomized, Phase 2a, double-blinded, biomarker-driven, placebo-controlled study to assess safety, CNS penetration, and target engagement of Mirivadelgat in Parkinson\u2019s disease \u2013 SLEIPNIR-2, a sub-protocol in the SLEIPNIR platform trial",
            "phase": "Phase II",
            "lead_sponsor": "Helse Bergen HF",
            "conditions": "Parkinson's Disease",
            "member_states": "Norway",
            "decision_date": "02/06/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523570-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524730-26-00",
            "title": "IMPD-Q-only application",
            "phase": "Phase I",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "prick test-induced itch",
            "member_states": "Austria",
            "decision_date": "01/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524730-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522434-32-00",
            "title": "A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY,  PHARMACOKINETICS AND PHARMACODYNAMICS OF  NXT007 PROPHYLAXIS VERSUS FACTOR VIII  PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Hemophilia A Without Inhibitors",
            "member_states": "France; Austria; Poland; Netherlands; Spain; Denmark; Italy; Germany; Hungary",
            "decision_date": "01/06/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522434-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524470-41-00",
            "title": "GRAIN, Prospective Pilot Study",
            "phase": "Phase I",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Esophageal dysplasia, Barrett's esophagus, Esophageal adenocarcinoma",
            "member_states": "Netherlands",
            "decision_date": "01/06/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524470-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522349-23-00",
            "title": "Post-INFECT: Investigating Neuroinflammation and its eFEcts in post-COVID syndrome: an imaging sTudy",
            "phase": "Phase III",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "post-COVID syndrome",
            "member_states": "Netherlands",
            "decision_date": "01/06/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522349-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523426-40-00",
            "title": "Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests",
            "phase": "Phase III",
            "lead_sponsor": "Inmunotek S.L.",
            "conditions": "Allergy to Lepidoglyphus destructor",
            "member_states": "Spain",
            "decision_date": "01/06/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523426-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523131-19-00",
            "title": "IJAMP-Trial",
            "phase": "Phase IV",
            "lead_sponsor": "Johannes Kepler University Linz",
            "conditions": "prick test-induced itch",
            "member_states": "Austria",
            "decision_date": "01/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523131-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2022-502365-26-00",
            "title": "A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Asthma",
            "member_states": "Poland; France; Slovakia; Spain; Hungary; Germany; Romania",
            "decision_date": "01/06/2026",
            "enrolled": "68",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2022-502365-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522435-33-00",
            "title": "A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF  NXT007 PROPHYLAXIS VERSUS EMICIZUMAB  PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Hemophilia A",
            "member_states": "Hungary; Spain; Ireland; Poland; Austria; Germany; Denmark; Belgium; Netherlands; Italy; France",
            "decision_date": "01/06/2026",
            "enrolled": "124",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522435-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521126-15-00",
            "title": "Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib",
            "phase": "Phase II",
            "lead_sponsor": "Grupo Espanol De Leucemia Mieloide Cronica (GELMC)",
            "conditions": "Chronic Myeloid Leukemia",
            "member_states": "Spain",
            "decision_date": "01/06/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521126-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524050-34-01",
            "title": "Use of DOTATOC labeled with V-Cu64 in PET-CT imaging of neuroendocrine tumors",
            "phase": "Phase III",
            "lead_sponsor": "Voxel S.A.",
            "conditions": "Neoplasms",
            "member_states": "Poland",
            "decision_date": "01/06/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524050-34-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524241-27-00",
            "title": "A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Na\u0457ve Mantle Cell Lymphoma",
            "phase": "Phase III",
            "lead_sponsor": "Innocare Pharma Inc.",
            "conditions": "Treatment-na\u0457ve mantle cell lymphoma (MCL)",
            "member_states": "Poland; France; Czechia; Spain; Romania",
            "decision_date": "01/06/2026",
            "enrolled": "102",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524241-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524082-25-00",
            "title": "A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease",
            "phase": "Phase I/II",
            "lead_sponsor": "Denali Therapeutics Inc.",
            "conditions": "Late-Onset Pompe Disease",
            "member_states": "Germany; Netherlands",
            "decision_date": "01/06/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524082-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518043-38-00",
            "title": "MOOD - MethOxyflurane analgesia in vasoOcclusive crises of sickle cell Disease",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Sickle cell disease",
            "member_states": "France",
            "decision_date": "29/05/2026",
            "enrolled": "198",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518043-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523653-34-00",
            "title": "Sublingual Birch Immunotherapy for Pollen-associated Food Allergy",
            "phase": "Phase II",
            "lead_sponsor": "Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)",
            "conditions": "Birch pollen Allergy, Pollen-associated Food Allergy",
            "member_states": "Germany",
            "decision_date": "29/05/2026",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523653-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524423-50-00",
            "title": "An open-label, single-arm, phase 1/2 first-in-human study to assess the safety and efficacy of autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene (SGX-001) in paediatric and adult patients with chronic granulomatous disease caused by p47phox deficiency",
            "phase": "Phase I/II",
            "lead_sponsor": "Somagenetix AG",
            "conditions": "Chronic granulomatous disease (CGD) caused by p47phox deficiency (p47-CGD)",
            "member_states": "Germany; Spain",
            "decision_date": "29/05/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524423-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516570-30-00",
            "title": "A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier De Versailles",
            "conditions": "Relapsed/refractory T-cell Acute Lymphoblastic Leukemia",
            "member_states": "Germany; France; Czechia; Netherlands; Spain",
            "decision_date": "29/05/2026",
            "enrolled": "86",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516570-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-504518-31-01",
            "title": "Leveraging the neural mechanisms of social reward for drug relapse prevention",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione Santa Lucia IRCCS",
            "conditions": "substance use disorder",
            "member_states": "Italy",
            "decision_date": "29/05/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-504518-31-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525613-31-00",
            "title": "Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Montpellier",
            "conditions": "Restless legs syndrome",
            "member_states": "France",
            "decision_date": "29/05/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525613-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524395-30-00",
            "title": "Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes \u2013 DISCO Study",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "heart failure",
            "member_states": "France",
            "decision_date": "29/05/2026",
            "enrolled": "458",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524395-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523523-21-00",
            "title": "C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.",
            "phase": "Phase I/II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Locally Advanced or Metastatic Urothelial Cancer",
            "member_states": "Netherlands; Spain",
            "decision_date": "29/05/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523523-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524062-16-00",
            "title": "A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Schizophrenia and Autism Spectrum Disorder (ASD)",
            "member_states": "Romania",
            "decision_date": "29/05/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524062-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523555-66-00",
            "title": "A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Myelofibrosis",
            "member_states": "Belgium; Germany; Austria; Poland; Spain; Italy; Netherlands; Czechia; France",
            "decision_date": "29/05/2026",
            "enrolled": "173",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523555-66-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524726-18-00",
            "title": "J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Non-Segmental Vitiligo (NSV), Vitiligo",
            "member_states": "Poland; Belgium",
            "decision_date": "29/05/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524726-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525317-31-00",
            "title": "Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "Retractile Capsulitis",
            "member_states": "France",
            "decision_date": "29/05/2026",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525317-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526142-27-01",
            "title": "Tranexamic Acid in Hind and Midfoot Arthrodesis Surgery: A Multicentre, Randomized, Placebo-Controlled Trial (TRASH Trial)",
            "phase": "Phase III",
            "lead_sponsor": "HUS-yhtymae",
            "conditions": "Deformity, Osteoarthritis",
            "member_states": "Finland",
            "decision_date": "29/05/2026",
            "enrolled": "450",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526142-27-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524580-21-00",
            "title": "A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis.",
            "phase": "Phase III",
            "lead_sponsor": "Inmunotek S.L.",
            "conditions": "Grass pollen induced allergic rhinitis or rhinoconjunctivitis",
            "member_states": "Germany",
            "decision_date": "29/05/2026",
            "enrolled": "450",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524580-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523873-41-00",
            "title": "A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Overweight\nObesity",
            "member_states": "Germany; Sweden",
            "decision_date": "29/05/2026",
            "enrolled": "145",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523873-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522956-25-00",
            "title": "COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial",
            "phase": "Phase III",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Chronic pancreatitis",
            "member_states": "Denmark",
            "decision_date": "29/05/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522956-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523400-72-00",
            "title": "A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX\u2011828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis",
            "phase": "Phase II",
            "lead_sponsor": "Vertex Pharmaceuticals Inc.",
            "conditions": "Cystic fibrosis",
            "member_states": "Spain; Sweden; Germany; Italy; Belgium; Czechia; Ireland; Portugal; Netherlands; France; Denmark",
            "decision_date": "29/05/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523400-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525263-41-00",
            "title": "Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)",
            "phase": "Phase III",
            "lead_sponsor": "Polska Grupa Badawcza Chloniakow",
            "conditions": "Hodgkin lymphoma",
            "member_states": "Poland",
            "decision_date": "29/05/2026",
            "enrolled": "370",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525263-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523950-15-01",
            "title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis",
            "phase": "Phase II",
            "lead_sponsor": "Vertex Pharmaceuticals Inc.",
            "conditions": "Generalized Myasthenia Gravis",
            "member_states": "Poland",
            "decision_date": "29/05/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523950-15-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525113-22-00",
            "title": "A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis",
            "phase": "Phase I",
            "lead_sponsor": "Neurocrine Biosciences Inc.",
            "conditions": "Rheumatoid Arthritis",
            "member_states": "Poland; Romania",
            "decision_date": "29/05/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525113-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513917-11-01",
            "title": "Prospective, multicentre, two-arms, I/II phase study to Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC)",
            "phase": "Phase I/II",
            "lead_sponsor": "Uniwersytet Medyczny W Lublinie",
            "conditions": "Adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (PBL) with an indication to start treatment of relapsed disease according to IWCLL recommendations.",
            "member_states": "Poland",
            "decision_date": "29/05/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513917-11-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524378-40-00",
            "title": "Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)",
            "phase": "Phase II",
            "lead_sponsor": "Institut Gustave Roussy",
            "conditions": "Locally advanced high\u2011risk stage III rectal adenocarcinoma (non\u2011metastatic)",
            "member_states": "France",
            "decision_date": "28/05/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524378-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523539-20-00",
            "title": "A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract  Urothelial Carcinoma (SURF303)",
            "phase": "Phase II",
            "lead_sponsor": "Tyra Biosciences Inc.",
            "conditions": "Low Grade Upper Tract Urothelial Carcinoma",
            "member_states": "Bulgaria; France; Spain",
            "decision_date": "28/05/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523539-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525291-26-00",
            "title": "A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.",
            "phase": "Phase III",
            "lead_sponsor": "Verisfield Single Member S.A.",
            "conditions": "Helicobacter Pylori Infection",
            "member_states": "Greece",
            "decision_date": "28/05/2026",
            "enrolled": "420",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525291-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522964-33-00",
            "title": "A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza\u00ae\u00a0/ Zemaira\u00ae Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency",
            "phase": "Phase IV",
            "lead_sponsor": "CSL Behring LLC",
            "conditions": "Alpha1-proteinase inhibitor deficiency, Alpha1 antitrypsin deficiency, Emphysema",
            "member_states": "Denmark",
            "decision_date": "28/05/2026",
            "enrolled": "33",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522964-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525640-14-00",
            "title": "A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial",
            "phase": "Phase IV",
            "lead_sponsor": "University Of Cologne",
            "conditions": "Candidemia",
            "member_states": "Germany",
            "decision_date": "28/05/2026",
            "enrolled": "420",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525640-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520910-67-01",
            "title": "A randomized, Phase 4, double-blind, placebo-controlled, 6-arm crossover study to investigate the systemic effect of lidocaine and ropivacaine when used for Transversus Abdominis Plane (TAP) blocks on hyperalgesia and pain perception in healthy volunteers aged 18 to 64 years.",
            "phase": "Phase IV",
            "lead_sponsor": "Oslo University Hospital HF",
            "conditions": "Acute pain",
            "member_states": "Norway",
            "decision_date": "28/05/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520910-67-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525770-19-00",
            "title": "Optimising the protocol of labour induction using misoprostol \u2013 randomised open-label clinical trial (OPTIMISO)",
            "phase": "Phase IV",
            "lead_sponsor": "Fakultni Nemocnice Brno",
            "conditions": "Labour induction",
            "member_states": "Czechia",
            "decision_date": "28/05/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525770-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523005-15-00",
            "title": "A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK\u20111045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma",
            "phase": "Phase I/II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Non-Hodgkin Lymphoma",
            "member_states": "Poland; Italy; France; Germany; Spain",
            "decision_date": "28/05/2026",
            "enrolled": "73",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523005-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522781-77-01",
            "title": "Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)",
            "phase": "Phase II",
            "lead_sponsor": "Helse Bergen HF",
            "conditions": "Epstein-Barr virus infection",
            "member_states": "Norway",
            "decision_date": "28/05/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522781-77-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519502-12-00",
            "title": "Bioavailability, Biopotency and Food effect study of SCD0503 compared to subcutaneous regular human insulin",
            "phase": "Phase I",
            "lead_sponsor": "Samchundang Pharm. Co. Ltd.",
            "conditions": "Type 1 diabetes",
            "member_states": "Germany",
            "decision_date": "28/05/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519502-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516796-33-00",
            "title": "Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.",
            "phase": "Phase II",
            "lead_sponsor": "Hospital Foch",
            "conditions": "The medical condition studied in IMMUNO-BOS is Bronchiolitis obliterans syndrome (BOS) after allogeneic stem cell transplantation",
            "member_states": "France",
            "decision_date": "27/05/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516796-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523276-23-00",
            "title": "A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC",
            "phase": "Phase I/II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Extensive stage small cell lung cancer",
            "member_states": "Spain; France",
            "decision_date": "27/05/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523276-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523579-47-00",
            "title": "An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "moderate to severe rheumatoid arthritis (RA)",
            "member_states": "Italy; Spain; Germany; France; Denmark; Poland; Belgium",
            "decision_date": "27/05/2026",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523579-47-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523997-18-00",
            "title": "Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas",
            "phase": "Phase I/II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Sarcoma",
            "member_states": "France",
            "decision_date": "27/05/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523997-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521590-13-00",
            "title": "A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Moderately to Severely Active Crohn\u2019s Disease",
            "member_states": "Slovakia; Germany; Denmark; France; Spain; Italy; Netherlands; Belgium; Poland; Sweden; Austria; Czechia; Hungary",
            "decision_date": "27/05/2026",
            "enrolled": "302",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521590-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521757-16-00",
            "title": "An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer\u2019s Disease Psychosis",
            "phase": "Phase II",
            "lead_sponsor": "Maplight Therapeutics Inc.",
            "conditions": "Hallucinations and Delusions Associated with Alzheimer\u2019s Disease Psychosis",
            "member_states": "Italy; Poland; Czechia; Portugal; Bulgaria; France; Slovakia; Romania; Hungary",
            "decision_date": "27/05/2026",
            "enrolled": "85",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521757-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522949-22-00",
            "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy",
            "phase": "Phase III",
            "lead_sponsor": "Solid Biosciences Inc.",
            "conditions": "Duchenne muscular dystrophy",
            "member_states": "Spain; Netherlands; France; Italy; Belgium; Germany",
            "decision_date": "26/05/2026",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522949-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522339-32-00",
            "title": "LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Neoplasm malignant",
            "member_states": "France; Spain; Sweden; Germany; Italy; Belgium; Denmark; Czechia; Hungary; Netherlands; Slovakia",
            "decision_date": "26/05/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522339-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-506420-93-00",
            "title": "POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Chronic recurrent multifocal osteomyelitis (CRMO)",
            "member_states": "France",
            "decision_date": "26/05/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-506420-93-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524885-12-00",
            "title": "Repurposed Drug Evaluation for Biological Aging, Pain, and Inflammation Reduction in Osteoarthritis",
            "phase": "Phase II",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Osteoarthritis",
            "member_states": "Netherlands",
            "decision_date": "26/05/2026",
            "enrolled": "175",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524885-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524999-37-00",
            "title": "A study comparing different dosage forms of midazolam and how they are taken up in the body.",
            "phase": "Phase I",
            "lead_sponsor": "MIDAS Pharma GmbH",
            "conditions": "Bioavailability Study under Fasting Conditions",
            "member_states": "Czechia",
            "decision_date": "26/05/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524999-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524040-35-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma",
            "phase": "Phase III",
            "lead_sponsor": "Generate Biomedicines Inc.",
            "conditions": "Severe uncontrolled asthma",
            "member_states": "Italy; Slovakia; Spain; Ireland; Belgium; France; Estonia",
            "decision_date": "26/05/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524040-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525604-99-00",
            "title": "First-in-human study to assess the safety and feasibility of intra-articular administration of allogeneic engineered gingival fibroblasts (aeGF) in participants with knee osteoarthritis.",
            "phase": "Phase I",
            "lead_sponsor": "Scarcell Therapeutics",
            "conditions": "Knee osteoarthritis",
            "member_states": "Denmark",
            "decision_date": "26/05/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525604-99-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521699-71-01",
            "title": "Platelet function testing in outpatients after heart transplantation on aspirin therapy",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "Patients who have undergone heart transplantation.",
            "member_states": "Austria",
            "decision_date": "25/05/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521699-71-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522469-31-00",
            "title": "D. pteronyssinus and D. farinae allergen extracts. Study of the sensitivity and specificity of the prick test diagnostic preparation",
            "phase": "Phase III",
            "lead_sponsor": "Inmunotek S.L.",
            "conditions": "Allergy to Dermatophagoides pteronyssinus, Allergy to Dermatophagoides farinae",
            "member_states": "Spain",
            "decision_date": "25/05/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522469-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524181-26-00",
            "title": "A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)",
            "phase": "Phase II",
            "lead_sponsor": "C4 Therapeutics Inc.",
            "conditions": "relapsed/refractory multiple myeloma",
            "member_states": "Italy; France; Spain; Poland",
            "decision_date": "25/05/2026",
            "enrolled": "43",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524181-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524884-18-01",
            "title": "Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angiography for the evaluation of unruptured intracranial aneurysms: towards a standardization of practices  (OPIAC)",
            "phase": "Phase III",
            "lead_sponsor": "Les Hopitaux Universitaires De Strasbourg",
            "conditions": "Intracranial aneurysms",
            "member_states": "France",
            "decision_date": "22/05/2026",
            "enrolled": "244",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524884-18-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521982-29-00",
            "title": "UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis",
            "phase": "Phase II",
            "lead_sponsor": "Unicancer",
            "conditions": "Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting",
            "member_states": "France",
            "decision_date": "22/05/2026",
            "enrolled": "51",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521982-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525704-98-00",
            "title": "A study in healthy people to compare two tablet formulations of pramipexole",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "22/05/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525704-98-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521589-83-00",
            "title": "Reassessment of statin-associated musscle symptoms in adults with familial hypercholesterolemia: A phase IV randomized double-blinded n-of-1 crossover trial including periods with atorvastatin, placebo and no study treatment",
            "phase": "Phase IV",
            "lead_sponsor": "Oslo University Hospital HF",
            "conditions": "Familial hypercholesterolaemia",
            "member_states": "Norway",
            "decision_date": "22/05/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521589-83-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523823-23-00",
            "title": "A study to test single and multiple doses of MER511 given to adults with Graves\u2019 disease",
            "phase": "Phase I",
            "lead_sponsor": "Merida Biosciences Inc.",
            "conditions": "Graves\u2019 disease",
            "member_states": "Spain",
            "decision_date": "22/05/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523823-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525788-42-00",
            "title": "Thorough QT/QTc study with GLPG3667, placebo, and active comparator in healthy subjects",
            "phase": "Phase I",
            "lead_sponsor": "Galapagos",
            "conditions": "Healthy volunteers",
            "member_states": "Netherlands",
            "decision_date": "22/05/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525788-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524564-38-00",
            "title": "A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants",
            "phase": "Phase I",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Neuropsychiatric indications and potentially other conditions",
            "member_states": "Belgium",
            "decision_date": "22/05/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524564-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524710-29-00",
            "title": "Comparing intraoperative indocyanine green fluorescence imaging with standard clinical assessment for flap perfusion in head and neck reconstruction: A randomised controlled Trial (VISION Trial)",
            "phase": "Phase IV",
            "lead_sponsor": "Region Skane",
            "conditions": "Head and neck cancer",
            "member_states": "Sweden",
            "decision_date": "22/05/2026",
            "enrolled": "244",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524710-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525895-25-00",
            "title": "A randomized, placebo-controlled, blinded, parallel-group clinical trial to assess the efficacy of N-acetylcysteine in adults with acute infections or sepsis and evidence of liver dysfunction: the IMPACT-NAC trial",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Acute infection, Sepsis",
            "member_states": "Denmark",
            "decision_date": "22/05/2026",
            "enrolled": "360",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525895-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525078-12-00",
            "title": "A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 mg film-coated tablets (Antibiotice SA) vs. Normix\u00ae 200 mg, film- coated tablets (Alfasigma S.P.A) in healthy subjects under fed conditions",
            "phase": "Phase I",
            "lead_sponsor": "Antibiotice S.A.",
            "conditions": "healthy subjects",
            "member_states": "Romania",
            "decision_date": "22/05/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525078-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525448-14-00",
            "title": "Bioequivalence study 1 to compare pharmacokinetics of Parkinson\u00b4s disease drugs in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Orion Corporation",
            "conditions": "Parkinson disease",
            "member_states": "Czechia",
            "decision_date": "22/05/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525448-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521563-13-01",
            "title": "Safety and efficacy of T10430 eye drops in controlling paediatric myopia progression",
            "phase": "Phase II",
            "lead_sponsor": "Laboratoires Thea",
            "conditions": "Paediatric myopia",
            "member_states": "Ireland; Austria",
            "decision_date": "22/05/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521563-13-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523850-15-00",
            "title": "Exogenous progesterone as ovulation trigger \u2013 a pilot study",
            "phase": "Phase IV",
            "lead_sponsor": "Instituto Valenciano De Infertilidade Clinica De Reproducao Assistida Lda.",
            "conditions": "Infertility",
            "member_states": "Portugal",
            "decision_date": "22/05/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523850-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526153-34-00",
            "title": "150 mg CIT-013 phase 1 trial",
            "phase": "Phase I",
            "lead_sponsor": "Citryll B.V.",
            "conditions": "Immune mediated inflammatory diseases",
            "member_states": "Netherlands",
            "decision_date": "22/05/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526153-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523576-23-00",
            "title": "ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Unresectable Stage III non-small cell lung cancer without progression",
            "member_states": "France; Ireland; Germany; Greece; Bulgaria; Spain; Netherlands; Italy; Sweden; Romania; Hungary; Belgium; Austria; Poland",
            "decision_date": "22/05/2026",
            "enrolled": "279",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523576-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523672-23-00",
            "title": "A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).",
            "phase": "Phase II",
            "lead_sponsor": "UroTrials GmbH, AIO-Studien gGmbH",
            "conditions": "Metastatic Castrate Sensitive Prostate Cancer - mCSPC",
            "member_states": "Germany",
            "decision_date": "22/05/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523672-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524620-22-00",
            "title": "A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours",
            "phase": "Phase I/II",
            "lead_sponsor": "Orion Corporation",
            "conditions": "Neoplasms benign malignant and unspecified (incl. cysts and polyps)",
            "member_states": "Finland; Denmark; Spain; France",
            "decision_date": "22/05/2026",
            "enrolled": "85",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524620-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525013-23-00",
            "title": "A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).",
            "phase": "Phase II",
            "lead_sponsor": "Eikon Therapeutics Inc.",
            "conditions": "Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)",
            "member_states": "Germany; Spain; Netherlands; Romania; Greece; Italy; Austria; Belgium; Bulgaria; France; Hungary; Poland",
            "decision_date": "21/05/2026",
            "enrolled": "192",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525013-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525200-99-00",
            "title": "Clinical trial to evaluate the safety, tolerability and effectiveness of a medicinal nasal insert in the treatment of chronic hay fever.- Inspicare",
            "phase": "Phase I",
            "lead_sponsor": "Dianosic",
            "conditions": "Chronic allergic rhinitis",
            "member_states": "Netherlands",
            "decision_date": "21/05/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525200-99-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524367-20-00",
            "title": "An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease",
            "phase": "Phase II",
            "lead_sponsor": "Pharming Technologies B.V.",
            "conditions": "Adult patients with primary mitochondrial disease",
            "member_states": "Belgium; Germany; Czechia; Spain; Denmark; Italy; France",
            "decision_date": "21/05/2026",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524367-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524165-25-00",
            "title": "First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors",
            "phase": "Phase I",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Neoplasms",
            "member_states": "Spain; Denmark; Finland; France",
            "decision_date": "21/05/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524165-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524612-11-00",
            "title": "Effect of an adjunctive intervention on the tolerability of semaglutide in overweight adults without diabetes: a prospective, randomised, double-blind, single-centre, placebo-controlled clinical trial (SEMTOL)",
            "phase": "Phase IV",
            "lead_sponsor": "University Of Tartu",
            "conditions": "Overweight and obesity",
            "member_states": "Estonia",
            "decision_date": "21/05/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524612-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525267-40-00",
            "title": "Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma",
            "phase": "Phase IV",
            "lead_sponsor": "Centro Di Riferimento Oncologico Di Aviano",
            "conditions": "Renal cell carcinoma",
            "member_states": "Italy",
            "decision_date": "21/05/2026",
            "enrolled": "216",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525267-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523280-38-00",
            "title": "An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up",
            "phase": "Phase II",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Thyroid Eye Disease",
            "member_states": "Spain; Poland; France; Italy; Greece",
            "decision_date": "20/05/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523280-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524078-40-00",
            "title": "An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Chronic Spontaneous Urticaria",
            "member_states": "Germany; Spain; France; Poland; Bulgaria; Czechia",
            "decision_date": "20/05/2026",
            "enrolled": "154",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524078-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524635-39-00",
            "title": "An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)",
            "phase": "Phase I/II",
            "lead_sponsor": "Fondazione Telethon Ets, San Raffaele Hospital",
            "conditions": "X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)",
            "member_states": "Italy",
            "decision_date": "20/05/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524635-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525333-22-00",
            "title": "SAR447971 first-in-human study",
            "phase": "Phase I",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Hidradenitis",
            "member_states": "Netherlands",
            "decision_date": "20/05/2026",
            "enrolled": "134",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525333-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523259-72-00",
            "title": "A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Hidradenitis Suppurativa (HS)",
            "member_states": "Portugal; Greece; Germany; Hungary; France; Spain; Bulgaria; Slovakia; Poland; Czechia; Belgium; Italy",
            "decision_date": "20/05/2026",
            "enrolled": "313",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523259-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523087-20-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping",
            "phase": "Phase III",
            "lead_sponsor": "Avidity Biosciences Inc.",
            "conditions": "Duchenne muscular dystrophy",
            "member_states": "Italy; Germany; France; Spain; Belgium; Poland; Netherlands",
            "decision_date": "20/05/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523087-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524821-42-00",
            "title": "Erdosteine effect on oxidative stress, inflammatory response and immune modulation in patients with COPD. A single center, open label, double arm, controlled, 4-week, explorative, ex vivo study.",
            "phase": "Phase IV",
            "lead_sponsor": "ASST Fatebenefratelli Sacco",
            "conditions": "COPD",
            "member_states": "Italy",
            "decision_date": "20/05/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524821-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524005-32-00",
            "title": "A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)",
            "phase": "Phase II",
            "lead_sponsor": "Elevara Medicines Limited",
            "conditions": "Rheumatoid arthritis",
            "member_states": "Czechia; Bulgaria; Hungary; Netherlands; Poland; Spain",
            "decision_date": "19/05/2026",
            "enrolled": "95",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524005-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524060-38-00",
            "title": "An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body\u2019s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Active Ulcerative Colitis (UC)",
            "member_states": "Germany; Poland; Belgium",
            "decision_date": "19/05/2026",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524060-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523464-20-00",
            "title": "A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Moderate to Severe Atopic Dermatitis",
            "member_states": "Germany; Poland",
            "decision_date": "19/05/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523464-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524408-30-01",
            "title": "Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial",
            "phase": "Phase III",
            "lead_sponsor": "Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard",
            "conditions": "Metastatic hormone-sensitive prostate cancer",
            "member_states": "Spain; Germany; France; Portugal; Italy",
            "decision_date": "19/05/2026",
            "enrolled": "292",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524408-30-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521632-12-00",
            "title": "A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)",
            "phase": "Phase III",
            "lead_sponsor": "VarmX B.V.",
            "conditions": "Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding",
            "member_states": "Belgium; Germany; Italy; France; Czechia; Bulgaria; Hungary; Spain; Netherlands; Poland; Austria; Estonia; Romania; Portugal; Lithuania",
            "decision_date": "19/05/2026",
            "enrolled": "443",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521632-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523425-17-00",
            "title": "PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases",
            "phase": "Phase II",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Proteinuric kidney diseases",
            "member_states": "Portugal; Greece; Italy; Poland; Estonia; Slovakia; Sweden; Denmark; Belgium; Norway; Romania; France; Spain; Germany; Netherlands; Croatia",
            "decision_date": "19/05/2026",
            "enrolled": "66",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523425-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523567-38-00",
            "title": "Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-na\u00efve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations",
            "phase": "Phase II",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "locally advanced or metastatic NSCLC",
            "member_states": "Germany; France; Spain",
            "decision_date": "19/05/2026",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523567-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524140-35-00",
            "title": "A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma",
            "phase": "Phase II",
            "lead_sponsor": "Fundacio Sant Joan De Deu",
            "conditions": "Neuroblastoma or ganglioneuroblastoma (nodular or intermixed)",
            "member_states": "Spain",
            "decision_date": "19/05/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524140-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519246-75-01",
            "title": "An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Patients With Muscle-Invasive Bladder Cancer",
            "member_states": "Italy; Spain; France; Netherlands",
            "decision_date": "19/05/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519246-75-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524765-24-00",
            "title": "A multicentre, open-label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens when administering a single-dose, intramuscular vaccination as simulated post-exposure prophylaxis at least five years following priming. \"BAZOOKA_221\"",
            "phase": "Phase III",
            "lead_sponsor": "Institute Of Tropical Medicine",
            "conditions": "Rabies infection/prophylaxis",
            "member_states": "Belgium",
            "decision_date": "19/05/2026",
            "enrolled": "561",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524765-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524308-31-00",
            "title": "A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone",
            "phase": "Phase II",
            "lead_sponsor": "Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe",
            "conditions": "Acute myeloid leukemia",
            "member_states": "Italy; Spain",
            "decision_date": "19/05/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524308-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523735-19-00",
            "title": "A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Metastatic Microsatellite Stable Colorectal Cancer",
            "member_states": "Poland; France; Denmark; Norway; Spain; Germany; Belgium; Netherlands; Austria; Italy",
            "decision_date": "19/05/2026",
            "enrolled": "292",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523735-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524377-16-00",
            "title": "Multicentre, randomised, double-blind, placebo-controlled clinical trial to confirm the efficacy, safety, and clinical impact of the mucosal bacterial therapeutic vaccine MV140 in women with non-complicated recurrent urinary tract infections (rUTIs).",
            "phase": "Phase III",
            "lead_sponsor": "Inmunotek S.L.",
            "conditions": "Recurrent Non-Complicated Urinary Tract Infections (rUTIs).",
            "member_states": "Portugal",
            "decision_date": "19/05/2026",
            "enrolled": "252",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524377-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524475-23-00",
            "title": "Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Neisseria gonorrhoeae Infections",
            "member_states": "France",
            "decision_date": "18/05/2026",
            "enrolled": "360",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524475-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517310-15-00",
            "title": "A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease",
            "phase": "Phase I",
            "lead_sponsor": "Mission Therapeutics Limited",
            "conditions": "Parkinson's Disease",
            "member_states": "Germany; Netherlands; France",
            "decision_date": "18/05/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517310-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525005-20-00",
            "title": "A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normal FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative",
            "phase": "Phase IV",
            "lead_sponsor": "Martin-Luther-Universitaet Halle-Wittenberg",
            "conditions": "Male Infertility",
            "member_states": "Italy; Spain; Germany",
            "decision_date": "18/05/2026",
            "enrolled": "138",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525005-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524697-42-00",
            "title": "EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management of complicated pleural infections",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire Amiens Picardie",
            "conditions": "Pleural infections",
            "member_states": "France",
            "decision_date": "18/05/2026",
            "enrolled": "244",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524697-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524093-41-00",
            "title": "INCREDIBLE: INCREmental DIalysis and diet for a Better Life Experience; Clinical relevance of an \u201cadd-on\u201d Ketosteril supplementation on incremental haemodialysis period in incident haemodialysis patients. An exploratory randomized controlled trial",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Le Mans",
            "conditions": "Incremental Haemodialysis",
            "member_states": "France",
            "decision_date": "18/05/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524093-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525590-40-00",
            "title": "Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184",
            "phase": "Phase I",
            "lead_sponsor": "Viiv Healthcare UK Limited",
            "conditions": "human immunodeficiency virus (HIV)",
            "member_states": "Netherlands",
            "decision_date": "18/05/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525590-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521816-20-00",
            "title": "A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.",
            "phase": "Phase II",
            "lead_sponsor": "Aimmune Nestle Health Science US R&D LLC",
            "conditions": "\u200b\u200bExocrine Pancreatic Insufficiency\u200b",
            "member_states": "Poland; Hungary; Spain; Bulgaria; Italy",
            "decision_date": "18/05/2026",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521816-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522773-12-00",
            "title": "Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Blomia tropicalis",
            "phase": "Phase III",
            "lead_sponsor": "Inmunotek S.L.",
            "conditions": "Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma",
            "member_states": "Spain",
            "decision_date": "18/05/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522773-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524978-42-00",
            "title": "Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Bordeaux",
            "conditions": "Asymptomatic anal LGV infection",
            "member_states": "France",
            "decision_date": "18/05/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524978-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520149-22-00",
            "title": "mRNA Therapy to restore lymphatic flow in secondary lymphedema",
            "phase": "Phase I/II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "Lymphedema",
            "member_states": "France",
            "decision_date": "18/05/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520149-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524942-87-00",
            "title": "Prognostic value of early assessment by \u2076\u2078Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with \u00b9\u2077\u2077Lutetium-oxodotreotide.\u201d",
            "phase": "Phase IV",
            "lead_sponsor": "Centre De Lutte Contre Le Cancer Eugene Marquis",
            "conditions": "Gastroenteropancreatic neuroendocrine tumors",
            "member_states": "France",
            "decision_date": "18/05/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524942-87-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524090-16-00",
            "title": "A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Relapsed/Refractory Small Cell Lung Cancer",
            "member_states": "Italy; Spain; Romania",
            "decision_date": "18/05/2026",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524090-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522431-34-00",
            "title": "TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)",
            "phase": "Phase II",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Advanced pancreatic cancer",
            "member_states": "Denmark",
            "decision_date": "18/05/2026",
            "enrolled": "1200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522431-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518871-74-00",
            "title": "A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification",
            "phase": "Phase II",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene",
            "member_states": "Spain; France; Denmark",
            "decision_date": "18/05/2026",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518871-74-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524541-27-00",
            "title": "THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation",
            "phase": "Phase II",
            "lead_sponsor": "Prinses Maxima Centrum voor Kinderoncologie B.V.",
            "conditions": "Sepsis, Hyperinflammation",
            "member_states": "Netherlands",
            "decision_date": "18/05/2026",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524541-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524316-11-00",
            "title": "A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis",
            "phase": "Phase III",
            "lead_sponsor": "Zenas Biopharma (USA) LLC",
            "conditions": "Primary Progressive Multiple Sclerosis (PPMS)",
            "member_states": "Italy; Finland; Bulgaria; Greece; Belgium; Estonia; Portugal; Spain; Germany; France; Czechia; Slovakia; Romania; Croatia; Poland; Austria; Netherlands; Denmark; Sweden; Hungary",
            "decision_date": "18/05/2026",
            "enrolled": "398",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524316-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522138-29-00",
            "title": "A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation",
            "member_states": "Spain; France; Germany; Poland; Italy; Netherlands; Greece; Hungary",
            "decision_date": "18/05/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522138-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525475-96-00",
            "title": "The effect of beta-blockers on how you feel and recover after a heart attack when your heart is still pumping well",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Myocardial infarction without reduced ejection fraction",
            "member_states": "Belgium",
            "decision_date": "18/05/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525475-96-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524289-56-00",
            "title": "A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 \u00b5g}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 \u00b5g}]) in asthma subjects.",
            "phase": "Phase IV",
            "lead_sponsor": "Chiesi Farmaceutici S.p.A.",
            "conditions": "Asthma",
            "member_states": "Germany; Romania; Italy; Bulgaria; Poland; Slovakia; Spain; France",
            "decision_date": "18/05/2026",
            "enrolled": "606",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524289-56-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522007-18-00",
            "title": "A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Relapsed or Refractory Multiple Myeloma",
            "member_states": "Spain; Norway; Germany; Greece; France; Italy; Netherlands",
            "decision_date": "18/05/2026",
            "enrolled": "157",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522007-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524192-24-00",
            "title": "A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Samsung Bioepis Co. Ltd.",
            "conditions": "advanced refractory solid tumors",
            "member_states": "Spain",
            "decision_date": "18/05/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524192-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525091-29-00",
            "title": "SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety study of half- vs standard dose immunosuppression in kidney transplant recipients with a well-matched donor.",
            "phase": "Phase II",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "Kidney Transplant Recipient",
            "member_states": "Austria",
            "decision_date": "17/05/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525091-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523586-18-00",
            "title": "ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 \u2265 50%",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Non-Small Cell Lung Cancer",
            "member_states": "Portugal; Norway; Sweden; Bulgaria; France; Belgium; Austria; Germany; Finland; Poland; Romania; Netherlands; Spain; Italy; Hungary; Czechia",
            "decision_date": "15/05/2026",
            "enrolled": "265",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523586-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525127-27-00",
            "title": "A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis",
            "phase": "Phase I/II",
            "lead_sponsor": "Aurinia Pharmaceuticals Inc.",
            "conditions": "Generalized Myasthenia Gravis",
            "member_states": "Poland",
            "decision_date": "15/05/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525127-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525543-32-00",
            "title": "A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma",
            "phase": "Phase I",
            "lead_sponsor": "Oncopeptides AB",
            "conditions": "Recurrent glioblastoma",
            "member_states": "Norway",
            "decision_date": "15/05/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525543-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525248-13-00",
            "title": "A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Na\u00efve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Eikon Therapeutics Inc.",
            "conditions": "Advanced Solid Tumors",
            "member_states": "France; Spain; Norway; Italy; Germany; Austria; Poland; Finland; Belgium; Denmark; Portugal",
            "decision_date": "15/05/2026",
            "enrolled": "81",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525248-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524052-58-00",
            "title": "Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Healthy Overweight or Obese",
            "member_states": "Netherlands",
            "decision_date": "15/05/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524052-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516734-35-00",
            "title": "NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)",
            "phase": "Phase III",
            "lead_sponsor": "WSG Women's Cancer Study Group GmbH",
            "conditions": "triple-negative early breast cancer",
            "member_states": "Germany; Poland",
            "decision_date": "15/05/2026",
            "enrolled": "765",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516734-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520446-31-00",
            "title": "Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Participants with overweight or obesity, and type 2 diabetes",
            "member_states": "Germany; Croatia; Portugal; Hungary; Bulgaria; Romania; Poland",
            "decision_date": "15/05/2026",
            "enrolled": "440",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520446-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521976-80-00",
            "title": "A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody",
            "phase": "Phase II",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Relapsed or Refractory \nMultiple Myeloma (RRMM)",
            "member_states": "Poland; Italy",
            "decision_date": "14/05/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521976-80-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522771-28-00",
            "title": "Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Lepidoglyphus destructor.",
            "phase": "Phase III",
            "lead_sponsor": "Inmunotek S.L.",
            "conditions": "Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma",
            "member_states": "Spain",
            "decision_date": "14/05/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522771-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523389-26-00",
            "title": "A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma",
            "phase": "Phase III",
            "lead_sponsor": "Deciphera Pharmaceuticals Inc.",
            "conditions": "Relapsed/refractory primary central nervous system lymphoma",
            "member_states": "Czechia; Germany; Italy; Belgium; Spain; Poland; Austria; France; Hungary",
            "decision_date": "14/05/2026",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523389-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524810-28-00",
            "title": "A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia",
            "phase": "Phase III",
            "lead_sponsor": "Quetzal Therapeutics LLC",
            "conditions": "Acute Promyelocytic Leukemia",
            "member_states": "Germany; Poland; Spain; Romania; Italy; France",
            "decision_date": "13/05/2026",
            "enrolled": "89",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524810-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524317-88-00",
            "title": "Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy",
            "phase": "Phase II",
            "lead_sponsor": "Alterity Therapeutics Limited",
            "conditions": "Multiple System Atrophy",
            "member_states": "France",
            "decision_date": "13/05/2026",
            "enrolled": "7",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524317-88-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526096-31-00",
            "title": "A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167",
            "phase": "Phase I",
            "lead_sponsor": "Corteria Pharmaceuticals",
            "conditions": "Chronic Heart Failure",
            "member_states": "Netherlands",
            "decision_date": "13/05/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526096-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517130-17-00",
            "title": "Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN",
            "phase": "Phase I/II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Bordeaux",
            "conditions": "FLT3-mutated Acute Myeloid Leukemia",
            "member_states": "France",
            "decision_date": "13/05/2026",
            "enrolled": "41",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517130-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524995-53-00",
            "title": "Reproductive outcomes with letrozole co-treatment during ovarian stimulation in women with endometriosis undergoing IVF/ICSI: a randomised, multicentre, parallel group pragmatic trial",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Brussel",
            "conditions": "Women with endometriosis undergoing IVF/ICSI",
            "member_states": "Belgium",
            "decision_date": "13/05/2026",
            "enrolled": "854",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524995-53-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523869-22-00",
            "title": "A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "advanced or metastatic extrapulmonary neuroendocrine carcinoma",
            "member_states": "Portugal; Spain; Poland; Sweden; Italy; Czechia; France; Netherlands; Finland; Denmark; Austria; Germany; Belgium; Norway",
            "decision_date": "13/05/2026",
            "enrolled": "144",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523869-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523404-74-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis",
            "phase": "Phase II",
            "lead_sponsor": "Innocare Pharma Inc.",
            "conditions": "Prurigo Nodularis",
            "member_states": "Belgium; Poland; Germany; France; Austria",
            "decision_date": "13/05/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523404-74-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524786-25-00",
            "title": "A phase IV proof-of-concept study to assess the safety and efficacy of Maribavir to inhibit high Virus Epstein-Barr (VEB) replication among young adult kidney transplant recipie",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio Hospital Universitari Vall D\u2019Hebron Institut De Recerca",
            "conditions": "Transplant patients with high recurrent Epstein-Barr infection",
            "member_states": "Spain",
            "decision_date": "13/05/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524786-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524214-28-00",
            "title": "Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, with Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)",
            "phase": "Phase III",
            "lead_sponsor": "LIB Therapeutics Inc.",
            "conditions": "Heterozygous Familial Hypercholesterolemia",
            "member_states": "Norway",
            "decision_date": "13/05/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524214-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525083-14-00",
            "title": "SCARFREE-001: A Phase 2 Dose-Finding and Proof-of-Concept Study of Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds",
            "phase": "Phase II",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Scar formation following surgical wounds",
            "member_states": "Denmark",
            "decision_date": "13/05/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525083-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523106-32-00",
            "title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Obesity or Overweight and Type 2 Diabetes",
            "member_states": "Germany; Romania; Czechia; Poland; Hungary; France; Spain; Italy",
            "decision_date": "13/05/2026",
            "enrolled": "551",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523106-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521891-78-00",
            "title": "IMMUNOTIME \u00ab EVALUATION OF THE EFFECT OF TIME OF ADMINISTRATION ON THE ACTIVITY ON FIRST LINE OF PEMBROLIZUMAB IN ASSOCIATION WITH CARBOPLATIN PEMETREXED IN METASTATIC NON-SQUAMOUS LUNG CANCER. A RANDOMISED MULTICENTER PHASE III TRIAL\u00bb",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)",
            "member_states": "France",
            "decision_date": "12/05/2026",
            "enrolled": "254",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521891-78-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525748-14-00",
            "title": "A clinical trial of MK-1824 in healthy participants (MK-1824-001)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Heart failure with preserved ejection fraction",
            "member_states": "Belgium",
            "decision_date": "12/05/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525748-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525153-39-00",
            "title": "Effect of vasopressin versus norepinephrine on post-operative mean pulmonary arterial pressure following pulmonary endarterectomy surgery, a randomized open label trial",
            "phase": "Phase III",
            "lead_sponsor": "Fondation Hopital Saint Joseph",
            "conditions": "Chronic thromboembolic pulmonary hypertension",
            "member_states": "France",
            "decision_date": "12/05/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525153-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525213-31-00",
            "title": "A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Esophageal squamous cell carcinoma",
            "member_states": "Czechia; Germany; France; Norway",
            "decision_date": "12/05/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525213-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521950-41-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma",
            "phase": "Phase III",
            "lead_sponsor": "Generate Biomedicines Inc.",
            "conditions": "severe uncontrolled asthma",
            "member_states": "Latvia; Hungary; Bulgaria; Romania; Portugal; Netherlands; Croatia; Germany; Greece; Czechia",
            "decision_date": "12/05/2026",
            "enrolled": "271",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521950-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520565-51-00",
            "title": "DAREON\u00ae-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "small cell lung cancer",
            "member_states": "Czechia; Sweden; Poland; Netherlands; Greece; Latvia; Finland; Norway; Belgium; Austria; Portugal; Romania; Italy; Estonia; France; Ireland; Germany; Spain; Bulgaria; Hungary",
            "decision_date": "12/05/2026",
            "enrolled": "295",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520565-51-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522586-30-00",
            "title": "A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Na\u00efve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs",
            "phase": "Phase III",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Psoriatic Arthritis",
            "member_states": "Germany; Belgium; Spain; Czechia; Croatia; Portugal; Poland; Latvia; Bulgaria; France; Estonia; Hungary; Italy",
            "decision_date": "12/05/2026",
            "enrolled": "638",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522586-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524077-16-00",
            "title": "Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025",
            "phase": "Phase II",
            "lead_sponsor": "G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica",
            "conditions": "metastatic urothelial carcinoma",
            "member_states": "Italy",
            "decision_date": "12/05/2026",
            "enrolled": "144",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524077-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523895-22-00",
            "title": "A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors",
            "phase": "Phase II",
            "lead_sponsor": "Dualitybio Inc.",
            "conditions": "Non-small cell lung cancer (NSCLC), Cervical cancer (CC), Melanoma, Hepatocellular carcinoma (HCC), Ovarian cancer (OC), Squamous cell carcinoma of head and neck",
            "member_states": "Italy; Poland; France; Spain; Germany",
            "decision_date": "12/05/2026",
            "enrolled": "102",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523895-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520906-36-00",
            "title": "Microdosing with a serotonergic agent for ADHD and emotion regulation: biological factors explaining and predicting treatment response",
            "phase": "Phase II",
            "lead_sponsor": "Universiteit Maastricht",
            "conditions": "Attention Deficit Hyperactivity Disorder (ADHD)",
            "member_states": "Netherlands",
            "decision_date": "11/05/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520906-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521331-36-00",
            "title": "MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis \u2013 interstitial lung disease",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Patient with stabilized SSc-ILD (as defined by a decline of FVC \u2264 5%) following RTX induction treatment",
            "member_states": "France",
            "decision_date": "11/05/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521331-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524703-76-00",
            "title": "A randomized controlled non-inferiority trial comparing 7 versus 14 days of ciprofloxacin for male urinary tract infections with systemic involvement.",
            "phase": "Phase III",
            "lead_sponsor": "UZ Brussel",
            "conditions": "Urinary tract infection with systemic involvement (UTI: definite, probable, or possible UTI according to the diagnostic criteria of the research reference standard for UTI proposed by Bilsen et al (see reference 19 in protocol)).\n\nSystemic involvement: one or more of the following, attributable to the UTI:\n\u2022\tTemperature \u226538\u00b0C\n\u2022\tFlank pain or costovertebral angle tenderness\n\u2022\tSystolic blood pressure <90 mmHg without alternative cause\n\u2022\tSignificant elevation of inflammatory markers related to the UTI:\no\tC-reactive protein concentration \u226550 mg/L, Procalcitonin concentration \u22650\u00b75 ng/mL or white blood cell count \u226512\u00d710^9 per L (all without other plausible source, based on at least history and examination).\n\u2022\tBacteraemia with the same pathogen as isolated from urine culture",
            "member_states": "Belgium",
            "decision_date": "11/05/2026",
            "enrolled": "264",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524703-76-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524069-26-00",
            "title": "Evaluation of hANP for prevention of acute kidney injury after cardiac surgery: A two-part randomized controlled trial with open-label extension in children aged 0\u201312 months.",
            "phase": "Phase II",
            "lead_sponsor": "Vaestra Goetalandsregionen",
            "conditions": "Acute kidney injury (AKI) occurring in newborns and infants after cardiac surgery with cardiopulmonary bypass. The study targets early postoperative renal dysfunction and fluid imbalance in this high-risk population.",
            "member_states": "Sweden",
            "decision_date": "11/05/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524069-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522744-40-00",
            "title": "A research study to see how NNC0487-0111 affects the body\u2019s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Obesity",
            "member_states": "Netherlands; Denmark",
            "decision_date": "11/05/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522744-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522883-34-00",
            "title": "PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer",
            "phase": "Phase IV",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Metastatic cervical cancer",
            "member_states": "Netherlands",
            "decision_date": "11/05/2026",
            "enrolled": "261",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522883-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525608-85-00",
            "title": "The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma",
            "phase": "Phase III",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Paraffin Oil Induced Granulomatous Disease",
            "member_states": "Denmark",
            "decision_date": "11/05/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525608-85-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524921-42-00",
            "title": "A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D",
            "phase": "Phase I",
            "lead_sponsor": "Gubra A/S",
            "conditions": "Type 2 Diabetes, Obesity",
            "member_states": "Germany",
            "decision_date": "11/05/2026",
            "enrolled": "220",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524921-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523562-24-00",
            "title": "A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a single dose of REGN22044 in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Heathy volunteer trial",
            "member_states": "Belgium",
            "decision_date": "11/05/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523562-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520631-17-00",
            "title": "A Study to Assess the Safety of RG6496 in Huntington\u2019s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Huntington\u2019s Disease Gene Expansion Carriers",
            "member_states": "Italy; Poland; Denmark; Germany; Portugal; Spain",
            "decision_date": "11/05/2026",
            "enrolled": "43",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520631-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524265-24-00",
            "title": "A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)",
            "phase": "Phase III",
            "lead_sponsor": "A. Menarini International Licensing S.A.",
            "conditions": "Dyslipidemia at High to Very High Cardiovascular Risk",
            "member_states": "Spain; Poland; Netherlands; Italy; Slovakia; Czechia; Germany",
            "decision_date": "11/05/2026",
            "enrolled": "338",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524265-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525350-11-00",
            "title": "A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants",
            "phase": "Phase I",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Immune Thrombocytopenia Purpura",
            "member_states": "Germany",
            "decision_date": "11/05/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525350-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522854-37-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of\nPanzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic\nConditions Receiving Treatment with B-cell Depletion Therapy  (\"PROTECT\")",
            "phase": "Phase III",
            "lead_sponsor": "Octapharma Pharmazeutika Produktionsgesellschaft mbH",
            "conditions": "Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.",
            "member_states": "Czechia; Lithuania; Greece; Poland; Germany; Latvia; Bulgaria; Italy",
            "decision_date": "11/05/2026",
            "enrolled": "215",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522854-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522255-25-00",
            "title": "J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms",
            "member_states": "Netherlands; Hungary; France; Austria; Poland; Italy; Denmark; Romania; Greece; Norway; Czechia; Belgium; Spain; Ireland; Germany",
            "decision_date": "11/05/2026",
            "enrolled": "486",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522255-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522983-33-00",
            "title": "A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Chronic rhinosinusitis with nasal polyps",
            "member_states": "Germany; Netherlands; Portugal; Denmark; Sweden; Finland; France; Spain; Austria; Italy; Hungary; Romania; Belgium; Czechia; Poland",
            "decision_date": "11/05/2026",
            "enrolled": "146",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522983-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523134-28-00",
            "title": "A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)",
            "phase": "Phase III",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "ABC borderline resectable pancreatic cancer",
            "member_states": "Netherlands",
            "decision_date": "11/05/2026",
            "enrolled": "143",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523134-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521173-13-00",
            "title": "First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "Advanced Solid Tumors",
            "member_states": "France; Spain",
            "decision_date": "08/05/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521173-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524769-26-00",
            "title": "FINACCESS - Finnish National Study for Early Access to Cancer Therapies",
            "phase": "Phase II",
            "lead_sponsor": "HUS-yhtymae",
            "conditions": "Cancer",
            "member_states": "Finland",
            "decision_date": "08/05/2026",
            "enrolled": "1500",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524769-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524435-39-00",
            "title": "A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)",
            "phase": "Phase II",
            "lead_sponsor": "Charite Universitaetsmedizin Berlin K\u00f6R",
            "conditions": "Localized Scleroderma",
            "member_states": "Germany",
            "decision_date": "08/05/2026",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524435-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523399-22-00",
            "title": "A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies",
            "phase": "Phase I/II",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Advanced Solid Tumours, Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)",
            "member_states": "Italy; Spain; Germany; France",
            "decision_date": "08/05/2026",
            "enrolled": "99",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523399-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523797-17-00",
            "title": "A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis",
            "phase": "Phase II",
            "lead_sponsor": "Oruka Therapeutics Inc.",
            "conditions": "Moderate-to-Severe Plaque Psoriasis",
            "member_states": "Germany; Spain",
            "decision_date": "08/05/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523797-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522618-22-00",
            "title": "A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.",
            "phase": "Phase III",
            "lead_sponsor": "Ipsen Innovation",
            "conditions": "Treatment of moderate to severe glabellar lines",
            "member_states": "France; Germany",
            "decision_date": "07/05/2026",
            "enrolled": "230",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522618-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522348-42-00",
            "title": "LAMP-COVID: Locating Amyloid-containing Microclots with total-body PET in post-COVID syndrome",
            "phase": "Phase I/II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "post-COVID syndrome (long COVID)",
            "member_states": "Netherlands",
            "decision_date": "07/05/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522348-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523104-71-00",
            "title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Obesity or Overweight Without Type 2 Diabetes",
            "member_states": "Poland; Hungary; France; Belgium; Italy; Netherlands; Czechia; Germany; Spain",
            "decision_date": "07/05/2026",
            "enrolled": "754",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523104-71-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524646-94-00",
            "title": "Optimizing Aspirin Use for Preeclampsia Prevention",
            "phase": "Phase III",
            "lead_sponsor": "Fundacio Hospital Universitari Vall D\u2019Hebron Institut De Recerca",
            "conditions": "Obstetrics \u2013 Preeclampsia",
            "member_states": "Spain",
            "decision_date": "07/05/2026",
            "enrolled": "11836",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524646-94-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525214-62-00",
            "title": "Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients with Stage I-III dMMR Colon Cancer: A National, Multicentre, Personalised, Phase II Study (RESET C2)",
            "phase": "Phase II",
            "lead_sponsor": "Region Sjaelland",
            "conditions": "Localised dMMR Colon Cancer",
            "member_states": "Denmark",
            "decision_date": "07/05/2026",
            "enrolled": "152",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525214-62-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524200-29-00",
            "title": "A prospective, multinational, multicenter, randomized, sequential, double-blind, placebo-controlled, phase 2a clinical study to assess the safety and pharmacokinetics (PK) of OMN6 in hospital-acquired bacterial pneumonia (HABP) or ventilated-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC).",
            "phase": "Phase II",
            "lead_sponsor": "Omnix Medical Ltd.",
            "conditions": "Hospital-acquired bacterial pneumonia or ventilated-associated bacterial pneumonia caused by Acinetobacter baumannii complex.",
            "member_states": "Italy; Hungary; Greece",
            "decision_date": "06/05/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524200-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525073-37-00",
            "title": "A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive",
            "phase": "Phase I",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Autosomal Dominant Polycystic Kidney Disease",
            "member_states": "Netherlands",
            "decision_date": "06/05/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525073-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523641-10-00",
            "title": "PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION",
            "phase": "Phase I",
            "lead_sponsor": "Zealand Pharma A/S",
            "conditions": "Healthy / hepatic impaired volunteers only study to assess PK parameters",
            "member_states": "Slovakia; Poland",
            "decision_date": "06/05/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523641-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524896-22-00",
            "title": "A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multicenter Trial Evaluating the Effects of Two Dosing Regimens of Nolasiban on Uterine Contractility and Endocrine Parameters",
            "phase": "Phase II",
            "lead_sponsor": "ReproNovo ApS",
            "conditions": "Women with an indication for IVF/ICSI",
            "member_states": "Spain",
            "decision_date": "06/05/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524896-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525627-24-00",
            "title": "A clinical trial of MK-4605 in healthy participants (MK-4605-001)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Dementia",
            "member_states": "Belgium",
            "decision_date": "06/05/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525627-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524843-11-00",
            "title": "A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Non-Small Cell Lung Cancer",
            "member_states": "France; Italy; Spain",
            "decision_date": "06/05/2026",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524843-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525547-32-01",
            "title": "Colchicine Assessment of Low-grade Inflammation and Biomarker Response in Atherosclerosis with Targeted Evaluation",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Ischemic Heart Disease, Coronary Artery Disease, Chronic Coronary Artery Syndrome",
            "member_states": "Denmark",
            "decision_date": "06/05/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525547-32-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521806-16-00",
            "title": "Single-centre, randomised, double-blind, split-face comparative design clinical trial to evaluate the efficacy and safety of the topical formulation with 4% hydroquinone and 0,025% tretinoin versus the formulation with 4% hydroquinone in patients with facial melasma",
            "phase": "Phase I/II",
            "lead_sponsor": "Mesoestetic Pharma Group S.L.",
            "conditions": "facial melasma",
            "member_states": "Spain",
            "decision_date": "05/05/2026",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521806-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522888-15-00",
            "title": "Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Small Cell Lung Cancer",
            "member_states": "Spain; Germany; Poland; Belgium; France",
            "decision_date": "05/05/2026",
            "enrolled": "53",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522888-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523947-36-00",
            "title": "A Phase II, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination with Anti-cancer Agents in Participants with Advanced/Metastatic Solid Tumors (eVOLVE-02)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).",
            "member_states": "Italy; Germany",
            "decision_date": "05/05/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523947-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524264-38-00",
            "title": "Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio Hospital Universitari Vall D\u2019Hebron Institut De Recerca",
            "conditions": "Infectious diseases",
            "member_states": "Spain",
            "decision_date": "05/05/2026",
            "enrolled": "136",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524264-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523411-11-00",
            "title": "An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of food and effect of apple sauce on bioavailability of the Test \nproduct (Bupropion Hydrochloride Extended Release Capsules 150 mg, manufactured by Sun Pharmaceutical Industries Limited, India) in healthy, adult, human subjects.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "Seasonal affective disorder, Major depressive disorder",
            "member_states": "Romania",
            "decision_date": "05/05/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523411-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523410-84-00",
            "title": "An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropion Hydrochloride Extended Release Capsules 150 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with WELLBUTRIN XL (Bupropion hydrochloride) extended release tablets 300 mg, Distributed by: Bausch Health US, LLC Bridgewater, NJ 08807 USA. Manufactured by: Bausch Health Companies, Inc. Steinbach, MB R5G 1Z7, Canada, in healthy, adult, human subjects under fasting condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "Seasonal affective disorder, Major depressive disorder",
            "member_states": "Romania",
            "decision_date": "05/05/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523410-84-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524613-89-00",
            "title": "PHASE\u202fIB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study)",
            "phase": "Phase I/II",
            "lead_sponsor": "Medica Scientia Innovation Research S.L.",
            "conditions": "HER2 positive advanced breast cancer",
            "member_states": "Spain",
            "decision_date": "05/05/2026",
            "enrolled": "129",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524613-89-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524376-36-00",
            "title": "Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects",
            "phase": "Phase I",
            "lead_sponsor": "Orion Corporation",
            "conditions": "short-term treatment of insomnia",
            "member_states": "Czechia",
            "decision_date": "05/05/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524376-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523443-35-00",
            "title": "Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)",
            "phase": "Phase III",
            "lead_sponsor": "Dompe' Farmaceutici S.p.A.",
            "conditions": "Persistent Corneal Epithelial Defect (PCED)",
            "member_states": "Czechia; Italy; Netherlands; Poland; Germany; Spain; Hungary; France",
            "decision_date": "05/05/2026",
            "enrolled": "91",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523443-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524001-33-00",
            "title": "A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease",
            "phase": "Phase II",
            "lead_sponsor": "Immunovant Sciences GmbH",
            "conditions": "Graves\u2019 Disease",
            "member_states": "Italy; Greece; Germany; Hungary; Poland; Czechia; Netherlands; Spain; Belgium; Bulgaria; Latvia",
            "decision_date": "05/05/2026",
            "enrolled": "128",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524001-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524935-38-00",
            "title": "An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatinib Mesylate Tablets 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Glivec\u00ae (Imatinib mesylate) Coated tablets 400 mg, Produced by Novartis Pharma Produktions GmbH, Wehr, Germany or Novartis Pharmaceutical Manufacturing LLC, Ljubljana; Imported and Registered by Novartis Biosciences SA, Prof. Vicente Rao Avenue, 90, Sao Paulo \u2013 SP, CNPJ: 56.994.502/0001-30, Brazilian Industry, in healthy adult, human subjects under fed condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "(Ph+) Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia (Ph+ ALL)",
            "member_states": "Romania",
            "decision_date": "05/05/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524935-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525752-29-00",
            "title": "A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra",
            "phase": "Phase I",
            "lead_sponsor": "Farco-Pharma GmbH",
            "conditions": "bioavailability trial with healthy participants, therapeutic indication not studied",
            "member_states": "Germany",
            "decision_date": "05/05/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525752-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523486-17-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes",
            "phase": "Phase III",
            "lead_sponsor": "Kailera Therapeutics Inc.",
            "conditions": "Obesity",
            "member_states": "Bulgaria; Hungary; Spain; Germany; Czechia; Poland",
            "decision_date": "05/05/2026",
            "enrolled": "539",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523486-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523811-12-00",
            "title": "A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia",
            "phase": "Phase III",
            "lead_sponsor": "Biomarin Pharmaceutical Inc.",
            "conditions": "Achondroplasia",
            "member_states": "Poland; Italy; Romania",
            "decision_date": "05/05/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523811-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523552-31-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Systemic Lupus Erythematosus",
            "member_states": "Denmark; Hungary; Portugal; Italy; Norway; Greece; Slovakia; Czechia; France; Poland; Bulgaria; Germany; Spain; Romania; Finland",
            "decision_date": "05/05/2026",
            "enrolled": "271",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523552-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520440-42-00",
            "title": "Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Obesity",
            "member_states": "Denmark; France; Germany; Belgium",
            "decision_date": "04/05/2026",
            "enrolled": "270",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520440-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523704-77-00",
            "title": "A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Geographic atrophy secondary to age-related macular degeneration",
            "member_states": "Bulgaria; Romania; Germany; Czechia; Spain; Poland; Italy; Hungary; France",
            "decision_date": "04/05/2026",
            "enrolled": "142",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523704-77-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523510-87-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes",
            "phase": "Phase III",
            "lead_sponsor": "Kailera Therapeutics Inc.",
            "conditions": "Obesity",
            "member_states": "Hungary; Poland; Bulgaria; Germany; Czechia; Spain",
            "decision_date": "04/05/2026",
            "enrolled": "400",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523510-87-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520441-23-00",
            "title": "Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Overweight or obesity, and type 2 diabetes",
            "member_states": "Italy; Croatia; Hungary; Slovakia; Romania",
            "decision_date": "04/05/2026",
            "enrolled": "310",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520441-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523488-39-00",
            "title": "Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)",
            "phase": "Phase II",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Systemic lupus erythematosus",
            "member_states": "Bulgaria; Romania; Germany; Spain; Hungary; Poland; Croatia",
            "decision_date": "04/05/2026",
            "enrolled": "106",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523488-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525163-41-00",
            "title": "Modafinil for debilitating fatigue in quiescent inflammatory bowel disease: a multicentre, randomised, double-blind, placebo-controlled, clinical trial (MODIFI-IBD trial)",
            "phase": "Phase III",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Inflammatory bowel disease, Fatigue",
            "member_states": "Netherlands",
            "decision_date": "04/05/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525163-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524794-16-00",
            "title": "Efficacy and Safety of Daridorexant in Patients with Major Depressive Disorder (MDD) and Insomnia: Double-blind, randomized, controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL",
            "conditions": "Patients with major depressive episode and moderate to severe insomnia disorder",
            "member_states": "Spain",
            "decision_date": "04/05/2026",
            "enrolled": "134",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524794-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521690-14-00",
            "title": "Antidepressant effects of psilocybin in the absence of serotoninergic psychedelic experience: a dimensional functional neuroimaging approach",
            "phase": "Phase II",
            "lead_sponsor": "Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau",
            "conditions": "Major depressive disorder",
            "member_states": "Spain",
            "decision_date": "04/05/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521690-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519638-22-00",
            "title": "A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "IgA nephropathy",
            "member_states": "Belgium; France; Czechia; Croatia; Greece; Germany; Italy; Spain",
            "decision_date": "04/05/2026",
            "enrolled": "69",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519638-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516993-31-00",
            "title": "A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Renal Cell Carcinoma",
            "member_states": "Denmark; Spain; Netherlands; Germany; France; Czechia; Poland; Italy; Greece",
            "decision_date": "04/05/2026",
            "enrolled": "311",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516993-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524638-24-00",
            "title": "CD5CAR-NK cells for refractory invasive mold disease",
            "phase": "Phase I",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "refractory invasive mold disease",
            "member_states": "Spain",
            "decision_date": "04/05/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524638-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521388-11-00",
            "title": "Staphylococcus aureus Network Adaptive Platform trial (SNAP)",
            "phase": "Phase II",
            "lead_sponsor": "Fundacion Para La Gestion De La Investigacion En Salud De Sevilla",
            "conditions": "Staphylococcus aureus bacteraemia",
            "member_states": "Spain",
            "decision_date": "04/05/2026",
            "enrolled": "230",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521388-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-506965-72-00",
            "title": "An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging pathological alpha-synuclein deposition in the brains of patients with Parkinson\u2019s disease (PD) or Multiple System Atrophy (MSA) compared to age-matched healthy controls (AMHC)",
            "phase": "Phase I",
            "lead_sponsor": "Modag GmbH",
            "conditions": "Parkinson Disease, Multiple System Atrophy, Healthy Volunteer",
            "member_states": "Germany",
            "decision_date": "04/05/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-506965-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525517-31-00",
            "title": "A PHASE 1, OPEN-LABEL, SINGLE-DOSE MASS BALANCE AND METABOLITE PROFILING STUDY OF 14C-LABELED IZICOPAN (INF904) IN HEALTHY MALE PARTICIPANTS",
            "phase": "Phase I",
            "lead_sponsor": "InflaRx GmbH",
            "conditions": "Not applicable, healthy volunteers",
            "member_states": "Netherlands",
            "decision_date": "01/05/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525517-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521526-15-00",
            "title": "PHASE IV, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY ON THE PAIN-RELIEF EFFECT OF BENZYDAMINE\nHYDROCHLORIDE LOZENGES 3 MG MINT TASTE (TANTUM VERDE) IN NON STREPTOCOCCAL PHARYNGOTONSILLITIS IN PEDIATRIC AGE (6-11 YEARS OLD).",
            "phase": "Phase IV",
            "lead_sponsor": "Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.",
            "conditions": "NON STREPTOCOCCAL PHARYNGOTONSILLITIS",
            "member_states": "Italy",
            "decision_date": "30/04/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521526-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523121-17-00",
            "title": "Multicenter clinical trial on the effectiveness and safety of outpatient treatment of acute uncomplicated diverticulitis without antibiotics versus antibiotic treatment. ADIANA Trial.",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia",
            "conditions": "Diverticular disease of the intestine,",
            "member_states": "Spain",
            "decision_date": "30/04/2026",
            "enrolled": "282",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523121-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524434-25-00",
            "title": "\"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment\" \"FAPGASTRO\"",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Bordeaux",
            "conditions": "gastric cancer",
            "member_states": "France",
            "decision_date": "30/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524434-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524511-36-00",
            "title": "Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity\nBRAVE",
            "phase": "Phase II",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "Neurology",
            "member_states": "France",
            "decision_date": "30/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524511-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524675-23-00",
            "title": "Switching to Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Sustained Remission: A Multicenter Randomized Controlled Trial (IDEA).",
            "phase": "Phase IV",
            "lead_sponsor": "Grupo Espanol De Trabajo En Enfermedad De Crohn y Colitis Ulcerosa",
            "conditions": "Ulcerative Colitis",
            "member_states": "Spain",
            "decision_date": "30/04/2026",
            "enrolled": "304",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524675-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524205-32-00",
            "title": "First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Atopic Dermatits",
            "member_states": "Belgium; Czechia; Germany; Poland",
            "decision_date": "30/04/2026",
            "enrolled": "115",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524205-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525176-26-00",
            "title": "Study to Learn How Safe EV25 is and the Amount of EV25 in the Body Over a Period of Time, When Given as a Single Dose to Adult Healthy People [CCI]",
            "phase": "Phase I",
            "lead_sponsor": "Eradivir Inc.",
            "conditions": "Influenza",
            "member_states": "Belgium",
            "decision_date": "30/04/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525176-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525575-22-00",
            "title": "A first in human study of the safety, pharmacokinetics and pharmacodynamics of KLR-003 in healthy participants and patients with immune mediated diseases.",
            "phase": "Phase I",
            "lead_sponsor": "Klear Bio Inc.",
            "conditions": "Psoriasis",
            "member_states": "Netherlands",
            "decision_date": "30/04/2026",
            "enrolled": "182",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525575-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524267-20-00",
            "title": "An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST\u00ae (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-na\u00efve patients or in combination with dabrafenib;",
            "member_states": "Romania",
            "decision_date": "30/04/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524267-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525619-15-00",
            "title": "A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection",
            "phase": "Phase I",
            "lead_sponsor": "Centauri Therapeutics Limited",
            "conditions": "Bacterial Infection",
            "member_states": "Netherlands",
            "decision_date": "30/04/2026",
            "enrolled": "68",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525619-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523750-14-00",
            "title": "A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors",
            "phase": "Phase III",
            "lead_sponsor": "Paion Pharma GmbH",
            "conditions": "refractory hypotension in distributive shock",
            "member_states": "Italy; Germany; France; Spain",
            "decision_date": "30/04/2026",
            "enrolled": "143",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523750-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524832-20-00",
            "title": "A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION, INCLUDING THE MASS BALANCE, OF A SINGLE ORAL DOSE OF [14C]-VAFIDEMSTAT IN HEALTHY MALE PARTICIPANTS",
            "phase": "Phase I",
            "lead_sponsor": "Oryzon Genomics S.A.",
            "conditions": "Healthy volunteers",
            "member_states": "Netherlands",
            "decision_date": "30/04/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524832-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514089-37-00",
            "title": "GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery",
            "phase": "Phase II",
            "lead_sponsor": "The University Of Birmingham",
            "conditions": "Patients with pulmonary metastasis from any primary tumour, or who have an abdominal or thoracic\nRhabdomyosarcoma (RMS), Non-rhabdomyosarcomatous soft tissue sarcoma (NRSTS), Neuroblastoma (NBL) or a \nMalignant Germ cell tumour (mGCT) where complete resection by keyhole or open surgery is planned, and/or patients with a renal tumour or para-testicular RMS (ptRMS) requiring lymph node dissection",
            "member_states": "Netherlands",
            "decision_date": "30/04/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514089-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520997-21-00",
            "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Psoriatic arthritis\u200b\u200b",
            "member_states": "Poland; Germany; Spain",
            "decision_date": "30/04/2026",
            "enrolled": "49",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520997-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523285-25-00",
            "title": "A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Relapsed or Refractory Multiple Myeloma",
            "member_states": "Norway; Poland; Spain; Germany; France; Italy",
            "decision_date": "30/04/2026",
            "enrolled": "153",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523285-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524857-15-00",
            "title": "A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "BeOne Medicines I GmbH",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Spain",
            "decision_date": "30/04/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524857-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524778-41-00",
            "title": "Oral rifaximin in patients with opioid use disorder (OUD): multicenter clinical trial on the microbiota\u2013gut\u2013brain axis",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione Santa Lucia",
            "conditions": "substance use disorder",
            "member_states": "Italy",
            "decision_date": "29/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524778-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520067-13-00",
            "title": "EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales (\"RAPID\")",
            "phase": "Phase IV",
            "lead_sponsor": "National University Of Singapore",
            "conditions": "Bloodstream Infection, Ventilator Associated Pneumonia and Hospital-Acquired Pneumonia",
            "member_states": "Italy",
            "decision_date": "29/04/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520067-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524134-26-00",
            "title": "Effect of NBI-921355 on corticospinal excitability in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Neurocrine Biosciences Inc.",
            "conditions": "Epilepsy",
            "member_states": "Netherlands",
            "decision_date": "29/04/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524134-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525053-39-00",
            "title": "An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospital Stay Following On-Pump Coronary Artery Bypass Grafting Surgery",
            "phase": "Phase III",
            "lead_sponsor": "EBI Anti Sepsis B.V.",
            "conditions": "Coronary artery disease",
            "member_states": "Belgium; Netherlands",
            "decision_date": "29/04/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525053-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524719-35-00",
            "title": "A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase I/II",
            "lead_sponsor": "Mage Biologics Inc.",
            "conditions": "Ulcerative Colitis",
            "member_states": "Poland",
            "decision_date": "29/04/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524719-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523511-11-00",
            "title": "A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living with Obesity Who Do Not Have Diabetes",
            "phase": "Phase III",
            "lead_sponsor": "Kailera Therapeutics Inc.",
            "conditions": "Obesity",
            "member_states": "Poland; Bulgaria",
            "decision_date": "29/04/2026",
            "enrolled": "268",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523511-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522468-34-00",
            "title": "Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.",
            "phase": "Phase I",
            "lead_sponsor": "Bioresearch Pharma S.A.",
            "conditions": "Androgenetic alopecia",
            "member_states": "Poland",
            "decision_date": "29/04/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522468-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525006-37-00",
            "title": "THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE  EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL",
            "phase": "Phase III",
            "lead_sponsor": "Elliniko Institouto Meletis Tis Sipsis",
            "conditions": "Infection and sepsis",
            "member_states": "Greece",
            "decision_date": "29/04/2026",
            "enrolled": "398",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525006-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524876-43-00",
            "title": "HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma",
            "phase": "Phase III",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "relapsed/refractory multiple myeloma",
            "member_states": "Netherlands",
            "decision_date": "29/04/2026",
            "enrolled": "126",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524876-43-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525944-14-00",
            "title": "Bioequivalence clinical trial of two formulations of canagliflozin",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Normon S.A.",
            "conditions": "Healthy volunteers",
            "member_states": "Spain",
            "decision_date": "29/04/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525944-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525278-20-00",
            "title": "Bioequivalence clinical trial of two formulations of loperamide.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Normon S.A.",
            "conditions": "Healthy volunteers",
            "member_states": "Spain",
            "decision_date": "29/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525278-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525930-47-00",
            "title": "Pilot, randomized, crossover, comparative bioavailability study of two tadalafil formulations (oral suspension and film-coated tablets) after a single oral dose of 20 mg under fasting conditions in healthy male volunteers.",
            "phase": "Phase I",
            "lead_sponsor": "Farmalider S.A.",
            "conditions": "Healthy volunteers",
            "member_states": "Spain",
            "decision_date": "29/04/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525930-47-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524058-32-00",
            "title": "A Phase 2a, Randomized, Participant- and Investigator blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with DSM-5 Schizophrenia (STAR-1)",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Schizophrenia",
            "member_states": "Bulgaria",
            "decision_date": "29/04/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524058-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521145-24-01",
            "title": "A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy",
            "phase": "Phase I/II",
            "lead_sponsor": "Cabaletta Bio Inc.",
            "conditions": "Active Idiopathic Inflammatory Myopathy including dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy or Juvenile Idiopathic Inflammatory Myopathy",
            "member_states": "Italy; Spain; Germany",
            "decision_date": "28/04/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521145-24-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522872-10-00",
            "title": "A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression",
            "phase": "Phase III",
            "lead_sponsor": "Xenon Pharmaceuticals Inc.",
            "conditions": "Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)",
            "member_states": "Bulgaria; Germany; France; Spain",
            "decision_date": "28/04/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522872-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523448-10-00",
            "title": "Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia",
            "conditions": "Gvhd Resistant to ruxolitinib and steroids",
            "member_states": "Italy",
            "decision_date": "28/04/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523448-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526135-18-00",
            "title": "A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Vicore Pharma AB",
            "conditions": "Idiopathic pulmonary fibrosis",
            "member_states": "Sweden",
            "decision_date": "28/04/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526135-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524056-63-00",
            "title": "\u200b\u200bAMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors \u200b",
            "phase": "Phase I",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors",
            "member_states": "Spain; France; Belgium",
            "decision_date": "28/04/2026",
            "enrolled": "77",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524056-63-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520218-23-00",
            "title": "An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.",
            "phase": "Phase III",
            "lead_sponsor": "Inhibikase Therapeutics Inc.",
            "conditions": "Pulmonary Arterial Hypertension",
            "member_states": "Spain; Poland; Italy; Belgium; Latvia; Denmark; Czechia; Germany; France; Netherlands; Portugal; Ireland; Austria; Greece; Lithuania",
            "decision_date": "28/04/2026",
            "enrolled": "112",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520218-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521983-36-00",
            "title": "A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications",
            "phase": "Phase II",
            "lead_sponsor": "Blue Earth Diagnostics Ireland Limited",
            "conditions": "Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).",
            "member_states": "Netherlands; Italy",
            "decision_date": "28/04/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521983-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521045-24-00",
            "title": "CIRCULATE III - Tailoring the decision for adjuvant chemotherapy using circulating tumour DNA, in patients with stage III colorectal cancer",
            "phase": "Phase III",
            "lead_sponsor": "Unicancer",
            "conditions": "Stage III colorectal cancer",
            "member_states": "France; Sweden",
            "decision_date": "28/04/2026",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521045-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524160-38-00",
            "title": "A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long\u2011term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor,  von Hippel-Lindau (VHL)Disease-Associated Tumors,  Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2\u03b1 related Genetic Alterations",
            "member_states": "Czechia; Spain; Poland; Belgium; Finland; Germany; France; Netherlands; Hungary; Denmark",
            "decision_date": "28/04/2026",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524160-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520842-31-00",
            "title": "ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Population of study participants\tPregnant women with PPROM at 22 to 33 weeks\u2019 gestation",
            "member_states": "France",
            "decision_date": "28/04/2026",
            "enrolled": "1008",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520842-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521154-42-00",
            "title": "Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease",
            "phase": "Phase II",
            "lead_sponsor": "CSL Behring LLC",
            "conditions": "Sickle Cell Disease",
            "member_states": "Belgium; Netherlands; France; Italy",
            "decision_date": "28/04/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521154-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524498-17-00",
            "title": "A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases",
            "member_states": "Belgium; France; Italy; Austria; Romania; Poland; Portugal; Czechia; Germany; Spain; Hungary",
            "decision_date": "28/04/2026",
            "enrolled": "237",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524498-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525125-12-00",
            "title": "A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Migraine with or without aura",
            "member_states": "Belgium",
            "decision_date": "28/04/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525125-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524373-17-00",
            "title": "MERCURE study: MEthotrexate in ReCurrent dVIN",
            "phase": "Phase IV",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "dVIN caused by Lichen Sclerosus",
            "member_states": "Netherlands",
            "decision_date": "28/04/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524373-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521967-11-00",
            "title": "Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.",
            "member_states": "France",
            "decision_date": "28/04/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521967-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522750-39-00",
            "title": "A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D",
            "phase": "Phase III",
            "lead_sponsor": "Cinclus Pharma Holding AB (publ)",
            "conditions": "Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)",
            "member_states": "Hungary; Germany; Romania; Bulgaria; Czechia; Poland",
            "decision_date": "28/04/2026",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522750-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-510873-11-00",
            "title": "A phase II, double-blinded, placebo-controlled, clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder.",
            "phase": "Phase II",
            "lead_sponsor": "Apurano Pharmaceuticals GmbH",
            "conditions": "Borderline personality disorder",
            "member_states": "Germany",
            "decision_date": "28/04/2026",
            "enrolled": "154",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-510873-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-503573-38-00",
            "title": "Safety of stem cells in treatmemt of retinal diseases.",
            "phase": "Phase I",
            "lead_sponsor": "Bioinova a.s.",
            "conditions": "Retinal degenerative diseases",
            "member_states": "Czechia",
            "decision_date": "28/04/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-503573-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522957-20-00",
            "title": "A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1",
            "phase": "Phase III",
            "lead_sponsor": "Dyne Therapeutics Inc.",
            "conditions": "Myotonic Dystrophy Type 1",
            "member_states": "Netherlands; Spain; Italy; Denmark; Germany; Belgium; France",
            "decision_date": "28/04/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522957-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509176-42-00",
            "title": "Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy\nand in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management\nin children and adolescents with overweight or obesity",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Obesity and T2D",
            "member_states": "Slovakia; Austria; Spain; Romania; Portugal; Italy; Denmark; Belgium; Sweden; Poland; Netherlands; Croatia; Hungary; Bulgaria",
            "decision_date": "28/04/2026",
            "enrolled": "157",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509176-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524386-24-00",
            "title": "A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral mucositis in head and neck cancer",
            "phase": "Phase III",
            "lead_sponsor": "OncoZenge AB",
            "conditions": "Head and neck cancer, Oral mucositis",
            "member_states": "Germany; Denmark; Norway; Sweden",
            "decision_date": "28/04/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524386-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508047-40-00",
            "title": "A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Ovarian cancer",
            "member_states": "Norway; Ireland; Spain; Greece; France; Poland; Denmark; Austria; Hungary; Belgium; Czechia; Finland; Germany; Italy; Sweden",
            "decision_date": "28/04/2026",
            "enrolled": "349",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508047-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522552-20-00",
            "title": "Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome",
            "phase": "Phase III",
            "lead_sponsor": "Epygenix Therapeutics Inc.",
            "conditions": "Lennox-Gastaut Syndrome",
            "member_states": "Italy; Spain; Hungary; Romania; Czechia; Poland",
            "decision_date": "28/04/2026",
            "enrolled": "98",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522552-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517388-22-00",
            "title": "Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer\u2019s Disease Dementia",
            "phase": "Phase III",
            "lead_sponsor": "Exciva GmbH",
            "conditions": "Agitation in Alzheimer's Disease Dementia",
            "member_states": "Italy; Slovakia; Spain; Poland; Czechia; Germany",
            "decision_date": "28/04/2026",
            "enrolled": "222",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517388-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524135-39-00",
            "title": "A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "28/04/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524135-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-504135-40-00",
            "title": "A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)",
            "phase": "Phase III",
            "lead_sponsor": "Travere Therapeutics Inc.",
            "conditions": "Classical Homocystinuria",
            "member_states": "Belgium; Ireland; Spain; Italy; Germany; France; Portugal; Poland",
            "decision_date": "27/04/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-504135-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523804-62-00",
            "title": "Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Obesity",
            "member_states": "Belgium; Germany; Bulgaria; France; Spain; Denmark; Italy; Netherlands",
            "decision_date": "27/04/2026",
            "enrolled": "325",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523804-62-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523495-23-00",
            "title": "RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2\u2011Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)",
            "phase": "Phase III",
            "lead_sponsor": "Revolution Medicines Inc.",
            "conditions": "Resected Pancreatic Ductal Adenocarcinoma (PDAC)",
            "member_states": "France; Spain; Italy; Germany",
            "decision_date": "27/04/2026",
            "enrolled": "98",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523495-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519298-21-00",
            "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)",
            "phase": "Phase III",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Cancer-Associated Thrombosis (CAT).",
            "member_states": "Belgium; Czechia; France; Romania; Germany; Poland; Bulgaria; Spain",
            "decision_date": "27/04/2026",
            "enrolled": "324",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519298-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514246-37-00",
            "title": "A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis",
            "phase": "Phase II",
            "lead_sponsor": "Chiesi Farmaceutici S.p.A.",
            "conditions": "Idiopathic pulmonary fibrosis (IPF)",
            "member_states": "Belgium; Germany; Italy; Czechia; Bulgaria; Netherlands; France; Portugal; Poland; Spain; Romania",
            "decision_date": "27/04/2026",
            "enrolled": "103",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514246-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511114-20-00",
            "title": "SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire D'Angers",
            "conditions": "Craniopharyngioma",
            "member_states": "France",
            "decision_date": "27/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511114-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521647-20-00",
            "title": "A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "hepatic impairment",
            "member_states": "Slovakia",
            "decision_date": "27/04/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521647-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524103-69-00",
            "title": "Phase II/III randomized controlled open-label trial to evaluate the efficacy and safety of personalized tissue engineered veins in patients with chronic venous insufficiency",
            "phase": "Phase III",
            "lead_sponsor": "VeriGraft AB",
            "conditions": "Chronic Venous Insufficiency",
            "member_states": "Spain",
            "decision_date": "27/04/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524103-69-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522362-78-00",
            "title": "A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication",
            "phase": "Phase IV",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "severely active ulcerative colitis (US) and CD (Crohn\u2019s disease)",
            "member_states": "Spain; Denmark; Germany; Italy; Poland",
            "decision_date": "27/04/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522362-78-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514541-11-00",
            "title": "A randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and quality of life outcomes of Vi-Siblin in patients with low anterior resection syndrome following rectal cancer surgery.",
            "phase": "Phase II",
            "lead_sponsor": "Sykehuset Telemark HF",
            "conditions": "Low anterior resection syndrome after low anterior resection for rectal cancer",
            "member_states": "Norway",
            "decision_date": "27/04/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514541-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524937-19-00",
            "title": "Methylphenidate for Early Awakening in Coma (MEAWAKE)",
            "phase": "Phase II",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Coma due to acute brain injury",
            "member_states": "Austria; Denmark; Germany; France",
            "decision_date": "27/04/2026",
            "enrolled": "324",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524937-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518858-17-00",
            "title": "The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
            "member_states": "Italy; Austria; Spain; Ireland; Czechia; Poland",
            "decision_date": "27/04/2026",
            "enrolled": "63",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518858-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523972-21-00",
            "title": "Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Fortvita Biologics (USA) Inc.",
            "conditions": "Extensive-Stage Small Cell Lung Cancer",
            "member_states": "Poland; Denmark; Spain",
            "decision_date": "27/04/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523972-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523738-21-00",
            "title": "Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome",
            "phase": "Phase II",
            "lead_sponsor": "Mirum Pharmaceuticals Inc.",
            "conditions": "\u200b\u200bFragile X Syndrome\u200b",
            "member_states": "Spain",
            "decision_date": "27/04/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523738-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522019-40-00",
            "title": "A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)",
            "phase": "Phase I/II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)",
            "member_states": "Italy; Spain; Germany; Netherlands; France; Denmark; Czechia",
            "decision_date": "27/04/2026",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522019-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525706-35-00",
            "title": "Relative bioavailability and effect of food study with GLPG3667 in healthy subjects",
            "phase": "Phase I",
            "lead_sponsor": "Galapagos",
            "conditions": "inflammatory and autoimmune diseases",
            "member_states": "Belgium",
            "decision_date": "27/04/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525706-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523760-21-00",
            "title": "A Study of GEN1106 in Participants with Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Metastatic or advanced malignant solid tumors",
            "member_states": "Spain",
            "decision_date": "27/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523760-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523739-20-00",
            "title": "A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 12-Week Trial to Evaluate the Efficacy and Safety of Treatment with K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg",
            "phase": "Phase III",
            "lead_sponsor": "Kowa Co. Ltd.",
            "conditions": "Hypercholesterolemia",
            "member_states": "Spain",
            "decision_date": "24/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523739-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524602-15-00",
            "title": "Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors\nNA2C-TEP-IRM",
            "phase": "Phase II",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "Neurology",
            "member_states": "France",
            "decision_date": "24/04/2026",
            "enrolled": "165",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524602-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524122-18-00",
            "title": "ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "Septic shock",
            "member_states": "France",
            "decision_date": "24/04/2026",
            "enrolled": "360",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524122-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523774-16-00",
            "title": "A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies",
            "phase": "Phase I/II",
            "lead_sponsor": "Pharma Mar S.A.",
            "conditions": "Advanced malignancies",
            "member_states": "Spain; France; Italy",
            "decision_date": "24/04/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523774-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518120-68-01",
            "title": "Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression \u2013 the PREVENT-MED randomized clinical trial",
            "phase": "Phase II",
            "lead_sponsor": "Vaestra Goetalandsregionen",
            "conditions": "Paraphilic disorder, Compulsive sexual behavior disorder",
            "member_states": "Sweden",
            "decision_date": "24/04/2026",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518120-68-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519673-18-00",
            "title": "A randomized phase 2 trial of neoadjuvant pembrolizumab plus belzutifan with or without lenvatinib in patients with localized renal cell carcinoma. The moonlanding trial",
            "phase": "Phase II",
            "lead_sponsor": "Vall D Hebron Institute Of Oncology",
            "conditions": "Patients with localized renal cell carcinoma",
            "member_states": "Spain",
            "decision_date": "24/04/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519673-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523678-17-00",
            "title": "Phase 1b study to assess the safety and tolerability of SR-878 in patients with rheumatoid arthritis",
            "phase": "Phase I",
            "lead_sponsor": "SciRhom GmbH",
            "conditions": "rheumatoid arthritis",
            "member_states": "Romania",
            "decision_date": "24/04/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523678-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526102-33-00",
            "title": "Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "No medical condition",
            "member_states": "Czechia",
            "decision_date": "24/04/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526102-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523589-26-00",
            "title": "Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)",
            "phase": "Phase IV",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Acute heart failure with volume overload",
            "member_states": "Denmark",
            "decision_date": "24/04/2026",
            "enrolled": "436",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523589-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525211-14-00",
            "title": "Curing HIV: proof of concept randomized clinical trial with Pyrimethamine, Lenalidomide, TOpiramate (PLUTO)",
            "phase": "Phase II",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "HIV-1",
            "member_states": "Netherlands",
            "decision_date": "24/04/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525211-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524255-32-00",
            "title": "Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.",
            "phase": "Phase II",
            "lead_sponsor": "Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL",
            "conditions": "Cutaneous squamous cell carcinoma (ccSCC)",
            "member_states": "Spain",
            "decision_date": "24/04/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524255-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521836-12-00",
            "title": "Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial",
            "phase": "Phase II",
            "lead_sponsor": "Universita' Degli Studi G. D'Annunzio Di Chieti",
            "conditions": "deep vein thrombosis",
            "member_states": "Italy",
            "decision_date": "23/04/2026",
            "enrolled": "122",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521836-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520641-69-00",
            "title": "A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease",
            "phase": "Phase II",
            "lead_sponsor": "Medizinische Universitaet Innsbruck",
            "conditions": "Kidney disease",
            "member_states": "Germany; Austria; France",
            "decision_date": "23/04/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520641-69-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524438-24-00",
            "title": "A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents.",
            "phase": "Phase I/II",
            "lead_sponsor": "Fractyl Health Inc.",
            "conditions": "Type 2 Diabetes",
            "member_states": "Netherlands",
            "decision_date": "23/04/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524438-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524212-11-00",
            "title": "A randomized double-blind placebo-controlled study to demonstrate the efficacy of PMBL\u00ae sublingual tablets in reducing the incidence of respiratory tract infections in children aged 3-12 years (PIRTIK).",
            "phase": "Phase IV",
            "lead_sponsor": "Lallemand Pharma Europe filial af Lallemand Pharma AG Schweiz",
            "conditions": "Respiratory Tract Infections",
            "member_states": "Poland",
            "decision_date": "23/04/2026",
            "enrolled": "224",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524212-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524031-39-00",
            "title": "Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY",
            "phase": "Phase I",
            "lead_sponsor": "Instytut Pomnik Centrum Zdrowia Dziecka",
            "conditions": "Medulloblastoma (recurrent or progressive)",
            "member_states": "Poland",
            "decision_date": "23/04/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524031-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522486-29-01",
            "title": "Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study",
            "phase": "Phase III",
            "lead_sponsor": "Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali",
            "conditions": "Diabetes Mellitus, Cardiovascular disease, Overweight (BMI \u226527 kg/m\u00b2), Obesity (BMI\u226530kg/m2)",
            "member_states": "Italy",
            "decision_date": "23/04/2026",
            "enrolled": "212",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522486-29-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523978-16-00",
            "title": "A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Type I diabetes",
            "member_states": "Germany",
            "decision_date": "23/04/2026",
            "enrolled": "146",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523978-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524814-27-00",
            "title": "Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting \u03b1CD19x\u03b1CD3 bispecific antibodies for malignant B-cell neoplasms",
            "phase": "Phase I",
            "lead_sponsor": "Fundacion Para La Investigacion Biom\u00e9dica Del Hospital Universitario 12 De Octubre",
            "conditions": "Malignant B-cell neoplasms",
            "member_states": "Spain",
            "decision_date": "22/04/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524814-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524279-22-00",
            "title": "Exploratory study on the effect of Rimonabant on hand function in patients with spinal cord injury (RIMOHANDOPEN)",
            "phase": "Phase I/II",
            "lead_sponsor": "Sinfatin S.L.",
            "conditions": "Spinal cord injury",
            "member_states": "Spain",
            "decision_date": "22/04/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524279-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524759-29-00",
            "title": "COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients",
            "phase": "Phase I/II",
            "lead_sponsor": "Centre Leon Berard",
            "conditions": "Vulvar Squamous Cell Carcinoma (VSCC) patients",
            "member_states": "France",
            "decision_date": "22/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524759-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526040-13-00",
            "title": "Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Institut De Recherches Internationales Servier IRIS",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "22/04/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526040-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522776-93-00",
            "title": "A FIRST-IN-HUMAN (FIH) PHASE 1/2 STUDY TO ASSESS SAFETY, TOLERABILITY, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF REGN17372, AN ANTI-GPRC5D X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY, IN COMBINATION WITH LINVOSELTAMAB, AN ANTI-BCMA X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Relapsed/Refractory Multiple Myeloma",
            "member_states": "Greece",
            "decision_date": "22/04/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522776-93-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522076-85-00",
            "title": "A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Rheumatoid arthritis",
            "member_states": "Hungary; Spain; Bulgaria; Germany; Poland",
            "decision_date": "22/04/2026",
            "enrolled": "97",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522076-85-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524514-28-00",
            "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus.",
            "phase": "Phase II",
            "lead_sponsor": "Corxel Pharmaceuticals Inc.",
            "conditions": "Type 2 Diabetes Mellitus",
            "member_states": "Poland",
            "decision_date": "22/04/2026",
            "enrolled": "121",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524514-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523602-33-00",
            "title": "ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)",
            "phase": "Phase I/II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Advanced or unresectable Hepatocellular Carcinoma (HCC)",
            "member_states": "Poland; Spain; Germany; France; Italy",
            "decision_date": "22/04/2026",
            "enrolled": "47",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523602-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522904-26-00",
            "title": "Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis",
            "phase": "Phase I",
            "lead_sponsor": "Genentech Inc.",
            "conditions": "Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)",
            "member_states": "Italy; Spain; France; Germany",
            "decision_date": "22/04/2026",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522904-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524594-16-00",
            "title": "A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.",
            "phase": "Phase I",
            "lead_sponsor": "Philogen S.p.A.",
            "conditions": "Patients with prostate cancer with:\n-\tsuspected metastasis who are candidates for initial definitive therapy\n-\tsuspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL)\n-\tmetastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands",
            "member_states": "Italy",
            "decision_date": "22/04/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524594-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523575-36-00",
            "title": "A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1\u2013expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation",
            "phase": "Phase II",
            "lead_sponsor": "Cliniques Universitaires Saint-Luc",
            "conditions": "Locally advanced head and neck squamous cell carcinoma (LA-HNSCC)",
            "member_states": "Belgium",
            "decision_date": "22/04/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523575-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523683-20-00",
            "title": "NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial",
            "phase": "Phase II",
            "lead_sponsor": "Unicancer",
            "conditions": "Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR\u207a) and HER2 negative (HER2\u207b) early breast cancer with a Luminal A phenotype and at low risk of recurrence.",
            "member_states": "France",
            "decision_date": "21/04/2026",
            "enrolled": "630",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523683-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524209-34-00",
            "title": "A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia",
            "phase": "Phase III",
            "lead_sponsor": "Jiangsu Hengrui Pharmaceuticals Co. Ltd.",
            "conditions": "Chemotherapy induced thrombocytopenia",
            "member_states": "France; Romania; Poland; Spain; Bulgaria",
            "decision_date": "21/04/2026",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524209-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523481-24-00",
            "title": "A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)",
            "member_states": "Netherlands; Germany; Spain; Italy; France; Belgium",
            "decision_date": "21/04/2026",
            "enrolled": "138",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523481-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523971-46-00",
            "title": "A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).",
            "phase": "Phase I/II",
            "lead_sponsor": "Quell Therapeutics Limited",
            "conditions": "Diffuse cutaneous systemic sclerosis (dcSSc)\nDifficult to treat rheumatoid arthritis (D2TRA)",
            "member_states": "Spain; Germany",
            "decision_date": "21/04/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523971-46-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521384-12-00",
            "title": "A research study to compare blood levels of cagrilintide after multiple doses of\ndifferent versions of cagrilintide in adults with overweight or obesity",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "obesity",
            "member_states": "Germany",
            "decision_date": "21/04/2026",
            "enrolled": "234",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521384-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525068-13-00",
            "title": "Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Chronic Kidney Disease",
            "member_states": "Germany; Spain; Netherlands",
            "decision_date": "21/04/2026",
            "enrolled": "95",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525068-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523524-53-00",
            "title": "C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA",
            "phase": "Phase I/II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "ADVANCED OR METASTATIC RENAL CELL CARCINOMA",
            "member_states": "Germany; Spain",
            "decision_date": "21/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523524-53-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523659-73-00",
            "title": "J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Obesity, Overweight",
            "member_states": "Spain; Romania; Belgium; Czechia",
            "decision_date": "21/04/2026",
            "enrolled": "286",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523659-73-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524100-29-00",
            "title": "An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren\u2019s Disease or Idiopathic Inflammatory Myopathy",
            "phase": "Phase I",
            "lead_sponsor": "Ouro Medicines Limited",
            "conditions": "Seropositive autoimmune disease: Sjogren\u2019s disease or idiopathic inflammatory myopathy",
            "member_states": "Czechia",
            "decision_date": "21/04/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524100-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523260-20-00",
            "title": "Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes \u2013 a dose-finding study",
            "phase": "Phase II",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "type 2 diabetes",
            "member_states": "Spain; Hungary; Portugal; Poland; Slovakia; Croatia",
            "decision_date": "21/04/2026",
            "enrolled": "165",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523260-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524313-86-00",
            "title": "A single center study to evaluate the safety and tolerability of oral Azathioprine in patients with ADPKD",
            "phase": "Phase II",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Autosomal dominant polycystic kidney and liver disease",
            "member_states": "Belgium",
            "decision_date": "21/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524313-86-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523474-16-00",
            "title": "A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",
            "phase": "Phase I/II",
            "lead_sponsor": "Institut De Recherches Internationales Servier IRIS",
            "conditions": "Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations",
            "member_states": "France; Spain; Denmark; Italy",
            "decision_date": "21/04/2026",
            "enrolled": "105",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523474-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523149-80-00",
            "title": "KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation",
            "member_states": "France",
            "decision_date": "20/04/2026",
            "enrolled": "640",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523149-80-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524366-21-00",
            "title": "A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia",
            "phase": "Phase III",
            "lead_sponsor": "BeOne Medicines I GmbH",
            "conditions": "treatment-naive Chronic Lymphocytic Leukemia",
            "member_states": "Netherlands; Poland; Italy; Germany; Spain; Romania; Czechia; France; Sweden",
            "decision_date": "20/04/2026",
            "enrolled": "186",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524366-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523793-16-00",
            "title": "A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)",
            "phase": "Phase II",
            "lead_sponsor": "CSL Behring LLC",
            "conditions": "Homeostatic iron regulator gene-related hereditary hemochromatosis",
            "member_states": "Austria; Poland; Spain; Germany; France; Ireland; Romania; Belgium; Italy; Czechia; Netherlands",
            "decision_date": "20/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523793-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525223-24-00",
            "title": "A randomized phase II study comparing the safety and efficacy of mifamurtide and standard therapy containing sorafenib in pediatric and young adult patients with high-risk osteosarcoma",
            "phase": "Phase II",
            "lead_sponsor": "Instytut Matki I Dziecka",
            "conditions": "Relapsed/refractory osteosarcoma, High-grade osteosarcoma",
            "member_states": "Poland",
            "decision_date": "20/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525223-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523630-59-00",
            "title": "Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases",
            "phase": "Phase I/II",
            "lead_sponsor": "HepaRegeniX GmbH",
            "conditions": "colon carcinoma metastases",
            "member_states": "France; Spain; Germany",
            "decision_date": "20/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523630-59-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523711-11-00",
            "title": "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Schizophrenia",
            "member_states": "Romania",
            "decision_date": "20/04/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523711-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522913-45-00",
            "title": "A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory germ cell tumours, Advanced relapsed or refractory endometrial cancer",
            "member_states": "Spain; France; Belgium; Germany",
            "decision_date": "20/04/2026",
            "enrolled": "102",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522913-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524311-37-00",
            "title": "An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code 06739-024, Vargem Grande Paulista \u2013 SP CNPJ No. 21,896,000/0001-91, in healthy adult, human subjects under fasting condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia",
            "member_states": "Romania",
            "decision_date": "20/04/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524311-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520125-36-00",
            "title": "A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).",
            "phase": "Phase I",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Relapsed or Refractory Acute Myeloid Leukemia;  Acute Myeloid Leukemia, Acute Myeloid Leukemia",
            "member_states": "Spain; Hungary; Czechia; France; Italy; Belgium",
            "decision_date": "20/04/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520125-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520014-22-00",
            "title": "A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator\u2019s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Locally advanced/metastatic urothelial carcinoma",
            "member_states": "Netherlands; Greece; Italy; Germany; Spain; Belgium; Sweden; France",
            "decision_date": "20/04/2026",
            "enrolled": "265",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520014-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525823-26-00",
            "title": "Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.",
            "phase": "Phase I",
            "lead_sponsor": "Institut De Recherches Internationales Servier IRIS",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "20/04/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525823-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522040-40-01",
            "title": "An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Ziekenhuis Antwerpen, Hospital Germans Trias I Pujol",
            "conditions": "Multiple Sclerosis",
            "member_states": "Belgium; Spain",
            "decision_date": "20/04/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522040-40-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523660-21-00",
            "title": "C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "severe to moderately severe hemophilia B (FIX:C \u2264 2%), hemophilia A",
            "member_states": "Italy; Germany; France; Spain; Sweden; Greece",
            "decision_date": "20/04/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523660-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524002-16-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis",
            "phase": "Phase III",
            "lead_sponsor": "Ferrer Internacional S.A., Prilenia Therapeutics B.V.",
            "conditions": "Amyotrophic Lateral Sclerosis",
            "member_states": "Belgium; Netherlands; Poland; France; Germany; Ireland; Italy; Sweden; Spain",
            "decision_date": "20/04/2026",
            "enrolled": "420",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524002-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522855-25-00",
            "title": "J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis",
            "member_states": "Italy; Poland; Denmark; Czechia; France; Hungary; Germany; Netherlands; Spain",
            "decision_date": "20/04/2026",
            "enrolled": "197",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522855-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523358-15-00",
            "title": "CoCo-PCOS - Comprehensive Health Effects of Combined Contraceptives: a 6-month randomized, controlled, open-label trial of E4+DRSP, EE20\u00b5g+DRSP, and DRSP-only in women with PCOS",
            "phase": "Phase IV",
            "lead_sponsor": "Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu",
            "conditions": "Contraception",
            "member_states": "Finland",
            "decision_date": "20/04/2026",
            "enrolled": "156",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523358-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523930-14-00",
            "title": "Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism",
            "phase": "Phase IV",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Hypoparathyroidism",
            "member_states": "Denmark",
            "decision_date": "20/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523930-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523304-68-00",
            "title": "A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Healthy participants and participants with type 2 diabetes",
            "member_states": "Austria",
            "decision_date": "19/04/2026",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523304-68-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522790-10-00",
            "title": "IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease",
            "phase": "Phase II",
            "lead_sponsor": "Intergroupe Francophone De Cancerologie Thoracique",
            "conditions": "Non Small Cell Lung Cancer, Interstitial Lung Disease",
            "member_states": "France",
            "decision_date": "17/04/2026",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522790-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524302-15-00",
            "title": "A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease",
            "phase": "Phase II",
            "lead_sponsor": "MaaT PHARMA",
            "conditions": "Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)",
            "member_states": "Netherlands; Italy; France; Spain",
            "decision_date": "17/04/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524302-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522748-42-00",
            "title": "A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)",
            "phase": "Phase III",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Ovarian cancer",
            "member_states": "Ireland; Poland; France; Netherlands; Spain; Italy; Germany; Belgium",
            "decision_date": "17/04/2026",
            "enrolled": "308",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522748-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521910-24-00",
            "title": "Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.",
            "phase": "Phase IV",
            "lead_sponsor": "Aristotle University Of Thessaloniki",
            "conditions": "Multiple Sclerosis",
            "member_states": "Greece",
            "decision_date": "17/04/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521910-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523717-29-00",
            "title": "Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "HFpEF or HFmrEF and obesity",
            "member_states": "Denmark; Greece; Bulgaria; Italy; Netherlands; Spain; Poland; Czechia; Germany; France",
            "decision_date": "17/04/2026",
            "enrolled": "1992",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523717-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523558-14-00",
            "title": "A Phase 1 Study of AIR-001 in Adults with AATD.",
            "phase": "Phase I",
            "lead_sponsor": "Airna Corp.",
            "conditions": "Alpha-1 Antitrypsin Deficiency",
            "member_states": "Sweden; Ireland; Spain; Netherlands; Portugal; Germany",
            "decision_date": "17/04/2026",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523558-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523359-71-00",
            "title": "CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial of E4+DRSP, EE20\u03bcg+DRSP and DRSP-only",
            "phase": "Phase IV",
            "lead_sponsor": "Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu",
            "conditions": "Contraception",
            "member_states": "Finland",
            "decision_date": "17/04/2026",
            "enrolled": "156",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523359-71-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523544-12-00",
            "title": "A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-na\u00efve Adult Participants Who Require Red Blood Cell Transfusions",
            "phase": "Phase III",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Myelodysplastic neoplasms/syndromes (MDS)",
            "member_states": "France; Belgium; Germany; Italy; Bulgaria; Ireland; Lithuania; Norway; Romania; Hungary; Spain; Greece; Poland; Netherlands",
            "decision_date": "17/04/2026",
            "enrolled": "114",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523544-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524629-42-00",
            "title": "Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin",
            "phase": "Phase II",
            "lead_sponsor": "Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud",
            "conditions": "Categoria 2, Patients with vegetable allergies due to sensitization to profilin and LTPs, and those patients in whom sublingual immunotherapy with Pru p 3 (peach LTP) has not been effective, were evaluated in a before-after study to assess changes in clinical reactivity to LTP (peach) and profilin (melon) and immunological changes after intervention with omalizumab.",
            "member_states": "Spain",
            "decision_date": "17/04/2026",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524629-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522655-26-00",
            "title": "METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0",
            "phase": "Phase II",
            "lead_sponsor": "Unicancer",
            "conditions": "METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). \nMETA-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)",
            "member_states": "France",
            "decision_date": "16/04/2026",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522655-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524573-16-00",
            "title": "OPTIMAL CARE WITH GUSELKUMAB IN CROHN\u2019S DISEASE",
            "phase": "Phase IV",
            "lead_sponsor": "i-GETAID",
            "conditions": "Crohn's disease",
            "member_states": "France",
            "decision_date": "16/04/2026",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524573-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521911-38-00",
            "title": "An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Advanced HR+/HER- breast cancer",
            "member_states": "Italy; Germany; France; Czechia; Denmark; Spain",
            "decision_date": "16/04/2026",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521911-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524987-39-00",
            "title": "A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma",
            "phase": "Phase I",
            "lead_sponsor": "Aclaris Therapeutics Inc.",
            "conditions": "Mild to Moderate Asthma",
            "member_states": "Germany",
            "decision_date": "16/04/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524987-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525039-15-01",
            "title": "A study to evaluate how well single and multiple doses of S072 are tolerated in healthy adult participants",
            "phase": "Phase I",
            "lead_sponsor": "Sea4us Biotecnologia E Recursos Marinhos S.A.",
            "conditions": "Pain",
            "member_states": "Spain",
            "decision_date": "16/04/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525039-15-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523096-34-00",
            "title": "The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia",
            "phase": "Phase III",
            "lead_sponsor": "Prinses Maxima Centrum voor Kinderoncologie B.V.",
            "conditions": "B-cell Acute Lymphoblastic Leukemia",
            "member_states": "Spain; Germany; Netherlands",
            "decision_date": "16/04/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523096-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521628-31-00",
            "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich\u2019s Ataxia",
            "phase": "Phase III",
            "lead_sponsor": "Larimar Therapeutics Inc.",
            "conditions": "Friedreich\u2019s ataxia is the most common inherited ataxia in humans and results from a deficiency\nof the mitochondrial protein, FXN. Friedreich\u2019s ataxia is a rare, progressive, multisystem disease\nwith an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.",
            "member_states": "France",
            "decision_date": "16/04/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521628-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523153-33-00",
            "title": "A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase III Therapeutic Superiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Diclofenac potassium + Thiocolchicoside to Diclofenac potassium (Cataflam\u00ae) in Patients with Acute Severe Low Back Pain.",
            "phase": "Phase III",
            "lead_sponsor": "Verisfield Single Member S.A.",
            "conditions": "LOW BACK PAIN",
            "member_states": "Cyprus; Greece",
            "decision_date": "16/04/2026",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523153-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523975-48-00",
            "title": "EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- \nBIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH \nOVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, \nMULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL \n(VESPER-5)",
            "phase": "Phase III",
            "lead_sponsor": "Metsera Inc.",
            "conditions": "Obesity",
            "member_states": "Czechia; Bulgaria; Slovakia; Spain; Hungary; Germany; Romania; Poland",
            "decision_date": "16/04/2026",
            "enrolled": "919",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523975-48-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523396-38-00",
            "title": "Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)",
            "phase": "Phase I/II",
            "lead_sponsor": "Aop Orphan Pharmaceuticals GmbH",
            "conditions": "Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)",
            "member_states": "Spain",
            "decision_date": "15/04/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523396-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522162-75-00",
            "title": "A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer",
            "phase": "Phase II",
            "lead_sponsor": "Academisch Ziekenhuis Maastricht",
            "conditions": "patients with asymptomatic active brain metastases from small cell lung cancer",
            "member_states": "Netherlands",
            "decision_date": "15/04/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522162-75-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523509-13-00",
            "title": "Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE",
            "phase": "Phase II",
            "lead_sponsor": "Qed Therapeutics Inc.",
            "conditions": "Hypochondroplasia",
            "member_states": "Spain; Norway",
            "decision_date": "15/04/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523509-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518835-13-00",
            "title": "A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease",
            "phase": "Phase III",
            "lead_sponsor": "Guerbet, Bracco Imaging S.p.A.",
            "conditions": "Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar), peripheral or abdominal/renal arteries",
            "member_states": "Italy; France; Czechia; Hungary; Spain; Germany; Poland",
            "decision_date": "15/04/2026",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518835-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524328-24-00",
            "title": "GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).",
            "phase": "Phase I",
            "lead_sponsor": "Granite Bio AG",
            "conditions": "Ulcerative colitis",
            "member_states": "Germany",
            "decision_date": "15/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524328-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523806-34-00",
            "title": "Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with a Glofitamab-based induction and consolidation concept",
            "phase": "Phase II",
            "lead_sponsor": "Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH",
            "conditions": "relapsed/refractory Large B-Cell Lymphoma",
            "member_states": "Germany",
            "decision_date": "15/04/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523806-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524136-19-00",
            "title": "A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "BeOne Medicines AG",
            "conditions": "Selected Advanced or Metastatic Solid Tumors",
            "member_states": "Italy; France",
            "decision_date": "15/04/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524136-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522647-17-00",
            "title": "A two-part study: open label, dose escalation phase aimed to evaluate the safety and tolerability of two different doses of allogeneic fibroblasts for the treatment of chronic refractory wounds and identifying the best dose for subsequent cohort expansion phase aimed to assess efficacy and confirm safety and tolerability",
            "phase": "Phase I/II",
            "lead_sponsor": "Hmg Biologics S.r.l.",
            "conditions": "Refractory wounds",
            "member_states": "Italy",
            "decision_date": "15/04/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522647-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524086-24-00",
            "title": "Efficacy of Dexmedetomidine on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Double-Blind Randomized Controlled Trial with Heart Rate Variability and Electroencephalography-Guided Anesthesia",
            "phase": "Phase III",
            "lead_sponsor": "Akershus University Hospital",
            "conditions": "Emergence delirium",
            "member_states": "Norway",
            "decision_date": "15/04/2026",
            "enrolled": "255",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524086-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523193-16-00",
            "title": "A study in healthy men to test how bosentan influences the amount of zongertinib in the blood",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "15/04/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523193-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523157-34-00",
            "title": "A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome",
            "phase": "Phase III",
            "lead_sponsor": "UCB Biosciences Inc.",
            "conditions": "Rett syndrome",
            "member_states": "Spain; Poland; France; Hungary; Belgium; Italy; Germany",
            "decision_date": "15/04/2026",
            "enrolled": "82",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523157-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524043-12-00",
            "title": "A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults",
            "phase": "Phase I",
            "lead_sponsor": "Bayer AG",
            "conditions": "atrial fibrillation, transient ischemic attack (TIA), ischemic stroke",
            "member_states": "Germany",
            "decision_date": "15/04/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524043-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522318-21-00",
            "title": "A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.",
            "phase": "Phase I/II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Neoplasms, Colorectal",
            "member_states": "Italy; Denmark; Spain; Sweden; Netherlands; France",
            "decision_date": "14/04/2026",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522318-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521000-22-00",
            "title": "A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Patients with advanced malignancies",
            "member_states": "Spain; Italy; France",
            "decision_date": "14/04/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521000-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523847-36-00",
            "title": "A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function",
            "member_states": "Hungary",
            "decision_date": "14/04/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523847-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511977-31-01",
            "title": "68Ga-FAPI-46 PET for Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "giant cell arteritis - polymyalgia rheumatica spectrum disease",
            "member_states": "Netherlands",
            "decision_date": "14/04/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511977-31-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522498-12-00",
            "title": "A low-intervention randomised, double-blind, placebo-controlled pilot trial evaluating the feasibility, tolerability and adherence of alternate-day oral Duroferon (ferrous sulphate) in adolescent girls with iron deficiency, and the diagnostic performance of the IRON-5 screening tool (IRONGIRLS-PILOT).",
            "phase": "Phase IV",
            "lead_sponsor": "Region Skane",
            "conditions": "iron deficiency in adolescent girls",
            "member_states": "Sweden",
            "decision_date": "14/04/2026",
            "enrolled": "279",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522498-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522692-29-00",
            "title": "Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).",
            "phase": "Phase II",
            "lead_sponsor": "Dompe' Farmaceutici S.p.A.",
            "conditions": "Subacute Moderate to Severe Traumatic Brain Injury (TBI)",
            "member_states": "Italy; Denmark; Finland; France; Germany; Spain; Sweden; Poland",
            "decision_date": "14/04/2026",
            "enrolled": "146",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522692-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524862-12-00",
            "title": "A single-center, randomized, single-blind, phase 4 study to evaluate the enhancement of mucosal immunity in infants through maternal vaccination during breastfeeding (MEALAC-01).",
            "phase": "Phase IV",
            "lead_sponsor": "Universite Libre de Bruxelles",
            "conditions": "Measles",
            "member_states": "Belgium",
            "decision_date": "14/04/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524862-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524111-37-00",
            "title": "Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Ottimo Pharma Limited",
            "conditions": "advanced solid tumors",
            "member_states": "Ireland; Spain; Portugal",
            "decision_date": "14/04/2026",
            "enrolled": "41",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524111-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522107-18-00",
            "title": "A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Locally advanced or metastatic Non-Small Cell Lung Cancer",
            "member_states": "Germany; Hungary; Netherlands; France; Italy; Belgium; Spain; Poland",
            "decision_date": "14/04/2026",
            "enrolled": "112",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522107-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521827-61-00",
            "title": "Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione Gimema Franco Mandelli Onlus",
            "conditions": "refractory/relapsed multiple myeloma",
            "member_states": "Italy",
            "decision_date": "14/04/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521827-61-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522730-31-00",
            "title": "Standardized Phleum pratense in TBU/ml in liquid formulation for sublingual immunotherapy: Phase II, randomized dose determination clinical trial. DEDO-G Study.",
            "phase": "Phase II",
            "lead_sponsor": "Asac Pharmaceutical Inmunology S.A.",
            "conditions": "Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy",
            "member_states": "Spain",
            "decision_date": "14/04/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522730-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523428-39-00",
            "title": "A phase II, multicenter study of GlOfitamab in patients with mantle cell Lymphoma and inaDequate response or relapse following CAR T-cell therapy (GOLD)",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione Italiana Linfomi Ets",
            "conditions": "Mantle Cell Lymphoma",
            "member_states": "Italy",
            "decision_date": "14/04/2026",
            "enrolled": "41",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523428-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522965-31-00",
            "title": "C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Atopic Dermatitis",
            "member_states": "Poland; Czechia; Germany; Bulgaria; France",
            "decision_date": "14/04/2026",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522965-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525625-21-00",
            "title": "A clinical trial of MK-6050 in healthy participants (MK-6050-002)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Hidradenitis suppurativa",
            "member_states": "Belgium",
            "decision_date": "13/04/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525625-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521571-30-00",
            "title": "PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)",
            "member_states": "France",
            "decision_date": "13/04/2026",
            "enrolled": "228",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521571-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520052-19-04",
            "title": "Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).",
            "phase": "Phase I/II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Malignant Melanoma",
            "member_states": "Netherlands",
            "decision_date": "13/04/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520052-19-04",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524195-29-00",
            "title": "A randomized, placebo-controlled trial to assess the efficacy, tolerability, and pharmacokinetics of clemastine in children and adults with Pitt-Hopkins syndrome",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Pitt-Hopkins syndrome",
            "member_states": "Netherlands",
            "decision_date": "13/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524195-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523117-28-00",
            "title": "A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)",
            "phase": "Phase II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Relapsed or Refractory Multiple Myeloma",
            "member_states": "France; Germany; Greece; Netherlands; Spain",
            "decision_date": "13/04/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523117-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524443-12-00",
            "title": "Randomized adaptive assessment of post COVID syndrome treatments (RAPID): Evaluating the Efficacy of Bupropion for the Treatment of Post-COVID-19 Syndrome-associated Fatigue (ELAPSE)",
            "phase": "Phase II",
            "lead_sponsor": "Goethe University Frankfurt",
            "conditions": "Post Covid Syndrome (PCS)",
            "member_states": "Germany",
            "decision_date": "13/04/2026",
            "enrolled": "250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524443-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524822-16-00",
            "title": "Prevention of chronic headache with anti-CGRP antibody treatment in patients with idiopathic intracranial hypertension",
            "phase": "Phase III",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Idiopathic intracranial hypertension",
            "member_states": "Denmark",
            "decision_date": "13/04/2026",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524822-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522953-21-00",
            "title": "A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "unresectable advanced or metastatic solid cancer",
            "member_states": "Spain",
            "decision_date": "13/04/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522953-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524668-39-00",
            "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients with Primary Knee Osteoarthritis",
            "phase": "Phase II",
            "lead_sponsor": "Enlivex Therapeutics Ltd.",
            "conditions": "Knee Osteoarthritis",
            "member_states": "Denmark; Poland",
            "decision_date": "13/04/2026",
            "enrolled": "135",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524668-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524129-42-00",
            "title": "Methotrexate in paediatric and adolescent Crohn\u2019s disease: an observational study",
            "phase": "Phase IV",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Crohn\u2019s disease",
            "member_states": "Netherlands",
            "decision_date": "11/04/2026",
            "enrolled": "215",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524129-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524038-24-00",
            "title": "A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures",
            "phase": "Phase III",
            "lead_sponsor": "Praxis Precision Medicines Inc.",
            "conditions": "Focal Epilepsy",
            "member_states": "Poland; Germany; Czechia; Italy; Spain",
            "decision_date": "10/04/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524038-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524725-41-00",
            "title": "Single-centre Phase I/II study with dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy in patients with Acute Myeloid Leukaemia (AML): TOCIVENA",
            "phase": "Phase I",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "Acute Myeloblastic Leukemia",
            "member_states": "France",
            "decision_date": "10/04/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524725-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522207-15-01",
            "title": "An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)",
            "phase": "Phase I/II",
            "lead_sponsor": "Aavantgarde Bio S.r.l.",
            "conditions": "Stargardt Disease (STGD1)",
            "member_states": "Belgium; Italy; Netherlands; Norway",
            "decision_date": "10/04/2026",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522207-15-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523180-38-00",
            "title": "A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma",
            "phase": "Phase II",
            "lead_sponsor": "Kymera Therapeutics Inc.",
            "conditions": "Uncontrolled Moderate to Severe Eosinophilic Asthma",
            "member_states": "Spain; Romania; Slovakia; Poland; Germany; Italy; Belgium; Austria",
            "decision_date": "10/04/2026",
            "enrolled": "121",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523180-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524723-52-00",
            "title": "LIBRETTO: Stimulan\u2122 Local Antibiotic Delivery System Versus 4-Week Systemic Antibiotic Therapy for Diabetic Foot Osteomyelitis \u2013 A Prospective, Randomized, Controlled Trial",
            "phase": "Phase III",
            "lead_sponsor": "Pirkanmaan hyvinvointialue",
            "conditions": "Diabetic Foot Osteomyelitis",
            "member_states": "Finland",
            "decision_date": "10/04/2026",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524723-52-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520976-25-00",
            "title": "A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Saint Etienne",
            "conditions": "Relapsed/refractory multiple myeloma",
            "member_states": "France",
            "decision_date": "09/04/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520976-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521001-40-00",
            "title": "A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Advanced Malignancies and Hepatic Impairment",
            "member_states": "Spain; France; Italy",
            "decision_date": "09/04/2026",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521001-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522916-17-00",
            "title": "Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics",
            "phase": "Phase I",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Urinary Tract Infections",
            "member_states": "Spain; Poland",
            "decision_date": "09/04/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522916-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519644-33-00",
            "title": "Retinoic acid and sperm production in infertile men",
            "phase": "Phase II",
            "lead_sponsor": "Les Hopitaux Universitaires De Strasbourg",
            "conditions": "oligozoospermia",
            "member_states": "France",
            "decision_date": "09/04/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519644-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523139-21-00",
            "title": "PHASE I/IIa CLINICAL TRIAL FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE WITH A NEW GENERATION OF MESENCHYMAL STROMAL CELLS ECTOPICALLY EXPRESSING CXCR4 AND IL-10 IN STEROID-REFRACTORY AND INTOLERANT OR RUXOLITINIB-REFRACTORY PATIENTS",
            "phase": "Phase I/II",
            "lead_sponsor": "Fundacion Instituto De Investigacion Sanitaria De Navarra",
            "conditions": "Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib",
            "member_states": "Spain",
            "decision_date": "09/04/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523139-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523547-35-00",
            "title": "A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies",
            "phase": "Phase I/II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Advanced Solid Tumor Malignancies",
            "member_states": "Spain",
            "decision_date": "09/04/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523547-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524298-18-00",
            "title": "A phase 2b, single-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of oral Ladarixin in association with a single low dose of Antithymocyte Globulin in patients with new-onset autoimmune type 1 diabetes.",
            "phase": "Phase II",
            "lead_sponsor": "Ospedale San Raffaele S.r.l.",
            "conditions": "new-onset autoimmune type 1 diabetes",
            "member_states": "Italy",
            "decision_date": "09/04/2026",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524298-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522867-13-00",
            "title": "A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.",
            "phase": "Phase II",
            "lead_sponsor": "Merus B.V.",
            "conditions": "Non Small Cell Lung Cancer",
            "member_states": "Spain; Belgium; Netherlands; Poland; Italy; France",
            "decision_date": "09/04/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522867-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523526-40-00",
            "title": "C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Italy; Spain; France; Germany",
            "decision_date": "09/04/2026",
            "enrolled": "53",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523526-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523525-17-00",
            "title": "C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma",
            "phase": "Phase I/II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma",
            "member_states": "Spain; Italy; Germany; France",
            "decision_date": "09/04/2026",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523525-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524764-38-00",
            "title": "Study of diclofenac skin reservoir formation and emptying after Voltaren Emulgel 2.32% application in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Haleon CH SARL",
            "conditions": "For the local, symptomatic treatment of pain in acute bruises, strains, or sprains due to blunt trauma, e.g., sports and accident injuries",
            "member_states": "Germany",
            "decision_date": "09/04/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524764-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-505247-39-00",
            "title": "Efficacy of intravenous dexamethasone in prolonging the duration of spinal anesthesia with chloroprocaine in knee arthroscopy.",
            "phase": "Phase III",
            "lead_sponsor": "Centre Medico Chirurgical Ambroise Pare Hartmann",
            "conditions": "Knee arthroscopy",
            "member_states": "France",
            "decision_date": "08/04/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-505247-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521090-14-00",
            "title": "A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd)  in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Patients with relapsed/refractory symptomatic multiple myeloma (MM)",
            "member_states": "France",
            "decision_date": "08/04/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521090-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514964-24-00",
            "title": "FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "University Hospital Of Clermont-Ferrand",
            "conditions": "ulcerative colitis",
            "member_states": "France",
            "decision_date": "08/04/2026",
            "enrolled": "240",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514964-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519304-28-00",
            "title": "A randomized, Phase 3, open-label study to investigate pharmacokinetics, safety, and efficacy of subcutaneous compared to intravenous frexalimab in adult participants with multiple sclerosis.",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Multiple Sclerosis",
            "member_states": "Belgium; Spain; Italy",
            "decision_date": "08/04/2026",
            "enrolled": "67",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519304-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524157-13-00",
            "title": "A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.",
            "phase": "Phase I",
            "lead_sponsor": "Precision Biosciences Inc.",
            "conditions": "Chronic Hepatitis B",
            "member_states": "Romania; France",
            "decision_date": "08/04/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524157-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522288-13-00",
            "title": "ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.",
            "phase": "Phase II",
            "lead_sponsor": "ETOP IBCSG Partners Foundation",
            "conditions": "Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2",
            "member_states": "France; Greece; Spain; Italy",
            "decision_date": "08/04/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522288-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522460-33-00",
            "title": "An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease",
            "phase": "Phase III",
            "lead_sponsor": "Belite Bio Inc.",
            "conditions": "Stargardt Disease",
            "member_states": "Netherlands; France; Belgium",
            "decision_date": "07/04/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522460-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524877-18-00",
            "title": "Pilot Study - Safety and Efficacy of Dalbavancin in Early Outpatient Treatment of Erysipelas and Limited Cellulitis",
            "phase": "Phase IV",
            "lead_sponsor": "Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH",
            "conditions": "Acute bacterial skin and skin structure infection (ABSSSI) \nErysipelas",
            "member_states": "Austria",
            "decision_date": "07/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524877-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523522-41-00",
            "title": "C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Extensive-Stage Small Cell Lung Cancer",
            "member_states": "France; Italy; Germany; Spain",
            "decision_date": "07/04/2026",
            "enrolled": "182",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523522-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523709-13-00",
            "title": "Sevoflurane vs. propofol for general Anesthesia in patients with acute ischemic stroke treated with endoVascular treatmEnt (SAVE trial)",
            "phase": "Phase III",
            "lead_sponsor": "Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau",
            "conditions": "Acute ischemic stroke",
            "member_states": "Spain",
            "decision_date": "07/04/2026",
            "enrolled": "330",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523709-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524123-45-00",
            "title": "Treatment of low-flow vascular malformations with bleomycin electrosclerotherapy (BEST)",
            "phase": "Phase II",
            "lead_sponsor": "Institute Of Oncology Ljubljana",
            "conditions": "VASCULAR MALFORMATION",
            "member_states": "Slovenia",
            "decision_date": "07/04/2026",
            "enrolled": "140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524123-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525025-12-00",
            "title": "A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people",
            "phase": "Phase I",
            "lead_sponsor": "Pharmacosmos A/S",
            "conditions": "Iron overload from thalassemia, transfusion-dependent myelodysplastic syndromea and haemolysis",
            "member_states": "Netherlands",
            "decision_date": "07/04/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525025-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521108-23-00",
            "title": "A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Chronic Obstructive Pulmonary Disease",
            "member_states": "Germany; Belgium; Netherlands; Denmark; Spain; Greece; Poland; Hungary; France; Italy; Bulgaria; Romania",
            "decision_date": "07/04/2026",
            "enrolled": "549",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521108-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523937-25-00",
            "title": "A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants with Diabetic Macular Edema (DME) (EYP-1901-303)",
            "phase": "Phase III",
            "lead_sponsor": "Eyepoint Inc.",
            "conditions": "Diabetic Macular Edema (DME)",
            "member_states": "Germany; Poland; Slovakia",
            "decision_date": "07/04/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523937-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521569-29-00",
            "title": "A non-commercial, randomized, open-label clinical trial to evaluate the efficacy of 1.8-cineole compared to mupirocin in the treatment of chronic rhinitis caused by carriage of methicillin-resistant Staphylococcus aureus (NOSE)",
            "phase": "Phase III",
            "lead_sponsor": "Wroclaw Medical University",
            "conditions": "chronic active Staphylococcus aureus mono-infection/asymptomatic carriage in the nasal cavity",
            "member_states": "Poland",
            "decision_date": "07/04/2026",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521569-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524624-21-00",
            "title": "Application of radiomics in molecular imaging (18F-FDG-PET/CT) for diagnosis and follow-up of cardiovascular device infections: PREDICT study",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "Cardiovascular device infections",
            "member_states": "Spain",
            "decision_date": "07/04/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524624-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520444-42-00",
            "title": "Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Overweight or obesity, and knee osteoarthritis",
            "member_states": "Italy; Greece; Spain; Bulgaria; Denmark; Poland",
            "decision_date": "07/04/2026",
            "enrolled": "220",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520444-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520445-23-00",
            "title": "Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Overweight or obesity, and knee osteoarthritis",
            "member_states": "Greece; Poland; Spain; Bulgaria; Italy; Denmark",
            "decision_date": "07/04/2026",
            "enrolled": "220",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520445-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511593-70-00",
            "title": "Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis",
            "phase": "Phase III",
            "lead_sponsor": "Alfasigma S.p.A.",
            "conditions": "Polyarticular-course juvenile idiopathic arthritis",
            "member_states": "Spain; Bulgaria; France; Belgium; Germany; Greece; Italy; Poland; Hungary; Czechia",
            "decision_date": "07/04/2026",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511593-70-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524774-42-00",
            "title": "The NOVA-NOA Trial \nA Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia",
            "phase": "Phase II",
            "lead_sponsor": "Herlev Hospital",
            "conditions": "Male Infertility",
            "member_states": "Denmark",
            "decision_date": "07/04/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524774-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524440-35-00",
            "title": "Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing \u2013 The Adapt Abi trial",
            "phase": "Phase IV",
            "lead_sponsor": "Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting",
            "conditions": "metastatic castration resistant prostate cancer (mCRPC)",
            "member_states": "Netherlands",
            "decision_date": "07/04/2026",
            "enrolled": "230",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524440-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523076-23-00",
            "title": "Randomized, Double-blind, Placebo-controlled, Proof-of-concept Phase II Trial Investigating the Effect of Valproic Acid in Women with Adenomyosis.",
            "phase": "Phase II",
            "lead_sponsor": "CCDRD Cooperative Clinical Drug Research and Development AG, Nadezhda Reproductive Science OOD",
            "conditions": "Adenomyosis",
            "member_states": "Bulgaria",
            "decision_date": "03/04/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523076-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520286-31-00",
            "title": "A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Astellas Pharma Global Development Inc.",
            "conditions": "Hot Flush",
            "member_states": "Bulgaria",
            "decision_date": "03/04/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520286-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520632-42-00",
            "title": "Evaluation of the efficacy and safety of bimekizumab (BZK) or adalimumab (ADA) in the treatment of anterior chest wall pain associated with active axial spondyloarthritis refractory to NSAIDs with hypothesis of superiority of bimekizumab. Randomized, open-label, in parallel arms, head to head trial (ThoracSPA)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire Rouen",
            "conditions": "axial or predominantly axial SpA with or without psoriasis",
            "member_states": "France",
            "decision_date": "03/04/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520632-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523757-33-00",
            "title": "A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability via Autoinjector Device versus Syringe in Patients with Multiple Sclerosis",
            "phase": "Phase II",
            "lead_sponsor": "Tg Therapeutics Inc.",
            "conditions": "multiple sclerosis",
            "member_states": "Poland",
            "decision_date": "03/04/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523757-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522630-31-00",
            "title": "Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria",
            "phase": "Phase I",
            "lead_sponsor": "Agios Pharmaceuticals Inc.",
            "conditions": "Phenylketonuria",
            "member_states": "Poland",
            "decision_date": "03/04/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522630-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522441-21-00",
            "title": "Open-Label, Multi Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)",
            "phase": "Phase II",
            "lead_sponsor": "Askbio Inc.",
            "conditions": "Parkinson's Disease",
            "member_states": "Poland",
            "decision_date": "03/04/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522441-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523017-28-00",
            "title": "A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases",
            "phase": "Phase III",
            "lead_sponsor": "Rakuten Medical Inc.",
            "conditions": "Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC)",
            "member_states": "Poland",
            "decision_date": "03/04/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523017-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515663-59-00",
            "title": "Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: \na randomised, double-blind, placebo-controlled, phase 3 trial\n\nPEACH 2",
            "phase": "Phase III",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "intracerebral haemorrhage",
            "member_states": "France",
            "decision_date": "02/04/2026",
            "enrolled": "580",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515663-59-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523868-20-00",
            "title": "Efficacy and safety of a novel dual pH-dependent delayed-release ColeseveLam for the trEatment of bile Acid diarrhoea: a Randomized, double-blind, parallel-group, placebo-controlled clinical trial - CLEAR",
            "phase": "Phase II",
            "lead_sponsor": "Monteresearch S.r.l.",
            "conditions": "Bile acid diarrhoea",
            "member_states": "Italy",
            "decision_date": "02/04/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523868-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523877-40-00",
            "title": "TREAT-EC (Tirzepatide in the treatment of endometrial cancer) - a clinical trial",
            "phase": "Phase II",
            "lead_sponsor": "University College Dublin",
            "conditions": "Endometrial adenocarcinoma",
            "member_states": "Ireland",
            "decision_date": "02/04/2026",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523877-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524342-96-00",
            "title": "Colonic Intramural Injections of Botulin toxin versus placebo to treat fragmented defecation and urgency after restorative total mesorectal excision (TME) for rectal cancer",
            "phase": "Phase II",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Rectal Cancer",
            "member_states": "Belgium",
            "decision_date": "02/04/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524342-96-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525349-65-00",
            "title": "Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion",
            "phase": "Phase II",
            "lead_sponsor": "Annexin Pharmaceuticals AB (publ)",
            "conditions": "Diabetic Retinopathy, Retinal Vein Occlusion",
            "member_states": "Germany",
            "decision_date": "02/04/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525349-65-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524206-15-00",
            "title": "A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Obesity",
            "member_states": "Germany",
            "decision_date": "02/04/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524206-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522246-43-00",
            "title": "Study in healthy male participants to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as multiple intravenous injections as well as safety, tolerability and the effects on certain blood values.",
            "phase": "Phase I",
            "lead_sponsor": "Blau Farmaceutica S.A.",
            "conditions": "Treatment of symptomatic anemia associated with chronic renal failure:",
            "member_states": "Germany",
            "decision_date": "02/04/2026",
            "enrolled": "124",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522246-43-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523974-18-00",
            "title": "EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- \nBIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH \nOVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER \nRANDOMIZED, CONTROLLED TRIAL (VESPER-4)",
            "phase": "Phase III",
            "lead_sponsor": "Metsera Inc.",
            "conditions": "Obesity",
            "member_states": "Germany; Hungary; Slovakia; Poland; Spain; Czechia; Romania; Bulgaria",
            "decision_date": "02/04/2026",
            "enrolled": "894",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523974-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519515-34-00",
            "title": "L-Thyroxine for the treatment of acute unilateral vestibulopathy (AUVP): a monocentric, double-blind, placebo-controlled trial (T4U)",
            "phase": "Phase II",
            "lead_sponsor": "Klinikum der Universitaet Muenchen A\u00f6R",
            "conditions": "Patients with acute unilateral vestibulopathy (AUVP)",
            "member_states": "Germany",
            "decision_date": "02/04/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519515-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522343-18-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy",
            "phase": "Phase II",
            "lead_sponsor": "Rycarma Therapeutics Inc.",
            "conditions": "Autosomal Dominant RYR1-Related Myopathy",
            "member_states": "Netherlands; Spain; France; Germany",
            "decision_date": "02/04/2026",
            "enrolled": "41",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522343-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509421-41-03",
            "title": "AUTOP 2 : Screen-and-treat strategy for vaginal flora abnormalities by molecular biology in pregnant women at high risk of preterm birth: A Multicentre, Randomized Study",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Marseille",
            "conditions": "Bacterial vaginosis, High risk preterm birth pregnancy, Vaginal flora abnormalities",
            "member_states": "France",
            "decision_date": "01/04/2026",
            "enrolled": "1794",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509421-41-03",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520479-25-00",
            "title": "A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)",
            "phase": "Phase III",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Symptomatic Venous Thromboembolism (VTE)",
            "member_states": "Greece; Italy; Spain",
            "decision_date": "01/04/2026",
            "enrolled": "208",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520479-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522567-15-00",
            "title": "A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis",
            "phase": "Phase III",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Plaque Psoriasis",
            "member_states": "Spain; Poland; Germany; Italy",
            "decision_date": "01/04/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522567-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524899-40-00",
            "title": "A First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MR-L45 in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Mironid Limited",
            "conditions": "Autosomal Dominant Polycystic Kidney Disease",
            "member_states": "Netherlands",
            "decision_date": "01/04/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524899-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524229-41-00",
            "title": "PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy \u2013 the multicenter, randomized phase III, pragmatic PLANET trial",
            "phase": "Phase III",
            "lead_sponsor": "Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting",
            "conditions": "Triple negative breast cancer",
            "member_states": "Netherlands",
            "decision_date": "01/04/2026",
            "enrolled": "1000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524229-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525041-43-00",
            "title": "A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up into the Blood of Healthy Adults After Taking Different Tablets of the Study Medicine Called Ibuzatrelvir.",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Coronavirus disease 2019",
            "member_states": "Belgium",
            "decision_date": "01/04/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525041-43-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523239-21-00",
            "title": "Open Label Extension (OLE), multiple dose study to evaluate pharmacokinetics, safety, tolerability and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with juvenile idiopathic arthritis (JIA).",
            "phase": "Phase III",
            "lead_sponsor": "Alfasigma S.p.A.",
            "conditions": "Juvenile idiopathic arthritis",
            "member_states": "France; Germany; Hungary",
            "decision_date": "01/04/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523239-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522523-96-00",
            "title": "A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "lead_sponsor": "Kyowa Kirin Inc.",
            "conditions": "T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)",
            "member_states": "Spain; Italy",
            "decision_date": "01/04/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522523-96-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521865-29-00",
            "title": "A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa",
            "phase": "Phase II",
            "lead_sponsor": "Almirall S.A.",
            "conditions": "moderate-to-severe hidradenitis suppurativa",
            "member_states": "Bulgaria; Spain; France; Poland; Germany",
            "decision_date": "01/04/2026",
            "enrolled": "4999995",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521865-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521101-40-00",
            "title": "GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE  ADMITTED IN THE EMERGENCY ROOM - A FEASIBILITY STUDY",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire",
            "conditions": "CHRONIC DECOMPENSATED HEART FAILURE",
            "member_states": "France",
            "decision_date": "31/03/2026",
            "enrolled": "144",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521101-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523460-21-00",
            "title": "A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.",
            "phase": "Phase II",
            "lead_sponsor": "Centro Di Riferimento Oncologico Di Aviano",
            "conditions": "Metastatic breast cancer",
            "member_states": "Italy",
            "decision_date": "31/03/2026",
            "enrolled": "159",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523460-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522440-41-00",
            "title": "A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)",
            "phase": "Phase II",
            "lead_sponsor": "Bluefin Biomedicine Inc.",
            "conditions": "Hidradenitis Suppurativa",
            "member_states": "Spain; Germany; Czechia; Poland; Bulgaria",
            "decision_date": "31/03/2026",
            "enrolled": "123",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522440-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522697-37-00",
            "title": "Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.",
            "phase": "Phase I/II",
            "lead_sponsor": "VectorY Therapeutics B.V.",
            "conditions": "Amyotrophic Lateral Sclerosis",
            "member_states": "Netherlands; Belgium; Spain",
            "decision_date": "31/03/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522697-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521936-12-00",
            "title": "A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS trial)",
            "phase": "Phase III",
            "lead_sponsor": "NewAmsterdam Pharma B.V.",
            "conditions": "Adults  with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)",
            "member_states": "Czechia; Slovakia; Netherlands",
            "decision_date": "31/03/2026",
            "enrolled": "118",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521936-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522448-41-00",
            "title": "OmaMig Pilot: An open-label, phase IIa, single arm pilot study evaluating the potential clinical benefit and safety of omalizumab in adults with episodic migraine.",
            "phase": "Phase II",
            "lead_sponsor": "Oslo University Hospital HF",
            "conditions": "Episodic migraine",
            "member_states": "Norway",
            "decision_date": "31/03/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522448-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524587-37-00",
            "title": "An Open-Label, Single-Arm Phase 1 Trial to Evaluate The Safety, Tolerability and Efficacy of Vididencel in Chronic Phase Chronic Myeloid Leukemia Patients with Measurable Residual Disease Unable to Meet Requirements of Treatment Free Remission under Tyrosine Kinase Inhibitor Treatment",
            "phase": "Phase I",
            "lead_sponsor": "Mendus B.V.",
            "conditions": "Chronic Phase Chronic Myeloid Leukemia",
            "member_states": "Norway",
            "decision_date": "31/03/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524587-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523269-31-00",
            "title": "SIE-1",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Farmaceuticos Rovi S.A.",
            "conditions": "Hormone receptor-positive early breast cancer in post-menopausal women",
            "member_states": "Spain",
            "decision_date": "31/03/2026",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523269-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-506019-16-03",
            "title": "CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III",
            "phase": "Phase I/II",
            "lead_sponsor": "Celica d.o.o.",
            "conditions": "TRIPLE NEGATIVE BREAST CANCER",
            "member_states": "Slovenia",
            "decision_date": "31/03/2026",
            "enrolled": "82",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-506019-16-03",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519786-22-01",
            "title": "A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "metastatic non-small cell lung cancer (NSCLC)",
            "member_states": "Germany; Spain; France; Poland; Belgium; Netherlands; Italy",
            "decision_date": "30/03/2026",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519786-22-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516976-14-00",
            "title": "A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination with Other Anticancer Agents in Participants with Metastatic Prostate Cancer (ANDROMEDA)",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Metastatic Prostate Cancer",
            "member_states": "Netherlands; Spain",
            "decision_date": "30/03/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516976-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524751-32-00",
            "title": "Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Epic",
            "conditions": "Acute coronary syndrome",
            "member_states": "Spain",
            "decision_date": "30/03/2026",
            "enrolled": "216",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524751-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524680-21-00",
            "title": "Intranasal insulin for the prevention of delirium in ICU patients undergoing elective cardiac surgery: a randomized, double blind, placebo controlled pilot trial (INSPIRE)",
            "phase": "Phase III",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Delirium",
            "member_states": "Netherlands",
            "decision_date": "30/03/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524680-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524738-24-00",
            "title": "Healing Diabetic Foot Ulcers with Semaglutide",
            "phase": "Phase IV",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Diabetic foot ulcer",
            "member_states": "Netherlands",
            "decision_date": "30/03/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524738-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525728-18-00",
            "title": "Rituximab for Treatment of Checkpoint Inhibitor Induced Immune Related Adverse Events",
            "phase": "Phase I",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "All CTCAE (v. 6.0) grade 2-4 immune-related adverse events",
            "member_states": "Denmark",
            "decision_date": "30/03/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525728-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524163-21-00",
            "title": "A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder",
            "phase": "Phase II",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Cannabis dependence (Cannabis Use Disorder or CUD)",
            "member_states": "Denmark",
            "decision_date": "30/03/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524163-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523881-26-00",
            "title": "Identification of mitochondrial biomarkers reflecting omaveloxolone treatment (in FA patients)",
            "phase": "Phase IV",
            "lead_sponsor": "Fakultni Nemocnice V Motole",
            "conditions": "Friedreich's ataxia",
            "member_states": "Czechia; Poland",
            "decision_date": "30/03/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523881-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523938-10-00",
            "title": "A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants with Diabetic Macular Edema (DME) (EYP-1901-304)",
            "phase": "Phase III",
            "lead_sponsor": "Eyepoint Inc.",
            "conditions": "Diabetic Macular Edema (DME)",
            "member_states": "Hungary; Czechia; Germany",
            "decision_date": "30/03/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523938-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523618-10-00",
            "title": "A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder",
            "phase": "Phase III",
            "lead_sponsor": "Xenon Pharmaceuticals Inc.",
            "conditions": "Major Depressive Disorder",
            "member_states": "Finland; Poland; Romania; Slovakia; Spain; Germany",
            "decision_date": "30/03/2026",
            "enrolled": "145",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523618-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524819-37-00",
            "title": "TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)",
            "phase": "Phase IV",
            "lead_sponsor": "Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre",
            "conditions": "obstructive sleep apnea",
            "member_states": "Spain",
            "decision_date": "30/03/2026",
            "enrolled": "345",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524819-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522617-39-00",
            "title": "Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia",
            "phase": "Phase I",
            "lead_sponsor": "Verve Therapeutics Inc.",
            "conditions": "Refractory hyperlipidemia",
            "member_states": "Netherlands",
            "decision_date": "30/03/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522617-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520442-36-00",
            "title": "Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with\noverweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure\n(AMAZE 3)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure",
            "member_states": "Denmark; Poland; Spain; Germany",
            "decision_date": "30/03/2026",
            "enrolled": "125",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520442-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524468-40-00",
            "title": "A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD)",
            "phase": "Phase I",
            "lead_sponsor": "Universitaetsklinikum Erlangen A\u00f6R",
            "conditions": "chronic Graft-versus-Host-Disease (cGvHD)",
            "member_states": "Germany",
            "decision_date": "27/03/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524468-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525449-57-00",
            "title": "Bioequivalence study 2 to compare pharmacokinetics of Parkinson\u00b4s disease drugs in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Orion Corporation",
            "conditions": "Parkinson desease",
            "member_states": "Czechia",
            "decision_date": "27/03/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525449-57-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521639-34-00",
            "title": "A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants with Solid Tumours (IMFINZI-subQ)",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "\u2022 Non-small cell lung cancer (Stage III, unresectable)\n\u2022 Small cell lung cancer (Limited stage)\n\u2022 Hepatocellular carcinoma (Unresectable)",
            "member_states": "Poland",
            "decision_date": "27/03/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521639-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520251-24-00",
            "title": "Evidence based empirical antibiotic treatment for urinary tract infections requiring hospitalisation - TRI-AB trial",
            "phase": "Phase IV",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Complicated urinary tract infections (cUTI) requiring hospitalisation",
            "member_states": "Denmark",
            "decision_date": "27/03/2026",
            "enrolled": "618",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520251-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524330-25-00",
            "title": "Phase 1, Randomized, Open-label, Single center study to evaluate Pharmacokinetic and Bioequivalence of Levonorgestrel Vaginal Delivery System in Healthy Female Volunteers after different days of use",
            "phase": "Phase I",
            "lead_sponsor": "Chemo Research S.L.",
            "conditions": "No medical condition",
            "member_states": "Spain",
            "decision_date": "27/03/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524330-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520466-22-00",
            "title": "Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FR\u03b1-high and AZD5335 Versus Investigator\u2019s Choice Chemotherapy in FR\u03b1-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Advanced Platinum-resistant Epithelial Ovarian Cancer",
            "member_states": "Ireland; Greece; Czechia; France; Sweden; Belgium; Denmark; Spain; Italy; Germany",
            "decision_date": "27/03/2026",
            "enrolled": "309",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520466-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523227-22-00",
            "title": "A Therapeutic Non-Inferiority, Randomized, Observer-blind, Active-comparator, Two-arm, Parallel Group, Multi-center Clinical Trial for Comparing the Efficacy and Tolerability of a Generic Fixed Dose Combination of Brimonidine Tartrate 2 mg/ml + Timolol 5 mg/ml Eye Drops versus Combigan\u00ae 2 mg/ml + 5 mg/ml Eye Drops in the Treatment of Intraocular Pressure in Patients with Open Angle Glaucoma or Ocular Hypertension",
            "phase": "Phase III",
            "lead_sponsor": "OmniVision GmbH",
            "conditions": "Ocular Hypertension, Glaucoma",
            "member_states": "Greece",
            "decision_date": "27/03/2026",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523227-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523657-34-00",
            "title": "J3R-MC-YDAG - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Obesity, Overweight",
            "member_states": "Germany; Poland; Belgium",
            "decision_date": "27/03/2026",
            "enrolled": "254",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523657-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524006-14-00",
            "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Lesigercept in Adult Patients with Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines (CLEAR)",
            "phase": "Phase II",
            "lead_sponsor": "Yuhan Corp.",
            "conditions": "Chronic Spontaneous Urticaria",
            "member_states": "Bulgaria; Poland",
            "decision_date": "27/03/2026",
            "enrolled": "53",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524006-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519818-31-01",
            "title": "A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator\u2019s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Endometrial Cancer\nAdvanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer",
            "member_states": "Poland; Denmark; Finland; Lithuania; France; Germany; Spain; Belgium; Greece; Norway; Italy",
            "decision_date": "26/03/2026",
            "enrolled": "290",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519818-31-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520887-17-00",
            "title": "Dexamethasone for the treatment of traumatic brain injured patients with brain contusions and pericontusional edema: Study protocol for a prospective, randomized and double blind trial",
            "phase": "Phase IV",
            "lead_sponsor": "University Hospital Son Espases",
            "conditions": "Post-traumatic brain contusion with edema",
            "member_states": "Spain",
            "decision_date": "26/03/2026",
            "enrolled": "1",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520887-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525521-20-00",
            "title": "The headache- and migraine-inducing effects of pitolisant in women with migraine without aura",
            "phase": "Phase I/II",
            "lead_sponsor": "Syddansk Universitet (University of Southern Denmark)",
            "conditions": "Migraine without aura",
            "member_states": "Denmark",
            "decision_date": "26/03/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525521-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523431-19-00",
            "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)",
            "phase": "Phase II",
            "lead_sponsor": "Avalyn Pharma Inc.",
            "conditions": "Idiopathic Pulmonary Fibrosis (IPF)",
            "member_states": "Germany; Italy; Spain; Ireland",
            "decision_date": "26/03/2026",
            "enrolled": "126",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523431-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521709-42-00",
            "title": "Clinical trial to evaluate the efficacy and safety of Depigoid DUO Grass-Mix/Olea (1000 DPP/mL + 1000 DPP/mL) compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.",
            "phase": "Phase III",
            "lead_sponsor": "LETI Pharma S.L.U.",
            "conditions": "Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.",
            "member_states": "Spain; Portugal",
            "decision_date": "25/03/2026",
            "enrolled": "343",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521709-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521736-10-00",
            "title": "Clinical trial to evaluate the efficacy and safety of Depigoid Grass-Mix at 1000 DPP/mL and Depigoid FORTE Grass-Mix at 3000 DPP/mL compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma due to clinically relevant sensitisation to grass pollen.",
            "phase": "Phase III",
            "lead_sponsor": "LETI Pharma S.L.U.",
            "conditions": "Allergic rhinoconjunctivitis with or without controlled asthma",
            "member_states": "Portugal; Spain",
            "decision_date": "25/03/2026",
            "enrolled": "324",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521736-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523922-42-00",
            "title": "Randomized, multicenter, open-label clinical trial to evaluate the clinical and microbiological impact of methenamine hippurate as an alternative prophylaxis to antibiotics in the management of recurrent urinary tract infections in women",
            "phase": "Phase IV",
            "lead_sponsor": "Consorci Mar Parc De Salut De Barcelona",
            "conditions": "recurrent urine infections",
            "member_states": "Spain",
            "decision_date": "25/03/2026",
            "enrolled": "204",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523922-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525165-52-00",
            "title": "A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin\u00ae (somatropin) Delivery and Taken Up Into the Blood in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Growth hormone deficiency",
            "member_states": "Belgium",
            "decision_date": "25/03/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525165-52-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524176-36-00",
            "title": "A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body",
            "phase": "Phase I",
            "lead_sponsor": "Bayer AG",
            "conditions": "Chronic Kidney Disease",
            "member_states": "Germany",
            "decision_date": "25/03/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524176-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511510-20-00",
            "title": "PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults",
            "phase": "Phase II",
            "lead_sponsor": "Prinses Maxima Centrum voor Kinderoncologie B.V.",
            "conditions": "craniopharyngioma",
            "member_states": "Netherlands; France; Germany",
            "decision_date": "25/03/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511510-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523828-51-00",
            "title": "IB1001-304: Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study",
            "phase": "Phase III",
            "lead_sponsor": "Intrabio Limited, IntraBio Inc",
            "conditions": "CACNA1A Disorders",
            "member_states": "Italy; Germany; Austria; Greece",
            "decision_date": "25/03/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523828-51-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523557-33-00",
            "title": "A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants with Moderate-to-Severe Hidradenitis Suppurativa",
            "phase": "Phase II",
            "lead_sponsor": "Navigator Medicines Inc.",
            "conditions": "Moderate-to-Severe Hidradenitis Suppurativa",
            "member_states": "Hungary; Poland; Germany; Bulgaria; Romania",
            "decision_date": "25/03/2026",
            "enrolled": "145",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523557-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522583-32-00",
            "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism (EMBARQ-COLDU and SD)",
            "phase": "Phase III",
            "lead_sponsor": "Celldex Therapeutics Inc.",
            "conditions": "Cold-Induced Urticaria and Symptomatic Dermographism",
            "member_states": "Germany; Lithuania; Spain; Poland",
            "decision_date": "25/03/2026",
            "enrolled": "126",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522583-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523803-31-00",
            "title": "An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)",
            "phase": "Phase II",
            "lead_sponsor": "Shanghai Henlius Biotech Inc.",
            "conditions": "Advanced non-small cell lung cancer (NSCLC)",
            "member_states": "Italy; Romania; Poland; Spain; France",
            "decision_date": "25/03/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523803-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523342-27-00",
            "title": "A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata",
            "phase": "Phase II",
            "lead_sponsor": "Almirall S.A.",
            "conditions": "Alopecia areata",
            "member_states": "Bulgaria; Romania; Poland; Germany; Spain",
            "decision_date": "24/03/2026",
            "enrolled": "126",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523342-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523931-21-00",
            "title": "Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Advanced Malignant Solid Tumors",
            "member_states": "Spain",
            "decision_date": "24/03/2026",
            "enrolled": "77",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523931-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524543-12-00",
            "title": "The efficacy of oral vancomycin therapy in managing different phenotypes of paediatric inflammatory bowel diseases by correlating treatment response to commensal microbiota composition and function (VERDA)",
            "phase": "Phase II",
            "lead_sponsor": "Pirkanmaan hyvinvointialue",
            "conditions": "Ulcerative colitis",
            "member_states": "Finland",
            "decision_date": "24/03/2026",
            "enrolled": "140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524543-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522319-41-00",
            "title": "Non-inferiority study of TOCILIZUMAB in dose-banding versus dose-weight in rheumatoid arthritis with low activity or clinical remission",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nice",
            "conditions": "rheumatoid arthritis",
            "member_states": "France",
            "decision_date": "24/03/2026",
            "enrolled": "122",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522319-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524709-34-00",
            "title": "MitOxyVit: Mitochondrial network modulation approach using hyperbaric oxygen (HBO) therapy and NNbUVB for treating vitiligo",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nice",
            "conditions": "Vitiligo",
            "member_states": "France",
            "decision_date": "24/03/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524709-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520443-16-00",
            "title": "Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)",
            "member_states": "Poland; Spain; Germany",
            "decision_date": "24/03/2026",
            "enrolled": "115",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520443-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523658-15-00",
            "title": "J3R-MC-YDAF - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Obesity or Overweight, and Type 2 Diabetes",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Obesity, Overweight",
            "member_states": "Germany; Spain; Poland; Czechia; Slovakia",
            "decision_date": "24/03/2026",
            "enrolled": "375",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523658-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522475-28-00",
            "title": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction",
            "phase": "Phase III",
            "lead_sponsor": "Tenax Therapeutics Inc.",
            "conditions": "Pulmonary Hypertension (PH) with Heart Failure with preserved left ventricular ejection fraction (PH-HFpEF)",
            "member_states": "France; Italy; Germany; Czechia; Austria; Poland; Hungary; Bulgaria; Spain",
            "decision_date": "24/03/2026",
            "enrolled": "319",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522475-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523461-17-01",
            "title": "AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER",
            "member_states": "France; Italy; Hungary; Greece; Czechia; Spain; Poland; Germany",
            "decision_date": "24/03/2026",
            "enrolled": "387",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523461-17-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523284-37-00",
            "title": "CHARACTERIZATION OF ASTROCYTE REACTIVITY WITH [18F]F-DED PET IN NEURODEGENERATIVE DISEASES",
            "phase": "Phase II",
            "lead_sponsor": "Barcelonabeta Brain Research Center",
            "conditions": "Dementia, Autosomal Dominant Alzheimer's Disease, Sporadic early onset Alzheimer Disease, Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Late onset Alzheimer Disease",
            "member_states": "Spain",
            "decision_date": "24/03/2026",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523284-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522961-31-00",
            "title": "The Acute and Long-term Impact of Support and Music in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)",
            "phase": "Phase II",
            "lead_sponsor": "Kobenhavns Universitet, Koebenhavns Universitet",
            "conditions": "Depression",
            "member_states": "Denmark",
            "decision_date": "24/03/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522961-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522932-15-00",
            "title": "A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.",
            "phase": "Phase I",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Systemic Lupus Erythematosus",
            "member_states": "Germany; France; Italy; Spain; Poland",
            "decision_date": "23/03/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522932-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520902-37-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Non-small cell lung cancer stage IV",
            "member_states": "Italy; Spain; Poland; France",
            "decision_date": "23/03/2026",
            "enrolled": "59",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520902-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523085-24-00",
            "title": "Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Biliary Tract Cancer",
            "member_states": "Germany; Poland; Italy; Belgium; France; Netherlands; Spain",
            "decision_date": "23/03/2026",
            "enrolled": "232",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523085-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524278-40-00",
            "title": "Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy",
            "phase": "Phase IV",
            "lead_sponsor": "Universitair Ziekenhuis Gent",
            "conditions": "Patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy, for hematological malignancy",
            "member_states": "Belgium",
            "decision_date": "23/03/2026",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524278-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523743-35-00",
            "title": "Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects in Patients with Heart Failure or Cardiovascular Disease and Chronic Kidney Disease (COMPARE-VS)",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Heart failure, cardiovascular disease, chronic kidney disease",
            "member_states": "Netherlands",
            "decision_date": "23/03/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523743-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522403-17-00",
            "title": "A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)",
            "phase": "Phase III",
            "lead_sponsor": "Almirall S.A.",
            "conditions": "Nummular Dermatitis",
            "member_states": "Italy; Bulgaria; Spain; Germany; Poland; France",
            "decision_date": "23/03/2026",
            "enrolled": "290",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522403-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523013-28-00",
            "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8P Loss and Without a PIK3CA Mutation",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation",
            "member_states": "France; Italy; Poland; Germany; Spain",
            "decision_date": "23/03/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523013-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524542-10-00",
            "title": "A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Acrivon Therapeutics Inc.",
            "conditions": "Endometrial cancer",
            "member_states": "Italy; Germany; Spain; France",
            "decision_date": "23/03/2026",
            "enrolled": "94",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524542-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521758-40-00",
            "title": "Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Geographic Atrophy",
            "member_states": "Romania",
            "decision_date": "23/03/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521758-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524168-39-00",
            "title": "A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer",
            "phase": "Phase I",
            "lead_sponsor": "Stemline Therapeutics Inc.",
            "conditions": "\u200b\u200bPlatinum-Resistant ovarian cancer\u200b",
            "member_states": "Spain",
            "decision_date": "23/03/2026",
            "enrolled": "23",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524168-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523521-18-00",
            "title": "C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NA\u00cfVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Metastatic Colorectal Cancer",
            "member_states": "Spain; Belgium; France; Italy; Netherlands; Germany; Poland; Denmark",
            "decision_date": "23/03/2026",
            "enrolled": "220",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523521-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519862-33-01",
            "title": "A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Oncusp Therapeutics Inc.",
            "conditions": "Platinum-resistant ovarian cancer (PROC), Advanced renal cell carcinoma (RCC), Other advanced CDH6-positive cancers",
            "member_states": "Denmark; Spain",
            "decision_date": "23/03/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519862-33-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520814-78-00",
            "title": "FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide \u2013 an exploratory pilot and feasibility trial",
            "phase": "Phase I/II",
            "lead_sponsor": "Universitair Medisch Centrum Utrecht",
            "conditions": "Diffuse Midline Glioma, H3K27-altered",
            "member_states": "Netherlands",
            "decision_date": "23/03/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520814-78-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523368-19-00",
            "title": "A study to investigate the pharmacokinetics and safety of KM04 compared to US-Gonal-f RFF Redi-ject and EU-Gonal-f in healthy adult female volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Xentria Inc.",
            "conditions": "Functional female infertility",
            "member_states": "Poland",
            "decision_date": "23/03/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523368-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521868-35-00",
            "title": "A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization",
            "phase": "Phase II",
            "lead_sponsor": "Neurocrine Biosciences Inc.",
            "conditions": "Schizophrenia",
            "member_states": "Romania; Poland; Bulgaria; Croatia",
            "decision_date": "23/03/2026",
            "enrolled": "101",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521868-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524495-39-00",
            "title": "Direct comparison of Tezepelumab and Dupilumab in CRSwNP in a real world setting",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "Chronic Rhinosinusitis with Nasal Polyps",
            "member_states": "Austria",
            "decision_date": "22/03/2026",
            "enrolled": "294",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524495-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524614-28-00",
            "title": "Pharmacokinetics of Aztreonam-Avibactam in Critically Ill Patients with Sepsis Receiving ECMO Support: A Prospective PK Study",
            "phase": "Phase I",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "Sepsis",
            "member_states": "Austria",
            "decision_date": "22/03/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524614-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524133-33-00",
            "title": "A Randomized, Single-Blind, Fixed-Order Crossover Study to Assess the Effects of CSX-1004 Injection on Fentanyl-Induced Respiratory Depression in Healthy Adult Subjects and Subjects with Opioid Use Disorder",
            "phase": "Phase II",
            "lead_sponsor": "Cessation Therapeutics Inc.",
            "conditions": "Opioid use disorder",
            "member_states": "Netherlands",
            "decision_date": "20/03/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524133-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523141-10-00",
            "title": "A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants with Active Psoriatic Arthritis",
            "phase": "Phase II",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Active Psoriatic Arthritis",
            "member_states": "Spain; Poland; Czechia; Germany; Hungary",
            "decision_date": "20/03/2026",
            "enrolled": "163",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523141-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524106-14-00",
            "title": "A study in healthy people to test how vicadrostat affects the heart",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "20/03/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524106-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524358-32-00",
            "title": "PAROCAINE : Evaluation of the Clinical Tolerance of an Intra-Parotid Injection of Bupivacaine Combined with Dexamethasone After Parotidectomy for a Benign Tumor \u2013 Prospective Single-Center Cohort Study",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nimes",
            "conditions": "Indication op\u00e9ratoire valid\u00e9e de parotidectomie partielle pour tumeur parotidienne",
            "member_states": "France",
            "decision_date": "19/03/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524358-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521683-35-00",
            "title": "GUselkumAb inteRvention and DIet evaluAtioN for pouchitis",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Pouchitis",
            "member_states": "Belgium",
            "decision_date": "19/03/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521683-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523033-26-00",
            "title": "Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (OSIBBBOOST)",
            "phase": "Phase II",
            "lead_sponsor": "Academisch Ziekenhuis Maastricht",
            "conditions": "Patients with EGFR-mutated metastatic NSCLC, without CNS metastases on brain MRI and without the ABCG2 34G>A SNP, treated with osimertinib as part of regular care are eligible for inclusion. Participants have at least radiologically proven stable disease (SD) or better on regular care osimertinib therapy.",
            "member_states": "Netherlands",
            "decision_date": "19/03/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523033-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523234-66-00",
            "title": "A Phase 2 Posology Study with Long-Term Extension in Participants with Well\u2011Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies",
            "phase": "Phase II",
            "lead_sponsor": "Kiniksa Pharmaceuticals GmbH",
            "conditions": "Well-Controlled Recurrent Pericarditis",
            "member_states": "Spain; Greece; Germany; France; Italy; Poland",
            "decision_date": "19/03/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523234-66-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524553-13-00",
            "title": "Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay",
            "phase": "Phase II",
            "lead_sponsor": "Fakultni Nemocnice Ostrava",
            "conditions": "lung and/or heart failure",
            "member_states": "Czechia",
            "decision_date": "19/03/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524553-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525343-33-00",
            "title": "A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid",
            "phase": "Phase II",
            "lead_sponsor": "Synact Pharma ApS",
            "conditions": "Polymyalgia rheumatica",
            "member_states": "Denmark",
            "decision_date": "19/03/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525343-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522512-16-00",
            "title": "Phase 1 trial of valemetostat and darolutamide in mCRPC",
            "phase": "Phase I",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "Metastatic Castration Resistant Prostate Cancer (mCRPC)",
            "member_states": "Ireland; Spain; France",
            "decision_date": "18/03/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522512-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517490-24-00",
            "title": "SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
            "phase": "Phase II",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Small Cell Lung Cancer",
            "member_states": "Spain; Germany; Italy; Poland; Belgium",
            "decision_date": "18/03/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517490-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522338-30-00",
            "title": "J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Ulcerative Colitis",
            "member_states": "Hungary; Spain; Denmark; Netherlands; Poland; Romania; Germany; Italy; Austria",
            "decision_date": "18/03/2026",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522338-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516545-39-01",
            "title": "Changes in the tumour microenvironment after intravenous or intradermal administration of anti-CTLA-4 in combination with anti-PD1 treatment in patients with melanoma",
            "phase": "Phase I/II",
            "lead_sponsor": "Stichting Amsterdam UMC",
            "conditions": "unresectable stage III \u2013 IV melanoma",
            "member_states": "Netherlands",
            "decision_date": "18/03/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516545-39-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-526044-12-00",
            "title": "Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates",
            "phase": "Phase IV",
            "lead_sponsor": "Institute For Clinical And Experimental Medicine",
            "conditions": "Obesity",
            "member_states": "Czechia",
            "decision_date": "18/03/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-526044-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523899-23-00",
            "title": "A study in healthy men to test how well different doses of BI 3821001 are tolerated",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "18/03/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523899-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514754-79-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension",
            "phase": "Phase II",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Pulmonary Arterial Hypertension (PAH)",
            "member_states": "Latvia; Belgium; France; Poland; Germany; Spain; Czechia",
            "decision_date": "18/03/2026",
            "enrolled": "47",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514754-79-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513445-37-00",
            "title": "A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2",
            "phase": "Phase III",
            "lead_sponsor": "University Of Cologne",
            "conditions": "previously untreated RT, irrespective of risk factors and disease stage",
            "member_states": "Austria; Germany; Denmark; Ireland; Netherlands",
            "decision_date": "18/03/2026",
            "enrolled": "71",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513445-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523759-76-01",
            "title": "A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 are Tolerated and Act in the Body of Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Rheumatoid arthritis and Systemic Lupus Erythematosus",
            "member_states": "Belgium",
            "decision_date": "17/03/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523759-76-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522147-18-00",
            "title": "A clinical trial of MK-7228 in adults  (MK-7228-002)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Atherosclerosis",
            "member_states": "Belgium",
            "decision_date": "17/03/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522147-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524673-16-00",
            "title": "Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children \u2013 open-label phase II clinical trial (FMT-PAS)",
            "phase": "Phase II",
            "lead_sponsor": "Masarykova Univerzita",
            "conditions": "Autism spectrum disorder",
            "member_states": "Czechia",
            "decision_date": "17/03/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524673-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522051-26-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency",
            "phase": "Phase III",
            "lead_sponsor": "Pharvaris Netherlands B.V.",
            "conditions": "Acquired Angioedema due to C1 Inhibitor Deficiency",
            "member_states": "Hungary; Spain; Austria; Germany; Poland; Netherlands; France; Italy; Bulgaria",
            "decision_date": "17/03/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522051-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519699-24-00",
            "title": "An open-label, uncontrolled, multicenter study to assess the effect of zigakibart treatment on histologic, circulating, and excreted markers of kidney disease and dysfunction in adult patients with IgA nephropathy",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "IgA nephropathy",
            "member_states": "Czechia; Germany; Spain; Italy; Poland",
            "decision_date": "17/03/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519699-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524901-33-00",
            "title": "Use of half the iodinated contrast medium for monitoring thoracic neoplasms using spectral CT: Randomized, crossover, non-inferiority clinical trial",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion De La Comunitat Valenciana Para La Gestion Del Instituto De Investigacion Sanitaria Y Biomedica De Alicante",
            "conditions": "Thoracic neoplasm",
            "member_states": "Spain",
            "decision_date": "17/03/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524901-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524010-28-00",
            "title": "A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Repertoire Immune Medicines Inc.",
            "conditions": "Advanced Solid Tumor",
            "member_states": "Spain; Ireland; Portugal; France",
            "decision_date": "17/03/2026",
            "enrolled": "87",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524010-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521779-30-00",
            "title": "A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)",
            "phase": "Phase II",
            "lead_sponsor": "Adarx Pharmaceuticals Inc.",
            "conditions": "Geographic atrophy secondary to age-related macular degeneration",
            "member_states": "Germany; Portugal; Italy; Spain",
            "decision_date": "17/03/2026",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521779-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524617-84-00",
            "title": "A study to investigate the pharmacokinetics and safety of a single dose of duvakitug in healthy adult participants",
            "phase": "Phase I",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Healthy Volunteers",
            "member_states": "Germany",
            "decision_date": "17/03/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524617-84-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523742-27-00",
            "title": "A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Medilink Therapeutics (Suzhou) Co. Ltd.",
            "conditions": "Advanced solid tumors",
            "member_states": "Poland; Spain; France; Romania; Italy; Belgium; Hungary; Germany",
            "decision_date": "17/03/2026",
            "enrolled": "133",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523742-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524191-38-00",
            "title": "Cholesterol lowering with atorvastatine for the prevention of gallstones following bariatric surgery (CHOLSTONE): an investigator- blinded randomised controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Spaarne Gasthuis Stichting",
            "conditions": "Gallstones (chole(cysto)lithiasis) following bariatric surgery",
            "member_states": "Netherlands",
            "decision_date": "17/03/2026",
            "enrolled": "202",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524191-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522191-86-00",
            "title": "A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Focal segmental glomerulosclerosis",
            "member_states": "Germany; Croatia; Poland; Sweden; Portugal; Netherlands; Italy; Denmark; Slovakia; Spain; Norway; Romania; Belgium; Greece; France",
            "decision_date": "17/03/2026",
            "enrolled": "86",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522191-86-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523686-15-00",
            "title": "Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Olema Pharmaceuticals Inc.",
            "conditions": "Advanced or Metastatic Solid Tumors",
            "member_states": "Ireland; Spain; France",
            "decision_date": "17/03/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523686-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524477-17-00",
            "title": "PREDICTION OF COMPLICATIONS IN PATIENTS UNDERGOING SURGICAL TREATMENT OF HEPATIC TUMORS",
            "phase": "Phase IV",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Hepatic tumor, Hepatic tumor(s)",
            "member_states": "Denmark",
            "decision_date": "17/03/2026",
            "enrolled": "192",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524477-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523914-10-00",
            "title": "Evaluating the clinical effectiveness of sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury",
            "phase": "Phase IV",
            "lead_sponsor": "Universitaet Muenster",
            "conditions": "Critical illness, Acute kidney injury, Metabolic acidosis",
            "member_states": "Germany",
            "decision_date": "17/03/2026",
            "enrolled": "660",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523914-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524883-39-00",
            "title": "A Phase 1, open label, randomised, 2-period, 2 sequence, 7-days repeat-dosing, crossover oral pharmacokinetic trial comparing multiple dosing of CS014 to valproic acid in healthy adults.",
            "phase": "Phase I",
            "lead_sponsor": "Cereno Scientific AB",
            "conditions": "Cardiopulmonary diseases with contributions of thrombosis, remodelling of pulmonary vessels and fibrosis.",
            "member_states": "Sweden",
            "decision_date": "17/03/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524883-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523350-13-02",
            "title": "SHIELD \u2013 Swift Hydrocortisone Intervention after trauma exposure",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Posttraumatic Stress Disorder (PTSD)",
            "member_states": "Netherlands",
            "decision_date": "17/03/2026",
            "enrolled": "196",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523350-13-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516896-34-00",
            "title": "Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)",
            "phase": "Phase I/II",
            "lead_sponsor": "Universitaetsklinikum Heidelberg A\u00f6R",
            "conditions": "progressive/relapsed/refractory pediatric low-grade glioma (pLGG)",
            "member_states": "Denmark; Czechia; Austria; Sweden; Germany",
            "decision_date": "17/03/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516896-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524057-13-00",
            "title": "AchilleS tendinoPathy treated with cortIcosteRoid injEctions.",
            "phase": "Phase III",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Achilles tendinopathy",
            "member_states": "Netherlands",
            "decision_date": "16/03/2026",
            "enrolled": "276",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524057-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522878-36-00",
            "title": "A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)",
            "phase": "Phase III",
            "lead_sponsor": "Celldex Therapeutics Inc.",
            "conditions": "Chronic Spontaneous Urticaria",
            "member_states": "Croatia; France; Netherlands; Bulgaria; Portugal; Slovakia; Hungary; Italy; Greece; Germany; Czechia; Lithuania; Spain; Belgium; Denmark; Poland",
            "decision_date": "16/03/2026",
            "enrolled": "438",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522878-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522782-30-00",
            "title": "A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults",
            "phase": "Phase I",
            "lead_sponsor": "UCB Biopharma",
            "conditions": "CCI",
            "member_states": "Croatia; Poland; Germany; Czechia; Slovakia; Bulgaria",
            "decision_date": "16/03/2026",
            "enrolled": "293",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522782-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511656-41-00",
            "title": "An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping",
            "phase": "Phase II",
            "lead_sponsor": "Biomarin Pharmaceutical Inc.",
            "conditions": "Duchenne Muscular Dystrophy",
            "member_states": "Spain; Italy; Netherlands",
            "decision_date": "16/03/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511656-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523600-68-00",
            "title": "A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies",
            "phase": "Phase II",
            "lead_sponsor": "Curis Inc.",
            "conditions": "Chronic Lymphocytic Leukemia and Other B-cell Malignancies",
            "member_states": "Spain; Italy",
            "decision_date": "16/03/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523600-68-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522864-34-00",
            "title": "Peri-operative intraperitoneal irinotecan and systemic FLOT in the curative treatment of gastric cancer and gastroesophageal junction cancer: a phase I study",
            "phase": "Phase I",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Gastric cancer",
            "member_states": "Netherlands",
            "decision_date": "16/03/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522864-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525208-90-00",
            "title": "A Phase 1, drug-drug interaction trial of IMU-838 with oral contraceptives in women",
            "phase": "Phase I",
            "lead_sponsor": "Immunic AG",
            "conditions": "Multiple sclerosis",
            "member_states": "Belgium",
            "decision_date": "16/03/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525208-90-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523996-45-00",
            "title": "The POST-PRANDIAL HYPO-AVOID STUDY\nLow-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced \nHypoglycemia in People with Type 1 Diabetes",
            "phase": "Phase IV",
            "lead_sponsor": "Steno Diabetes Center Copenhagen",
            "conditions": "Type 1 Diabetes Mellitus",
            "member_states": "Denmark",
            "decision_date": "16/03/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523996-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522627-10-00",
            "title": "Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "13/03/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522627-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522545-22-00",
            "title": "Comparison of esketamine mouthwash versus intravenous administration for the treatment of chemotherapy/radiotherapy-induced mucositis",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Oral mucositis",
            "member_states": "Netherlands",
            "decision_date": "13/03/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522545-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521475-31-00",
            "title": "Prestige 2- RimegePant in RElation to obeSiTy in miGainE",
            "phase": "Phase III",
            "lead_sponsor": "Konvent Der Barmherzigen Brueder",
            "conditions": "Migraine",
            "member_states": "Austria",
            "decision_date": "13/03/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521475-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523262-25-00",
            "title": "A study to test how different doses of BI 3814916 are tolerated by healthy people",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "healthy volunteer trial",
            "member_states": "Belgium",
            "decision_date": "13/03/2026",
            "enrolled": "136",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523262-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523501-15-00",
            "title": "A Phase 2, monocentric, prospective, nonrandomized, open-label, experimental study to evaluate efficacy and safety of intrabronchial instillation of liposomal Amphotericin B in patients with simple pulmonary aspergilloma.",
            "phase": "Phase II",
            "lead_sponsor": "Pauls Stradins Clinical University Hospital",
            "conditions": "Simple aspergilloma",
            "member_states": "Latvia",
            "decision_date": "13/03/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523501-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524501-32-02",
            "title": "The effect of Broncho-Vaxom on the COPD exacerbations in terms of lung function, lung mechanics, immune state, body composition, quality of life and physical activity.",
            "phase": "Phase IV",
            "lead_sponsor": "Semmelweis University, University Of Pecs",
            "conditions": "COPD exacerbation",
            "member_states": "Hungary",
            "decision_date": "13/03/2026",
            "enrolled": "260",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524501-32-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522244-40-00",
            "title": "Study in healthy volunteers to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as a single intravenous injection as well as safety, tolerability and the effects on certain blood values.",
            "phase": "Phase I",
            "lead_sponsor": "Blau Farmaceutica S.A.",
            "conditions": "It is used to treat symptomatic anaemia in chronic renal failure",
            "member_states": "Germany",
            "decision_date": "13/03/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522244-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524446-10-00",
            "title": "Phase 1 open label trial of MST-0312 alone and in combination in subjects with solid malignancies",
            "phase": "Phase I",
            "lead_sponsor": "Mestag Therapeutics Limited",
            "conditions": "Solid Malignancies",
            "member_states": "Spain",
            "decision_date": "13/03/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524446-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522118-21-00",
            "title": "Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis\n(UP-FOR-U)",
            "phase": "Phase IV",
            "lead_sponsor": "Care Arthritis Ltd.",
            "conditions": "Axial Spondyloarthritis, Acute Anterior Uveitis",
            "member_states": "Spain; Poland; Netherlands; France; Bulgaria; Germany",
            "decision_date": "13/03/2026",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522118-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521393-34-00",
            "title": "A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Participants with obesity, but otherwise healthy",
            "member_states": "Germany",
            "decision_date": "13/03/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521393-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520127-89-00",
            "title": "GASPS Study: General Anaesthesia vs Spinal anaesthesia: Patient outcomes and Success in Outpatient primary total knee and hip Arthroplasty",
            "phase": "Phase IV",
            "lead_sponsor": "Region Oerebro Laen",
            "conditions": "Total knee and hip arthroplasties",
            "member_states": "Sweden",
            "decision_date": "12/03/2026",
            "enrolled": "600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520127-89-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520414-21-00",
            "title": "\u201cIntravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicentre Randomized Controlled Trial\u201d\nTHE IVT ALL IN TRIAL",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.",
            "member_states": "France",
            "decision_date": "12/03/2026",
            "enrolled": "486",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520414-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524834-24-00",
            "title": "IL-1\u03b2 blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)",
            "phase": "Phase I/II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "diabetic patients \npancreatic transplant",
            "member_states": "France",
            "decision_date": "12/03/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524834-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522580-15-00",
            "title": "A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)",
            "phase": "Phase II",
            "lead_sponsor": "Zydus Therapeutics Inc.",
            "conditions": "Amyotrophic Lateral Sclerosis (ALS)",
            "member_states": "Spain; Germany; Sweden; Ireland; Poland; Italy; Belgium; France; Netherlands",
            "decision_date": "12/03/2026",
            "enrolled": "206",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522580-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512515-45-01",
            "title": "A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",
            "phase": "Phase I",
            "lead_sponsor": "Theras Inc.",
            "conditions": "Non-Small Cell Lung Cancer",
            "member_states": "Spain; Denmark",
            "decision_date": "12/03/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512515-45-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524431-39-00",
            "title": "An open label, pharmacokinetic and safety study of Combogesic\u00ae IV in pediatric patients with acute pain.",
            "phase": "Phase III",
            "lead_sponsor": "Aft Pharmaceuticals Limited",
            "conditions": "Acute pain",
            "member_states": "Hungary",
            "decision_date": "12/03/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524431-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521269-28-00",
            "title": "A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.",
            "phase": "Phase II",
            "lead_sponsor": "Oslo University Hospital HF",
            "conditions": "Acute ischemic stroke",
            "member_states": "Norway; Denmark",
            "decision_date": "12/03/2026",
            "enrolled": "236",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521269-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523553-34-00",
            "title": "A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, Alone and in Combination with Other Agents in Patients with Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "BeOne Medicines I GmbH",
            "conditions": "Advanced and Metastatic Solid tumors",
            "member_states": "Italy; Spain",
            "decision_date": "12/03/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523553-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521062-10-00",
            "title": "A Study to Evaluate the Safety and Tolerability of ARV-806 in Adults with Advanced Cancer that has the KRAS G12D Mutation",
            "phase": "Phase I",
            "lead_sponsor": "Arvinas Operations Inc.",
            "conditions": "KRAS G12D Mutated Advanced Solid Tumors",
            "member_states": "Spain; Italy",
            "decision_date": "12/03/2026",
            "enrolled": "51",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521062-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523845-90-00",
            "title": "Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease",
            "phase": "Phase I",
            "lead_sponsor": "CRISPR Therapeutics AG",
            "conditions": "Relapsed/Refractory Hematologic Autoimmune Disease",
            "member_states": "Spain; Germany; France; Denmark; Italy; Netherlands",
            "decision_date": "12/03/2026",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523845-90-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517943-29-00",
            "title": "A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)",
            "phase": "Phase III",
            "lead_sponsor": "Liquidia Technologies Inc.",
            "conditions": "Pulmonary Hypertension associated with interstitial lung disease (WHO Group 3)",
            "member_states": "Latvia; Germany; Italy; Czechia; France; Belgium; Portugal; Poland; Austria; Spain",
            "decision_date": "11/03/2026",
            "enrolled": "121",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517943-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524856-73-00",
            "title": "A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Not Applicable",
            "member_states": "Netherlands",
            "decision_date": "11/03/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524856-73-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515009-24-00",
            "title": "INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS",
            "phase": "Phase II",
            "lead_sponsor": "Clinica Universidad De Navarra",
            "conditions": "High grade malignant brain neoplasm",
            "member_states": "Netherlands; Spain",
            "decision_date": "11/03/2026",
            "enrolled": "39",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515009-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522542-40-00",
            "title": "TENACITY \u2013 A Phase III, prospective, randomized, open-label, blinded endpoint assessment (PROBE) to assess efficacy and safety of i.v. tenecteplase vs standard of care in patients with acute ischemic stroke (including wake-up stroke), last known well >4.5 h with imaging evidence of salvageable ischemic tissue",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Acute Ischemic Stroke",
            "member_states": "Greece; Norway; Hungary; Romania; Spain; Bulgaria",
            "decision_date": "11/03/2026",
            "enrolled": "350",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522542-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525342-29-00",
            "title": "A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 mg Tablet in Healthy Adults Under Fed Conditions",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Transthyretin amyloidosis",
            "member_states": "Belgium",
            "decision_date": "11/03/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525342-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519884-16-00",
            "title": "Ultimate dePletion of autoReactive b cells using Obinutuzumab from sj\u00d6gren's syndrome affected Tissues study- UPROOT study",
            "phase": "Phase II",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Sj\u00f6gren's syndrome",
            "member_states": "Netherlands",
            "decision_date": "11/03/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519884-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522705-37-00",
            "title": "B7981119 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Evaluating the Safety and Efficacy of Ritlecitinib (PF-06651600) in Adults with Moderate to Severe Hidradenitis Suppurativa",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "HIDRADENITIS SUPPURATIVA",
            "member_states": "Germany; Poland; Spain; Greece",
            "decision_date": "11/03/2026",
            "enrolled": "71",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522705-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525434-33-00",
            "title": "Bioequivalence Study of Empagliflozin",
            "phase": "Phase I",
            "lead_sponsor": "Tarchominskie Zaklady Farmaceutyczne Polfa S.A.",
            "conditions": "Not applicable (submitted trial is a BE study in healthy participants)",
            "member_states": "Czechia",
            "decision_date": "11/03/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525434-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521456-35-00",
            "title": "A Phase II, multinational, multicentre, double-blind, randomised, active-controlled, 3-way cross-over study to evaluate the therapeutic equivalence of CHF5993 pMDI 100/6/12.5 \u00b5g HFA-152a versus CHF5993 pMDI 100/6/12.5 \u00b5g HFA-134a in subjects with mild to moderate asthma. [TRECONY]",
            "phase": "Phase II",
            "lead_sponsor": "Chiesi Farmaceutici S.p.A.",
            "conditions": "Mild to moderate asthma",
            "member_states": "Slovakia; Czechia; Romania; Latvia; Germany; Hungary; Bulgaria; Poland",
            "decision_date": "11/03/2026",
            "enrolled": "250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521456-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522484-15-00",
            "title": "Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)",
            "phase": "Phase III",
            "lead_sponsor": "WSG Women's Cancer Study Group GmbH",
            "conditions": "ER+/HER2- early breast cancer",
            "member_states": "Germany; Spain; Austria",
            "decision_date": "11/03/2026",
            "enrolled": "1520",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522484-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524320-21-00",
            "title": "Prehospital pulse-dose glucocorticoid in patients with STEMI \u2013 the PULSE-MI 2 trial",
            "phase": "Phase III",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "ST-segment Elevation Myocardial Infarction",
            "member_states": "Denmark",
            "decision_date": "11/03/2026",
            "enrolled": "5204",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524320-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525309-11-00",
            "title": "Exploratory,  non-randomized, 3-group, microdosing clinical trial to investigate Gallium-68 (68Ga) labeled Platelet-Derived Growth Factor Beta (PDGFR\u00df) targeting Positron Emission Tomography (PET) tracer (68Ga-ATH001) binding in the lungs in healthy participants versus participants with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)",
            "phase": "Phase I",
            "lead_sponsor": "Antaros Medical AB",
            "conditions": "Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)",
            "member_states": "Sweden",
            "decision_date": "11/03/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525309-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522462-73-00",
            "title": "ILHEP : Effect of perioperative Intravenous Lidocaine on postoperative opioid related-side effects after open HEPatectomy: a multicentre prospective randomized controlled study",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Rennes",
            "conditions": "Postanesthetic complications in patients undergoing open hepatectomy",
            "member_states": "France",
            "decision_date": "10/03/2026",
            "enrolled": "312",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522462-73-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523263-37-00",
            "title": "ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in\nCombination with Chemotherapy Versus Nivolumab in Combination with\nChemotherapy in Participants with Previously Untreated Advanced or Metastatic\nGastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal \nJunction, or Esophageal Adenocarcinoma",
            "member_states": "Germany; Spain; Poland; France; Italy; Romania",
            "decision_date": "10/03/2026",
            "enrolled": "184",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523263-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523224-45-00",
            "title": "ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Untreated, Unresectable or Metastatic Colorectal Cancer",
            "member_states": "Sweden; Czechia; Belgium; Romania; Netherlands; Italy; France; Spain; Germany; Poland; Austria",
            "decision_date": "10/03/2026",
            "enrolled": "334",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523224-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522775-29-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",
            "phase": "Phase III",
            "lead_sponsor": "Xenon Pharmaceuticals Inc.",
            "conditions": "Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)",
            "member_states": "Germany; Bulgaria; Spain; Poland",
            "decision_date": "10/03/2026",
            "enrolled": "123",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522775-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522295-91-00",
            "title": "HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstrom\u2019s macroglobulinemia",
            "phase": "Phase I/II",
            "lead_sponsor": "Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting",
            "conditions": "relapsed or refractory Waldenstrom\u2019s macroglobulinemia",
            "member_states": "Denmark; Belgium; Netherlands",
            "decision_date": "10/03/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522295-91-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524480-21-00",
            "title": "The clinical trial to study a new drug, AP-2.",
            "phase": "Phase I",
            "lead_sponsor": "Molefy Pharma S.L.",
            "conditions": "ALS and related disorders like frontotemporal dementia and Alexander disease.",
            "member_states": "Spain",
            "decision_date": "10/03/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524480-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518013-25-00",
            "title": "A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis",
            "phase": "Phase II",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Idiopathic Pulmonary Fibrosis",
            "member_states": "Greece; Italy; Sweden; Germany; Portugal; Spain; France; Hungary; Poland; Bulgaria; Romania",
            "decision_date": "10/03/2026",
            "enrolled": "86",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518013-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522870-35-00",
            "title": "Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris: a prospective multicenter randomized placebo-controlled study.\n(Upa30-LP)",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nice",
            "conditions": "Lichen",
            "member_states": "France",
            "decision_date": "09/03/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522870-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519711-33-01",
            "title": "REVEAL Study: Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome",
            "phase": "Phase III",
            "lead_sponsor": "Ionis Pharmaceuticals Inc.",
            "conditions": "Angelman syndrome",
            "member_states": "Italy; Germany; Poland; Spain",
            "decision_date": "09/03/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519711-33-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522713-29-00",
            "title": "A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
            "member_states": "Belgium; Italy; Spain; Germany; France",
            "decision_date": "09/03/2026",
            "enrolled": "171",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522713-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522005-38-00",
            "title": "Evaluation of the efficacy of iloprost in the management of vaso-occlusive crises in adult patients with sickle cell: a multicentre, randomised, double-blind, placebo-controlled study _ PROSTASICKLE",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire Rouen",
            "conditions": "sickle cell anaemia with vaso-occlusive crisis",
            "member_states": "France",
            "decision_date": "09/03/2026",
            "enrolled": "144",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522005-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524045-27-00",
            "title": "Late immunity following single immunization with GA2 sporozoites (GACHA)",
            "phase": "Phase I/II",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Falciparum malaria",
            "member_states": "Netherlands",
            "decision_date": "09/03/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524045-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523928-52-00",
            "title": "PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism",
            "phase": "Phase III",
            "lead_sponsor": "Ascendis Pharma Bone Diseases A/S",
            "conditions": "Chronic hypoparathyroidism",
            "member_states": "Germany; France; Romania; Poland",
            "decision_date": "09/03/2026",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523928-52-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522578-35-00",
            "title": "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
            "phase": "Phase II",
            "lead_sponsor": "UCB Biopharma",
            "conditions": "Atopic Dermatitis",
            "member_states": "Bulgaria; Czechia; Germany; Poland; Hungary",
            "decision_date": "09/03/2026",
            "enrolled": "92",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522578-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522293-37-00",
            "title": "A Phase 1, placebo-controlled, randomized, participant- and assessor-blind, single-center study to assess the safety and immunogenicity of 2 dose levels of Nipah measles vector (MV-NiV) vaccine administered subcutaneously either as a single dose or as 2 consecutive doses at 4-week interval, in healthy non-exposed volunteers, aged 18-40 years",
            "phase": "Phase I",
            "lead_sponsor": "Teikyo University",
            "conditions": "Nipah Virus",
            "member_states": "Belgium",
            "decision_date": "09/03/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522293-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524178-40-00",
            "title": "A study to learn more about how safe nurandociguat is and how it affects the way the body processes rosuvastatin and dabigatran in healthy adults",
            "phase": "Phase I",
            "lead_sponsor": "Bayer AG",
            "conditions": "Chronic Kidney Disease",
            "member_states": "Germany",
            "decision_date": "09/03/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524178-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517594-24-01",
            "title": "CAT-01",
            "phase": "Phase I/II",
            "lead_sponsor": "Karolinska Institutet",
            "conditions": "Cervical carcinoma",
            "member_states": "Sweden",
            "decision_date": "09/03/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517594-24-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518774-14-00",
            "title": "SGL-TX-PTDM: SGLT2i effect on PTDM development and kidney allograft function in kidney transplant recipients: A randomized, double-blind, placebo controlled, national multicenter trial",
            "phase": "Phase II",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Kidney transplant recipients",
            "member_states": "Denmark",
            "decision_date": "09/03/2026",
            "enrolled": "184",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518774-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524327-53-00",
            "title": "Luteal phase support following letrozole treatment in women undergoing intrauterine insemination: a multicenter randomized trial",
            "phase": "Phase IV",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Infertility",
            "member_states": "Denmark",
            "decision_date": "09/03/2026",
            "enrolled": "690",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524327-53-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521595-55-00",
            "title": "Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Type 2 Diabetes",
            "member_states": "Germany",
            "decision_date": "09/03/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521595-55-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-510723-18-00",
            "title": "Allogeneic adipose tissue-derived Mesenchymal stromal cells for the treatment of chronic-active antibody mediated rejection in Kidney transplant recipients",
            "phase": "Phase I/II",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Chronic active antibody mediated rejection",
            "member_states": "Denmark",
            "decision_date": "09/03/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-510723-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514244-81-00",
            "title": "CANDISHORT : A randomized study of a short duration therapy for candidemia",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Uncomplicated candidemia",
            "member_states": "France",
            "decision_date": "06/03/2026",
            "enrolled": "399",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514244-81-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522831-33-00",
            "title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa",
            "phase": "Phase II",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Hidradenitis Suppurativa",
            "member_states": "France; Poland; Netherlands; Germany",
            "decision_date": "06/03/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522831-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511790-30-00",
            "title": "APICALE - Cervical facet injection of corticosteroids for the management of cervicobrachialgia : protocol for a randomized pilot study",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Cervicobrachial Neuralgia",
            "member_states": "France",
            "decision_date": "06/03/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511790-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511198-31-00",
            "title": "A Long-Term Follow-Up Study for Participants Previously Treated with KYV-101 (KYSA-4)",
            "phase": "Phase III",
            "lead_sponsor": "Kyverna Therapeutics Inc.",
            "conditions": "Myasthenia Gravis, Rheumatoid Arthritis, Lupus Nephritis, Systemic Sclerosis, Stiff Person Syndrome",
            "member_states": "Germany",
            "decision_date": "06/03/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511198-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524693-42-00",
            "title": "A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Stable Coronary Artery Disease (CAD)",
            "member_states": "Netherlands",
            "decision_date": "06/03/2026",
            "enrolled": "196",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524693-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524823-34-00",
            "title": "Doxycycline post-exposure prophylaxis: Weekly versus event-driven Intake for STI prevention among MSM and TGW taking PrEP (Doxy-WISE study)",
            "phase": "Phase III",
            "lead_sponsor": "Institute Of Tropical Medicine",
            "conditions": "Sexually Transmitted Infections",
            "member_states": "Belgium",
            "decision_date": "06/03/2026",
            "enrolled": "556",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524823-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521327-67-00",
            "title": "A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Metastatic Castration-Resistant Prostate Cancer",
            "member_states": "Germany; France; Italy; Spain",
            "decision_date": "06/03/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521327-67-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524172-29-00",
            "title": "A Phase I, open-label, non-randomized study to assess the absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics of LTP001 following a single oral dose of [14C]LTP001 in healthy male participants",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Healthy volunteers",
            "member_states": "Netherlands",
            "decision_date": "06/03/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524172-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523802-34-00",
            "title": "An Adaptive Dose Escalation and Expansion Basket\u00a0Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies",
            "phase": "Phase I/II",
            "lead_sponsor": "TargED Biopharmaceuticals B.V.",
            "conditions": "Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy",
            "member_states": "Germany; France; Italy; Spain",
            "decision_date": "06/03/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523802-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522511-42-00",
            "title": "A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn\u2019s disease or ulcerative colitis",
            "phase": "Phase II",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Crohn's disease, Colitis Ulcerative",
            "member_states": "Belgium; Germany; Czechia; Netherlands; Spain; Austria; Italy; Greece; Croatia; Bulgaria; Poland; France; Romania; Hungary",
            "decision_date": "06/03/2026",
            "enrolled": "131",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522511-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522231-34-00",
            "title": "A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea High Dose (HD) in Participants with Diabetic Macular Edema (ALVOEYE-HD)",
            "phase": "Phase III",
            "lead_sponsor": "Alvotech Swiss AG",
            "conditions": "Diabetic Macular Edema",
            "member_states": "Latvia; Slovakia; Czechia; Hungary; Poland; Bulgaria",
            "decision_date": "06/03/2026",
            "enrolled": "172",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522231-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524852-74-00",
            "title": "A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Hypercholesterolaemia",
            "member_states": "Belgium",
            "decision_date": "06/03/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524852-74-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522920-28-00",
            "title": "Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Obesity, CCI, CCI",
            "member_states": "Denmark",
            "decision_date": "06/03/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522920-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524053-14-00",
            "title": "Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321",
            "phase": "Phase I",
            "lead_sponsor": "Lycia Therapeutics Inc.",
            "conditions": "Graves Disease",
            "member_states": "Netherlands",
            "decision_date": "06/03/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524053-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523756-31-00",
            "title": "A Study of PHN-012 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Pheon Therapeutics Limited",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Spain",
            "decision_date": "06/03/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523756-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523677-41-00",
            "title": "(21174) Relative bioavailability study to investigate the pharmacokinetics of a single oral dose of asundexian administered as 50 mg pediatric formulation in comparison to 50 mg tablet (adult formulation) in fasted state and to investigate the effect of a high-fat, high-calorie meal on the 50 mg pediatric formulation in healthy adult participants",
            "phase": "Phase I",
            "lead_sponsor": "Bayer AG",
            "conditions": "Prevention of thromboembolic events",
            "member_states": "Germany",
            "decision_date": "06/03/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523677-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524297-42-00",
            "title": "Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial\nPALADIN [PeripherAL Arterial DIsease Network] -DAPTCLTI",
            "phase": "Phase III",
            "lead_sponsor": "Fondation Hopital Saint Joseph",
            "conditions": "CLTI defined as Rutherford category 4  or 5",
            "member_states": "France",
            "decision_date": "05/03/2026",
            "enrolled": "614",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524297-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522119-41-00",
            "title": "Effect of Empagliflozin in patients with eGFR between 10 and 20 ml/min/1.73m2 - EMPA [10-20]",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nice",
            "conditions": "Patients with renal impairment and type 2 diabetes.",
            "member_states": "France",
            "decision_date": "05/03/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522119-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-507010-27-00",
            "title": "CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)",
            "member_states": "France",
            "decision_date": "05/03/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-507010-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521713-57-00",
            "title": "A Phase 1/2a Study of REGN7041 (anti-CD3 monoclonal antibody) in patients with Active Noninfectious Uveitis affecting the Posterior Segment",
            "phase": "Phase I/II",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Noninfectious Uveitis",
            "member_states": "France",
            "decision_date": "05/03/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521713-57-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524841-28-00",
            "title": "KET01-IIT03: A Pilot, Open-label Phase II Trial of Adjunctive Treatment with Ketamine Hydrochloride Prolonged-Release Tablets (KET01) during the Initiation of Antidepressant Therapy in Major Depressive Disorder",
            "phase": "Phase II",
            "lead_sponsor": "Region Skane",
            "conditions": "Major Depressive Disorder",
            "member_states": "Sweden",
            "decision_date": "05/03/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524841-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521859-23-00",
            "title": "A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)",
            "phase": "Phase I/II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "PSMA-positive mCRPC with prior exposure to at least one prior ARPI",
            "member_states": "Germany; France; Spain; Italy",
            "decision_date": "05/03/2026",
            "enrolled": "73",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521859-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522367-15-00",
            "title": "A Study of LY4257496 in Participants With Cancer (OMNIRAY)",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Breast Neoplasms\nColorectal Neoplasms\nProstate Neoplasm\nEndometrial Neoplasms\nNeoplasm Metastasis\nStomach Neoplasms\nEsophageal Neoplasms",
            "member_states": "Germany",
            "decision_date": "05/03/2026",
            "enrolled": "53",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522367-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522410-23-00",
            "title": "Botulinum toxin in open abdomen closure. A multicentric randomized controlled single-blind clinical trial to evaluate the efficacy of early administration of botulinum toxin for primary midline closure in patients with an open abdomen.",
            "phase": "Phase IV",
            "lead_sponsor": "Hospital Universitario La Paz",
            "conditions": "open abdomen",
            "member_states": "Spain",
            "decision_date": "04/03/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522410-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524679-22-00",
            "title": "Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY \u2013 A Steno MODERN-MODY project (MM-SUUP)",
            "phase": "Phase II",
            "lead_sponsor": "Steno Diabetes Center Copenhagen",
            "conditions": "Maturity-onset diabetes of the young type 3 (HNF1A-MODY), Maturity-onset diabetes of the young type 1 (HNF4A-MODY)",
            "member_states": "Denmark",
            "decision_date": "04/03/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524679-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522381-68-00",
            "title": "Intrathecal drug delivery systems versus comprehensive medical management for severe cancer pain: a randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Vrije Universiteit Brussel",
            "conditions": "Severe refractory cancer pain",
            "member_states": "Belgium",
            "decision_date": "04/03/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522381-68-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525256-29-00",
            "title": "Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.",
            "phase": "Phase I",
            "lead_sponsor": "ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.",
            "conditions": "Comparative bioavailability study under fasting conditions",
            "member_states": "Czechia",
            "decision_date": "04/03/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525256-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521884-12-00",
            "title": "A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease",
            "phase": "Phase III",
            "lead_sponsor": "BioNTech SE",
            "conditions": "First line triple-negative breast cancer (TNBC)",
            "member_states": "Czechia; Poland; Italy; France; Belgium; Netherlands; Germany; Spain",
            "decision_date": "04/03/2026",
            "enrolled": "169",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521884-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525076-29-00",
            "title": "Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral).",
            "phase": "Phase I",
            "lead_sponsor": "Nucleus Medical GmbH",
            "conditions": "Phase I study in healthy male volunteers. Intended indication: prophylaxis of transplant rejection in liver, kidney or heart allograft recipients and for treatment of allograft rejection",
            "member_states": "Germany",
            "decision_date": "04/03/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525076-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523037-25-00",
            "title": "A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated - Acute Kidney Injury.",
            "phase": "Phase II",
            "lead_sponsor": "River 2 Renal Corp.",
            "conditions": "Patients at high risk for Cardiac Surgery Associated \u2013 Acute Kidney Injury (CSA-AKI) following coronary artery bypass graft (CABG), valve surgery, aortic surgery, or a combination of the above, involving cardiopulmonary bypass (CPB).",
            "member_states": "Italy; Germany",
            "decision_date": "04/03/2026",
            "enrolled": "440",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523037-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512248-47-00",
            "title": "Protocol Title:\tKEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations",
            "phase": "Phase I/II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Non-small Cell Lung Cancer (NSCLC)",
            "member_states": "Italy; Germany; Greece; Poland; Hungary; Spain",
            "decision_date": "04/03/2026",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512248-47-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524944-37-00",
            "title": "A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above",
            "phase": "Phase IV",
            "lead_sponsor": "Gentofte Hospital, GlaxoSmithKline Biologicals",
            "conditions": "Herpes Zoster",
            "member_states": "Denmark",
            "decision_date": "04/03/2026",
            "enrolled": "162000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524944-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524343-13-00",
            "title": "Pilot study of the efficacy of nicotinamide (vitamin B3) in Leber's hereditary optic neuropathy - NICOLHON",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire D'Angers",
            "conditions": "Leber's Hereditary Optic Neuropathy",
            "member_states": "France",
            "decision_date": "03/03/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524343-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523232-39-00",
            "title": "Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Merck Healthcare KGaA",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Spain",
            "decision_date": "03/03/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523232-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521546-23-00",
            "title": "A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Secondary progressive multiple sclerosis",
            "member_states": "Denmark; Slovenia; Netherlands; Portugal; Ireland; Sweden; Croatia; Greece; Germany; Latvia; Czechia; Spain; Romania; Belgium; Austria; Lithuania; Slovakia; Poland; Estonia; Bulgaria; France; Italy; Hungary; Finland; Norway",
            "decision_date": "03/03/2026",
            "enrolled": "677",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521546-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524175-23-00",
            "title": "Impact of Early Thyroid Hormone Replacement on Kidney Function and Health-Related Quality of Life in Patients at Risk of Postoperative Hypothyroidism after Hemithyroidectomy: A Randomised Controlled Trial",
            "phase": "Phase IV",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Hypothyroidism, Incident Kidney Dysfunction, Chronic Kidney Disease",
            "member_states": "Denmark",
            "decision_date": "03/03/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524175-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522383-33-00",
            "title": "A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Pulmonary fibrosis, Interstitial lung diseases, Familial pulmonary fibrosis",
            "member_states": "Belgium; Spain; Netherlands; Italy; Germany; France",
            "decision_date": "03/03/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522383-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523060-20-00",
            "title": "A prospective, open-label, single-arm, multicenter study evaluating the efficacy of Xanomeline/Trospium (XT) on cognitive impairment after 24 and 52 weeks of treatment in adult participants with schizophrenia.",
            "phase": "Phase III",
            "lead_sponsor": "European Group for Research in Schizophrenia Stichting",
            "conditions": "Schizophrenia",
            "member_states": "Denmark; Belgium; Italy; Netherlands; Hungary; Czechia; Austria; Spain; Germany",
            "decision_date": "03/03/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523060-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516698-56-00",
            "title": "A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics,\nPharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1)",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Hepatocellular Carcinoma",
            "member_states": "Spain",
            "decision_date": "03/03/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516698-56-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521756-39-00",
            "title": "C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Non-muscle invasive bladder cancer (NMIBC)",
            "member_states": "France; Spain",
            "decision_date": "02/03/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521756-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521752-26-00",
            "title": "A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease",
            "phase": "Phase II",
            "lead_sponsor": "Adarx Pharmaceuticals Inc.",
            "conditions": "Complement-Mediated Kidney Disease",
            "member_states": "Spain; Italy",
            "decision_date": "02/03/2026",
            "enrolled": "7",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521752-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521437-88-00",
            "title": "A phase II study of ficerafusp alfa (BCA 101) in combination with nivolumab in platinum refractory head and neck squamous cell carcinoma patients who progressed within 6 months after multimodal treatment for locally advanced disease ( BICARA)",
            "phase": "Phase II",
            "lead_sponsor": "Groupe Oncologie Radiotherapie Tete Cou",
            "conditions": "head and neck squamous cell carcinoma",
            "member_states": "France",
            "decision_date": "02/03/2026",
            "enrolled": "121",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521437-88-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522060-32-00",
            "title": "Randomised EValuation of Therapies for microvAscuLar Injury in STEACS \u2013 REVITALISE Study",
            "phase": "Phase II",
            "lead_sponsor": "CorFlow Therapeutics AG, CorFlow Therapeutics AG",
            "conditions": "STEMI (ST elevated Myocardial Infarction)",
            "member_states": "Netherlands; Spain; France",
            "decision_date": "02/03/2026",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522060-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522834-30-01",
            "title": "Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Systemic sclerosis (SSc), Idiopathic pulmonary fibrosis (IPF), Ulcerative colitis (UC), Fibrotic hypersensitivity pneumonitis (FHP), Crohn's disease (CD), Unclassifiable interstitial lung disease (uILD), Idiopathic inflammatory myopathy (IIM)",
            "member_states": "Netherlands",
            "decision_date": "02/03/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522834-30-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523372-24-00",
            "title": "COMPARISON OF ZINC ACETATE DOSE REGIMENS (GALZIN VS. ET-700) FOR THE TREATMENT OF WILSON DISEASE: A PHARMACODYNAMIC 64CUCL2 PET/CT STUDY IN HEALTHY PARTICIPANTS",
            "phase": "Phase II",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Wilson's Disease",
            "member_states": "Denmark",
            "decision_date": "02/03/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523372-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524570-41-00",
            "title": "A clinical trial of MK-6916 in healthy participants (MK-6916-010)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Acute and Chronic pain",
            "member_states": "Belgium",
            "decision_date": "02/03/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524570-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523120-53-00",
            "title": "Prospective Multicenter Randomized Non-Inferiority Study Comparing 7 Days Versus 14 Days of Antibiotic Treatment for Graft Pyelonephritis in Kidney Transplant Recipients (KTI)",
            "phase": "Phase III",
            "lead_sponsor": "Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL",
            "conditions": "Graft pyelonephritis in kidney transplant recipients",
            "member_states": "Spain",
            "decision_date": "02/03/2026",
            "enrolled": "360",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523120-53-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522896-27-00",
            "title": "An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301",
            "phase": "Phase II",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Asthma",
            "member_states": "Poland; Italy; Belgium; Sweden; Hungary; France; Germany; Spain; Denmark",
            "decision_date": "02/03/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522896-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522695-83-00",
            "title": "A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa",
            "phase": "Phase II",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Hidradenitis suppurativa",
            "member_states": "Hungary; Spain; France; Belgium; Sweden; Germany; Italy",
            "decision_date": "02/03/2026",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522695-83-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513644-28-00",
            "title": "Efficacy and safety of Ursodeoxycholic Acid as a new therapy for the treatment of hepatorenal polycystic diseases, genetic study and determination of prognostic biomarkers.",
            "phase": "Phase II",
            "lead_sponsor": "Asociacion Instituto Biogipuzkoa",
            "conditions": "Hepatorenal polycystic diseases",
            "member_states": "Spain",
            "decision_date": "02/03/2026",
            "enrolled": "138",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513644-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521020-30-00",
            "title": "A Phase 1 study to evaluate the effect of BV100 on the pharmacokinetics of polymyxin B in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Bioversys S.A.S.",
            "conditions": "Healthy volunteer trial. Intended indication: treatment of infections due to A. baumannii.",
            "member_states": "Austria",
            "decision_date": "01/03/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521020-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523367-38-00",
            "title": "Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postoperative inflammation after cataract surgery: a randomized, multicentre, blinded-assessor, parallel-group clinical study \u2013 NE.DE.F. STUDY",
            "phase": "Phase III",
            "lead_sponsor": "Medivis S.r.l.",
            "conditions": "Postoperative inflammation after cataract surgery",
            "member_states": "Italy",
            "decision_date": "27/02/2026",
            "enrolled": "432",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523367-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523100-77-00",
            "title": "C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Ulcerative Colitis",
            "member_states": "Finland; Poland; France; Germany; Italy; Slovakia",
            "decision_date": "27/02/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523100-77-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511807-41-01",
            "title": "TIC-TAC-SAM \u00ab Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: a randomized trial \u00bb",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Hemophagocytic lymphohistiocytosis (HLH)",
            "member_states": "France",
            "decision_date": "27/02/2026",
            "enrolled": "176",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511807-41-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523261-25-00",
            "title": "A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patients",
            "phase": "Phase II",
            "lead_sponsor": "UZ Leuven",
            "conditions": "colorectal cancer",
            "member_states": "Belgium",
            "decision_date": "27/02/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523261-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522944-41-00",
            "title": "A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)",
            "phase": "Phase I/II",
            "lead_sponsor": "Pathios Therapeutics Limited",
            "conditions": "Solid Tumours",
            "member_states": "France; Spain",
            "decision_date": "27/02/2026",
            "enrolled": "95",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522944-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523079-44-00",
            "title": "HighLiGHts - A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents with Growth Failure or Short Stature due to Growth Hormone Sufficient Disorders \u2013 Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature",
            "phase": "Phase III",
            "lead_sponsor": "Ascendis Pharma Endocrinology Division A/S",
            "conditions": "Turner Syndrome (TS), idiopathic short stature (ISS), short stature homeobox containing gene deficiency (SHOX-D), small for gestational age (SGA)",
            "member_states": "Germany; Spain; Italy; France; Romania",
            "decision_date": "27/02/2026",
            "enrolled": "66",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523079-44-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515147-32-02",
            "title": "POSITRON - PsilOcybin with pSychologIcal supporT foR cOcaiNe: a randomised controlled pilot feasibility trial of psilocybin with psychological support for cocaine use disorder",
            "phase": "Phase II",
            "lead_sponsor": "Trinity College Dublin",
            "conditions": "Cocaine addiction",
            "member_states": "Ireland",
            "decision_date": "27/02/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515147-32-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524784-20-00",
            "title": "A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis",
            "phase": "Phase II",
            "lead_sponsor": "Zomagen Biosciences Limited",
            "conditions": "Recurrent Pericarditis",
            "member_states": "Belgium; France; Greece",
            "decision_date": "27/02/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524784-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524872-51-00",
            "title": "A multicentre randomized double-blind placebo-controlled 48-week superiority study to compare the efficacy and safety of rituximab versus placebo in rheumatoid arthritis-associated interstitial lung disease - the BELLRA trial.",
            "phase": "Phase IV",
            "lead_sponsor": "Vaestra Goetalandsregionen",
            "conditions": "Rheumatoid arthritis-associated interstitial lung disease (RA-ILD)",
            "member_states": "Sweden",
            "decision_date": "27/02/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524872-51-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521603-46-00",
            "title": "A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME.",
            "phase": "Phase I",
            "lead_sponsor": "T-Knife GmbH",
            "conditions": "Advanced PRAME Positive Solid Tumors",
            "member_states": "Germany",
            "decision_date": "27/02/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521603-46-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521666-10-01",
            "title": "PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione Italiana Linfomi Ets",
            "conditions": "Mantle Cell Lymphoma",
            "member_states": "Italy",
            "decision_date": "26/02/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521666-10-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522687-33-00",
            "title": "DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL (DARLENE)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Lille",
            "conditions": "Stroke",
            "member_states": "France",
            "decision_date": "26/02/2026",
            "enrolled": "192",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522687-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516215-24-00",
            "title": "STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "TAkayasu ARteritiS",
            "member_states": "France",
            "decision_date": "26/02/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516215-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520101-39-00",
            "title": "A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.",
            "member_states": "Spain; Poland; Hungary; Italy; Germany; France; Belgium; Austria",
            "decision_date": "26/02/2026",
            "enrolled": "103",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520101-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524334-26-01",
            "title": "A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Endometrial cancer (EC), Advanced or metastatic breast cancer, Gastroesophageal cancer (GEC), Advanced or metastatic solid tumors, Platinum-resistant ovarian cancer (PROC), High grade serous ovarian cancer (HGSOC)",
            "member_states": "Denmark",
            "decision_date": "26/02/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524334-26-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523297-16-00",
            "title": "Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs",
            "phase": "Phase I",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Non-Hodgkin Lymphoid Malignancies (NHLs)",
            "member_states": "Belgium; France; Spain",
            "decision_date": "26/02/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523297-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519359-27-00",
            "title": "A double-blind, randomized, placebo-controlled, two arm, phase II clinical trial in parallel groups to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories compared to placebo suppositories for amelioration of acute radiation proctitis symptoms in\nmale patients aged 18 years or older with prostate carcinoma",
            "phase": "Phase II",
            "lead_sponsor": "Dr. Falk Pharma GmbH",
            "conditions": "Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma",
            "member_states": "Germany; Austria",
            "decision_date": "26/02/2026",
            "enrolled": "320",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519359-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522835-32-00",
            "title": "A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)",
            "phase": "Phase II",
            "lead_sponsor": "Elion Therapeutics Inc.",
            "conditions": "Suspected Invasive Mould Infection",
            "member_states": "Belgium; France; Spain; Italy",
            "decision_date": "26/02/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522835-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-525059-23-00",
            "title": "The effect of losartan on cephalexin",
            "phase": "Phase I",
            "lead_sponsor": "Varsinais-Suomen hyvinvointialue",
            "conditions": "healthy volunteers",
            "member_states": "Finland",
            "decision_date": "26/02/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-525059-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523866-26-00",
            "title": "In vivo biological standardization of Olea europaea allergen extracts.",
            "phase": "Phase II",
            "lead_sponsor": "Asac Pharmaceutical Inmunology S.A.",
            "conditions": "Allergies",
            "member_states": "Spain",
            "decision_date": "25/02/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523866-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517595-38-00",
            "title": "ASPIRIN - Acetylsalicylic acid versus placebo in addition to a local non-steroidal anti-inflammatory drug in the treatment of thrombotic episodes in superficial venous malformations in children aged 6 to 17 years: a controlled randomised, double-blind, cross-over, multicenter trial",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire De Tours",
            "conditions": "Thrombotic episodes in superficial venous malformations in children",
            "member_states": "France",
            "decision_date": "25/02/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517595-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520131-33-00",
            "title": "Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation. Multicenter, open-label, randomized phase II controlled trial.",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire Grenoble Alpes",
            "conditions": "atrial fibrillation",
            "member_states": "France",
            "decision_date": "25/02/2026",
            "enrolled": "136",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520131-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519384-18-00",
            "title": "A Phase 2/3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients with Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)",
            "phase": "Phase III",
            "lead_sponsor": "GE Healthcare Limited",
            "conditions": "Colorectal, Gastric, Ovarian or Pancreatic Cancer",
            "member_states": "Sweden; Netherlands",
            "decision_date": "25/02/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519384-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522642-44-00",
            "title": "B7981118 - A Phase 2b Randomized, Double Blind, 12-Week Placebo Controlled Study With a 12-Week Double-Blind Extension Period to Evaluate the Efficacy, Safety and Tolerability of Ritlecitinib (PF 06651600) in Adult Participants with Chronic Spontaneous Urticaria",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "CHRONIC SPONTANEOUS URTICARIA",
            "member_states": "Spain; Germany; Bulgaria; Poland",
            "decision_date": "25/02/2026",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522642-44-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522611-42-00",
            "title": "Long Covid (LC)-Revitalize - A Long Covid Repurposed Drug Study",
            "phase": "Phase III",
            "lead_sponsor": "Dr. Douglas D. Fraser",
            "conditions": "Long Covid",
            "member_states": "Italy",
            "decision_date": "25/02/2026",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522611-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522145-21-00",
            "title": "Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)",
            "phase": "Phase III",
            "lead_sponsor": "University College London",
            "conditions": "Metastatic hormone sensitive prostate cancer",
            "member_states": "Ireland; Germany; Spain",
            "decision_date": "25/02/2026",
            "enrolled": "346",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522145-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523499-22-00",
            "title": "An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema \n[Donidalorsen Treatment in Children with Hereditary Angioedema]",
            "phase": "Phase III",
            "lead_sponsor": "Ionis Pharmaceuticals Inc.",
            "conditions": "Hereditary Angioedema (HAE)",
            "member_states": "Italy; Spain; Poland",
            "decision_date": "25/02/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523499-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522471-28-00",
            "title": "A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)",
            "phase": "Phase III",
            "lead_sponsor": "MoonLake Immunotherapeutics AG",
            "conditions": "psoriatic arthritis (PsA)",
            "member_states": "Estonia; Croatia; Slovakia; Lithuania; Romania; Hungary; Germany; France; Latvia; Poland; Portugal; Greece; Czechia; Bulgaria; Finland; Spain",
            "decision_date": "25/02/2026",
            "enrolled": "948",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522471-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520988-41-00",
            "title": "Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)",
            "phase": "Phase II",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Immunoglobulin G4 related Disease (IgG4-RD)",
            "member_states": "Greece; Poland; Italy; Spain",
            "decision_date": "25/02/2026",
            "enrolled": "7",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520988-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520238-31-01",
            "title": "A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "BioNTech SE",
            "conditions": "Advanced Lung Cancer",
            "member_states": "Spain; France; Italy; Poland",
            "decision_date": "24/02/2026",
            "enrolled": "112",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520238-31-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524258-32-00",
            "title": "A study of the safety, tolerability, pharmacokinetics and preliminary efficacy of TNV108 in healthy adults and patients with diabetic peripheral neuropathy",
            "phase": "Phase I",
            "lead_sponsor": "Tenvie Therapeutics Inc.",
            "conditions": "Diabetic Peripheral Neuropathy (DPN)",
            "member_states": "Netherlands",
            "decision_date": "24/02/2026",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524258-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522784-15-00",
            "title": "A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults with Major Depressive Disorder",
            "phase": "Phase II",
            "lead_sponsor": "Draig Therapeutics Limited",
            "conditions": "Major Depressive Disorder",
            "member_states": "Czechia; Bulgaria; Poland",
            "decision_date": "24/02/2026",
            "enrolled": "175",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522784-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524296-23-01",
            "title": "A multi-center, open label, longitudinal, observational, 12-week study of Flexilev treatment with the dosing device OraFID and accompanying digital app in Parkinson patients.",
            "phase": "Phase IV",
            "lead_sponsor": "Navamedic AB",
            "conditions": "Parkinsons Disease",
            "member_states": "Sweden",
            "decision_date": "24/02/2026",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524296-23-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523123-22-00",
            "title": "J2A-MC-GZPW: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease",
            "member_states": "Germany; Czechia; Lithuania; Spain; Austria; France; Hungary; Greece; Estonia; Netherlands; Slovakia; Poland; Romania; Bulgaria; Italy; Belgium",
            "decision_date": "24/02/2026",
            "enrolled": "1793",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523123-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523737-26-00",
            "title": "A Pilot, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of a Single Intra-articular Injection of CNTX-0066 in Participants with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain",
            "phase": "Phase I",
            "lead_sponsor": "Centrexion Therapeutics Corp.",
            "conditions": "Osteoarthritis of the knee",
            "member_states": "Denmark",
            "decision_date": "24/02/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523737-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521939-36-00",
            "title": "KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC",
            "member_states": "Italy; Poland; Spain; Finland; Netherlands; Greece",
            "decision_date": "24/02/2026",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521939-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521037-86-00",
            "title": "A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn\u2019s disease",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Immune system diseases",
            "member_states": "Spain; Czechia; Lithuania; Hungary; Greece; Bulgaria; Poland; Belgium; France; Germany; Norway; Austria; Netherlands; Italy; Slovakia",
            "decision_date": "24/02/2026",
            "enrolled": "204",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521037-86-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521036-11-00",
            "title": "A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Immune system disseases",
            "member_states": "Slovakia; Netherlands; Poland; Greece; Czechia; Italy; Bulgaria; Belgium; Germany; Lithuania; Austria; Spain; Hungary; Norway; France",
            "decision_date": "24/02/2026",
            "enrolled": "577",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521036-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522541-21-00",
            "title": "A Phase 1 Study to Assess Radiation Biodistribution, Dosimetry, Pharmacokinetics and Safety of GEH300079 (68Ga) Injection and Determine the Optimal Injected Activity and Timing of PET/CT Imaging in Patients with Peritoneal Carcinomatosis of Colorectal, Gastric, Pancreatic or Ovarian Origin",
            "phase": "Phase I",
            "lead_sponsor": "GE Healthcare Limited",
            "conditions": "Peritoneal Carcinomatosis of Colorectal,Gastric, Pancreatic or Ovarian Origin",
            "member_states": "Sweden",
            "decision_date": "24/02/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522541-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522592-29-00",
            "title": "Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporotic Women: A Phase IV, Low-Risk, Pharmacological Intervention Study. ATRIO Study.",
            "phase": "Phase IV",
            "lead_sponsor": "Ospedale Galeazzi S.p.A.",
            "conditions": "Coronary atherosclerotic status in women with postmenopausal osteoporosis",
            "member_states": "Italy",
            "decision_date": "23/02/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522592-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522204-24-00",
            "title": "J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Neoplasms, Vomiting, Drug-Related Side Effects and Adverse Reactions, Nausea",
            "member_states": "Romania; Spain; France; Italy",
            "decision_date": "23/02/2026",
            "enrolled": "77",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522204-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521286-27-00",
            "title": "INCA000585-201 - A PHASE 2A, OPEN-LABEL, MULTI-CENTER STUDY OF TAFASITAMAB IN ADULT PARTICIPANTS WITH AUTOIMMUNE BLOOD CELL DISORDERS",
            "phase": "Phase III",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia",
            "member_states": "Netherlands; Italy; Spain; France",
            "decision_date": "23/02/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521286-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2022-502911-12-00",
            "title": "A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study",
            "phase": "Phase I/II",
            "lead_sponsor": "Moderna Inc.",
            "conditions": "Propionic Acidemia",
            "member_states": "Spain; Netherlands; France",
            "decision_date": "23/02/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2022-502911-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523959-65-00",
            "title": "ADCX-020 for the treatment of patients with locally advanced or metastatic cancers",
            "phase": "Phase I",
            "lead_sponsor": "Adcytherix",
            "conditions": "Locally Advanced or Metastatic Solid Tumors",
            "member_states": "Spain",
            "decision_date": "23/02/2026",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523959-65-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524362-20-00",
            "title": "Open-label safety and efficacy trial of chlorhexidine and/or metronidazole pre-treatment followed by FB301 in women with bacterial vaginosis (BV)",
            "phase": "Phase II",
            "lead_sponsor": "Freya Biosciences ApS",
            "conditions": "Bacterial vaginosis",
            "member_states": "Germany",
            "decision_date": "23/02/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524362-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521830-27-00",
            "title": "Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects.",
            "phase": "Phase I",
            "lead_sponsor": "Recordati AG",
            "conditions": "Post-bariatric hypoglycaemia",
            "member_states": "Germany",
            "decision_date": "23/02/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521830-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523306-33-00",
            "title": "Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm, open, prospective, intervention trial",
            "phase": "Phase II",
            "lead_sponsor": "Istituto Di Ricerche Farmacologiche Mario Negri",
            "conditions": "Idiopathic Nephrotic Syndrome",
            "member_states": "Italy",
            "decision_date": "23/02/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523306-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524277-16-00",
            "title": "A Phase 1 Study of Fentanyl Vaccine",
            "phase": "Phase I/II",
            "lead_sponsor": "ARMR Sciences Inc.",
            "conditions": "Opioid induced respiratory depression",
            "member_states": "Netherlands",
            "decision_date": "23/02/2026",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524277-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524375-23-00",
            "title": "OV-PRIME-R (Oncolytic Virotherapy to enhance PReoperative IMmunotherapy Efficacy in patients with proficient mismatch repair (pMMR) Rectal cancer",
            "phase": "Phase I",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Rectal cancer with proficient mismatch repair (pMMR)",
            "member_states": "Denmark",
            "decision_date": "23/02/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524375-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521521-33-00",
            "title": "A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Kidney transplant rejection",
            "member_states": "Germany; Hungary; Italy; Belgium; Czechia; Finland; Spain; Austria; Sweden; France; Denmark; Netherlands",
            "decision_date": "23/02/2026",
            "enrolled": "269",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521521-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522742-46-00",
            "title": "CANIDIAP; CANagliflozin In DIAlysis Patients",
            "phase": "Phase IV",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Chronic Kidney disease",
            "member_states": "Netherlands",
            "decision_date": "23/02/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522742-46-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-503293-21-00",
            "title": "Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Osteogenesis Imperfecta",
            "member_states": "Germany; Hungary; Italy; Belgium; Austria; Slovakia; Spain",
            "decision_date": "23/02/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-503293-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519922-19-00",
            "title": "PRODIGE 113 (FFCD 2314) \u2013 REWENEC \u2013 01 STUDY\nRandomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic control arm in second line treatment of metastatic neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin.\nPhase II comparative randomized study \u2013 multicentric",
            "phase": "Phase II",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "Neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin (GEP/UK NEC)",
            "member_states": "France",
            "decision_date": "22/02/2026",
            "enrolled": "77",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519922-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521314-25-00",
            "title": "Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia",
            "phase": "Phase III",
            "lead_sponsor": "Kura Oncology Inc.",
            "conditions": "NPM1-m and KMT2A-r Acute Myeloid Leukemia",
            "member_states": "Belgium; Spain; Italy; Czechia; Hungary; Poland; France; Portugal; Germany; Greece",
            "decision_date": "20/02/2026",
            "enrolled": "719",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521314-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523864-19-00",
            "title": "Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea",
            "phase": "Phase II",
            "lead_sponsor": "Oryzon Genomics S.A.",
            "conditions": "Essential Thrombocythemia",
            "member_states": "Spain",
            "decision_date": "20/02/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523864-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522544-40-00",
            "title": "TRITON-PN: A Phase 3, Global, Randomized, Open-Label  Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)",
            "phase": "Phase III",
            "lead_sponsor": "Alnylam Pharmaceuticals Inc.",
            "conditions": "Hereditary transthyretin-mediated amyloidosis with polyneuropathy",
            "member_states": "France; Italy; Greece; Spain; Sweden; Ireland; Cyprus; Portugal; Germany",
            "decision_date": "20/02/2026",
            "enrolled": "86",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522544-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523748-11-00",
            "title": "Efficacy and tolerability of a simethicone-containing evacuating solution for colorectal cancer screening colonoscopy: a randomized parallel comparative trial. CLEAN+",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "colorectal cancer early detection",
            "member_states": "Spain",
            "decision_date": "20/02/2026",
            "enrolled": "818",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523748-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523530-30-00",
            "title": "Single-centre clinical trial investigating the safety and tolerability of increasing multiple doses of nebulised SS0331 in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Softox Defense Solutions AS",
            "conditions": "Treatment and post exposure prevention of respiratory tract infection, Biologic countermeasure",
            "member_states": "Ireland",
            "decision_date": "20/02/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523530-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523619-12-00",
            "title": "A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults with Chronic Hepatitis B",
            "phase": "Phase I/II",
            "lead_sponsor": "Nchroma Bio Inc.",
            "conditions": "Chronic Hepatitis B",
            "member_states": "France",
            "decision_date": "20/02/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523619-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524733-11-00",
            "title": "A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer\u00ae Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients with Unresectable Locally Advanced Pancreatic Cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Smartwise Sweden AB",
            "conditions": "Unresectable Locally Advanced Pancreatic Cancer",
            "member_states": "Sweden",
            "decision_date": "20/02/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524733-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521438-27-00",
            "title": "A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "advanced, unresectable and/or metastatic solid tumors",
            "member_states": "Sweden; France; Spain; Germany",
            "decision_date": "19/02/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521438-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521164-36-00",
            "title": "A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours",
            "phase": "Phase I/II",
            "lead_sponsor": "Apmonia Therapeutics",
            "conditions": "Patients with relapsed/refractory advanced/metastatic ovarian cancer (aOC), metastatic colorectal cancer (mCRC), metastatic pancreatic cancer (mPC), or cutaneous metastatic melanoma (MM) who have exhausted all treatment options.",
            "member_states": "Belgium; France",
            "decision_date": "19/02/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521164-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523838-13-00",
            "title": "An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fasting condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "plaque psoriasis",
            "member_states": "Romania",
            "decision_date": "19/02/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523838-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523839-18-00",
            "title": "An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fed condition",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "plaque psoriasis",
            "member_states": "Romania",
            "decision_date": "19/02/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523839-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523238-17-00",
            "title": "A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy",
            "phase": "Phase II",
            "lead_sponsor": "Fundacion PETHEMA",
            "conditions": "Acute myeloid leukemia",
            "member_states": "Spain; Portugal",
            "decision_date": "19/02/2026",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523238-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519412-13-00",
            "title": "Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease",
            "phase": "Phase I/II",
            "lead_sponsor": "Myrtelle Inc.",
            "conditions": "Canavan Disease, Canavan disease",
            "member_states": "France",
            "decision_date": "18/02/2026",
            "enrolled": "7",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519412-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523820-26-00",
            "title": "A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Na\u00efve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)",
            "phase": "Phase III",
            "lead_sponsor": "Lumos Pharma LLC",
            "conditions": "Growth Hormone Deficiency (GHD)",
            "member_states": "Romania; France; Italy; Poland; Spain",
            "decision_date": "18/02/2026",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523820-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521985-82-00",
            "title": "Efficacy and safety of a combined therapy with Alpha-Lipoic Acid and Benfotiamine in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial",
            "phase": "Phase II",
            "lead_sponsor": "Woerwag Pharma GmbH & Co. KG",
            "conditions": "Diabetic sensorimotor polyneuropathy (DSPN)",
            "member_states": "Hungary",
            "decision_date": "18/02/2026",
            "enrolled": "136",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521985-82-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522492-28-00",
            "title": "Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis.\n\nISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.",
            "phase": "Phase II",
            "lead_sponsor": "Argenx",
            "conditions": "AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG",
            "member_states": "Spain; Poland; Germany; Netherlands; Greece; Italy; Belgium",
            "decision_date": "18/02/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522492-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524910-28-00",
            "title": "A bioequivalence study comparing Empagliflozin 25 mg film-coated tablets, VIANEX S.A., Greece versus Jardiance 25 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Vianex S.A.",
            "conditions": "none - healthy volunteers",
            "member_states": "Czechia",
            "decision_date": "18/02/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524910-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509247-27-00",
            "title": "Double blind, multicenter, randomized, controlled trial of dexmedetomidine vs placebo in premature neonates receiving invasive ventilation",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Intercommunal Creteil",
            "conditions": "Neonatal respiratory distress.\nPain and discomfort",
            "member_states": "France",
            "decision_date": "18/02/2026",
            "enrolled": "246",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509247-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523515-11-00",
            "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer\u2019s Disease",
            "phase": "Phase I",
            "lead_sponsor": "Denali Therapeutics Inc.",
            "conditions": "Early Alzheimer's Disease",
            "member_states": "Netherlands",
            "decision_date": "18/02/2026",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523515-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522406-20-00",
            "title": "A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis",
            "phase": "Phase I/II",
            "lead_sponsor": "Immunabs Inc.",
            "conditions": "Generalized Myasthenia Gravis and Ocular Myasthenia Gravis",
            "member_states": "Bulgaria; Poland; Spain; Italy",
            "decision_date": "18/02/2026",
            "enrolled": "83",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522406-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520897-21-00",
            "title": "A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Multiple Myeloma",
            "member_states": "Norway; France; Spain",
            "decision_date": "18/02/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520897-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521651-22-00",
            "title": "Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimarin.",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione Oncotech Impresa Sociale",
            "conditions": "hormone receptor positive, HER2-negative breast cancer",
            "member_states": "Italy",
            "decision_date": "17/02/2026",
            "enrolled": "170",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521651-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523283-21-00",
            "title": "J2A-MC-GZPR: A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants with Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Peripheral Arterial Disease",
            "member_states": "Slovakia; Poland; France; Netherlands",
            "decision_date": "17/02/2026",
            "enrolled": "185",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523283-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522873-12-00",
            "title": "A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)",
            "phase": "Phase III",
            "lead_sponsor": "Olema Pharmaceuticals Inc.",
            "conditions": "ER+, HER2- Advanced Breast Cancer",
            "member_states": "Hungary; Portugal; Italy; France; Poland; Czechia; Germany; Spain; Belgium; Austria; Romania; Greece; Netherlands",
            "decision_date": "17/02/2026",
            "enrolled": "384",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522873-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2026-525230-27-00",
            "title": "Bioequivalence clinical trial of two formulations of rosuvastatin.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Alter S.A.",
            "conditions": "Hypercholesterolemia",
            "member_states": "Spain",
            "decision_date": "17/02/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2026-525230-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524259-30-00",
            "title": "AMOXICILLIN VERSUS AMOXICILLIN-CLAVULANATE VERSUS PLACEBO IN ACUTE OTITIS MEDIA IN CHILDREN \u2013 A PARALLEL-GROUP TRIPLE-BLINDED RANDOMIZED CONTROLLED SUPERIORITY TRIAL",
            "phase": "Phase III",
            "lead_sponsor": "Pohjois-Savon hyvinvointialue",
            "conditions": "Acute otitis media",
            "member_states": "Finland",
            "decision_date": "17/02/2026",
            "enrolled": "219",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524259-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522595-87-00",
            "title": "A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.",
            "phase": "Phase I/II",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "Hematological Malignancies",
            "member_states": "France; Italy",
            "decision_date": "16/02/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522595-87-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523478-17-00",
            "title": "Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Graz",
            "conditions": "Neovascular age-related macular degeneration",
            "member_states": "Austria",
            "decision_date": "16/02/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523478-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523863-39-00",
            "title": "Changes in the wound microbiome and their impact on chronic wound healing under hyperbaric conditions",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Graz",
            "conditions": "chronic wounds",
            "member_states": "Austria",
            "decision_date": "16/02/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523863-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524008-32-00",
            "title": "A phase 2a exploratory study of TAR-0520 gel in prevention of Hand and Foot Syndrome",
            "phase": "Phase II",
            "lead_sponsor": "Tarian Pharma",
            "conditions": "Capecitabine-induced hand and foot syndrome",
            "member_states": "France",
            "decision_date": "16/02/2026",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524008-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521670-34-00",
            "title": "A randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes: Victorion \u2013 RIDES",
            "phase": "Phase III",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.",
            "member_states": "Germany; Hungary; Poland; France; Spain",
            "decision_date": "16/02/2026",
            "enrolled": "135",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521670-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522519-40-00",
            "title": "A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Na\u00efve Adult Participants Living With HIV 1",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "HIV",
            "member_states": "France; Spain",
            "decision_date": "16/02/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522519-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523160-20-00",
            "title": "A Phase 1 Study of IM-1021 in Participants with Advanced Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Immunome Inc.",
            "conditions": "Advanced B-cell lymphomas, Advanced solid tumors",
            "member_states": "France; Spain; Denmark; Italy",
            "decision_date": "16/02/2026",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523160-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521390-14-00",
            "title": "Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)",
            "phase": "Phase II",
            "lead_sponsor": "Pediatric Research International GmbH",
            "conditions": "Acute Myeloid Leukemia",
            "member_states": "Denmark; Italy; Czechia; Sweden; Poland; Netherlands; Germany; Austria",
            "decision_date": "16/02/2026",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521390-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524022-18-00",
            "title": "A multicenter prospective trial estimating the persistence of remission after stopping BCMA-CD3 bispecific antibody in multiple myeloma patients with major M-spike response by use MaldiTOF-based high sensitivity monitoring",
            "phase": "Phase II",
            "lead_sponsor": "Vaestra Goetalandsregionen",
            "conditions": "Multiple myeloma",
            "member_states": "Sweden",
            "decision_date": "16/02/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524022-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521702-18-00",
            "title": "A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC)",
            "member_states": "Germany; Portugal; France; Spain; Denmark",
            "decision_date": "16/02/2026",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521702-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523826-41-00",
            "title": "A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.",
            "phase": "Phase I",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Dermatitis atopic",
            "member_states": "Belgium; Czechia; France; Hungary; Poland; Spain; Bulgaria",
            "decision_date": "16/02/2026",
            "enrolled": "291",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523826-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522624-27-00",
            "title": "Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fed Conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "16/02/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522624-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523817-27-00",
            "title": "KF2025#1 trial: Ketamine, cannabidiol and cobicistat interaction study",
            "phase": "Phase I",
            "lead_sponsor": "HUS-yhtymae",
            "conditions": "Terveet vapaaehtoiset tutkittavat",
            "member_states": "Finland",
            "decision_date": "16/02/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523817-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522809-38-00",
            "title": "Continuous antibiotic infusion in children",
            "phase": "Phase III",
            "lead_sponsor": "Pirkanmaan hyvinvointialue",
            "conditions": "Infection disease",
            "member_states": "Finland",
            "decision_date": "16/02/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522809-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521416-19-00",
            "title": "A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Recurrence of Clostridioides difficile Infection",
            "member_states": "Greece; Spain; France; Germany; Italy; Hungary; Denmark; Sweden",
            "decision_date": "16/02/2026",
            "enrolled": "122",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521416-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524598-17-00",
            "title": "A randomized, placebo controlled, observer-blind, phase IV pragmatic trial to evaluate the effect of Recombinant Zoster Vaccine (Shingrix\u00ae) on incident dementia diagnosis in an older adult population aged \u226576 years in Finland",
            "phase": "Phase IV",
            "lead_sponsor": "GlaxoSmithKline Biologicals",
            "conditions": "Incident dementia",
            "member_states": "Finland",
            "decision_date": "16/02/2026",
            "enrolled": "35000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524598-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523142-28-00",
            "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)",
            "phase": "Phase I",
            "lead_sponsor": "Bambusa Therapeutics Inc.",
            "conditions": "Chronic Obstructive Pulmonary Disease (COPD)\nChronic Rhinosinusitis with Nasal Polyps (CRSwNP)\nComorbid Asthma",
            "member_states": "Poland",
            "decision_date": "16/02/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523142-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522407-23-00",
            "title": "A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Baxdrostat on Albuminuria in Participants with Chronic Kidney Disease and High Blood Pressure",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Chronic kidney disease (CKD) and hypertension.",
            "member_states": "Spain; Bulgaria",
            "decision_date": "16/02/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522407-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522546-52-00",
            "title": "Sustained-release oral morphine to alleviate persistent dyspnea in patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis outside the administration of ventilatory assistance: prospective multicenter randomized, placebo-controlled study, parallel arms. (OPIDYS-ALS).",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis.",
            "member_states": "France",
            "decision_date": "13/02/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522546-52-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523533-25-00",
            "title": "Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia",
            "phase": "Phase III",
            "lead_sponsor": "CatalYm GmbH",
            "conditions": "Cancer-associated Cachexia",
            "member_states": "France; Czechia; Romania; Italy; Germany; Poland; Spain; Bulgaria; Norway; Ireland; Netherlands",
            "decision_date": "13/02/2026",
            "enrolled": "434",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523533-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524674-42-00",
            "title": "A Phase 2, Randomized, Double-blind, Placebo-Controlled, Single-Center Study to Assess the effects of SUL-238 on High Energy Phosphates with Magnetic Resonance Spectroscopy (31P-MRS) in patients with Early, untreated Parkinson\u2019s Disease (\u201cSHEPHERD\u201d STUDY)",
            "phase": "Phase II",
            "lead_sponsor": "Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.S.",
            "conditions": "Parkinson\u2019s Disease",
            "member_states": "Netherlands",
            "decision_date": "13/02/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524674-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521671-31-00",
            "title": "A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)",
            "phase": "Phase I/II",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia",
            "member_states": "France; Netherlands; Italy",
            "decision_date": "13/02/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521671-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522279-27-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)",
            "phase": "Phase III",
            "lead_sponsor": "Syndax Pharmaceuticals Inc.",
            "conditions": "Newly Diagnosed AML with an NPM1 mutation",
            "member_states": "Greece; Poland; Spain; Austria; Italy; Romania; Belgium; France; Lithuania; Germany; Hungary; Czechia; Portugal",
            "decision_date": "13/02/2026",
            "enrolled": "395",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522279-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523646-27-00",
            "title": "Accuracy for Imaging Cardiac Sarcoidosis with 68Ga-Pentixafor Positron Emission Tomography/Computed Tomography (68Ga-Pentixafor PET/CT): ASPECT study",
            "phase": "Phase II",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Cardiac Sarcoidosis",
            "member_states": "Netherlands",
            "decision_date": "12/02/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523646-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524177-16-00",
            "title": "An open-label, single-center, non-controlled pilot clinical trial to assess the efficacy of weekly semaglutide in combination with regular counselling sessions to reduce craving and use of chemsex associated drugs (CoSem4Chemsex) study.",
            "phase": "Phase II",
            "lead_sponsor": "Institute Of Tropical Medicine",
            "conditions": "Craving for and use of chemsex-related drugs",
            "member_states": "Belgium",
            "decision_date": "12/02/2026",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524177-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522981-61-00",
            "title": "Inavolisib for PIK3CA mutated advanced endometrial cancer:a multicentric, phase II, MITO END-4 trial",
            "phase": "Phase II",
            "lead_sponsor": "IRCCS Istituto Nazionale Tumori Fondazione Pascale",
            "conditions": "endometrial cancer",
            "member_states": "Italy",
            "decision_date": "12/02/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522981-61-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520622-38-00",
            "title": "Personalized antibiotic TREATment for febrile Urinary Tract Infections in children (TREAT-UTI study): multicenter randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo",
            "conditions": "Urinary Tract Infections",
            "member_states": "Italy",
            "decision_date": "12/02/2026",
            "enrolled": "520",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520622-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523275-27-00",
            "title": "HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).",
            "phase": "Phase III",
            "lead_sponsor": "Disc Medicine Inc.",
            "conditions": "Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)",
            "member_states": "Italy; France; Ireland; Belgium; Sweden; Germany; Netherlands; Norway; Spain",
            "decision_date": "12/02/2026",
            "enrolled": "49",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523275-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519811-32-00",
            "title": "An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis",
            "phase": "Phase IV",
            "lead_sponsor": "Region Oestergoetland",
            "conditions": "Atopic dermatitis",
            "member_states": "Sweden",
            "decision_date": "12/02/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519811-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524691-33-00",
            "title": "A multicenter, Phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary clinical activity of TUB-040, in combination with standard ovarian cancer drugs in patients with high-grade epithelial serous or endometrioid epithelial ovarian cancer (OC) (NAPISTAR 1-02)",
            "phase": "Phase I/II",
            "lead_sponsor": "Tubulis GmbH",
            "conditions": "High-grade epithelial serous or endometrioid epithelial ovarian cancer",
            "member_states": "Belgium",
            "decision_date": "12/02/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524691-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523476-23-00",
            "title": "Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) \u2013 A phase 2 proof-of-concept, national, multicenter, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy of remdesivir in adult patients hospitalized for TBE",
            "phase": "Phase II",
            "lead_sponsor": "Region Stockholm \u2013 SLSO",
            "conditions": "Tick-Borne Encephalitis (TBE)",
            "member_states": "Sweden",
            "decision_date": "12/02/2026",
            "enrolled": "126",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523476-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521732-11-00",
            "title": "Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets  to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "No medical condition",
            "member_states": "Czechia",
            "decision_date": "12/02/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521732-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521587-35-00",
            "title": "A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)",
            "phase": "Phase III",
            "lead_sponsor": "Summit Therapeutics Inc.",
            "conditions": "Metastatic colorectal cancer",
            "member_states": "Belgium; Italy; Spain; Germany; France; Poland; Czechia; Hungary",
            "decision_date": "12/02/2026",
            "enrolled": "220",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521587-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522987-34-00",
            "title": "A Long-term Extension Study of the Safety and Efficacy of Cleminorexton in Participants with Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored Cleminorexton Clinical Trial",
            "phase": "Phase III",
            "lead_sponsor": "Centessa Pharmaceuticals UK Limited",
            "conditions": "Narcolepsy and Idiopathic Hypersomnia",
            "member_states": "France; Spain; Italy",
            "decision_date": "12/02/2026",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522987-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522796-28-00",
            "title": "A Multicenter, Prospective, Randomized, Open-label Phase 2b Study, with Blinded Evaluation, Comparing the Combination of Amodiaquine and Potassium Canrenoate with Either Exenatide or Glibenclamide Versus Best Medical Therapy, in Patients with Acute Ischemic Stroke",
            "phase": "Phase II",
            "lead_sponsor": "Genesis Pharma S.A.",
            "conditions": "Acute Ischemic Stroke",
            "member_states": "Greece",
            "decision_date": "12/02/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522796-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523465-21-00",
            "title": "Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept",
            "phase": "Phase III",
            "lead_sponsor": "Region Stockholm \u2013 SLSO",
            "conditions": "Fibromyalgia",
            "member_states": "Sweden",
            "decision_date": "12/02/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523465-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522399-10-00",
            "title": "Nordic PREdnisolon for VEstibular NeuriTis Study \u2013 an investigator-driven, triple blind, placebo controlled randomized trial",
            "phase": "Phase III",
            "lead_sponsor": "Region Vaesterbotten, Umea University",
            "conditions": "Vestibular neuritis",
            "member_states": "Sweden; Denmark; Norway",
            "decision_date": "11/02/2026",
            "enrolled": "404",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522399-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521634-29-00",
            "title": "A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Na\u00efve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction (SEVENAZA)",
            "phase": "Phase III",
            "lead_sponsor": "Institut Gustave Roussy",
            "conditions": "ONCOLOGY, Acute Myeloid Leukemia",
            "member_states": "France; Spain",
            "decision_date": "11/02/2026",
            "enrolled": "262",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521634-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524210-28-00",
            "title": "A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Not Applicable",
            "member_states": "Netherlands",
            "decision_date": "11/02/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524210-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522193-37-00",
            "title": "Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR]",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Septic arthritis",
            "member_states": "France",
            "decision_date": "10/02/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522193-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523172-23-00",
            "title": "A phase 1, open-label, dose-escalation and dose-expansion study evaluating the safety, feasability and efficacy of ODI-2001 vaccine, a personalized immunotherapy, in patients with metastatic or locally advanced colon cancer of pancreatic cancer",
            "phase": "Phase I",
            "lead_sponsor": "Centr Georges Francois Leclerc",
            "conditions": "Metastatic or locally advanced pancreatic cancer, Metastatic or locally advanced colorectal cancer",
            "member_states": "France",
            "decision_date": "10/02/2026",
            "enrolled": "83",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523172-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522582-30-00",
            "title": "A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer\u2019s Disease",
            "phase": "Phase I",
            "lead_sponsor": "Alnylam Pharmaceuticals Inc.",
            "conditions": "Alzheimer\u2019s Disease",
            "member_states": "Spain; Netherlands",
            "decision_date": "10/02/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522582-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520978-18-00",
            "title": "A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease",
            "phase": "Phase I",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Chronic Kidney Disease",
            "member_states": "Germany; Romania",
            "decision_date": "10/02/2026",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520978-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522120-28-00",
            "title": "Total Neoadjuvant Treatment with or without Tislelizumab for Locally Advanced Rectal Cancer: An Open-label Randomized Controlled Phase II Study (The TOTAL Trial)",
            "phase": "Phase II",
            "lead_sponsor": "Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz K\u00f6R, Rabin Medical Center",
            "conditions": "Locally Advanced Rectal Cancer (LARC) stage II (T3-4N0M0) or stage III (TxN1-2M0)",
            "member_states": "Germany",
            "decision_date": "10/02/2026",
            "enrolled": "67",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522120-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520138-31-00",
            "title": "PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma",
            "phase": "Phase II",
            "lead_sponsor": "University Of Cologne",
            "conditions": "Early-stage favorable classic Hodgkin lymphoma",
            "member_states": "Germany",
            "decision_date": "10/02/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520138-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519005-35-00",
            "title": "A Phase 1/2, Randomized, Double-blind, Placebo-controlled 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-4324 in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-4324 in Overweight to Obese Patients With Type 2 Diabetes Mellitus (T2DM)",
            "phase": "Phase I/II",
            "lead_sponsor": "Alnylam Pharmaceuticals Inc.",
            "conditions": "Type 2 Diabetes Mellitus",
            "member_states": "Germany; Poland",
            "decision_date": "10/02/2026",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519005-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523231-19-00",
            "title": "A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment.",
            "phase": "Phase II",
            "lead_sponsor": "Philogen S.p.A.",
            "conditions": "Cutaneous Squamous Cell Carcinoma",
            "member_states": "Italy; Germany; Greece; Spain; Austria; France; Netherlands",
            "decision_date": "10/02/2026",
            "enrolled": "83",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523231-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523229-16-00",
            "title": "A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients.",
            "phase": "Phase II",
            "lead_sponsor": "Philogen S.p.A.",
            "conditions": "locally advanced basal cell carcinoma patients",
            "member_states": "Greece; Italy; Germany; Spain",
            "decision_date": "10/02/2026",
            "enrolled": "85",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523229-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519504-27-00",
            "title": "An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase III",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Relapsed Refractory Multiple Myeloma",
            "member_states": "Greece; Spain; Poland; Italy; Austria; Czechia; Belgium; Germany; Netherlands; France",
            "decision_date": "10/02/2026",
            "enrolled": "315",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519504-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523230-77-00",
            "title": "A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed on or intolerant to systemic treatment.",
            "phase": "Phase II",
            "lead_sponsor": "Philogen S.p.A.",
            "conditions": "Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.",
            "member_states": "Germany; Italy; Greece; Spain",
            "decision_date": "10/02/2026",
            "enrolled": "53",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523230-77-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522703-14-00",
            "title": "A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-1)",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "\"Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity\"",
            "member_states": "Poland; Germany; Czechia; Hungary; Spain; France",
            "decision_date": "10/02/2026",
            "enrolled": "115",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522703-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517838-17-00",
            "title": "Bioavailability study with naloxone hydrochloride in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "CCDRD Cooperative Clinical Drug Research and Development AG, Vaccpower Limited",
            "conditions": "No therapeutic indication in the current trial with healthy volunteers.",
            "member_states": "Bulgaria",
            "decision_date": "10/02/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517838-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520923-25-00",
            "title": "Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA)",
            "phase": "Phase III",
            "lead_sponsor": "Duke Clinical Research Institute",
            "conditions": "Juvenile Idiopathic Arthritis",
            "member_states": "Italy; Netherlands; Germany",
            "decision_date": "10/02/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520923-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521583-35-00",
            "title": "Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 \u2265 50% NSCLC: a biomarker guided phase 2 trial \u2013 HYPERBOLIC study",
            "phase": "Phase II",
            "lead_sponsor": "Universita' Vita-salute S. Raffaele",
            "conditions": "non-small cell lung cancer (NSCLC)",
            "member_states": "Italy",
            "decision_date": "10/02/2026",
            "enrolled": "700",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521583-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520805-10-00",
            "title": "A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and\u202fSafety of\u202fEmpasiprubart\u202fIV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy",
            "phase": "Phase III",
            "lead_sponsor": "Argenx",
            "conditions": "Chronic inflammatory demyelinating polyneuropathy (CIDP)",
            "member_states": "Czechia; Denmark; Poland; Slovenia; Netherlands; Austria; Estonia; Slovakia; Hungary; Finland; Bulgaria; France; Italy; Greece; Romania",
            "decision_date": "10/02/2026",
            "enrolled": "86",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520805-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520993-20-00",
            "title": "A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics,  Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG)",
            "phase": "Phase II",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Generalized Myasthenia Gravis",
            "member_states": "Spain; Italy; Poland; France",
            "decision_date": "09/02/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520993-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523880-39-02",
            "title": "A novel fibroblast imaging biomarker and ultrahigh resolution PET to improve the diagnosis and follow-up of giant cell arteritis",
            "phase": "Phase III",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Giant Cell Arteritis",
            "member_states": "Belgium",
            "decision_date": "09/02/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523880-39-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523213-29-00",
            "title": "A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants with Invasive Ventilator-dependent X-linked Myotubular Myopathy",
            "phase": "Phase I/II",
            "lead_sponsor": "Astellas Gene Therapies Inc.",
            "conditions": "X-linked myotubular myopathy",
            "member_states": "France",
            "decision_date": "09/02/2026",
            "enrolled": "3",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523213-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522033-64-00",
            "title": "A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor",
            "phase": "Phase I",
            "lead_sponsor": "Ajax Therapeutics Inc.",
            "conditions": "Myelofibrosis",
            "member_states": "Italy; France; Spain",
            "decision_date": "09/02/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522033-64-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522543-18-00",
            "title": "A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC",
            "phase": "Phase I",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Advanced Clear Cell Renal Cell Carcinoma",
            "member_states": "Spain; France",
            "decision_date": "09/02/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522543-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522652-58-01",
            "title": "A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults.",
            "phase": "Phase I",
            "lead_sponsor": "H. Lundbeck A/S",
            "conditions": "Narcolepsy",
            "member_states": "France",
            "decision_date": "09/02/2026",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522652-58-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522729-36-00",
            "title": "Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta.",
            "phase": "Phase I/II",
            "lead_sponsor": "Gilead Sciences Inc.",
            "conditions": "Chronic Hepatitis Delta.",
            "member_states": "Italy; Romania; Germany; Bulgaria",
            "decision_date": "09/02/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522729-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521621-33-00",
            "title": "Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products",
            "phase": "Phase IV",
            "lead_sponsor": "Replimune Group Inc.",
            "conditions": "Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Advanced solid tumors",
            "member_states": "Germany; Greece; France; Poland; Spain",
            "decision_date": "09/02/2026",
            "enrolled": "41",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521621-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521124-29-00",
            "title": "Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination with Osimertinib, Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Non-Small Cell Lung Cancer",
            "member_states": "Portugal; Italy; Spain; Poland; Netherlands; Germany; Belgium; Austria; France",
            "decision_date": "09/02/2026",
            "enrolled": "193",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521124-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521142-22-00",
            "title": "A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema \u2013 ORBIT-EXPANSE",
            "phase": "Phase III",
            "lead_sponsor": "Astria Therapeutics Inc.",
            "conditions": "Hereditary Angioedema",
            "member_states": "Netherlands; Spain; Poland; Germany; Czechia; Austria; Portugal; Hungary; France; Italy; Bulgaria",
            "decision_date": "09/02/2026",
            "enrolled": "53",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521142-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521038-27-00",
            "title": "A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Immune system diseases",
            "member_states": "Slovakia; Germany; Austria; Italy; Czechia; Netherlands; Poland; Belgium; Hungary; Lithuania; Greece; France; Bulgaria; Spain; Norway",
            "decision_date": "09/02/2026",
            "enrolled": "209",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521038-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521035-37-00",
            "title": "A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis.",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Immune system diseases",
            "member_states": "Austria; France; Norway; Hungary; Bulgaria; Netherlands; Czechia; Slovakia; Germany; Lithuania; Greece; Belgium; Italy; Spain; Poland",
            "decision_date": "09/02/2026",
            "enrolled": "499",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521035-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521742-15-00",
            "title": "A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI)- (299AR201-TRANSPIRE)",
            "phase": "Phase II",
            "lead_sponsor": "Biogen Idec Research Limited",
            "conditions": "Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants",
            "member_states": "Germany; Austria; Spain; Czechia; France",
            "decision_date": "09/02/2026",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521742-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523475-33-00",
            "title": "Caffeine Administration for Preterms: Pharmacokinetics, Utilization and Correlation Inhibiting Nociception Outcome",
            "phase": "Phase IV",
            "lead_sponsor": "Masarykova Univerzita",
            "conditions": "Primary apnea in preterms newborns",
            "member_states": "Czechia",
            "decision_date": "09/02/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523475-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522752-45-00",
            "title": "Prospective, multi-center, randomized, double-blinded, placebo-controlled phase IIb clinical trial to evaluate safety and efficacy of DUOFAG\u00ae in bacterial infection treatment in patients with complicated wounds",
            "phase": "Phase III",
            "lead_sponsor": "MB PHARMA s.r.o.",
            "conditions": "Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.",
            "member_states": "Czechia",
            "decision_date": "09/02/2026",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522752-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524768-39-00",
            "title": "The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in PABAL 100 \u03bcg/mL Solution for Injection when administered sublingually in the dose of 500 \u03bcg and intramuscularly in the dose of 100 \u03bcg.",
            "phase": "Phase I",
            "lead_sponsor": "Oxytone Bioscience B.V.",
            "conditions": "Not applicable (submitted trial is a bioavalability study in healthy participants).",
            "member_states": "Czechia",
            "decision_date": "09/02/2026",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524768-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522892-27-00",
            "title": "A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis",
            "phase": "Phase II",
            "lead_sponsor": "GSK PLC",
            "conditions": "Bronchiectasis",
            "member_states": "Denmark; France; Spain; Italy; Germany; Poland",
            "decision_date": "09/02/2026",
            "enrolled": "207",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522892-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524527-46-00",
            "title": "A single and multiple ascending dose study of topical ladarixin ophthalmic solution in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Dompe' Farmaceutici S.p.A.",
            "conditions": "Ocular inflammatory conditions",
            "member_states": "Netherlands",
            "decision_date": "09/02/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524527-46-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521831-35-00",
            "title": "(23026) A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) previously treated with tafamidis.",
            "phase": "Phase IV",
            "lead_sponsor": "Bayer Consumer Care AG",
            "conditions": "Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",
            "member_states": "Austria; Germany; Italy; Belgium",
            "decision_date": "07/02/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521831-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523133-26-00",
            "title": "The effect of anifrolumab on cutaneous lupus erythematosus characterized by the change of the inflammatory infiltrate analyzed by immunohistochemistry, spatial transcriptomics and single-cell RNA- and TCR-sequencing as well as on the clinical outcome - an open label, single arm phase IV pilot study",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "cutaneous lupus erythematosus",
            "member_states": "Austria",
            "decision_date": "07/02/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523133-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523375-29-00",
            "title": "Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus",
            "phase": "Phase III",
            "lead_sponsor": "Humanitas Mirasole S.p.A.",
            "conditions": "diabetes mellitus, Myocardial Infarction",
            "member_states": "Italy",
            "decision_date": "06/02/2026",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523375-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519881-32-00",
            "title": "A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease",
            "phase": "Phase I/II",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Sickle Cell Disease",
            "member_states": "France",
            "decision_date": "06/02/2026",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519881-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524199-40-00",
            "title": "A PET-MRI study of serotoninergic brainstem pathway in patients with Dravet Syndrome - DRAPETONINE",
            "phase": "Phase II",
            "lead_sponsor": "Hospices Civils De Lyon",
            "conditions": "neurology",
            "member_states": "France",
            "decision_date": "06/02/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524199-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522603-15-00",
            "title": "A Phase IIb, Monocentric, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50)",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii",
            "conditions": "Hereditary Spastic Paraplegia Type 50 (SPG50)",
            "member_states": "Italy",
            "decision_date": "06/02/2026",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522603-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524061-24-01",
            "title": "Study to compare drug availability in the bloodstream of two oral formulations of dexketoprofen in healthy volunteers under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Faes Farma S.A.",
            "conditions": "Bioequivalence clinical trial in healthy volunteers under fasting conditions.",
            "member_states": "Czechia",
            "decision_date": "06/02/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524061-24-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524484-20-00",
            "title": "Rapid Oral Switch in Infectious Endocarditis, the ROSIE trial",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Infective Endocarditis",
            "member_states": "Belgium",
            "decision_date": "06/02/2026",
            "enrolled": "152",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524484-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521839-36-00",
            "title": "Phase II study of Cemiplimab before and after standard chemoradiotherapy for patients with locally advanced cervical carcinoma. CADILLACC TRIAL",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione IRCCS Istituto Nazionale Dei Tumori",
            "conditions": "locally advanced cervical carcinoma",
            "member_states": "Italy",
            "decision_date": "06/02/2026",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521839-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524044-35-00",
            "title": "A Randomized, Non-inferiority Trial Comparing 7-Day Versus 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia",
            "phase": "Phase IV",
            "lead_sponsor": "Landspitali",
            "conditions": "Dyspepsia",
            "member_states": "Iceland",
            "decision_date": "06/02/2026",
            "enrolled": "128",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524044-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522229-37-00",
            "title": "A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Gastrointestinal Neoplasms",
            "member_states": "France; Romania; Spain; Netherlands; Norway; Belgium; Hungary; Italy; Poland; Germany",
            "decision_date": "06/02/2026",
            "enrolled": "148",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522229-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523071-34-00",
            "title": "Adductor canal and IPACK (infiltration between the popliteal artery and the capsule of the knee) blocks versus genicular nerves block for total knee arthroplasty: A randomized clinical trial",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "Knee Osteoarthritis",
            "member_states": "Spain",
            "decision_date": "06/02/2026",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523071-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523108-59-00",
            "title": "A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects",
            "phase": "Phase I",
            "lead_sponsor": "Basilea Pharmaceutica International AG Allschwil",
            "conditions": "Severe infections caused by Gram-negative bacteria",
            "member_states": "Netherlands",
            "decision_date": "06/02/2026",
            "enrolled": "136",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523108-59-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522756-97-00",
            "title": "Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone for Coronavirus Disease 2019 (COVID-19) in Patients with Severely Impaired B-cell Function",
            "phase": "Phase II",
            "lead_sponsor": "Region Vaesterbotten, Umea University",
            "conditions": "COVID-19 and Severely Impaired B-cell Function",
            "member_states": "Sweden",
            "decision_date": "06/02/2026",
            "enrolled": "92",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522756-97-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523328-31-00",
            "title": "A study on the safety, tolerability, and effectiveness of the new drug LAD106 in healthy volunteers.",
            "phase": "Phase I",
            "lead_sponsor": "Almirall S.A.",
            "conditions": "Inflammatory diseases",
            "member_states": "Netherlands",
            "decision_date": "06/02/2026",
            "enrolled": "93",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523328-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522509-39-00",
            "title": "Pacritinib For The Reduction Of Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia; A Multicenter, Open-Label, Single Arm, Phase II Exploratory Study",
            "phase": "Phase II",
            "lead_sponsor": "Grupo Espanol De Enfermedades Mieloproliferativas Cronicas Ph",
            "conditions": "Patients with myelofibrosis and platelets counts between 50 - 120 x 10e9/L",
            "member_states": "Spain",
            "decision_date": "06/02/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522509-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521889-95-00",
            "title": "Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohn\u2019s Disease : EMINENT CD",
            "phase": "Phase IV",
            "lead_sponsor": "Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif",
            "conditions": "Crohn's Disease",
            "member_states": "France",
            "decision_date": "05/02/2026",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521889-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524194-17-00",
            "title": "EFFICACY OF PROPRANOLOL IN TRAUMATIC BRAIN INJURY PATIENTS ADMITTED TO THE ICU: A PROSPECTIVE, RANDOMIZED, TRIPLE-BLIND STUDY (ProP TBI in ICU)",
            "phase": "Phase III",
            "lead_sponsor": "University Hospital Son Espases",
            "conditions": "Head injury",
            "member_states": "Spain",
            "decision_date": "05/02/2026",
            "enrolled": "600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524194-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520571-66-00",
            "title": "CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids.",
            "phase": "Phase III",
            "lead_sponsor": "Region Vaesterbotten",
            "conditions": "Prostate cancer",
            "member_states": "Sweden",
            "decision_date": "05/02/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520571-66-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519292-26-00",
            "title": "A  Phase 2, Randomised, Double-masked, Placebo-controlled, Parallel-group, Multi-centre Study to Evaluate K1-70 in Patients with Active Thyroid Eye Disease in Europe",
            "phase": "Phase II",
            "lead_sponsor": "Av7 Limited",
            "conditions": "Graves\u2019 disease and active thyroid eye disease",
            "member_states": "Spain; Italy",
            "decision_date": "05/02/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519292-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522313-38-00",
            "title": "J2S-MC-GZME: A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Alcohol Use Disorder",
            "member_states": "Belgium; Germany",
            "decision_date": "05/02/2026",
            "enrolled": "97",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522313-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524385-18-00",
            "title": "A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor",
            "phase": "Phase I",
            "lead_sponsor": "Inventiva",
            "conditions": "Non-alcoholic steatohepatitis",
            "member_states": "France",
            "decision_date": "04/02/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524385-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521394-13-00",
            "title": "A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes",
            "phase": "Phase I",
            "lead_sponsor": "Auron Therapeutics Inc.",
            "conditions": "Relapsed/refractory Acute Myeloid Leukemia or relapsed/refractory myelodysplastic syndromes",
            "member_states": "France",
            "decision_date": "04/02/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521394-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-504654-35-00",
            "title": "Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) with Atorvastatin (ATORGO)",
            "phase": "Phase II",
            "lead_sponsor": "Region Skane",
            "conditions": "Graves Ofthalmopathy",
            "member_states": "Sweden",
            "decision_date": "04/02/2026",
            "enrolled": "554",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-504654-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523692-39-00",
            "title": "Multicentre, open-label, randomised, controlled, parallel-arms, phase III, clinical trial of Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer: MEND-IT II",
            "phase": "Phase III",
            "lead_sponsor": "Catharina Ziekenhuis Stichting",
            "conditions": "locally advanced rectal cancer",
            "member_states": "Netherlands",
            "decision_date": "04/02/2026",
            "enrolled": "394",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523692-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524953-15-00",
            "title": "Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma",
            "phase": "Phase I",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Uveal melanoma",
            "member_states": "Denmark",
            "decision_date": "04/02/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524953-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521642-14-00",
            "title": "An Open-Label Extension, Multi-centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy",
            "phase": "Phase II",
            "lead_sponsor": "Teva Branded Pharmaceutical Products R&D LLC",
            "conditions": "Multiple System Atrophy",
            "member_states": "France; Germany; Italy; Spain",
            "decision_date": "04/02/2026",
            "enrolled": "149",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521642-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521966-91-00",
            "title": "An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer with Liver Dominant Disease",
            "phase": "Phase II",
            "lead_sponsor": "Delcath Systems Inc.",
            "conditions": "Refractory Metastatic Breast Cancer with Liver Dominant Disease",
            "member_states": "Italy; Spain; Sweden; France; Germany",
            "decision_date": "04/02/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521966-91-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522015-42-00",
            "title": "A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)",
            "phase": "Phase III",
            "lead_sponsor": "Mirum Pharmaceuticals Inc.",
            "conditions": "Chronic Hepatitis D Infection",
            "member_states": "Czechia; Austria; Spain; Romania; Germany; Italy; France",
            "decision_date": "03/02/2026",
            "enrolled": "115",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522015-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522273-10-00",
            "title": "A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid arthritis or systemic lupus erythematosus.",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus",
            "member_states": "Germany; Spain; Belgium",
            "decision_date": "03/02/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522273-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523032-39-00",
            "title": "Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer \u2013 a pilot study",
            "phase": "Phase II",
            "lead_sponsor": "Academisch Ziekenhuis Maastricht",
            "conditions": "Non-small cell lung cancer",
            "member_states": "Netherlands",
            "decision_date": "03/02/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523032-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522253-19-00",
            "title": "A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04\u2013Substudy 04D",
            "phase": "Phase I/II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Urothelial carcinoma",
            "member_states": "Netherlands; France; Spain",
            "decision_date": "03/02/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522253-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522960-34-00",
            "title": "ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease",
            "phase": "Phase III",
            "lead_sponsor": "Alnylam Pharmaceuticals Inc.",
            "conditions": "Hypertension, Established cardiovascular disease, High cardiovascular risk",
            "member_states": "Belgium; Hungary; Czechia; Austria; Germany; France; Greece; Spain; Romania; Netherlands; Italy; Poland; Slovakia; Sweden; Portugal; Denmark; Bulgaria",
            "decision_date": "03/02/2026",
            "enrolled": "3980",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522960-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523347-35-00",
            "title": "A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Atopic Dermatitis",
            "member_states": "Spain; Italy; Romania",
            "decision_date": "02/02/2026",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523347-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524029-41-00",
            "title": "A Pilot Study on the Use of Gadopiclenol for Enhanced Cardiac MRI in Children with Congenital Heart Conditions: A self-controlled, non-randomised, open-label study to compare the image quality and diagnostic performance of gadopiclenol versus gadoterate meglumine",
            "phase": "Phase III",
            "lead_sponsor": "Fundacio Sant Joan De Deu",
            "conditions": "Cardiomyopathy, tetralogy of Fallot, or complex congenital heart disease",
            "member_states": "Spain",
            "decision_date": "02/02/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524029-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523349-86-00",
            "title": "MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Acute Myocardial Infarction",
            "member_states": "France",
            "decision_date": "02/02/2026",
            "enrolled": "700",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523349-86-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521619-37-00",
            "title": "NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients \u226575 years old",
            "phase": "Phase III",
            "lead_sponsor": "Unicancer",
            "conditions": "Patients \u226575 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy,\nFOLFOX chemotherapy and total mesorectal excision (TME) surgery",
            "member_states": "France",
            "decision_date": "02/02/2026",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521619-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523412-36-00",
            "title": "A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Systemic lupus erythematosus, Rheumatoid arthritis",
            "member_states": "Italy; Belgium; Romania",
            "decision_date": "02/02/2026",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523412-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522914-22-00",
            "title": "A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC",
            "phase": "Phase I",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)",
            "member_states": "France; Spain",
            "decision_date": "02/02/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522914-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521560-36-00",
            "title": "A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)",
            "phase": "Phase II",
            "lead_sponsor": "Sab Biotherapeutics Inc.",
            "conditions": "Type 1 Diabetes",
            "member_states": "Austria; Germany; Poland; Italy; Denmark; Spain; Belgium; Finland; France; Lithuania; Slovenia",
            "decision_date": "02/02/2026",
            "enrolled": "66",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521560-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523487-21-00",
            "title": "An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITY\u00ae (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguari\u00fana Administrative Building -SP CNPJ 60.397.775/0001-74 SAC: 0800 - 7710345, in healthy adult, human subjects under fasting condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)",
            "member_states": "Romania",
            "decision_date": "02/02/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523487-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-504404-28-00",
            "title": "ASPIRE-1: Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial",
            "phase": "Phase II",
            "lead_sponsor": "University Medical Center Groningen",
            "conditions": "Chronic Kidney Disease, Type 1 Diabetes",
            "member_states": "Netherlands; Finland; Denmark",
            "decision_date": "02/02/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-504404-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524102-15-00",
            "title": "Safety and tolerability of medicated chewing gum with sodium alginate, calcium carbonate and sodium bicarbonate.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Liconsa S.A.",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "02/02/2026",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524102-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522491-89-00",
            "title": "Efficacy and safety of SP16 in preventing Acute Kidney Injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine: A prospective, randomized, double-blind, placebo-controlled clinical trial (EASE-AKI)",
            "phase": "Phase II",
            "lead_sponsor": "Universitaetsklinikum Erlangen A\u00f6R",
            "conditions": "Cardiovascular Disease, Valvular Disease, Chronic Kidney Disease",
            "member_states": "Germany",
            "decision_date": "02/02/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522491-89-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522029-37-00",
            "title": "A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 followed by AZD0486 versus R-mini-CHOP x6 in Elderly or Unfit Participants with Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Large B-cell Lymphoma",
            "member_states": "Poland; Belgium",
            "decision_date": "30/01/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522029-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522853-21-01",
            "title": "An open label, phase I/II study investigating the safety and efficacy of a CD3/CD20 bispecific T-cell engager therapy in patients with active, treatment refractory, ANCA-IgG-positive associated vasculitis. The RENEWAL study",
            "phase": "Phase I/II",
            "lead_sponsor": "Fraunhofer Institute For Translational Medicine And Pharmacology ITMP",
            "conditions": "Active, treatment refractory, ANCA-IgG-positive associated vasculitis",
            "member_states": "Germany",
            "decision_date": "30/01/2026",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522853-21-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522553-19-00",
            "title": "A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).",
            "phase": "Phase III",
            "lead_sponsor": "Kardigan Inc.",
            "conditions": "Symptomatic genetic and familial dilated cardiomyopathy.",
            "member_states": "Spain; Denmark; Belgium; Hungary; Italy; Poland; France; Sweden; Netherlands",
            "decision_date": "30/01/2026",
            "enrolled": "230",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522553-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523409-13-00",
            "title": "A study to find how safe different doses of LFD-200 are and how it works in both  healthy people and people with moderate to severe rheumatoid arthritis",
            "phase": "Phase I",
            "lead_sponsor": "Lifordi Immunotherapeutics Inc.",
            "conditions": "Moderate to Severe Rheumatoid Arthritis",
            "member_states": "Poland",
            "decision_date": "30/01/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523409-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523781-25-00",
            "title": "PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).",
            "phase": "Phase I",
            "lead_sponsor": "CimCure B.V.",
            "conditions": "metastatic solid cancer, muscle invasive bladder cancer, localized or locally advanced renal cell cancer (RCC)",
            "member_states": "Netherlands",
            "decision_date": "29/01/2026",
            "enrolled": "83",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523781-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522613-26-00",
            "title": "First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9",
            "phase": "Phase I/II",
            "lead_sponsor": "BioNTech SE",
            "conditions": "Advanced Solid Cancers",
            "member_states": "Spain; Germany",
            "decision_date": "29/01/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522613-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513579-42-00",
            "title": "A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are \u226518 to \u226465 Years",
            "phase": "Phase I/II",
            "lead_sponsor": "Sarepta Therapeutics Inc.",
            "conditions": "Type 1 Myotonic Dystrophy",
            "member_states": "Spain; Germany; Belgium; Italy",
            "decision_date": "29/01/2026",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513579-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522312-16-00",
            "title": "J2S-MC-GZMP: A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Alcohol Use Disorder",
            "member_states": "Germany; Belgium",
            "decision_date": "29/01/2026",
            "enrolled": "151",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522312-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522387-32-00",
            "title": "A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC  UVEAL MELANOMA (OptimUM-10)",
            "phase": "Phase III",
            "lead_sponsor": "Ideaya Biosciences Inc.",
            "conditions": "Uveal Melanoma",
            "member_states": "France; Spain; Poland; Italy; Czechia; Belgium; Austria; Netherlands; Denmark; Germany",
            "decision_date": "29/01/2026",
            "enrolled": "297",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522387-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523977-40-00",
            "title": "Changes in Coronary Plaque Composition By Semaglutide Use in Diabetic Patients With Acute Coronary Syndrome: A Randomized Optical Coherence Tomography Trial - ARMYDA - 10 study",
            "phase": "Phase IV",
            "lead_sponsor": "Azienda Ospedaliero-Universitaria Maggiore Della Carita",
            "conditions": "non-ST-elevation myocardial infarction (NSTEMI); unstable angina, diabetes mellitus",
            "member_states": "Italy",
            "decision_date": "28/01/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523977-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523065-16-00",
            "title": "Tailored antiplatelet secondary prevention in non-cardioembolic ischemic stroke: a phase IV gender-stratified randomized controlled trial (TAILOR trial)",
            "phase": "Phase IV",
            "lead_sponsor": "Azienda Unita Sanitaria Locale Di Bologna",
            "conditions": "Non-cardioembolic ischemic stroke",
            "member_states": "Italy",
            "decision_date": "28/01/2026",
            "enrolled": "1506",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523065-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522533-54-00",
            "title": "Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)",
            "phase": "Phase II",
            "lead_sponsor": "Institut Gustave Roussy",
            "conditions": "Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma",
            "member_states": "France",
            "decision_date": "28/01/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522533-54-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520140-42-00",
            "title": "Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)",
            "phase": "Phase III",
            "lead_sponsor": "Institut Gustave Roussy",
            "conditions": "Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.",
            "member_states": "France",
            "decision_date": "28/01/2026",
            "enrolled": "984",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520140-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521877-14-00",
            "title": "Guttmann NeuroRecovery \u2013 Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous spinal cord stimulation in the rehabilitation of chronic spinal cord injuries: a pilot study",
            "phase": "Phase I/II",
            "lead_sponsor": "Fundacio Institut Guttmann",
            "conditions": "Traumatic spinal cord injury",
            "member_states": "Spain",
            "decision_date": "28/01/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521877-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520262-58-01",
            "title": "Multicentre, open-label, randomized controlled non-inferiority trial comparing single dose intrathecal morphine and continuous thoracic epidural analgesia for multimodal analgesia in open colorectal surgery: the ColoREDIT protocol",
            "phase": "Phase IV",
            "lead_sponsor": "Region Vaestmanland",
            "conditions": "All diseases requiring resective colorectal surgery with a midline incision.",
            "member_states": "Sweden",
            "decision_date": "28/01/2026",
            "enrolled": "124",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520262-58-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521636-10-00",
            "title": "A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Progressive Forms of Multiple Sclerosis (PMS)",
            "member_states": "Germany; Spain; France; Hungary; Italy; Poland; Portugal",
            "decision_date": "28/01/2026",
            "enrolled": "235",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521636-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522974-35-00",
            "title": "EFFICACY OF INFILTRATED MEPIVACAINE AS A LOCAL ANESTHETIC PRIOR TO ARTERIAL PUNCTURE: A RANDOMIZED CONTROLLED CLINICAL TRIAL",
            "phase": "Phase IV",
            "lead_sponsor": "University Of The Basque Country",
            "conditions": "Respiratory disease.\nPrescripcion o indicaci\u00f3n de gasometr\u00eda.",
            "member_states": "Spain",
            "decision_date": "28/01/2026",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522974-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519614-30-00",
            "title": "A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "28/01/2026",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519614-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522099-10-00",
            "title": "Antisense Oligonucleotide Eye Drops against IRS-1 to Optimize Pretransplant Lymphangio-regression Prior to High-Risk Keratoplasty (Olisens-Precon)",
            "phase": "Phase II",
            "lead_sponsor": "University Of Cologne",
            "conditions": "Pathologically prevascularized corneas due to herpetic keratopathy prior to \u201chigh-risk\u201d corneal transplantation (keratoplasty)",
            "member_states": "Germany",
            "decision_date": "28/01/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522099-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519833-51-00",
            "title": "The efficacy of pipamperone and aripiprazole on behaviors that challenge in people with intellectual disabilities: A series of N-of-1 cross-over trials",
            "phase": "Phase IV",
            "lead_sponsor": "Stichting GGZ Drenthe",
            "conditions": "Behaviors that challenge",
            "member_states": "Netherlands",
            "decision_date": "28/01/2026",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519833-51-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516446-18-00",
            "title": "Study to look at the safety, tolerability, and how the body processes the study medicine WAL0623 after single or repeated doses, with or without food, in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Walden Biosciences Inc.",
            "conditions": "Glomerular kidney diseases with proteinuria",
            "member_states": "Italy",
            "decision_date": "27/01/2026",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516446-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522792-29-00",
            "title": "An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)",
            "phase": "Phase III",
            "lead_sponsor": "Grifols Therapeutics LLC",
            "conditions": "Alpha-1 Antitrypsin Deficiency",
            "member_states": "Poland; Denmark; Netherlands; Ireland; Sweden; Spain; Portugal; Germany; France",
            "decision_date": "27/01/2026",
            "enrolled": "47",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522792-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522674-36-00",
            "title": "N1T-MC-MALO:  A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Metabolic Dysfunction-Associated Steatotic Liver Disease",
            "member_states": "Czechia; France; Netherlands; Bulgaria; Norway; Austria; Poland; Spain; Italy; Hungary; Germany; Romania; Sweden; Portugal; Belgium",
            "decision_date": "27/01/2026",
            "enrolled": "505",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522674-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515770-27-00",
            "title": "A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma",
            "phase": "Phase I/II",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Multiple Myeloma",
            "member_states": "Norway",
            "decision_date": "27/01/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515770-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522404-24-01",
            "title": "Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)",
            "phase": "Phase III",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Lung Cancer",
            "member_states": "Netherlands",
            "decision_date": "27/01/2026",
            "enrolled": "7",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522404-24-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521919-39-00",
            "title": "A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo\u00ae in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting",
            "phase": "Phase I",
            "lead_sponsor": "H e x a l AG",
            "conditions": "Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment",
            "member_states": "Spain; Romania; Italy; Greece",
            "decision_date": "27/01/2026",
            "enrolled": "83",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521919-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522753-19-02",
            "title": "Exploring the Psychoactive Effects of Paracetamol: A parallel group, basic science, double blind, two armed study, to investigate potential emotional and cognitive effects of paracetamol (tablet form) compared to a placebo (tablet form) in healthy male and female participants between ages 18 and 30.",
            "phase": "Phase IV",
            "lead_sponsor": "Oslo Metropolitan University",
            "conditions": "Healthy adults aged 18-30.",
            "member_states": "Norway",
            "decision_date": "27/01/2026",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522753-19-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518822-33-01",
            "title": "Intrathecal baclofen pump versus selective dorsal rhizotomy for non-ambulatory children with cerebral palsy",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Cerebral Palsy",
            "member_states": "Netherlands; Belgium",
            "decision_date": "27/01/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518822-33-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523151-66-00",
            "title": "Early Lyophilised plasma In Patients with haemorrhagic Shock (ELIPS-Trial)",
            "phase": "Phase IV",
            "lead_sponsor": "Johannes Kepler University Linz",
            "conditions": "Haemorrhagic shock",
            "member_states": "Austria",
            "decision_date": "26/01/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523151-66-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521558-40-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease",
            "phase": "Phase III",
            "lead_sponsor": "Insmed Inc.",
            "conditions": "Pulmonary Hypertension Associated with Interstitial Lung Disease",
            "member_states": "Portugal; Italy; Czechia; Poland; Denmark; Greece; Germany; Romania; Spain; France; Belgium; Austria",
            "decision_date": "26/01/2026",
            "enrolled": "251",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521558-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523286-23-00",
            "title": "Evaluation of a [68Ga] Ga-HER2 single domain antibody PET/CT for predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in HER2-positive early breast cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Centre Henri Becquerel",
            "conditions": "Breast Cancer",
            "member_states": "France",
            "decision_date": "26/01/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523286-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521805-41-00",
            "title": "Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-POsitive Metastatic Breast Cancer with Proactive Toxicity ManagementReflecting Real-World Clinical Practice / TOP-REAL Trial",
            "phase": "Phase III",
            "lead_sponsor": "Solti Group",
            "conditions": "Patients with HER2-positive, locally advanced or metastatic breast cancer (BC), who have not received prior chemotherapy or HER2-targeted therapy for advanced/metastatic disease",
            "member_states": "France; Germany; Spain",
            "decision_date": "26/01/2026",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521805-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518273-34-02",
            "title": "Safety, Tolerability and Efficacy against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-na\u00efve Adults",
            "phase": "Phase I",
            "lead_sponsor": "Universitaetsklinikum Tuebingen A\u00f6R",
            "conditions": "Malaria",
            "member_states": "Germany",
            "decision_date": "26/01/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518273-34-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522530-31-01",
            "title": "PASSION (olaParib mAintenance in chemotherapy-Sensitive metaStatic pancreatIc adenOcarciNoma - mPDAC): a phase II, proof of principle, study",
            "phase": "Phase II",
            "lead_sponsor": "Universita' Degli Studi Di Verona",
            "conditions": "Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy",
            "member_states": "Italy",
            "decision_date": "26/01/2026",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522530-31-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519068-42-00",
            "title": "An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants with Heterozygous Familial Hypercholesterolemia",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "\u200bHeterozygous Familial Hypercholesterolemia\u200b in pediatric patients",
            "member_states": "Germany; Spain; Belgium; Czechia; Norway; France; Poland; Netherlands; Italy; Finland",
            "decision_date": "26/01/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519068-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523777-41-01",
            "title": "Morphine PCA vs Morphine and Lidocaine PCA for the treatment of vaso-occlusive crisis-related pain in sickle-cell anaemia patients: a prospective, randomized, double blind monocentric trial.",
            "phase": "Phase IV",
            "lead_sponsor": "CHU Saint Pierre",
            "conditions": "sickle cell anaemia",
            "member_states": "Belgium",
            "decision_date": "26/01/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523777-41-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521329-34-00",
            "title": "A study understanding how much CDR132L enters  the bloodstream after injection under the skin compared to injection into a vein in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Healthy volunteers, treatment for heart failure",
            "member_states": "Germany",
            "decision_date": "26/01/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521329-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523995-21-00",
            "title": "A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Healthy participants",
            "member_states": "Germany",
            "decision_date": "26/01/2026",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523995-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523202-32-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder",
            "phase": "Phase III",
            "lead_sponsor": "Xenon Pharmaceuticals Inc.",
            "conditions": "Major Depressive Disorder",
            "member_states": "Spain; Czechia; Slovakia; Romania; Poland; Finland; Germany",
            "decision_date": "26/01/2026",
            "enrolled": "162",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523202-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522923-81-00",
            "title": "A multicenter, prospective clinical TRrial evaluating patient\u2019s ability to make an independent and safe decision regarding the USe of the medicinal product Sildenafil Polpharma100 mg indicated in the Treatment of erectile dysfunction.\nTRUST Trial on Responsible Use and Self-assessed Treatment.",
            "phase": "Phase IV",
            "lead_sponsor": "ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.",
            "conditions": "Erectile dysfunction",
            "member_states": "Poland",
            "decision_date": "26/01/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522923-81-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523355-59-00",
            "title": "A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911",
            "phase": "Phase I",
            "lead_sponsor": "Qilu Pharmaceutical Co. Ltd.",
            "conditions": "Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Radiation Syndrome",
            "member_states": "Poland",
            "decision_date": "26/01/2026",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523355-59-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522514-23-00",
            "title": "J2A-MC-GZPS: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared with Placebo in Female Participants with Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) ;\nJ2A-MC-GZS1: A Study to Investigate Efficacy and Safety of Orforglipron Once Daily in Participants with Stress Urinary Incontinence Who Have Obesity or Overweight ;\nJ2A-MC-GZS2: A Study to Investigate Efficacy and Safety of Orforglipron Once Daily in Participants with Stress Urinary Incontinence Who Have Obesity or Overweight",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Urinary Incontinence, Stress",
            "member_states": "Romania; Czechia; Poland",
            "decision_date": "26/01/2026",
            "enrolled": "295",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522514-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516558-24-00",
            "title": "SARUPANC - A multicentric, single arm, phase II trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer",
            "phase": "Phase II",
            "lead_sponsor": "Centre Leon Berard",
            "conditions": "Pancreatic (PAAD)",
            "member_states": "France",
            "decision_date": "23/01/2026",
            "enrolled": "700",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516558-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523264-21-00",
            "title": "CIRAANO: Multimodal exploration (including radiopharmaceuticals Amyvid\u00ae and Tauvid\u00ae) of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.",
            "phase": "Phase III",
            "lead_sponsor": "Institut National De La Sante Et De La Recherche Medicale",
            "conditions": "Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia",
            "member_states": "France",
            "decision_date": "23/01/2026",
            "enrolled": "600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523264-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522556-10-01",
            "title": "Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome",
            "phase": "Phase II",
            "lead_sponsor": "TOXILYON",
            "conditions": "Ocular Sequelae in Lyell syndrome",
            "member_states": "France",
            "decision_date": "23/01/2026",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522556-10-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522609-39-00",
            "title": "Antisense Oligonucleotide Eye Drops Against IRS-1 to Treat Pathological Corneal Neovascularisation in Aniridia-Associated Keratopathy (Olisens-Aniridia)",
            "phase": "Phase II",
            "lead_sponsor": "University Of Cologne",
            "conditions": "Corneal Neovascularization in Aniridia-associated Keratopathy",
            "member_states": "Germany",
            "decision_date": "23/01/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522609-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522805-39-00",
            "title": "A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination with Fulvestrant in Participants with PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer",
            "member_states": "Belgium; Spain",
            "decision_date": "23/01/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522805-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522444-40-00",
            "title": "An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of leniolisib for immune dysregulation in patients with primary immunodeficiency",
            "phase": "Phase II",
            "lead_sponsor": "Pharming Technologies B.V.",
            "conditions": "primary immunodeficiency",
            "member_states": "Spain",
            "decision_date": "23/01/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522444-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522012-16-00",
            "title": "Master Protocol: A Phase 1b / 2, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09)\nSubstudy Protocol: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with  Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)",
            "phase": "Phase II",
            "lead_sponsor": "Alx Oncology Holdings Inc.",
            "conditions": "Breast Cancer",
            "member_states": "Spain; Italy; France",
            "decision_date": "23/01/2026",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522012-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521792-31-01",
            "title": "Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)",
            "phase": "Phase III",
            "lead_sponsor": "Arrowhead Pharmaceuticals Inc.",
            "conditions": "Homozygous Familial Hypercholesterolemia (HoFH)",
            "member_states": "Greece; France; Belgium; Germany; Netherlands; Austria; Sweden; Spain; Czechia; Italy",
            "decision_date": "23/01/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521792-31-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524310-28-00",
            "title": "A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants",
            "phase": "Phase I",
            "lead_sponsor": "Quralis Corp.",
            "conditions": "Epilepsy, amotrophic lateral sclerosis, neuropathy",
            "member_states": "Netherlands",
            "decision_date": "23/01/2026",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524310-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521918-26-00",
            "title": "A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Na\u00efve Viremic Persons with HIV-1.( INNOVATE Study)",
            "phase": "Phase II",
            "lead_sponsor": "Viiv Healthcare UK Limited",
            "conditions": "HIV Infections",
            "member_states": "Spain; Belgium; France; Germany; Italy; Portugal; Poland",
            "decision_date": "23/01/2026",
            "enrolled": "175",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521918-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523699-21-00",
            "title": "An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptoms",
            "phase": "Phase I",
            "lead_sponsor": "Cell to Cure ApS",
            "conditions": "Gastrointestinal symptoms, Autism spectrum disorder",
            "member_states": "Denmark",
            "decision_date": "23/01/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523699-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523543-36-00",
            "title": "Study on the influence of FLUMAzenil regarding the incidence of pediatric emergence delirium (ED) in children undergoing ENT surgery \u2013 FLUMA Study",
            "phase": "Phase III",
            "lead_sponsor": "Rheinische Friedrich-Wilhelms-Universitaet Bonn",
            "conditions": "pediatric emergence delirium",
            "member_states": "Germany",
            "decision_date": "23/01/2026",
            "enrolled": "1",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523543-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522039-33-00",
            "title": "A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis",
            "phase": "Phase I/II",
            "lead_sponsor": "Leal Therapeutics Inc.",
            "conditions": "Amyotrophic Lateral Sclerosis",
            "member_states": "Sweden; Italy; Germany; Netherlands",
            "decision_date": "23/01/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522039-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522522-13-01",
            "title": "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients",
            "phase": "Phase II",
            "lead_sponsor": "Satellos Bioscience Inc.",
            "conditions": "Duchenne muscular dystrophy",
            "member_states": "Spain; Belgium; Poland",
            "decision_date": "22/01/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522522-13-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523018-10-00",
            "title": "Evaluation of a New Pain Management Regime for Oocyte Pick-Up During Fertility Treatment",
            "phase": "Phase III",
            "lead_sponsor": "UZ Brussel",
            "conditions": "Acute procedural pain associated with oocyte pick-up (oocyte retrieval) in women undergoing IVF/ART.",
            "member_states": "Belgium",
            "decision_date": "22/01/2026",
            "enrolled": "318",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523018-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522335-34-00",
            "title": "(22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease.",
            "phase": "Phase I",
            "lead_sponsor": "Bayer AG",
            "conditions": "Chronic kidney disease, Coronary artery disease",
            "member_states": "Germany; Bulgaria",
            "decision_date": "22/01/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522335-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520652-28-00",
            "title": "An Experimental Medicine multicenter Trial to evaluate the safety and immunogenicity of experimental versus\nauthorized SARS-CoV-2 vaccine candidates as a booster dose in healthy participants previously vaccinated with\nauthorized mRNA SARS-CoV-2 vaccines.",
            "phase": "Phase I",
            "lead_sponsor": "ANRS Maladies Infectieuses Emergentes",
            "conditions": "healthy participants",
            "member_states": "France",
            "decision_date": "21/01/2026",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520652-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518609-17-00",
            "title": "The effect of CBD on sleep quality following late evening exercise",
            "phase": "Phase II",
            "lead_sponsor": "UZ Leuven",
            "conditions": "healthy individuals",
            "member_states": "Belgium",
            "decision_date": "21/01/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518609-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524368-39-00",
            "title": "The effect op corticosteroids on quality of life following total hip arthroplasty: HIPSTER study",
            "phase": "Phase IV",
            "lead_sponsor": "Ziekenhuis Oost Limburg",
            "conditions": "Patients aged 60 years or older undergoing total hip arthroplasty",
            "member_states": "Belgium",
            "decision_date": "21/01/2026",
            "enrolled": "234",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524368-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522743-18-00",
            "title": "Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a pilot study",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "Gambling disorder",
            "member_states": "France",
            "decision_date": "21/01/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522743-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522640-41-00",
            "title": "J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma",
            "phase": "Phase II",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Asthma",
            "member_states": "Germany; Netherlands; France; Poland",
            "decision_date": "21/01/2026",
            "enrolled": "137",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522640-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521973-16-00",
            "title": "A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME",
            "phase": "Phase I/II",
            "lead_sponsor": "Biocryst Pharmaceuticals Inc.",
            "conditions": "Netherton Syndrome",
            "member_states": "France; Netherlands; Germany",
            "decision_date": "20/01/2026",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521973-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523597-17-00",
            "title": "A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic symptoms, nerve fibers, and microcirculation in painful diabetic peripheral neuropathy",
            "phase": "Phase II",
            "lead_sponsor": "Deutsche Diabetes Forschungsgesellschaft e.V.",
            "conditions": "Painful diabetic peripheral neuropathy",
            "member_states": "Germany",
            "decision_date": "20/01/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523597-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521319-38-00",
            "title": "A phase II, open label, multicenter trial investigating Irinotecan plus cetuximab rechallenge compared with trifluridine/tipiracil plus bevacizumab as third line treatment in circulating tumor DNA molecularly selected metastatic colorectal cancer: the ROMANCE-GOIM trial",
            "phase": "Phase II",
            "lead_sponsor": "Gruppo Oncologico Dell'Italia Meridionale",
            "conditions": "metastatic colorectal cancer",
            "member_states": "Italy",
            "decision_date": "19/01/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521319-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521284-12-00",
            "title": "Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Non-small cell lung cancer",
            "member_states": "Austria; Portugal; Netherlands; Greece; Belgium; Spain; Germany; France; Romania; Sweden; Italy; Denmark",
            "decision_date": "19/01/2026",
            "enrolled": "93",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521284-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521908-22-00",
            "title": "IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "EGFR-mutated Non-small Cell Lung Cancer",
            "member_states": "Poland; Germany; Italy; Norway; Netherlands; Belgium; Romania; France; Greece; Spain",
            "decision_date": "19/01/2026",
            "enrolled": "193",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521908-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521962-83-00",
            "title": "AdaptNK \u2013Cell Therapy for High-risk Myeloid Disease",
            "phase": "Phase I/II",
            "lead_sponsor": "Karolinska Institutet",
            "conditions": "Relapsed and/or refractory AML or MDS",
            "member_states": "Sweden",
            "decision_date": "19/01/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521962-83-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521606-18-00",
            "title": "A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)",
            "phase": "Phase II",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Ovarian Cancer",
            "member_states": "Spain; Czechia; France; Belgium; Denmark",
            "decision_date": "19/01/2026",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521606-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-503766-24-00",
            "title": "A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Moderate to Severe Plaque Psoriasis",
            "member_states": "Romania; Bulgaria; Germany; Spain; Czechia; France; Hungary; Italy; Sweden; Poland; Denmark; Belgium",
            "decision_date": "19/01/2026",
            "enrolled": "1289",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-503766-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519550-36-00",
            "title": "International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis",
            "phase": "Phase IV",
            "lead_sponsor": "Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l.",
            "conditions": "Allergic rhinoconjunctivitis",
            "member_states": "Poland; Spain; Italy",
            "decision_date": "19/01/2026",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519550-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522027-95-00",
            "title": "Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation",
            "phase": "Phase III",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "oral squamous cell carcinoma",
            "member_states": "Netherlands",
            "decision_date": "19/01/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522027-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524256-64-00",
            "title": "The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.",
            "phase": "Phase IV",
            "lead_sponsor": "CHU Saint Pierre",
            "conditions": "Chronic Obstructive Pulmonary Disease",
            "member_states": "Belgium",
            "decision_date": "19/01/2026",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524256-64-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522125-36-00",
            "title": "A study to determine the safety and effect of antibodies against hepatitis D (the SAMBA-D study)",
            "phase": "Phase I",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Chronic hepatitis D infection",
            "member_states": "Germany; Denmark",
            "decision_date": "19/01/2026",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522125-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521257-17-00",
            "title": "DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional \u03b2AS3m/miR7m lentiviral vector expressing the \u03b2AS3m and a micro-RNA (miRNA) targeting specifically the endogenous \u03b2S-globin mRNA in Patients with Sickle Cell Disease (SCD)",
            "phase": "Phase I/II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "SCD severe patients",
            "member_states": "France",
            "decision_date": "16/01/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521257-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523273-41-00",
            "title": "A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "T.O.A.D. Oncology S.A.",
            "conditions": "Metastatic castration-resistant prostate cancer",
            "member_states": "Spain; France",
            "decision_date": "16/01/2026",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523273-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523020-50-00",
            "title": "A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER 01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease",
            "phase": "Phase II",
            "lead_sponsor": "Aer Therapeutics Inc.",
            "conditions": "Chronic Obstructive Pulmonary Disease",
            "member_states": "Bulgaria; Poland; Spain",
            "decision_date": "16/01/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523020-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523549-92-00",
            "title": "Melatonin versus placebo for bipolar disorder - a double blinded randomised controlled trial (The M-bipolar RCT)",
            "phase": "Phase III",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Bipolar disorder",
            "member_states": "Denmark",
            "decision_date": "16/01/2026",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523549-92-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523101-15-00",
            "title": "First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)",
            "phase": "Phase I",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome",
            "member_states": "Denmark; Spain",
            "decision_date": "16/01/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523101-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523088-39-00",
            "title": "A Phase 1 Study for ZW251 in Participants with Solid Tumors.",
            "phase": "Phase I",
            "lead_sponsor": "Zymeworks Bc Inc.",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Portugal; Ireland; Spain",
            "decision_date": "15/01/2026",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523088-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522731-34-00",
            "title": "A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Ovarian cancer\nPrimary peritoneal cancer\nFallopian tube cancer",
            "member_states": "Spain; Ireland; Portugal",
            "decision_date": "15/01/2026",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522731-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521614-26-00",
            "title": "A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in\nAdult Participants with Advanced Solid Tumors Previously Treated with Standard of Care\nTherapy",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Spain",
            "decision_date": "15/01/2026",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521614-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521858-42-00",
            "title": "An open-label, parallel, Phase 3, two-arm study to investigate the efficacy and safety of fitusiran \nprophylaxis in male participants aged 1 to less than 12 years with hemophilia A or B with or without inhibitory antibodies to Factors VIII or IX",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Hemophilia",
            "member_states": "Belgium; Italy; Romania; Germany; Hungary; Spain; Poland",
            "decision_date": "15/01/2026",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521858-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523058-16-00",
            "title": "A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors CLEER Trial (Chemotherapy Longevity by Evading EGFR Inhibitor Reactions)",
            "phase": "Phase II",
            "lead_sponsor": "Hoth Therapeutics Inc.",
            "conditions": "Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors",
            "member_states": "Spain; Hungary; Poland",
            "decision_date": "15/01/2026",
            "enrolled": "98",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523058-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521845-26-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "BP-I mania or mania with mixed features",
            "member_states": "Romania; Poland; France; Italy; Denmark; Bulgaria",
            "decision_date": "15/01/2026",
            "enrolled": "185",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521845-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522767-15-00",
            "title": "HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study",
            "phase": "Phase III",
            "lead_sponsor": "Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting",
            "conditions": "Acute Myeloid Leukemia",
            "member_states": "Belgium; Netherlands; Germany; Austria; Denmark; Estonia; Finland; Ireland; Italy; Lithuania; Spain; Sweden; Norway; Poland",
            "decision_date": "15/01/2026",
            "enrolled": "423",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522767-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519326-20-00",
            "title": "A phase 2, three-arm, randomized study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 pembrolizumab, in stage III and IV unresectable melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors and with presence of injectable metastases",
            "phase": "Phase II",
            "lead_sponsor": "Philogen S.p.A.",
            "conditions": "Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy",
            "member_states": "Italy; Germany",
            "decision_date": "14/01/2026",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519326-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521917-24-00",
            "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to\nCarboplatin and Pembrolizumab, Compared to Standard of Care Platinum and\nPembrolizumab and 5-FU, in Participants with Treatment-Na\u00efve Recurrent/Metastatic\nHead and Neck Squamous Cell Carcinoma",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Treatment-Na\u00efve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
            "member_states": "Italy; Portugal; Spain; Romania; Hungary; France; Czechia; Germany; Netherlands; Austria; Poland; Belgium",
            "decision_date": "14/01/2026",
            "enrolled": "192",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521917-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521503-43-00",
            "title": "A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Atopic dermatitis",
            "member_states": "France; Germany; Poland; Czechia; Bulgaria",
            "decision_date": "14/01/2026",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521503-43-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522398-12-00",
            "title": "A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)",
            "phase": "Phase I",
            "lead_sponsor": "Astellas Pharma Global Development Inc.",
            "conditions": "Locally advanced or metastatic NSCLC",
            "member_states": "France; Spain",
            "decision_date": "14/01/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522398-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520353-21-00",
            "title": "A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.",
            "phase": "Phase I",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Myeloproliferative Neoplasms",
            "member_states": "Norway; Germany; France; Italy",
            "decision_date": "14/01/2026",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520353-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523758-15-00",
            "title": "A Phase 1/2, multicentre, open-label clinical trial of DT-7012 as monotherapy and in combination with an immune checkpoint inhibitor in participants with selected advanced solid tumours",
            "phase": "Phase I/II",
            "lead_sponsor": "Domain Therapeutics Australia Pty Limited",
            "conditions": "Cancer",
            "member_states": "France",
            "decision_date": "14/01/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523758-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524274-41-00",
            "title": "OPEN-LABEL PALATABILITY STUDY OF A NOVEL ORODISPERSIBLE PARACETAMOL/IBUPROFEN FORMULATION AFTER A SINGLE ORAL ADMINISTRATION IN HEALTHY SUBJECTS",
            "phase": "Phase I",
            "lead_sponsor": "Farmalider S.A.",
            "conditions": "Healthy volunteers",
            "member_states": "Spain",
            "decision_date": "14/01/2026",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524274-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521514-26-00",
            "title": "A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1",
            "member_states": "Greece; Ireland; France; Belgium; Czechia; Hungary; Austria; Spain; Sweden; Germany; Poland; Denmark; Italy",
            "decision_date": "14/01/2026",
            "enrolled": "295",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521514-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523551-54-00",
            "title": "Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.",
            "phase": "Phase IV",
            "lead_sponsor": "Azienda Sanitaria Universitaria Friuli Centrale",
            "conditions": "PSORIATIC ARTHRITIS PATIENTS IN CLINICAL TRANSITION",
            "member_states": "Italy",
            "decision_date": "14/01/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523551-54-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522232-13-00",
            "title": "A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Sepsis-associated acute kidney injury (AKI)",
            "member_states": "Germany; France; Spain; Italy; Belgium; Czechia; Greece; Denmark; Hungary",
            "decision_date": "14/01/2026",
            "enrolled": "66",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522232-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523620-44-02",
            "title": "BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology",
            "phase": "Phase IV",
            "lead_sponsor": "Semmelweis University",
            "conditions": "non small cell lung cancer (NSCLC), renal cell carcinoma, small cell lung cancer (SCLC), tumors of the head and neck region, bladder carcinoma, malignant melanoma",
            "member_states": "Hungary",
            "decision_date": "14/01/2026",
            "enrolled": "1000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523620-44-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521912-21-00",
            "title": "A multi- center, randomized, double-blind, placebo-controlled parallel\u2013group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a)",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Cardiovascular risk reduction in participants with elevated Lp(a)",
            "member_states": "Germany",
            "decision_date": "13/01/2026",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521912-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522370-36-00",
            "title": "A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Kymera Therapeutics Inc.",
            "conditions": "Moderate to Severe Atopic Dermatitis",
            "member_states": "Czechia; Germany; Poland",
            "decision_date": "13/01/2026",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522370-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523898-42-00",
            "title": "The SURF trial: Optimizing Surgical excision Using Real-time Fluorescence imaging with indocyanine green",
            "phase": "Phase III",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)",
            "member_states": "Netherlands",
            "decision_date": "13/01/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523898-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523119-12-00",
            "title": "Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy.\nA prospective, international, randomized, double-blind, placebo-controlled, multicentre,\nphase II-III trial.",
            "phase": "Phase III",
            "lead_sponsor": "ROXALL Medizin GmbH",
            "conditions": "Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to house dust mites (HDM) for at least one year according to the Allergic Rhinitis and its Impact on Asthma (ARIA, Bousquet et al., 2008) guideline",
            "member_states": "Germany; Spain",
            "decision_date": "13/01/2026",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523119-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523885-25-00",
            "title": "A Single-Center, Double-Blind, Randomized, Placebo Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses of ACI-19764 in Healthy Participants and in Participants with Cardiovascular Risk Factors",
            "phase": "Phase I",
            "lead_sponsor": "AC Immune S.A.",
            "conditions": "Healthy Volunteers, Participants with diabetes and/or obesity",
            "member_states": "Netherlands",
            "decision_date": "13/01/2026",
            "enrolled": "114",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523885-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522084-15-00",
            "title": "A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36",
            "phase": "Phase III",
            "lead_sponsor": "IRCCS Istituto Nazionale Tumori Fondazione Pascale",
            "conditions": "metastatic NSCLC patients",
            "member_states": "Italy",
            "decision_date": "13/01/2026",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522084-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-510075-63-00",
            "title": "A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-associated tracheobronchitis (AMIVAT)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire De Tours",
            "conditions": "Patients with ventilator-associated tracheobronchitis",
            "member_states": "France",
            "decision_date": "12/01/2026",
            "enrolled": "250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-510075-63-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523635-19-00",
            "title": "Open-label proof-of-concept trial of topical delgocitinib in patients with facial vitiligo",
            "phase": "Phase II",
            "lead_sponsor": "Gentofte Hospital",
            "conditions": "Vitiligo",
            "member_states": "Denmark",
            "decision_date": "12/01/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523635-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522967-13-00",
            "title": "A multicenter randomized, controlled, single-blind, adaptive phase IV clinical trial to evaluate the efficiency and effectiveness of a pre-emptive pharmacogenetic strategy for antidepressant selection in patients with depressive disorder: The PREDICT adaptive clinical trial.",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz",
            "conditions": "Depressive disorder",
            "member_states": "Spain",
            "decision_date": "11/01/2026",
            "enrolled": "240",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522967-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519663-17-01",
            "title": "Evaluation of the Pharmacokinetics of Subcutaneous Administration of Piperacillin/Tazobactam: An Open-Label, Multicentric, Non-Inferiority Randomized Clinical Trial (STUPITA01)",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Sanitaria Universitaria Friuli Centrale",
            "conditions": "Infectious disease",
            "member_states": "Italy",
            "decision_date": "09/01/2026",
            "enrolled": "240",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519663-17-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522513-30-00",
            "title": "A trial to learn how well different doses of andexanet alfa work and how they affect blood clotting throughout the body in healthy adults who have taken an FXa inhibitor",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Healthy Volunteers",
            "member_states": "Germany",
            "decision_date": "09/01/2026",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522513-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522955-25-00",
            "title": "Next Generation StaR TREC - Save the rectum by watchful waiting after (chemo)Radiotherapy or Total mesorectal excision for early REctal Cancer?",
            "phase": "Phase IV",
            "lead_sponsor": "Vaestra Goetalandsregionen",
            "conditions": "Rectal cancer",
            "member_states": "Sweden",
            "decision_date": "09/01/2026",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522955-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521043-20-00",
            "title": "A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors",
            "phase": "Phase III",
            "lead_sponsor": "Exelixis Inc.",
            "conditions": "Neuroendocrine tumors",
            "member_states": "France; Poland; Netherlands; Belgium; Germany; Spain; Italy; Austria",
            "decision_date": "09/01/2026",
            "enrolled": "172",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521043-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523706-32-00",
            "title": "To evaluate the pharmacokinetics and safety of nolasiban",
            "phase": "Phase I",
            "lead_sponsor": "ReproNovo ApS",
            "conditions": "not applicable (submitted trial is a pharmacokinetic study in healthy subjects)",
            "member_states": "Czechia",
            "decision_date": "09/01/2026",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523706-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522091-84-00",
            "title": "NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab \u2013 A randomized, double-blind, placebo-controlled, non-comparative Phase II study",
            "phase": "Phase II",
            "lead_sponsor": "Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH",
            "conditions": "Merkel Cell Carcinoma",
            "member_states": "Germany",
            "decision_date": "09/01/2026",
            "enrolled": "135",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522091-84-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522966-61-00",
            "title": "A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in peritoneal dialysis patients.",
            "phase": "Phase I",
            "lead_sponsor": "OPTERION Health AG",
            "conditions": "Chronic kidney disease",
            "member_states": "Latvia",
            "decision_date": "09/01/2026",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522966-61-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523115-11-00",
            "title": "A study to compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 with US-Dupixent\u00ae, and EU-Dupixent\u00ae in Healthy Adult Participants.",
            "phase": "Phase I",
            "lead_sponsor": "Chong Kun Dang Pharmaceutical Corp.",
            "conditions": "Phase I study in healthy participants. Intended indication: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease",
            "member_states": "Germany",
            "decision_date": "09/01/2026",
            "enrolled": "335",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523115-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523086-22-00",
            "title": "An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination with Other Anti-Tumor Agents, in Patients with Advanced KRAS Mutant Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Treeline Biosciences Inc.",
            "conditions": "Locally advanced or metastatic solid tumors",
            "member_states": "Spain",
            "decision_date": "07/01/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523086-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523051-64-00",
            "title": "A multicenter, double-blind, randomized, placebo-controlled, parallel-group, twelve-week treatment proof-of-concept trial to explore the efficacy and safety of IDOR-1117-2520 in adults with moderate to severe chronic plaque psoriasis with or without psoriatic arthritis.",
            "phase": "Phase II",
            "lead_sponsor": "Idorsia Pharmaceuticals Ltd.",
            "conditions": "Moderate to severe chronic plaque psoriasis",
            "member_states": "Romania; Bulgaria",
            "decision_date": "07/01/2026",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523051-64-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521602-18-00",
            "title": "Efficacy and safety of Remimazolam compared to Ketamine and Propofol in Rapid Sequence Induction. A monocentric pilot randomised-controlled study",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "Rapid Sequence Induction in operating room",
            "member_states": "France",
            "decision_date": "06/01/2026",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521602-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521696-31-00",
            "title": "DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone receptor-positive localized breast cancer",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Poitiers",
            "conditions": "HR+, HER2- breast cancer at high risk of recurrence",
            "member_states": "France",
            "decision_date": "06/01/2026",
            "enrolled": "235",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521696-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521420-30-00",
            "title": "Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)",
            "phase": "Phase I/II",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Inflammatory Bowel Disease (IBD)",
            "member_states": "Netherlands",
            "decision_date": "06/01/2026",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521420-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521819-39-00",
            "title": "Prospective, Open-Label, Single-Center Pilot Study on the Efficacy of Daily Tadalafil in Early-Stage Parkinson\u2019s Disease",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Parkinson's disease",
            "member_states": "Netherlands",
            "decision_date": "05/01/2026",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521819-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522673-11-00",
            "title": "Single-center phase I/IIa study of infusion of autologous peripheral blood T cells expanded and genetically modified by Sleeping Beauty family transposons to express a chimeric antigen receptor with anti-CD19 specificity conjugated with the 4-1BB costimulatory region and CD3z and huEGFRt signal transmission (TranspoCART19) in patients with CD19+ acute lymphoblastic leukemia resistant or refractory to treatment",
            "phase": "Phase I/II",
            "lead_sponsor": "Clinica Universidad De Navarra",
            "conditions": "refractory or resistant CD19+ acute lymphoblastic leukemia",
            "member_states": "Spain",
            "decision_date": "02/01/2026",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522673-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521841-26-00",
            "title": "Inhibiting the anti-apoptotic factor, BCL-2, at the time of ART initiation to promote apoptosis of HIV-infected cells and restrict the seeding of the HIV reservoir: An investigator-initiated randomised, controlled, open-label clinical trial (The INITIATE Study)",
            "phase": "Phase I/II",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "HIV-1 infection",
            "member_states": "Denmark; Spain",
            "decision_date": "02/01/2026",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521841-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522848-40-00",
            "title": "Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. \"The EX-AI study\"",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Grupo Espanol De Investigacion En Cancer De Mama",
            "conditions": "Early Breast Cancer",
            "member_states": "Spain",
            "decision_date": "29/12/2025",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522848-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514661-19-01",
            "title": "A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Stemline Therapeutics Inc.",
            "conditions": "Advanced ER+/HER2- Breast Cancer",
            "member_states": "Spain",
            "decision_date": "29/12/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514661-19-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520086-31-00",
            "title": "HYDrochlorothiazidE compared to valsartan to treat arterial hypertension in patients with Hypertrophic obstructive CardioMyopathy \u2013 the multicenter, randomized, double-blind, controlled, crossover HYDE-HCM Trial",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Graz",
            "conditions": "Hypertrophic cardiomyopathy",
            "member_states": "Austria",
            "decision_date": "29/12/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520086-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522631-34-00",
            "title": "J2A-MC-GZPT A Phase 3 Study to Investigate the Efficacy and Safety of Orfor-glipron Once Daily in Participants Who Have Obesity or Overweight and Osteoar-thritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Pla-cebo-Controlled Trial\nList of Intervention-Specific Appendices (ISAs):\nISA1 (GZT1): A Study to Investigate Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee\nISA2 (GZT2): A Study to Investigate Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Osteoarthritis",
            "member_states": "Germany; Spain",
            "decision_date": "29/12/2025",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522631-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523469-79-00",
            "title": "A Study to Investigate ARV-027 in Healthy Male Participants and Participants with Spinal and Bulbar Muscular Atrophy",
            "phase": "Phase I",
            "lead_sponsor": "Arvinas Operations Inc.",
            "conditions": "Spinal and Bulbar Muscular Atrophy",
            "member_states": "Netherlands",
            "decision_date": "24/12/2025",
            "enrolled": "106",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523469-79-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523690-41-00",
            "title": "A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Chronic Obstructive Pulmonary Disease (COPD)",
            "member_states": "France",
            "decision_date": "24/12/2025",
            "enrolled": "82",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523690-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523374-17-01",
            "title": "Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio Hospital Universitari Vall D\u2019Hebron Institut De Recerca",
            "conditions": "Type 2 diabetes",
            "member_states": "Spain",
            "decision_date": "23/12/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523374-17-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508784-68-00",
            "title": "A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Na\u00efve Adult Patients with Metastatic Uveal Melanoma",
            "phase": "Phase III",
            "lead_sponsor": "Replimune Inc.",
            "conditions": "metastatic uveal melanoma",
            "member_states": "Germany; Italy; France; Spain; Poland",
            "decision_date": "23/12/2025",
            "enrolled": "98",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508784-68-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522495-84-00",
            "title": "A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)",
            "phase": "Phase I/II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Cancer \u2013 Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)",
            "member_states": "Spain",
            "decision_date": "23/12/2025",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522495-84-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521729-33-00",
            "title": "C5951001- A Phase 1 Study of PF-08046876 in Participants with Advanced Solid Tumors.",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "advanced solid tumors",
            "member_states": "Spain",
            "decision_date": "23/12/2025",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521729-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522139-33-00",
            "title": "An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants with Locally Advanced or Metastatic Solid Tumours.",
            "phase": "Phase I/II",
            "lead_sponsor": "Ipsen Pharma",
            "conditions": "Advanced or metastatic solid tumours",
            "member_states": "France; Spain",
            "decision_date": "23/12/2025",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522139-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520675-86-00",
            "title": "A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)",
            "phase": "Phase II",
            "lead_sponsor": "CatalYm GmbH",
            "conditions": "Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A)",
            "member_states": "Germany; France; Italy; Spain",
            "decision_date": "23/12/2025",
            "enrolled": "59",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520675-86-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522683-32-00",
            "title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early-Stage Parkinson\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Early-Stage Parkinson\u2019s Disease (PD)",
            "member_states": "France; Austria; Portugal; Netherlands; Poland; Germany; Spain; Denmark; Italy",
            "decision_date": "23/12/2025",
            "enrolled": "405",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522683-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520027-88-00",
            "title": "PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER\u200b (THE CADILLAC STUDY)",
            "phase": "Phase II",
            "lead_sponsor": "Medica Scientia Innovation Research S.L.",
            "conditions": "Patients with hormone receptor-positive (HR+) breast cancer",
            "member_states": "Spain; Germany",
            "decision_date": "23/12/2025",
            "enrolled": "131",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520027-88-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523010-89-00",
            "title": "Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)",
            "phase": "Phase I",
            "lead_sponsor": "35Pharma Inc.",
            "conditions": "Pulmonary arterial hypertension",
            "member_states": "Hungary; Spain; Poland; Germany; Czechia",
            "decision_date": "23/12/2025",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523010-89-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522698-13-00",
            "title": "Phase IV open-label clinical trial of the immunogenicity and safety of standard dose trivalent inactivated influenza vaccine (Influvac) in a population of people with obesity",
            "phase": "Phase IV",
            "lead_sponsor": "Region Stockholm \u2013 SLSO",
            "conditions": "Influenza, Obesity, Type 2 diabetes",
            "member_states": "Sweden",
            "decision_date": "23/12/2025",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522698-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522333-61-00",
            "title": "A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa",
            "phase": "Phase II",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Hidradenitis suppurativa",
            "member_states": "Poland; Hungary; Netherlands; Germany; Czechia; Spain; France; Italy; Greece",
            "decision_date": "22/12/2025",
            "enrolled": "132",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522333-61-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523327-21-00",
            "title": "TRAMORNOT: Tramadol versus morphine in postoperative analgesia after laparoscopic abdominal surgery: a randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire Amiens Picardie",
            "conditions": "Postoperative pain following scheduled major laparoscopic abdominal surgery",
            "member_states": "France",
            "decision_date": "22/12/2025",
            "enrolled": "140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523327-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523204-68-00",
            "title": "A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer",
            "phase": "Phase II",
            "lead_sponsor": "Jazz Pharmaceuticals Ireland Limited",
            "conditions": "HER2-positive breast cancer",
            "member_states": "Italy; Spain; Germany",
            "decision_date": "22/12/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523204-68-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511255-17-00",
            "title": "Pressurized intrathoracic aerosol chemotherapy (PITAC) in patients with malignant pleural effusion: a single-center phase II trial. PITAC_ MaPEPi",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Ospedaliero Universitaria Pisana",
            "conditions": "Pleural carcinosis",
            "member_states": "Italy",
            "decision_date": "22/12/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511255-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522046-42-00",
            "title": "A Phase 3, multicentre, randomised (1:1), parallel-group, active-controlled, central reader colonoscopist-blind study to evaluate the bowel cleansing efficacy, safety, tolerability, palatability, and acceptability of PLENVU\u00ae as compared to\nsodium picosulfate in paediatric participants from 1 to < 18 years of age in preparation for colonoscopy (CLARITY)",
            "phase": "Phase III",
            "lead_sponsor": "Norgine Limited",
            "conditions": "Colonic disease",
            "member_states": "Poland; Netherlands; Hungary; Spain; Italy; Belgium; Germany; Croatia; Portugal",
            "decision_date": "22/12/2025",
            "enrolled": "249",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522046-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523430-14-00",
            "title": "A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Psoriasis",
            "member_states": "Netherlands",
            "decision_date": "22/12/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523430-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522105-38-00",
            "title": "A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)",
            "phase": "Phase III",
            "lead_sponsor": "Mirum Pharmaceuticals Inc.",
            "conditions": "Chronic Hepatitis Delta Infection",
            "member_states": "Belgium; Hungary; Bulgaria",
            "decision_date": "22/12/2025",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522105-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521117-88-00",
            "title": "A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Cardiovascular Disease",
            "member_states": "France; Denmark; Germany; Spain; Italy; Netherlands",
            "decision_date": "22/12/2025",
            "enrolled": "178",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521117-88-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515765-34-00",
            "title": "A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer",
            "phase": "Phase III",
            "lead_sponsor": "BioNTech SE",
            "conditions": "English\nFirst-line extensive-stage small-cell lung cancer (ES-SCLC)",
            "member_states": "Poland; Spain; France; Italy; Germany; Romania; Netherlands",
            "decision_date": "22/12/2025",
            "enrolled": "209",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515765-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523846-29-00",
            "title": "A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV",
            "phase": "Phase I",
            "lead_sponsor": "BioNTech SE",
            "conditions": "HIV-1 infection",
            "member_states": "Germany",
            "decision_date": "22/12/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523846-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514052-32-00",
            "title": "Phase Ib, non-randomized, single-arm, open-label, single-center clinical trial to evaluate the safety of the first-in-human administration of the combination of dendritic cell (DC) immunization pulsed with tumor lysate and CAR-T cells targeting IL13Ra2 in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)",
            "phase": "Phase I",
            "lead_sponsor": "Fundacio Sant Joan De Deu",
            "conditions": "Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)",
            "member_states": "Spain",
            "decision_date": "22/12/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514052-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520467-40-00",
            "title": "Phase 1/2 Study of Intravesical MK-3120 in BCG-Na\u00efve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors",
            "member_states": "Belgium; Greece; Austria; Spain; Norway; Netherlands; Italy; France",
            "decision_date": "22/12/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520467-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522269-30-00",
            "title": "Normothermic intraperitoneal chemotherapy (NIPEC) with carboplatin following cytoreductive surgery in elderly and fragile ovarian cancer patients: a feasibility study",
            "phase": "Phase II",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Ovarian cancer",
            "member_states": "Denmark",
            "decision_date": "22/12/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522269-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519369-24-00",
            "title": "C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER",
            "member_states": "Belgium; Finland; France; Germany; Netherlands; Bulgaria; Spain; Slovakia; Italy; Czechia; Poland; Greece",
            "decision_date": "22/12/2025",
            "enrolled": "434",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519369-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522243-17-00",
            "title": "A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.",
            "phase": "Phase I",
            "lead_sponsor": "Philogen S.p.A.",
            "conditions": "Advanced solid tumors, specifically: \n\u2022\tmetastatic clear cell renal carcinoma\n\u2022\tproficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma\n\u2022\tlocally advanced or metastatic pancreatic adenocarcinoma",
            "member_states": "Italy",
            "decision_date": "22/12/2025",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522243-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522257-19-00",
            "title": "Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)",
            "phase": "Phase III",
            "lead_sponsor": "Tg Therapeutics Inc.",
            "conditions": "Relapsing Multiple Sclerosis",
            "member_states": "Poland; Slovakia",
            "decision_date": "22/12/2025",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522257-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522653-19-00",
            "title": "(ASK-PD0-CS002) Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants with Parkinson\u2019s Disease or Multiple System Atrophy",
            "phase": "Phase IV",
            "lead_sponsor": "Askbio Inc.",
            "conditions": "Multiple System Atrophy, Parkinson's Disease",
            "member_states": "Poland",
            "decision_date": "22/12/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522653-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523166-24-00",
            "title": "SPRAYDYE-Trial - A phase I/II study to assess the efficacy, safety and tolerability of topically applied 6qc-ICG, a cathepsin-activatable fluorescent probe, for real-time intraoperative resection margin assessment in breast conserving surgery",
            "phase": "Phase I/II",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Breast cancer",
            "member_states": "Netherlands",
            "decision_date": "22/12/2025",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523166-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522309-40-00",
            "title": "A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.",
            "phase": "Phase II",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Non-segmental vitiligo",
            "member_states": "Poland; Italy; Spain; France",
            "decision_date": "19/12/2025",
            "enrolled": "151",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522309-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523587-20-00",
            "title": "A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.",
            "phase": "Phase I",
            "lead_sponsor": "Gruenenthal GmbH",
            "conditions": "Not applicable for phase I study",
            "member_states": "France",
            "decision_date": "19/12/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523587-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523875-48-00",
            "title": "Open-labelled, single-centre investigation of safety and tolerability of multiple ascending doses of nebulised SS0331 in healthy participants followed by investigation of preliminary efficacy of nebulised SS0331 in airway-infected patients with chronic airway infections",
            "phase": "Phase I/II",
            "lead_sponsor": "Softox Solutions AS",
            "conditions": "Chronic airway infections",
            "member_states": "Denmark",
            "decision_date": "19/12/2025",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523875-48-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524218-27-00",
            "title": "An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon\u00ae retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fed conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Vianex S.A.",
            "conditions": "treatment of myasthenia gravis",
            "member_states": "Czechia",
            "decision_date": "19/12/2025",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524218-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522400-24-00",
            "title": "IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Metastatic urothelial cancer",
            "member_states": "Ireland; Belgium; Germany; Italy; Norway; Spain; Austria; Sweden; France; Romania; Czechia",
            "decision_date": "19/12/2025",
            "enrolled": "207",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522400-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522361-30-00",
            "title": "A Phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G variant.",
            "phase": "Phase III",
            "lead_sponsor": "Khondrion B.V.",
            "conditions": "Primary Mitochondrial Disease, Mitochondrial DNA 3243A>G variant and Associated Phenotypes (MIDD, MELAS, Multi System Phenotypes",
            "member_states": "Italy; Germany; France; Netherlands; Denmark",
            "decision_date": "19/12/2025",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522361-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522632-14-00",
            "title": "A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications",
            "phase": "Phase II",
            "lead_sponsor": "Synthekine Inc.",
            "conditions": "Non-small cell lung cancer (NSCLC)",
            "member_states": "Ireland; Poland; Spain; Italy",
            "decision_date": "19/12/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522632-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522160-32-00",
            "title": "A single arm, open label, multicenter, single-dose, phase 2b clinical study evaluating efficacy and safety of gene therapy using autologous CD34+ hematopoietic stem cells transduced with the GLOBE lentiviral vector using an improved transduction protocol in subjects with transfusion-dependent beta-thalassemia.",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione Telethon Ets, San Raffaele Hospital",
            "conditions": "transfusion-dependent beta-thalassemia",
            "member_states": "Italy",
            "decision_date": "18/12/2025",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522160-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523278-18-00",
            "title": "Phase IV, single-center, randomized, crossover clinical trial to validate the use of gadopiclenol versus gadobutrol in the evaluation of magnetic resonance imaging (MRI) diagnosis of perianal fistula associated with Crohn's disease",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio Hospital Universitari Vall D\u2019Hebron Institut De Recerca",
            "conditions": "Perianal fistula associated with Crohn's disease",
            "member_states": "Spain",
            "decision_date": "18/12/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523278-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521902-17-00",
            "title": "Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)",
            "phase": "Phase I/II",
            "lead_sponsor": "Idp Discovery Pharma S.L.",
            "conditions": "Unresectable/metastatic Small cell Lung Cancer (SCLC)",
            "member_states": "Spain",
            "decision_date": "18/12/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521902-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522996-27-00",
            "title": "A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC)",
            "phase": "Phase III",
            "lead_sponsor": "Groupe Oncologie Radiotherapie Tete Cou",
            "conditions": "recurrent and/or metastatic squamous cell carcinoma of the head and neck",
            "member_states": "France; Spain; Belgium",
            "decision_date": "18/12/2025",
            "enrolled": "310",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522996-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521873-15-00",
            "title": "TulmiSTAR-02:  A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Metastatic hormone-sensitive prostate cancer",
            "member_states": "Hungary; Spain; Italy; Germany; France",
            "decision_date": "18/12/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521873-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523207-29-00",
            "title": "Evaluation of postoperative recovery when combining intravenous lidocaine with ropivacaine infiltration in laparoscopic colorectal oncologic surgery: a randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire Amiens Picardie",
            "conditions": "colorectal cancer laparoscopic surgery",
            "member_states": "France",
            "decision_date": "17/12/2025",
            "enrolled": "182",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523207-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516660-28-01",
            "title": "A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial",
            "phase": "Phase I",
            "lead_sponsor": "Vall D Hebron Institute Of Oncology",
            "conditions": "Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)",
            "member_states": "Spain",
            "decision_date": "17/12/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516660-28-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522798-13-00",
            "title": "Sodium selenite in patients with advanced carcinoma: A phase I/II study with 99 hours of continuous selenite treatment followed by chemotherapy",
            "phase": "Phase I/II",
            "lead_sponsor": "Karolinska University Hospital",
            "conditions": "Advanced carcinoma",
            "member_states": "Sweden",
            "decision_date": "17/12/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522798-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523791-24-00",
            "title": "A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in the treatment of multiple sclerosis, and the effect of IMU 838 on the absorption and elimination of rosuvastatin.",
            "phase": "Phase I",
            "lead_sponsor": "Immunic AG",
            "conditions": "Multiple sclerosis",
            "member_states": "Netherlands",
            "decision_date": "17/12/2025",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523791-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522963-14-00",
            "title": "An Exploratory, First-in-Human, study to investigate the safety and preliminary efficacy of InvivoLPrint-U-Therapy, a combination of an advanced therapy medicinal product (ATMP) of expanded autologous urothelial cells with an in vivo bioprinter for administration during orthotopic neobladder surgery",
            "phase": "Phase I",
            "lead_sponsor": "Phosprint S.A.",
            "conditions": "\u039cuscle-invasive bladder cancer (MIBC) patients, eligible for neobladder reconstruction following radical cystectomy",
            "member_states": "Greece",
            "decision_date": "17/12/2025",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522963-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521244-38-00",
            "title": "An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12-month Treatment with Migalastat in Pediatric Subjects (aged 2 to < 12 years) with Fabry Disease and Amenable GLA Variants",
            "phase": "Phase III",
            "lead_sponsor": "Amicus Therapeutics Inc.",
            "conditions": "Fabry disease",
            "member_states": "Spain; Germany; Belgium",
            "decision_date": "17/12/2025",
            "enrolled": "3",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521244-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515333-14-03",
            "title": "Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoing oncologic surgery (POST CARE Trial)",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione IRCCS Istituto Nazionale Dei Tumori",
            "conditions": "Patients scheduled for major surgery for oncologic indication",
            "member_states": "Italy",
            "decision_date": "17/12/2025",
            "enrolled": "83",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515333-14-03",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524182-25-00",
            "title": "Waiting on Atrial fibrillation Intervention Therapy (WAIT) Study",
            "phase": "Phase IV",
            "lead_sponsor": "Karolinska University Hospital",
            "conditions": "Atrial fibrillation",
            "member_states": "Sweden",
            "decision_date": "17/12/2025",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524182-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523712-37-00",
            "title": "Effect of COV2 vaccine formulation on the ability to generate antibodies against coronavirus",
            "phase": "Phase I",
            "lead_sponsor": "Rokote Laboratories Finland Oy",
            "conditions": "Booster immunisation against COVID-19 disease caused by SARS-COV-2 Virus",
            "member_states": "Finland",
            "decision_date": "17/12/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523712-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522026-13-00",
            "title": "A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2a trial to evaluate the efficacy and safety of BP1.4979 in adult participants with obsessive compulsive disorder",
            "phase": "Phase II",
            "lead_sponsor": "Bioprojet Pharma",
            "conditions": "Obsessive compulsive disorder",
            "member_states": "Portugal; Spain; Italy; Poland",
            "decision_date": "16/12/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522026-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521795-58-00",
            "title": "Contrast Strategy In Fenestrated EndoVascular Aneurysm Repair Randomized Control Trial",
            "phase": "Phase III",
            "lead_sponsor": "Region Skane",
            "conditions": "Abdominal aortic aneurysm",
            "member_states": "Sweden; Denmark",
            "decision_date": "16/12/2025",
            "enrolled": "293",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521795-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523265-15-00",
            "title": "A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid Arthritis",
            "phase": "Phase I",
            "lead_sponsor": "Candid Therapeutics Inc.",
            "conditions": "Seropositive Rheumatoid Arthritis",
            "member_states": "Romania",
            "decision_date": "16/12/2025",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523265-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522093-36-00",
            "title": "C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Cancer cachexia",
            "member_states": "Slovakia; Italy; Belgium; Germany; Spain; France; Bulgaria; Poland",
            "decision_date": "16/12/2025",
            "enrolled": "289",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522093-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523094-42-00",
            "title": "Effects of butyrate enemas on postoperative intestinal motility disorders in Hirschsprung\u2019s disease",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Marseille",
            "conditions": "Hirschsprung's disease",
            "member_states": "France",
            "decision_date": "16/12/2025",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523094-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523135-19-00",
            "title": "A study in healthy men to test how itraconazole influences the amount of BI 764198 in the blood",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "16/12/2025",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523135-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-507597-40-00",
            "title": "A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND FEASIBILITY OF POINT-OF-CARE HUMAN-CD19 TARGETING CAR T-CELLS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (PACMAN)",
            "phase": "Phase I/II",
            "lead_sponsor": "Prinses Maxima Centrum voor Kinderoncologie B.V.",
            "conditions": "B-cell precursor ALL, B-cell Non Hodgkin Lymphoma",
            "member_states": "Netherlands",
            "decision_date": "16/12/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-507597-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523965-97-00",
            "title": "The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients",
            "phase": "Phase II",
            "lead_sponsor": "Turku University Hospital",
            "conditions": "Non small cell lung cancer",
            "member_states": "Finland",
            "decision_date": "16/12/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523965-97-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521762-99-00",
            "title": "Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants \u2013 a multicentre randomised placebo-controlled clinical trial",
            "phase": "Phase III",
            "lead_sponsor": "University Medical Center Hamburg-Eppendorf",
            "conditions": "acute ischemic stroke",
            "member_states": "Germany",
            "decision_date": "16/12/2025",
            "enrolled": "668",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521762-99-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522184-15-00",
            "title": "An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies",
            "phase": "Phase I/II",
            "lead_sponsor": "Ipsen Pharma",
            "conditions": "Advanced Solid Tumor, Metastatic Solid Tumor",
            "member_states": "Spain; France",
            "decision_date": "16/12/2025",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522184-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522768-33-00",
            "title": "Is [18F]-DPA-714 PET a good marker of neuroinflammation in autoimmune encephalitis? (EAI-714)",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "autoimmune encephalitis",
            "member_states": "France",
            "decision_date": "15/12/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522768-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522187-32-01",
            "title": "Assessing residual inflammation and macrophage presence in lupus nephritis after 3 months of intensified treatment with prednisolone, mycofenolate mofetil and voclosporin as compared to mycofenolate mofetil and prednisolone: an open label randomized controlled trial (MAPLE study)",
            "phase": "Phase IV",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Lupus Nephritis",
            "member_states": "Netherlands",
            "decision_date": "15/12/2025",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522187-32-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522701-38-00",
            "title": "EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPERREFLECTIVE MATERIAL ASSOCIATED WITH TYPE 2 OR MIXED NEOVASCULAR MEMBRANES ASSESSED BY MULTIMODAL IMAGING",
            "phase": "Phase IV",
            "lead_sponsor": "Asociacion Instituto De Investigacion Sanitaria Biobizkaia",
            "conditions": "SUBRETINAL HYPERREFLECTIVE MATERIAL",
            "member_states": "Spain",
            "decision_date": "15/12/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522701-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523075-32-00",
            "title": "FINE-START; A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in participants with chronic kidney disease not using renin-angiotensin-system inhibitors",
            "phase": "Phase III",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "chronic kidney disease",
            "member_states": "Spain",
            "decision_date": "15/12/2025",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523075-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523714-92-00",
            "title": "Comparison of treatment efficacy in the patients with Systemic sclerOsis: dapagliFlozin vs. Tocilizumab \u2013 a randomized head to head study",
            "phase": "Phase II",
            "lead_sponsor": "Centrum Medyczne Ksztalcenia Podyplomowego",
            "conditions": "Systemic Sclerosis",
            "member_states": "Poland",
            "decision_date": "15/12/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523714-92-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523214-83-00",
            "title": "The effect of transdermal 17-\u03b2-estradiol/progesterone supplementation on glucose regulation in peri- and postmenopausal women with type 1 and type 2 diabetes",
            "phase": "Phase IV",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Diabetes Mellitus, (peri) Menopause",
            "member_states": "Netherlands",
            "decision_date": "15/12/2025",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523214-83-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521113-13-00",
            "title": "A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "Biohaven Therapeutics Ltd.",
            "conditions": "Early Parkinson\u2019s Disease",
            "member_states": "Germany; France; Italy; Belgium; Czechia; Poland; Austria; Netherlands; Spain; Portugal",
            "decision_date": "15/12/2025",
            "enrolled": "713",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521113-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522529-36-00",
            "title": "Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vomiting. A prospective, double-blind, randomized trial in laparoscopic surgery.",
            "phase": "Phase III",
            "lead_sponsor": "Region Vaesternorrland, Umea University",
            "conditions": "Post-operative nausea and vomiting (PONV)",
            "member_states": "Sweden",
            "decision_date": "15/12/2025",
            "enrolled": "220",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522529-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523676-23-00",
            "title": "The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention \u2013 A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "ST-elevation acute coronary syndrome",
            "member_states": "Austria",
            "decision_date": "14/12/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523676-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521513-14-00",
            "title": "A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression \u201c(MAESTRA 1)\u201d",
            "phase": "Phase II",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Ovarian Cancer",
            "member_states": "Spain; Belgium",
            "decision_date": "12/12/2025",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521513-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521989-95-00",
            "title": "Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Oncomatryx Biopharma S.L.",
            "conditions": "Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer",
            "member_states": "Spain",
            "decision_date": "12/12/2025",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521989-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522936-14-00",
            "title": "A randomized, double-blind, placebo-controlled, multicentre trial, assessing the impact of ferric carboxymaltose on exercise capacity and functional status in pulmonary hypertension (IRON-PH)",
            "phase": "Phase IV",
            "lead_sponsor": "Ziekenhuis Oost Limburg",
            "conditions": "Pulmonary hypertension, Iron deficiency",
            "member_states": "Belgium",
            "decision_date": "12/12/2025",
            "enrolled": "306",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522936-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-510345-21-00",
            "title": "A study in healthy men and women to test how BI 3000202 is taken up and processed by the body",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Netherlands",
            "decision_date": "12/12/2025",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-510345-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522500-24-00",
            "title": "IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. \nThe IMCISION II trial, an investigator-initiated multicentre randomised phase 3 trial \n(M24IMS)",
            "phase": "Phase III",
            "lead_sponsor": "Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting",
            "conditions": "Head and Neck squamous cell carcinoma",
            "member_states": "Netherlands",
            "decision_date": "12/12/2025",
            "enrolled": "308",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522500-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523612-37-00",
            "title": "A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson\u2019s Disease and Apathy",
            "phase": "Phase I",
            "lead_sponsor": "Integrative Research Laboratories Sweden AB",
            "conditions": "Parkinson's Disease and Apathy",
            "member_states": "Bulgaria; Poland; Spain; Germany",
            "decision_date": "12/12/2025",
            "enrolled": "125",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523612-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516472-15-00",
            "title": "A phase 1 glucose clamp trial investigating the bioequivalence of CVC-001 cartridge vs U.S.-Licensed Lantus\u00ae in healthy male volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Civica Inc.",
            "conditions": "Type 1 diabetes mellitus (healthy participants)",
            "member_states": "Germany",
            "decision_date": "12/12/2025",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516472-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520026-11-00",
            "title": "A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Metastatic Prostate Cancer.",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Metastatic Prostate Cancer",
            "member_states": "Italy; Spain; Poland",
            "decision_date": "12/12/2025",
            "enrolled": "107",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520026-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521661-27-00",
            "title": "A Phase 2b/3 Adaptive, Randomized, Active controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy",
            "phase": "Phase III",
            "lead_sponsor": "Vertex Pharmaceuticals Inc.",
            "conditions": "Primary Membranous Nephropathy",
            "member_states": "Hungary; Ireland; Czechia; Italy; Spain; Germany; Netherlands",
            "decision_date": "12/12/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521661-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522832-16-00",
            "title": "Intermediate versus standard dose enoxaparin to prevent venous thromboembolism in severe trauma patients: a multicenter double blind randomised controlled trial (HEPTRAUMA)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire Grenoble Alpes",
            "conditions": "Severe trauma",
            "member_states": "France",
            "decision_date": "11/12/2025",
            "enrolled": "540",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522832-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522786-29-00",
            "title": "Randomized, Double-Blinded, Vehicle-Controlled, Crossover Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Pediatric Participants with Spastic Cerebral Palsy (CP).",
            "phase": "Phase II",
            "lead_sponsor": "Dompe' Farmaceutici S.p.A.",
            "conditions": "Spastic Cerebral Palsy",
            "member_states": "Italy",
            "decision_date": "11/12/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522786-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519444-33-00",
            "title": "A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer\n(DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)",
            "phase": "Phase III",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "HER2-expressing endometrial cancer (IHC 3+/2+)",
            "member_states": "Germany; Poland; France; Greece; Spain; Portugal; Italy",
            "decision_date": "11/12/2025",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519444-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521764-35-01",
            "title": "A prospective, randomised, multi-centre, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges with benzydamine hydrochloride and dichlorobenzyl alcohol in the symptomatic treatment of patients suffering from acute pharyngitis",
            "phase": "Phase III",
            "lead_sponsor": "MEDICE Arzneimittel Puetter GmbH & Co. KG",
            "conditions": "acute pharyngitis",
            "member_states": "Germany",
            "decision_date": "11/12/2025",
            "enrolled": "810",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521764-35-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519393-39-00",
            "title": "A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome",
            "phase": "Phase II",
            "lead_sponsor": "Ultragenyx Pharmaceutical Inc.",
            "conditions": "Angelman Syndrome",
            "member_states": "Portugal; Italy; France",
            "decision_date": "11/12/2025",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519393-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523165-19-00",
            "title": "A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "BeOne Medicines I GmbH",
            "conditions": "Advanced, metastatic or unresectable solid tumors",
            "member_states": "Denmark",
            "decision_date": "11/12/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523165-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522311-41-00",
            "title": "A study in healthy men to test how BI 1584862 is processed in the body",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Netherlands",
            "decision_date": "10/12/2025",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522311-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518072-31-00",
            "title": "Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia",
            "phase": "Phase II",
            "lead_sponsor": "Qed Therapeutics Inc.",
            "conditions": "Achondroplasia",
            "member_states": "Spain; Norway",
            "decision_date": "10/12/2025",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518072-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521130-28-00",
            "title": "Efficacy and Safety of Nipocalimab vs Efgartigimod for Patients with Generalized Myasthenia Gravis in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "generalized myasthenia gravis",
            "member_states": "Austria; Germany; Spain; Italy",
            "decision_date": "10/12/2025",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521130-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520800-81-00",
            "title": "THE EFFECT OF ROPINIROLE ON FUNCTIONAL CONNECTIVITY AND METACOGNITION IN HEALTHY SUBJECTS",
            "phase": "Phase III",
            "lead_sponsor": "Universita' Degli Studi Di Modena E Reggio Emilia",
            "conditions": "Healthy volunteers (mechanistic study evaluating the effect of a single oral dose of ropinirole 1 mg on metacognition and resting\u2011state functional brain connectivity. Product has MA and has been shown to be safe in humans)",
            "member_states": "Italy",
            "decision_date": "10/12/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520800-81-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522151-26-00",
            "title": "A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator\u2019s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)",
            "phase": "Phase III",
            "lead_sponsor": "Arrivent Biopharma Inc.",
            "conditions": "Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations",
            "member_states": "Greece; France; Spain; Italy",
            "decision_date": "10/12/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522151-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523091-23-00",
            "title": "ZANUBRUTINIB, A SECOND GENERATION BTK INHIBITOR, IN ANTI-MAG ANTIBODY NEUROPATHY: A PHASE II ITALIAN MULTICENTER CLINICAL TRIAL (MAZINGA)",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Ospedaliera di Padova",
            "conditions": "Peripheral anti-MAG neuropathy, waldenstrom macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia, monoclonal gammopathy of unknown significance",
            "member_states": "Italy",
            "decision_date": "10/12/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523091-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523356-31-01",
            "title": "Comparison of low versus intermediate intravenous dexamethasone doses on rebound pain\nafter ambulatory open foot surgery under popliteal sciatic nerve block: a double-blind clinical\ntrial.",
            "phase": "Phase III",
            "lead_sponsor": "Hospital Universitario Dr Peset Aleixandre",
            "conditions": "Postoperative pain, Rebound pain after regional anaesthesia",
            "member_states": "Spain",
            "decision_date": "10/12/2025",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523356-31-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520982-39-00",
            "title": "AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia",
            "phase": "Phase III",
            "lead_sponsor": "Universita Degli Studi Di Milano Bicocca",
            "conditions": "Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia",
            "member_states": "France; Lithuania; Norway; Finland; Spain; Italy; Czechia; Germany; Hungary; Slovakia; Denmark; Austria; Netherlands",
            "decision_date": "09/12/2025",
            "enrolled": "87",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520982-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519788-16-00",
            "title": "An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors (EZHiSWITCH)",
            "phase": "Phase II",
            "lead_sponsor": "Institut Gustave Roussy",
            "conditions": "Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.",
            "member_states": "France",
            "decision_date": "09/12/2025",
            "enrolled": "600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519788-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509713-37-00",
            "title": "SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells:\na multicentre, single-arm, open-label phase II trial",
            "phase": "Phase II",
            "lead_sponsor": "Hopital Fondation Adolphe De Rothschild",
            "conditions": "Patient with severe eye chemical burns",
            "member_states": "France",
            "decision_date": "09/12/2025",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509713-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521489-80-00",
            "title": "A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER\n(The ADJUNCT Study)",
            "phase": "Phase II",
            "lead_sponsor": "Medica Scientia Innovation Research S.L.",
            "conditions": "PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER",
            "member_states": "Spain",
            "decision_date": "09/12/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521489-80-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519578-38-00",
            "title": "A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension",
            "phase": "Phase III",
            "lead_sponsor": "Crinetics Pharmaceuticals Inc.",
            "conditions": "Classic congenital adrenal hyperplasia",
            "member_states": "Italy; Germany; France; Belgium; Netherlands; Poland",
            "decision_date": "09/12/2025",
            "enrolled": "61",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519578-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521150-42-00",
            "title": "A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Type 2 diabetes",
            "member_states": "Poland",
            "decision_date": "09/12/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521150-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522113-35-00",
            "title": "A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-509 in Adults with Moderate to Severe Atopic Dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Triveni Bio Inc.",
            "conditions": "Atopic dermatitis",
            "member_states": "Poland; Bulgaria; Czechia; Hungary",
            "decision_date": "09/12/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522113-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524035-39-00",
            "title": "Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "Bioavailability study in healthy volunteers under fasting conditions.",
            "member_states": "Czechia",
            "decision_date": "09/12/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524035-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523340-12-00",
            "title": "Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib",
            "phase": "Phase I",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Glioma",
            "member_states": "Netherlands",
            "decision_date": "09/12/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523340-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518899-31-00",
            "title": "CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy",
            "member_states": "Germany; France; Belgium; Italy; Denmark; Netherlands; Spain; Czechia",
            "decision_date": "09/12/2025",
            "enrolled": "545",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518899-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518644-21-01",
            "title": "An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of WEF-001 in participants with Advanced KRAS- Mutant Solid Tumours.",
            "phase": "Phase I/II",
            "lead_sponsor": "Auricula Biosciences Inc.",
            "conditions": "Advanced KRAS- Mutant Solid Tumours",
            "member_states": "Spain",
            "decision_date": "09/12/2025",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518644-21-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509392-17-00",
            "title": "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020",
            "phase": "Phase III",
            "lead_sponsor": "Charite Universitaetsmedizin Berlin K\u00f6R",
            "conditions": "Relapsed Acute Lymphoblastic Leukemia (ALL)",
            "member_states": "Netherlands; Czechia; Italy; Spain; Denmark; Austria; Norway; Sweden; Germany; France; Finland; Slovenia",
            "decision_date": "09/12/2025",
            "enrolled": "775",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509392-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521852-45-00",
            "title": "An Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PTX-100 Monotherapy in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.",
            "phase": "Phase II",
            "lead_sponsor": "Prescient Therapeutics Limited",
            "conditions": "Cutaneous T-Cell Lymphoma",
            "member_states": "Italy; France",
            "decision_date": "08/12/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521852-45-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522056-10-01",
            "title": "A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6)",
            "phase": "Phase III",
            "lead_sponsor": "Vega Therapeutics Inc.",
            "conditions": "von Willebrand Disease",
            "member_states": "Austria; Italy; Ireland; Germany; Finland",
            "decision_date": "08/12/2025",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522056-10-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522215-42-00",
            "title": "Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections (IMPACT)",
            "phase": "Phase IV",
            "lead_sponsor": "Copenhagen University Hospital",
            "conditions": "Severe acute infection",
            "member_states": "Denmark",
            "decision_date": "08/12/2025",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522215-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521180-13-00",
            "title": "PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults with Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors.",
            "phase": "Phase I",
            "lead_sponsor": "Prinses Maxima Centrum voor Kinderoncologie B.V.",
            "conditions": "Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors",
            "member_states": "Netherlands",
            "decision_date": "08/12/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521180-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519163-18-00",
            "title": "COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients",
            "phase": "Phase IV",
            "lead_sponsor": "Nordsjaellands Hospital",
            "conditions": "Chronic Obstructive Pulmonary Disease (COPD)",
            "member_states": "Denmark",
            "decision_date": "08/12/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519163-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521299-76-00",
            "title": "A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes",
            "member_states": "Germany; Italy; Denmark",
            "decision_date": "08/12/2025",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521299-76-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512804-20-00",
            "title": "AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Metastatic Colorectal Cancer",
            "member_states": "Germany; Poland; France; Italy; Netherlands; Spain",
            "decision_date": "08/12/2025",
            "enrolled": "87",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512804-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522922-11-00",
            "title": "A single-center, randomized, double blind, placebo-controlled, parallel-group, proof-of-concept trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis",
            "phase": "Phase II",
            "lead_sponsor": "Idorsia Pharmaceuticals Ltd.",
            "conditions": "Progressive multiple sclerosis (MS)",
            "member_states": "Netherlands",
            "decision_date": "08/12/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522922-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520837-22-00",
            "title": "A Danish, double-blind, randomized placebo-controlled clinical trial evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy in patients with recently diagnosed non-ischemic heart failure with reduced ejection fraction.",
            "phase": "Phase II",
            "lead_sponsor": "Cell2Cure ApS",
            "conditions": "Non-ischemic heart failure with reduced ejection fraction",
            "member_states": "Denmark",
            "decision_date": "08/12/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520837-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518231-11-00",
            "title": "Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have \nPreviously Benefited from Ianalumab (VAY RE-HIT)",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Immune thrombocytopenia (ITP) \nWarm autoimmune hemolytic anemia (wAIHA)",
            "member_states": "Germany; Czechia; Belgium; Spain; Italy; Bulgaria; Romania; France; Hungary",
            "decision_date": "08/12/2025",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518231-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522307-14-00",
            "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo\u00ae in Patients with Resected Melanoma",
            "phase": "Phase I",
            "lead_sponsor": "Intas Pharmaceuticals Limited",
            "conditions": "Melanoma",
            "member_states": "Spain; Romania",
            "decision_date": "08/12/2025",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522307-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516471-33-00",
            "title": "(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome",
            "phase": "Phase II",
            "lead_sponsor": "Bayer AG",
            "conditions": "Alport Syndrome, Chronic kidney disease",
            "member_states": "Spain; Italy; Poland; Czechia; Germany; Portugal; France",
            "decision_date": "05/12/2025",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516471-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517980-22-00",
            "title": "A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients with Multiple Sclerosis",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Multiple Sclerosis (MS)",
            "member_states": "Poland; Italy; France; Spain; Germany",
            "decision_date": "05/12/2025",
            "enrolled": "86",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517980-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522575-29-00",
            "title": "Evaluation of the persistency of the preoperative anxiolytic  effect of music therapy vs midazolam: electroencephalographic and clinical analysis",
            "phase": "Phase IV",
            "lead_sponsor": "Consorci Mar Parc De Salut De Barcelona",
            "conditions": "Preoperative anxiety",
            "member_states": "Spain",
            "decision_date": "05/12/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522575-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515935-31-04",
            "title": "A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and Alzheimer\u00b4s disease.",
            "phase": "Phase I",
            "lead_sponsor": "Karolinska Institutet",
            "conditions": "Alzheimer\u00b4s disease",
            "member_states": "Sweden",
            "decision_date": "05/12/2025",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515935-31-04",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519830-22-00",
            "title": "(21467) A Phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients, from birth to 18 years of age, with left ventricular systolic dysfunction (LVSD)",
            "phase": "Phase III",
            "lead_sponsor": "Bayer AG",
            "conditions": "Heart failure due to systemic left ventricular systolic dysfunction",
            "member_states": "Czechia; Germany; Greece; Italy; Finland; Bulgaria; Belgium; Poland; Austria; Portugal; Spain; Hungary; Sweden",
            "decision_date": "05/12/2025",
            "enrolled": "61",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519830-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519829-38-00",
            "title": "(21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD)",
            "phase": "Phase III",
            "lead_sponsor": "Bayer AG",
            "conditions": "Heart failure due to systemic left ventricular systolic dysfunction",
            "member_states": "Czechia; Poland; Portugal; Austria; Finland; Greece; Bulgaria; Sweden; Spain; Italy; Belgium; Hungary; Germany",
            "decision_date": "05/12/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519829-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521940-39-00",
            "title": "Phase 2 Trial to determine the efficacy of belumosudil for patients with steroid-refractory overlap of syndrome Graft-versus-Host-Disease (SR-osGVHD) - BEAT-GVHD",
            "phase": "Phase II",
            "lead_sponsor": "Medical Center - University Of Freiburg",
            "conditions": "steroid-refractory overlap syndrom Graft-versus-Host-Disease",
            "member_states": "Germany",
            "decision_date": "05/12/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521940-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512486-14-00",
            "title": "A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome\u2013Intestinal Failure (SBS-IF)",
            "phase": "Phase III",
            "lead_sponsor": "Zealand Pharma A/S",
            "conditions": "Short Bowel Syndrome",
            "member_states": "Finland; France; Belgium; Germany; Hungary; Spain; Austria; Netherlands; Italy; Denmark; Czechia; Norway; Poland; Sweden; Estonia",
            "decision_date": "04/12/2025",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512486-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521547-20-00",
            "title": "Herpes zoster after recombinant herpes zoster vaccination - Immediate post-RHZ-vaccination evolution of CMI, HMI and lymphocyte count and typing.",
            "phase": "Phase IV",
            "lead_sponsor": "Centre hospitalier universitaire de Liege",
            "conditions": "Herpes Zoster virus prevention",
            "member_states": "Belgium",
            "decision_date": "04/12/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521547-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522074-37-00",
            "title": "A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)",
            "phase": "Phase II",
            "lead_sponsor": "Allrock Bio Inc.",
            "conditions": "Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH)",
            "member_states": "Spain; Italy; Poland; France; Latvia; Germany",
            "decision_date": "04/12/2025",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522074-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522979-29-00",
            "title": "A randomized phase III, global, multicentre, open label clinical trial comparing Venetoclax Azacitidine and Quizartinib vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient\u00b4s ineligible for standard induction chemotherapy.",
            "phase": "Phase III",
            "lead_sponsor": "Fundacion PETHEMA",
            "conditions": "Acute myeloid leukemia",
            "member_states": "Spain; Portugal",
            "decision_date": "04/12/2025",
            "enrolled": "350",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522979-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520482-52-03",
            "title": "Clinical Application of the Androgen Receptor Inhibitor Darolutamide to Upregulate the Prostate-Specific Membrane Antigen (PSMA) Protein Expression in Patients with Hormone Sensitive Prostate Cancer. \n- The DARO-flare Trial -",
            "phase": "Phase I/II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Prostate cancer",
            "member_states": "Netherlands",
            "decision_date": "04/12/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520482-52-03",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521886-28-00",
            "title": "First-in-Human trial of DS9051b in participants with advanced solid tumors",
            "phase": "Phase I",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)",
            "member_states": "France",
            "decision_date": "03/12/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521886-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522659-24-00",
            "title": "OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Ovarian carcinoma",
            "member_states": "Netherlands",
            "decision_date": "03/12/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522659-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522421-36-00",
            "title": "Phase IV, open-label, randomized clinical trial on the effect of intravenous iron on quality of life in elderly patients with Acute Coronary Syndrome.",
            "phase": "Phase IV",
            "lead_sponsor": "Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA",
            "conditions": "Acute coronary syndrome",
            "member_states": "Spain",
            "decision_date": "03/12/2025",
            "enrolled": "538",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522421-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-505469-95-00",
            "title": "Fecal microbiota transplantation for primary sclerosing cholangitis - randomized study versus sham transplantation (FMT-SCLER).",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Primary Sclerosing Cholangitis",
            "member_states": "France",
            "decision_date": "02/12/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-505469-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521217-46-00",
            "title": "Impact of influenza vaccination on nasal resident memory immune responses and respiratory peripheral memory immune responses - MUCOVAC 2",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Saint Etienne",
            "conditions": "Adults seeking active immunisation against the seasonal influenza virus",
            "member_states": "France",
            "decision_date": "02/12/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521217-46-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523339-20-00",
            "title": "A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy \u2013 The REVISE Study",
            "phase": "Phase II",
            "lead_sponsor": "Gensight Biologics",
            "conditions": "Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial\nNADH Dehydrogenase 4 gene",
            "member_states": "France",
            "decision_date": "02/12/2025",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523339-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516415-24-03",
            "title": "Rapid sequence emergence of general Anaesthesia",
            "phase": "Phase IV",
            "lead_sponsor": "Stichting Radboud universitair medisch centrum",
            "conditions": "General anesthesia",
            "member_states": "Netherlands",
            "decision_date": "02/12/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516415-24-03",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522726-12-00",
            "title": "Phase 1 study to investigate the pharmacokinetic profile and safety of 3 testosterone gel formulations in postmenopausal female participants.",
            "phase": "Phase I",
            "lead_sponsor": "Chemo Research S.L.",
            "conditions": "No medical conditions.",
            "member_states": "Spain",
            "decision_date": "02/12/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522726-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521866-92-01",
            "title": "SON4PEM study: Sonlicromanol in post-COVID: A randomized, double-blind, placebo-controlled, phase II trial",
            "phase": "Phase II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "long COVID",
            "member_states": "Netherlands",
            "decision_date": "02/12/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521866-92-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512298-28-00",
            "title": "A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Neovascular age-related macular degeneration",
            "member_states": "Czechia; Portugal; Hungary; Spain; Belgium; Italy; Austria; France; Slovakia; Croatia; Germany; Bulgaria; Greece",
            "decision_date": "02/12/2025",
            "enrolled": "272",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512298-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519579-24-00",
            "title": "A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia",
            "phase": "Phase III",
            "lead_sponsor": "Crinetics Pharmaceuticals Inc.",
            "conditions": "Classic Congenital Adrenal Hyperplasia",
            "member_states": "Sweden; Austria; Poland; Netherlands; Italy; France; Germany",
            "decision_date": "02/12/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519579-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522101-37-00",
            "title": "First-in-Human Study of RO7812653",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Early Symptomatic Alzheimer\u2019s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)",
            "member_states": "Sweden; Poland; Spain; Netherlands",
            "decision_date": "02/12/2025",
            "enrolled": "117",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522101-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521155-23-00",
            "title": "C5001004 - A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Pulmonary Arterial Hypertension",
            "member_states": "Italy; Czechia; Germany; Greece; Spain; Belgium; France",
            "decision_date": "02/12/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521155-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519344-32-00",
            "title": "A Phase Ib/II, multi-site, open-label, dose finding trial to evaluate the safety, efficacy, and pharmacokinetics of BNT326 in combination with BNT327 in participants with advanced non-small cell lung cancer (NSCLC)",
            "phase": "Phase I/II",
            "lead_sponsor": "BioNTech SE",
            "conditions": "Non-small Cell Lung Cancer",
            "member_states": "Poland; Germany; Italy; Spain",
            "decision_date": "02/12/2025",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519344-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520337-80-00",
            "title": "A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis",
            "phase": "Phase III",
            "lead_sponsor": "UCB Biopharma",
            "conditions": "Palmoplantar Pustulosis",
            "member_states": "Czechia; Denmark; Spain; Poland; Germany; Hungary; Italy; France",
            "decision_date": "02/12/2025",
            "enrolled": "190",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520337-80-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521382-27-00",
            "title": "A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Moderately to Severely Active Crohn's Disease",
            "member_states": "Netherlands; Italy; Portugal; Spain; Czechia; Romania; France; Sweden; Hungary; Belgium; Germany; Greece; Poland",
            "decision_date": "01/12/2025",
            "enrolled": "435",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521382-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524217-89-00",
            "title": "An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon\u00ae retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Vianex S.A.",
            "conditions": "treatment of myasthenia gravis",
            "member_states": "Czechia",
            "decision_date": "01/12/2025",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524217-89-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515332-80-00",
            "title": "A Phase III, randomized, open label, non-inferiority study comparing the efficacy and safety of furazidin vaginal tablets and clindamycin vaginal cream in the local treatment of bacterial vaginosis",
            "phase": "Phase III",
            "lead_sponsor": "Adamed Pharma S.A.",
            "conditions": "Bacterial vaginosis",
            "member_states": "Italy; Czechia; Poland; Slovakia",
            "decision_date": "01/12/2025",
            "enrolled": "600",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515332-80-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521381-10-00",
            "title": "A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Moderately to Severely Active Ulcerative Colitis",
            "member_states": "Netherlands; Romania; Italy; Spain; Sweden; Czechia; Greece; Hungary; France; Portugal; Belgium; Germany; Poland",
            "decision_date": "01/12/2025",
            "enrolled": "391",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521381-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521880-10-00",
            "title": "TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Metastatic castrate resistant prostate cancer (mCRPC)",
            "member_states": "Italy; Germany; Poland; France; Denmark; Spain",
            "decision_date": "01/12/2025",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521880-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521970-33-00",
            "title": "An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "\u200b\u200bPulmonary Arterial Hypertension (PAH)",
            "member_states": "Czechia; Germany; Sweden; Greece; Croatia; Belgium; Poland; Spain; Portugal; Italy; Denmark; France; Netherlands",
            "decision_date": "01/12/2025",
            "enrolled": "389",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521970-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522754-39-00",
            "title": "Duration of Surfactant administration and impact on Stabilisation of vital parameters in very preterm neonates: 1 minute versus 5 minutes \u2013 a prospective randomised-controlled phase IV trial",
            "phase": "Phase IV",
            "lead_sponsor": "Medical University Of Graz",
            "conditions": "Neonatal respiratory distress syndrome",
            "member_states": "Austria",
            "decision_date": "01/12/2025",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522754-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521921-34-00",
            "title": "A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin",
            "phase": "Phase I",
            "lead_sponsor": "Genentech Inc.",
            "conditions": "Overweight or Obese (otherwise healthy)",
            "member_states": "Netherlands",
            "decision_date": "01/12/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521921-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520097-36-00",
            "title": "A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and\u202fSafety of\u202fIntravenous Empasiprubart\u202fVersus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy",
            "phase": "Phase III",
            "lead_sponsor": "Argenx",
            "conditions": "Chronic inflammatory demyelinating polyneuropathy (CIDP)",
            "member_states": "Czechia; Bulgaria; Netherlands; Hungary; Sweden; Slovakia; Slovenia; Greece; Norway; Poland; Italy; Spain; Estonia; Denmark; France; Romania; Portugal; Austria; Germany",
            "decision_date": "01/12/2025",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520097-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522146-40-00",
            "title": "A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.",
            "phase": "Phase II",
            "lead_sponsor": "Shionogi B.V.",
            "conditions": "Late-onset Pompe disease.",
            "member_states": "Belgium; Germany; Denmark; France; Italy; Spain; Netherlands",
            "decision_date": "01/12/2025",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522146-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522972-97-00",
            "title": "Evaluation of the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome",
            "phase": "Phase II",
            "lead_sponsor": "Connecta Therapeutics S.L.",
            "conditions": "Fragile X Syndrome",
            "member_states": "Spain",
            "decision_date": "01/12/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522972-97-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517393-13-00",
            "title": "A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants",
            "phase": "Phase II",
            "lead_sponsor": "Vertex Pharmaceuticals Inc.",
            "conditions": "Autosomal Dominant Polycystic Kidney Disease (ADPKD)",
            "member_states": "France; Germany; Italy; Belgium; Spain; Netherlands",
            "decision_date": "28/11/2025",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517393-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522082-29-00",
            "title": "A study to find a suitable dose of ASP5834 in adults with solid tumors",
            "phase": "Phase I",
            "lead_sponsor": "Astellas Pharma Inc.",
            "conditions": "Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification",
            "member_states": "Spain; France",
            "decision_date": "28/11/2025",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522082-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522857-20-00",
            "title": "An open label, phase I/II study investigating the safety and efficacy of the bispecific T-cell engaging antibody cizutamig (BCMAxCD3) in patients with immune-mediated inflammatory diseases \u2013 the SPLENDID Trial",
            "phase": "Phase I/II",
            "lead_sponsor": "Fraunhofer Institute For Translational Medicine And Pharmacology ITMP",
            "conditions": "Severe, treatment refractory primary Sj\u00f6gren\u2019s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)",
            "member_states": "Germany",
            "decision_date": "28/11/2025",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522857-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522598-12-00",
            "title": "A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Untreated Metastatic Pancreatic Ductal Adenocarcinoma",
            "member_states": "Czechia; Austria; Belgium; Ireland; Spain; Germany; Romania; Netherlands; Slovakia; Greece; Poland; Italy; Denmark; France; Sweden",
            "decision_date": "28/11/2025",
            "enrolled": "162",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522598-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519335-42-01",
            "title": "A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis",
            "phase": "Phase II",
            "lead_sponsor": "Zura Bio Inc.",
            "conditions": "Systemic Sclerosis",
            "member_states": "Hungary; Romania; Poland; Spain",
            "decision_date": "27/11/2025",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519335-42-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522034-31-00",
            "title": "Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to less than 18 years of age with narcolepsy type 1 (NT1)",
            "phase": "Phase I",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Narcolepsy with Cataplexy (Narcolepsy Type 1)",
            "member_states": "Italy",
            "decision_date": "27/11/2025",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522034-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508116-32-00",
            "title": "BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to support delisting for transplant access in highly-sensitiZED.",
            "phase": "Phase II",
            "lead_sponsor": "Academisch Ziekenhuis Leiden",
            "conditions": "Antibody-mediated rejection of renal grafts, High HLA-immunization in transplant candidates",
            "member_states": "Netherlands",
            "decision_date": "27/11/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508116-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519620-24-01",
            "title": "Avacopan added to standard-of-care therapy in ANCA-associated vasculitis with severe kidney involvement: a randomized, placebo-controlled, double-blinded multicenter superiority study",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "ANCA-associated vasculitis",
            "member_states": "France",
            "decision_date": "27/11/2025",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519620-24-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522551-25-00",
            "title": "A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Type 2 Diabetes Mellitus",
            "member_states": "Germany",
            "decision_date": "27/11/2025",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522551-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520730-28-00",
            "title": "A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
            "member_states": "Germany; Spain; Finland; Greece; Portugal; Italy; Belgium; Poland; France",
            "decision_date": "27/11/2025",
            "enrolled": "118",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520730-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514500-14-00",
            "title": "A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With  Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of  Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC",
            "member_states": "Germany; Italy; France; Poland; Spain; Hungary; Romania; Greece; Austria; Netherlands; Belgium",
            "decision_date": "27/11/2025",
            "enrolled": "234",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514500-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511595-32-00",
            "title": "Erector Spinae Plane Block for acute low back pain: a prospective double-blind randomized multicenter study. ESP-BACK",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Montpellier",
            "conditions": "Acute low back pain",
            "member_states": "France",
            "decision_date": "26/11/2025",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511595-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522510-23-00",
            "title": "InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2 part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN 6400 in Adult Patients with Hereditary Hemorrhagic Telangiectasia (HHT)",
            "phase": "Phase I/II",
            "lead_sponsor": "Alnylam Pharmaceuticals Inc.",
            "conditions": "Hereditary Hemorrhagic Telangiectasia (HHT)",
            "member_states": "France; Spain; Germany",
            "decision_date": "26/11/2025",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522510-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520166-63-00",
            "title": "Hysteroscopic resection versus medical management of early pregnancy loss (HyME): a randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "UZ Brussel",
            "conditions": "Early pregnancy loss (< 10 weeks of gestation)",
            "member_states": "Belgium",
            "decision_date": "26/11/2025",
            "enrolled": "152",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520166-63-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509729-33-00",
            "title": "A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101\u2122) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)",
            "phase": "Phase I",
            "lead_sponsor": "Institut De Cancerologie De L Ouest",
            "conditions": "Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory",
            "member_states": "France",
            "decision_date": "26/11/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509729-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523841-82-00",
            "title": "A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness and Safety of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (DAN-COVID)",
            "phase": "Phase IV",
            "lead_sponsor": "Gentofte Hospital, Moderna Inc.",
            "conditions": "SARS-CoV-2 infection",
            "member_states": "Denmark",
            "decision_date": "26/11/2025",
            "enrolled": "275000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523841-82-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521888-13-00",
            "title": "A Study Investigating the Safety and Absorption of Different Administration forms of RO7795074, a New Compound that may Potentially be Used in the Treatment of Type 1 Diabetes",
            "phase": "Phase I",
            "lead_sponsor": "Genentech Inc.",
            "conditions": "Overweight or Obese (otherwise healthy)",
            "member_states": "Netherlands",
            "decision_date": "26/11/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521888-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520775-81-00",
            "title": "A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trials",
            "phase": "Phase III",
            "lead_sponsor": "Zealand Pharma A/S",
            "conditions": "Short Bowel Syndrome",
            "member_states": "Poland; France; Germany; Belgium",
            "decision_date": "26/11/2025",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520775-81-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522054-40-00",
            "title": "A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma",
            "phase": "Phase II",
            "lead_sponsor": "Iovance Biotherapeutics Inc.",
            "conditions": "Previously treated advanced melanoma",
            "member_states": "France; Italy; Germany; Spain",
            "decision_date": "26/11/2025",
            "enrolled": "69",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522054-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522000-24-00",
            "title": "A Phase 1B, Open-Label Study of Mirdametinib in Infants and Toddlers with Neurofibromatosis Type 1 associated Plexiform Neurofibromas",
            "phase": "Phase I",
            "lead_sponsor": "Springworks Therapeutics Inc.",
            "conditions": "Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)",
            "member_states": "Spain; Germany",
            "decision_date": "26/11/2025",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522000-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523266-24-00",
            "title": "\u201cA phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo\u201d",
            "phase": "Phase II",
            "lead_sponsor": "I.F.O. Istituti Fisioterapici Ospitalieri",
            "conditions": "Vitiligo",
            "member_states": "Italy",
            "decision_date": "26/11/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523266-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521128-31-00",
            "title": "A Phase Ib/ II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Have Previously Progressed During or After a CDK4/6 Inhibitor",
            "phase": "Phase I/II",
            "lead_sponsor": "Genentech Inc.",
            "conditions": "Locally Advanced or Metastatic Estrogen Receptor-Positive, human epidermal growth factor receptor 2-negative (HER2-Negative) Breast Cancer who Have Previously Progressed During or After a cyclin-dependent kinase 4/6 (CDK4/6) Inhibitor",
            "member_states": "Spain; Italy; France; Germany",
            "decision_date": "26/11/2025",
            "enrolled": "73",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521128-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520387-34-00",
            "title": "A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study",
            "phase": "Phase IV",
            "lead_sponsor": "Fondazione IRCCS Policlinico San Matteo",
            "conditions": "electrical storm",
            "member_states": "Italy",
            "decision_date": "25/11/2025",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520387-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513911-28-00",
            "title": "Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)",
            "phase": "Phase III",
            "lead_sponsor": "Diamedica Therapeutics Inc.",
            "conditions": "Acute Ischemic Stroke",
            "member_states": "Romania; Hungary; Belgium; Poland; Spain; France",
            "decision_date": "25/11/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513911-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-506982-73-00",
            "title": "A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative",
            "phase": "Phase II",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer",
            "member_states": "Netherlands",
            "decision_date": "25/11/2025",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-506982-73-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518780-36-00",
            "title": "A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)",
            "phase": "Phase I",
            "lead_sponsor": "Cullinan Therapeutics Inc.",
            "conditions": "Systemic Lupus Erythematosus",
            "member_states": "Bulgaria; Romania; France; Germany; Spain; Poland",
            "decision_date": "25/11/2025",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518780-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522718-22-00",
            "title": "ZANGEA \u2013 Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients",
            "phase": "Phase II",
            "lead_sponsor": "Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH",
            "conditions": "Gastroesophageal Adenocarcinoma",
            "member_states": "Germany",
            "decision_date": "25/11/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522718-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520790-39-00",
            "title": "CLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL)",
            "phase": "Phase I",
            "lead_sponsor": "Universitaetsklinikum Heidelberg A\u00f6R",
            "conditions": "relapsed or refractory AL amyloidosis",
            "member_states": "Germany",
            "decision_date": "25/11/2025",
            "enrolled": "7",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520790-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523158-15-00",
            "title": "A multi-center, open-label, drug-drug interaction study to evaluate the effect of pralsetinib (Gavreto) on the pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9\nsubstrates, and hormones estradiol/norethisterone acetate in patients with advanced or metastatic solid tumors.",
            "phase": "Phase III",
            "lead_sponsor": "Rigel Pharmaceuticals Inc.",
            "conditions": "Patients with advanced or metastatic solid tumors",
            "member_states": "Spain",
            "decision_date": "25/11/2025",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523158-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521791-63-00",
            "title": "Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in \nAdults with Moderately to Severely Active Rheumatologic Disease",
            "phase": "Phase II",
            "lead_sponsor": "Spyre Therapeutics Inc.",
            "conditions": "Moderately to Severely Active Rheumatologic Disease",
            "member_states": "Czechia; Poland; Spain; Bulgaria",
            "decision_date": "25/11/2025",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521791-63-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508071-36-00",
            "title": "RASBU-SEPSIS Study: Effects of rasburicase on renal function during sepsis \u2013 a randomized, placebo-controlled, double-blind trial",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level \u2265200\u00b5mol/L, adults, negative G6PD deficiency",
            "member_states": "France",
            "decision_date": "24/11/2025",
            "enrolled": "240",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508071-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514848-88-00",
            "title": "BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Folliculitis decalvans",
            "member_states": "France",
            "decision_date": "24/11/2025",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514848-88-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522817-50-00",
            "title": "Comparison of morphine and alfentanil in the emergency treatment of severe acute pain in the pre-hospital setting",
            "phase": "Phase IV",
            "lead_sponsor": "CHU De Martinique",
            "conditions": "Severe pain",
            "member_states": "France",
            "decision_date": "24/11/2025",
            "enrolled": "242",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522817-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521371-31-00",
            "title": "PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Sepsis",
            "member_states": "France",
            "decision_date": "24/11/2025",
            "enrolled": "2000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521371-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515023-11-00",
            "title": "Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma",
            "phase": "Phase III",
            "lead_sponsor": "Arcus Biosciences Inc.",
            "conditions": "Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma",
            "member_states": "Italy; Spain; Romania; Germany; Netherlands; Poland; France; Czechia; Hungary",
            "decision_date": "24/11/2025",
            "enrolled": "342",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515023-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520831-18-00",
            "title": "A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren\u2019s Disease with Moderate to Severe Systemic Disease Activity",
            "phase": "Phase II",
            "lead_sponsor": "Immunovant Sciences GmbH",
            "conditions": "Primary Sjogren\u2019s Disease",
            "member_states": "Germany; Greece; Romania; Spain; Poland; Italy; Hungary",
            "decision_date": "24/11/2025",
            "enrolled": "143",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520831-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522372-93-00",
            "title": "A modular Phase I/II, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of AZD4512 monotherapy or in combination with anticancer agent(s) in participants with Acute Lymphoblastic Leukemia",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "B-cell acute lymphoblastic leukemia (B-ALL)",
            "member_states": "Spain",
            "decision_date": "24/11/2025",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522372-93-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521620-29-01",
            "title": "Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis compared to no treatment: A prospective, controlled, split-body study",
            "phase": "Phase II",
            "lead_sponsor": "Galenica AB",
            "conditions": "Atopic Dermatitis",
            "member_states": "Norway; Sweden",
            "decision_date": "24/11/2025",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521620-29-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522680-14-00",
            "title": "Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD)",
            "phase": "Phase I",
            "lead_sponsor": "Qurient Co. Ltd.",
            "conditions": "Chronic Graft-versus-Host Disease",
            "member_states": "Spain",
            "decision_date": "24/11/2025",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522680-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522397-36-00",
            "title": "Study of GS-5319 in Adults With Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Gilead Sciences Inc.",
            "conditions": "Advanced solid tumors",
            "member_states": "Spain",
            "decision_date": "24/11/2025",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522397-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520418-22-00",
            "title": "A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Chronic Obstructive Pulmonary Disease",
            "member_states": "Slovakia; Denmark; France; Sweden; Ireland; Belgium; Netherlands; Spain; Croatia; Germany; Poland; Hungary; Norway; Portugal",
            "decision_date": "24/11/2025",
            "enrolled": "453",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520418-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520417-41-00",
            "title": "A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Chronic Obstructive Pulmonary Disease",
            "member_states": "Czechia; Greece; Latvia; Austria; Germany; Bulgaria; Romania; Italy",
            "decision_date": "24/11/2025",
            "enrolled": "327",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520417-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517923-38-00",
            "title": "A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment",
            "phase": "Phase I",
            "lead_sponsor": "Institut De Recherches Internationales Servier IRIS",
            "conditions": "Newly diagnosed and/or previously treated IDH1-mutated malignancies",
            "member_states": "Czechia; Spain",
            "decision_date": "24/11/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517923-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522970-35-00",
            "title": "REVERsal to normoglycemia by Treating PREDIABETES: the REVERT-PREDIABETES trial",
            "phase": "Phase III",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Coronary artery disease, Prediabetes",
            "member_states": "Denmark",
            "decision_date": "23/11/2025",
            "enrolled": "158",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522970-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521034-28-00",
            "title": "A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Moderate to Severe Rheumatoid Arthritis (RA)",
            "member_states": "Italy; Denmark; France; Poland; Germany; Spain; Belgium",
            "decision_date": "23/11/2025",
            "enrolled": "89",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521034-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522452-16-00",
            "title": "A Phase 2, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of 2 doses of vipoglanstat in patients with moderate to severe endometriosis-related pain \u2013 the NOVA trial",
            "phase": "Phase II",
            "lead_sponsor": "Gesynta Pharma AB",
            "conditions": "Endometriosis related pain",
            "member_states": "Italy; Hungary; Poland; Czechia; Bulgaria; Romania",
            "decision_date": "21/11/2025",
            "enrolled": "353",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522452-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521407-52-00",
            "title": "A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors.",
            "phase": "Phase I",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Advanced Solid Tumors",
            "member_states": "France",
            "decision_date": "21/11/2025",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521407-52-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521316-19-00",
            "title": "Optimization of pain management for acute renal colic in the Emergency Department \u2013  The OPTIMIZED trial",
            "phase": "Phase IV",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Urolithiasis",
            "member_states": "Netherlands",
            "decision_date": "21/11/2025",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521316-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521672-60-00",
            "title": "A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Crinetics Pharmaceuticals Inc.",
            "conditions": "Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults",
            "member_states": "Spain; France; Germany; Italy",
            "decision_date": "21/11/2025",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521672-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516898-72-00",
            "title": "Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomised Controlled Trial",
            "phase": "Phase III",
            "lead_sponsor": "Stichting Amsterdam UMC",
            "conditions": "Perihilar cholangiocarcinoma, distal cholangiocarcinoma",
            "member_states": "Netherlands",
            "decision_date": "21/11/2025",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516898-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522274-37-00",
            "title": "A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in combination with Standard of Care (SoC) or other agents in Participants with Advanced Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Neoplasms",
            "member_states": "Spain",
            "decision_date": "21/11/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522274-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518834-95-02",
            "title": "An open-label, non-randomized, extension study to further investigate the long-term efficacy, safety, and tolerability of Guanabenz in patients with early childhood onset vanishing white matter (VWM)",
            "phase": "Phase I/II",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Vanishing white matter",
            "member_states": "Netherlands",
            "decision_date": "21/11/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518834-95-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521349-25-00",
            "title": "A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)",
            "phase": "Phase III",
            "lead_sponsor": "4d Molecular Therapeutics Inc.",
            "conditions": "Macular neovascularization secondary to age-related macular degeneration (nAMD)",
            "member_states": "Germany; Italy; Hungary; Bulgaria; Lithuania; France; Spain; Latvia; Portugal",
            "decision_date": "21/11/2025",
            "enrolled": "298",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521349-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522346-46-00",
            "title": "Study of Oral MC-1 for the Treatment of Patients with PNPO Deficiency",
            "phase": "Phase III",
            "lead_sponsor": "Medicure International Inc.",
            "conditions": "Seizures associated with Pyridox(am)ine 5\u2019-Phosphate Oxidase (PNPO) deficiency",
            "member_states": "Poland",
            "decision_date": "21/11/2025",
            "enrolled": "3",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522346-46-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522918-23-00",
            "title": "BBT001 in Healthy Volunteers and in Adult Patients with Atopic Dermatitis",
            "phase": "Phase I",
            "lead_sponsor": "Bambusa Therapeutics Inc.",
            "conditions": "Atopic Dermatitis",
            "member_states": "Poland",
            "decision_date": "21/11/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522918-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521216-19-00",
            "title": "A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia",
            "phase": "Phase III",
            "lead_sponsor": "Neurocrine Biosciences Inc.",
            "conditions": "Schizophrenia, Schizophrenia",
            "member_states": "Romania; Hungary; Bulgaria",
            "decision_date": "21/11/2025",
            "enrolled": "154",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521216-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522377-12-00",
            "title": "Randomized study to compare first-line treatment with either continuous or intermittent cetuximab plus FOLFIRI in patients with RAS/BRAF-wild-type metastatic colorectal cancer (mCRC): AIO-KRK-0524 / FIRE-11",
            "phase": "Phase III",
            "lead_sponsor": "Charite Universitaetsmedizin Berlin K\u00f6R",
            "conditions": "metastatic colorectal cancer",
            "member_states": "Germany",
            "decision_date": "20/11/2025",
            "enrolled": "267",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522377-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520780-40-00",
            "title": "A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants with PMN (Primary Membranous Nephropathy) who are at a High Risk for Disease Progression (AUTUMN)",
            "phase": "Phase II",
            "lead_sponsor": "Alexion Pharmaceuticals Inc.",
            "conditions": "Primary Mebranous Nephropathy (PMN)",
            "member_states": "Spain; France; Italy",
            "decision_date": "20/11/2025",
            "enrolled": "9",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520780-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522573-11-00",
            "title": "Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral hydroxychloroquine 200 mg BID for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)",
            "phase": "Phase II",
            "lead_sponsor": "Varsinais-Suomen hyvinvointialue",
            "conditions": "Multiple Sclerosis",
            "member_states": "Finland",
            "decision_date": "20/11/2025",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522573-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519941-32-00",
            "title": "A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE LUPUS NEPHRITIS",
            "phase": "Phase II",
            "lead_sponsor": "Autolus Limited",
            "conditions": "Systemic Lupus Erythematosus with Active Lupus Nephritis",
            "member_states": "Greece",
            "decision_date": "20/11/2025",
            "enrolled": "3",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519941-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521875-30-00",
            "title": "An open-label, phase 2 study, evaluating the efficacy of treatment with Gilteritinib in measurable residual disease eradication in patients with FLT3-ITD mutated acute myeloid leukemia",
            "phase": "Phase II",
            "lead_sponsor": "Hellenic Society Of Hematology",
            "conditions": "Acute myeloid leukaemia, Acute myeloid leukaemia",
            "member_states": "Greece",
            "decision_date": "20/11/2025",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521875-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521593-33-00",
            "title": "A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Diabetes type 1",
            "member_states": "Germany",
            "decision_date": "20/11/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521593-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515125-28-00",
            "title": "A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy \u2013 FORTITUDE-HCM",
            "phase": "Phase II",
            "lead_sponsor": "Imbria Pharmaceuticals Inc.",
            "conditions": "Non-obstructive hypertrophic cardiomyopathy",
            "member_states": "Austria; Germany; Belgium; France; Portugal; Spain; Netherlands; Italy; Poland",
            "decision_date": "20/11/2025",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515125-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518615-19-00",
            "title": "A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Major Depressive Disorder",
            "member_states": "Italy; Hungary; Spain; Romania",
            "decision_date": "19/11/2025",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518615-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523695-23-00",
            "title": "Pharmacokinetics of NTRX-07 in fed and fasted participants",
            "phase": "Phase I",
            "lead_sponsor": "Neurotherapia Inc.",
            "conditions": "Not applicable (trial is a pharmacokinetic study in healthy volunteers). Intended indication: neuroinflammation-related diseases, including Alzheimer\u2019s Disease",
            "member_states": "Hungary",
            "decision_date": "19/11/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523695-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522233-62-00",
            "title": "A multi-center, open-label Phase 1/2 study to evaluate the safety, efficacy, PK and PD of ONA-255 in study participants with advanced cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Ona Therapeutics S.L.",
            "conditions": "Advanced cancer; breast cancer; metastatic gastric / gastroesophageal junction cancer",
            "member_states": "Spain",
            "decision_date": "19/11/2025",
            "enrolled": "117",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522233-62-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521495-54-00",
            "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Hyperlipidemia",
            "member_states": "Spain; Hungary",
            "decision_date": "19/11/2025",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521495-54-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520763-41-00",
            "title": "A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Older adults at risk of malnutrition",
            "member_states": "Spain",
            "decision_date": "19/11/2025",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520763-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522378-36-00",
            "title": "A Randomised, Placebo-Controlled, Double-Blind, Single-Ascending Dose and Multiple-Ascending Dose First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered ALE1 With or Without Food in Healthy Adult Participants and Adult Patients With Hypophosphatasia",
            "phase": "Phase I/II",
            "lead_sponsor": "Alesta Therapeutics B.V.",
            "conditions": "Hypophosphatasia",
            "member_states": "Germany",
            "decision_date": "19/11/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522378-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523534-11-00",
            "title": "Evaluation of the effect of intravenous lidocaine on the systemic inflammatory response associated with cardiopulmonary bypass in patients undergoing elective valvular and coronary cardiac surgery: A randomized double-blind clinical trial.",
            "phase": "Phase II",
            "lead_sponsor": "Hospital San Pedro",
            "conditions": "Patients undergoing elective cardiac valve surgery and/or coronary artery bypass grafting with cardiopulmonary bypass, at risk of systemic inflammatory response and related postoperative complications.",
            "member_states": "Spain",
            "decision_date": "19/11/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523534-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521828-30-00",
            "title": "Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Pyxis Oncology Inc.",
            "conditions": "Advanced Solid Tumors",
            "member_states": "France; Spain; Poland",
            "decision_date": "19/11/2025",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521828-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522860-34-00",
            "title": "A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
            "phase": "Phase III",
            "lead_sponsor": "BeOne Medicines AG",
            "conditions": "Small lymphocytic lymphoma (SLL), Chronic lymphocytic leukemia (CLL)",
            "member_states": "Sweden; Belgium; Spain; Germany; Austria; Netherlands; Italy; Romania; Poland; France",
            "decision_date": "18/11/2025",
            "enrolled": "196",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522860-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520927-26-00",
            "title": "A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
            "member_states": "France; Belgium; Spain; Poland; Italy; Netherlands; Germany",
            "decision_date": "18/11/2025",
            "enrolled": "215",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520927-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522371-29-00",
            "title": "A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Non-Hodgkin lymphoma (NHL)",
            "member_states": "Italy",
            "decision_date": "18/11/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522371-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521003-52-00",
            "title": "C5731006 - A PHASE 1B/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER",
            "phase": "Phase I/II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "HER2 Expressing Advanced Breast Cancer",
            "member_states": "Germany; Spain; Italy",
            "decision_date": "18/11/2025",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521003-52-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523156-31-00",
            "title": "A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease",
            "phase": "Phase II",
            "lead_sponsor": "Shionogi B.V.",
            "conditions": "Respiratory Syncytial Virus",
            "member_states": "Bulgaria; Poland",
            "decision_date": "18/11/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523156-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523146-27-00",
            "title": "Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.",
            "phase": "Phase I",
            "lead_sponsor": "Fuics Development Limited",
            "conditions": "Herpes simplex virus encephalitis",
            "member_states": "Bulgaria",
            "decision_date": "18/11/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523146-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2022-503070-36-00",
            "title": "C1091009 - A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Group B streptococcus (GBS) disease",
            "member_states": "Finland; Netherlands; Spain",
            "decision_date": "18/11/2025",
            "enrolled": "764",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2022-503070-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521562-95-00",
            "title": "Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo  in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)",
            "phase": "Phase III",
            "lead_sponsor": "Mabxience Research S.L.",
            "conditions": "Previously Untreated Advanced (Unresectable or Metastatic) Melanoma",
            "member_states": "Italy; Spain; Slovakia; Romania; Portugal; Greece; Poland",
            "decision_date": "18/11/2025",
            "enrolled": "119",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521562-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520660-18-00",
            "title": "Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)",
            "phase": "Phase IV",
            "lead_sponsor": "Policlinico San Donato S.p.A.",
            "conditions": "Heart Failure",
            "member_states": "Italy",
            "decision_date": "17/11/2025",
            "enrolled": "368",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520660-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521706-17-00",
            "title": "Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
            "phase": "Phase II",
            "lead_sponsor": "Alexion Pharmaceuticals Inc.",
            "conditions": "Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis",
            "member_states": "Spain; France; Italy; Germany; Poland",
            "decision_date": "17/11/2025",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521706-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521322-14-00",
            "title": "FILO-AML-01-MIVONU\nA single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg\u00ae) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.",
            "phase": "Phase II",
            "lead_sponsor": "French Innovative Leukemia Organization",
            "conditions": "Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy.",
            "member_states": "France",
            "decision_date": "17/11/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521322-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522841-23-00",
            "title": "ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Autism Spectrum disorder ASD",
            "member_states": "France",
            "decision_date": "17/11/2025",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522841-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520518-79-00",
            "title": "A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Atrial Fibrillation",
            "member_states": "Netherlands; Germany",
            "decision_date": "17/11/2025",
            "enrolled": "41",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520518-79-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521074-34-00",
            "title": "A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.",
            "phase": "Phase II",
            "lead_sponsor": "Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare",
            "conditions": "Allogeneic peripheral hematopoietic stem cell transplant, Cytomegalovirus infection",
            "member_states": "Italy",
            "decision_date": "17/11/2025",
            "enrolled": "81",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521074-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519540-32-00",
            "title": "sElective Serotonin reuPtake inhibitoRs In posT-covid: ESPRIT",
            "phase": "Phase III",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "post COVID",
            "member_states": "Netherlands",
            "decision_date": "17/11/2025",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519540-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521281-97-00",
            "title": "C5851005 - PADLINK-005: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Non-Small Cell Lung Cancer (NSCLC)",
            "member_states": "Greece; Italy; Belgium; Slovakia; Czechia; Germany; France; Poland; Denmark; Spain; Netherlands; Sweden; Finland; Bulgaria",
            "decision_date": "17/11/2025",
            "enrolled": "251",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521281-97-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521459-22-00",
            "title": "A phase II, randomized, open-label, national, multicenter study evaluating the efficacy and safety of the combination of atezolizumab and bevacizumab as neoadjuvant plus adjuvant treatment in hepatocellular carcinoma (ASPIRE)",
            "phase": "Phase II",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.",
            "member_states": "Spain",
            "decision_date": "17/11/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521459-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520979-13-00",
            "title": "NoLEEta - No chemotherapy in intermediate-risk HR+ HER2- early breast cancer treated with Ribociclib (LEE-011) in the adjuvant setting, a noninferiority\nPhase III trial",
            "phase": "Phase III",
            "lead_sponsor": "Unicancer",
            "conditions": "Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy",
            "member_states": "Germany; Spain; Netherlands; France; Italy",
            "decision_date": "17/11/2025",
            "enrolled": "3306",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520979-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522626-12-00",
            "title": "Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "17/11/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522626-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522423-95-00",
            "title": "Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects with MASLD",
            "phase": "Phase I",
            "lead_sponsor": "Bionorica SE",
            "conditions": "chronic liver disease",
            "member_states": "Germany",
            "decision_date": "17/11/2025",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522423-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523879-34-00",
            "title": "An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette\u00ae lozenge 4 mg in healthy adults who use cigarettes",
            "phase": "Phase I",
            "lead_sponsor": "Swedish Match North Europe AB",
            "conditions": "Nicotine use",
            "member_states": "Sweden",
            "decision_date": "17/11/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523879-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523872-22-00",
            "title": "Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS",
            "phase": "Phase I",
            "lead_sponsor": "Nrg Therapeutics Limited",
            "conditions": "Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)",
            "member_states": "Netherlands",
            "decision_date": "17/11/2025",
            "enrolled": "118",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523872-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518777-34-00",
            "title": "A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician\u2019s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "B7-H4-Selected Advanced/Metastatic Endometrial Cancer.",
            "member_states": "Italy; Netherlands; Lithuania; Finland; Greece; Austria; Belgium; Hungary; Spain; Poland; Czechia; Germany; France; Denmark; Slovenia",
            "decision_date": "17/11/2025",
            "enrolled": "201",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518777-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522052-13-00",
            "title": "Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.",
            "phase": "Phase III",
            "lead_sponsor": "Ospedale Pediatrico Bambino Gesu",
            "conditions": "Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL",
            "member_states": "Germany; Denmark; Finland; Norway; Austria; Italy; Poland; France; Czechia; Belgium; Croatia; Hungary; Lithuania; Sweden; Netherlands; Slovakia",
            "decision_date": "17/11/2025",
            "enrolled": "963",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522052-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521738-27-00",
            "title": "A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel in Patients with Recurrent Metastatic Head and Neck Cancer - AVETUX-HN",
            "phase": "Phase II",
            "lead_sponsor": "Charite Universitaetsmedizin Berlin K\u00f6R",
            "conditions": "Recurrent Metastatic Head and Neck Cancer",
            "member_states": "Germany",
            "decision_date": "17/11/2025",
            "enrolled": "126",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521738-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521013-10-00",
            "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE 2B TRIAL TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AEF0217 FOR 24 WEEKS IN ADULTS AND OLDER ADOLESCENTS WITH DOWN SYNDROME",
            "phase": "Phase II",
            "lead_sponsor": "Aelis Farma",
            "conditions": "Treatment of behavioural and cognitive impairments in Down syndrome.",
            "member_states": "Spain; Italy; France",
            "decision_date": "17/11/2025",
            "enrolled": "188",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521013-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521431-37-00",
            "title": "First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson\u2019s Disease (PD)",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Parkinson's disease",
            "member_states": "Netherlands",
            "decision_date": "17/11/2025",
            "enrolled": "23",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521431-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521530-28-00",
            "title": "A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA",
            "phase": "Phase I/II",
            "lead_sponsor": "Universitaetsklinikum Erlangen A\u00f6R",
            "conditions": "Progressive systemic autoimmune disease resistant to B cell depletion",
            "member_states": "Germany",
            "decision_date": "17/11/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521530-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522565-30-00",
            "title": "A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR-130A-01 contraceptive transdermal patch",
            "phase": "Phase II",
            "lead_sponsor": "Mylan Pharmaceuticals Inc.",
            "conditions": "Investigation of maintenance of ovulation inhibition after intentional application errors for indication of contraception in healthy subjects",
            "member_states": "Germany",
            "decision_date": "17/11/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522565-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520598-38-00",
            "title": "Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI \u226527.0 kg/m2",
            "phase": "Phase I",
            "lead_sponsor": "Zealand Pharma A/S",
            "conditions": "Weight reduction",
            "member_states": "Germany",
            "decision_date": "17/11/2025",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520598-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520089-70-00",
            "title": "LEISURE : Lenalidomide vs methotrexate in difficult-to-treat cutaneous lupus erythematosus (LEISURE trial): An assessor-blinded randomized clinical trial",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Cutaneous lupus erythematosus",
            "member_states": "France",
            "decision_date": "14/11/2025",
            "enrolled": "122",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520089-70-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522217-27-00",
            "title": "The effect of SYX-5219 on an immune response in the skin.",
            "phase": "Phase I",
            "lead_sponsor": "Sitryx Therapeutics Limited",
            "conditions": "Atopic dermatitis (AD)",
            "member_states": "Netherlands",
            "decision_date": "14/11/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522217-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518730-88-00",
            "title": "Enhancing Lung Health in Kids with structural Lung Damage and Malformations: a randomized controlled trial on Azithromycin (AZI) for Airway Infection Prevention",
            "phase": "Phase IV",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Chronic Atelectasis, Cystic Lung Malformations, Bronchiectasis, BronchoPulmonary Dysplasia, Tracheomalacia, Lobar Hyperinflation Syndrome, Post-Vascular Ring with central airway compression",
            "member_states": "Denmark",
            "decision_date": "14/11/2025",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518730-88-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523370-16-00",
            "title": "A Phase 1, Multi-Cohort, Open-Label, Randomized Pilot Study to Evaluate the Effect of Food and a Proton-Pump Inhibitor (esomeprazole) on the Single-Dose Pharmacokinetics of ARV-102 in Healthy Participants.",
            "phase": "Phase I",
            "lead_sponsor": "Arvinas Operations Inc.",
            "conditions": "Parkinsonian syndromes",
            "member_states": "Netherlands",
            "decision_date": "14/11/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523370-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522045-21-00",
            "title": "A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Solid tumours, Melanoma",
            "member_states": "Belgium; Netherlands",
            "decision_date": "14/11/2025",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522045-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517711-70-01",
            "title": "A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)",
            "phase": "Phase II",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Narcolepsy without Cataplexy (NT2)",
            "member_states": "Spain; Italy; France",
            "decision_date": "14/11/2025",
            "enrolled": "43",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517711-70-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523577-42-00",
            "title": "Open label study to investigate patch adhesion of an Esflurbiprofen-containing patch in healthy volunteers",
            "phase": "Phase I",
            "lead_sponsor": "Teikoku Seiyaku Co. Ltd.",
            "conditions": "Patch adhesion trial with healthy subjects, therapeutical indication not studied",
            "member_states": "Germany",
            "decision_date": "13/11/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523577-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522534-31-00",
            "title": "A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 versus US-licensed Entyvio\u00ae after subcutaneous administration in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Polpharma Biologics S.A.",
            "conditions": "Not applicable, healthy volunteers",
            "member_states": "Germany",
            "decision_date": "13/11/2025",
            "enrolled": "132",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522534-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520771-59-00",
            "title": "An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who Participated in Previous Afimkibart Clinical Trials",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Atopic Dermatitis",
            "member_states": "Italy; Poland; Germany; Spain; France",
            "decision_date": "13/11/2025",
            "enrolled": "49",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520771-59-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516551-41-00",
            "title": "A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206)",
            "phase": "Phase II",
            "lead_sponsor": "Jazz Pharmaceuticals Ireland Limited",
            "conditions": "Patients with HER2-expressing solid tumors",
            "member_states": "Spain; France",
            "decision_date": "13/11/2025",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516551-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522291-83-00",
            "title": "A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Adult Participants with Atopic Keratoconjunctivitis (AKC)",
            "phase": "Phase III",
            "lead_sponsor": "Dompe' Farmaceutici S.p.A.",
            "conditions": "Atopic Keratoconjunctivitis",
            "member_states": "Spain; Italy",
            "decision_date": "12/11/2025",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522291-83-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521946-82-00",
            "title": "A DOSE-DETERMINATION STUDY OF SUGAMMADEX AS A ROCURONIUM DECURARIZATION AGENT IN CHILDREN UNDER 2 YEARS OF AGE",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Caen Normandie",
            "conditions": "Non-urgent non-cardiac surgical procedure or relative emergency >12h that will require curarisation with rocuronium and decurarisation with sugammadex",
            "member_states": "France",
            "decision_date": "12/11/2025",
            "enrolled": "99",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521946-82-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522168-34-00",
            "title": "BRECHE : Efficacy of sphenopalatine block compared to blood patch in the management of post-dural puncture syndrome.",
            "phase": "Phase II",
            "lead_sponsor": "University Hospital Of Clermont-Ferrand",
            "conditions": "Post-dural puncture syndrome",
            "member_states": "France",
            "decision_date": "12/11/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522168-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514399-42-00",
            "title": "MATVAC-1 : EVALUATION OF UCPVAX VACCINE +/- PEMBROLIZUMAB COMBINED WITH STANDARD TREATMENT AS ADJUVANT THERAPY IN PATIENTS WITH UNMETHYLATED MGMT GLIOBLASTOMA",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire",
            "conditions": "Glioblastoma",
            "member_states": "France",
            "decision_date": "12/11/2025",
            "enrolled": "98",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514399-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520972-24-00",
            "title": "Exploring the anti-aging effects of Metformin in COPD",
            "phase": "Phase III",
            "lead_sponsor": "Fundacion Instituto De Investigacion Sanitaria De Navarra",
            "conditions": "Chronic Obstructive Pulmonary Disease (COPD)",
            "member_states": "Spain",
            "decision_date": "12/11/2025",
            "enrolled": "212",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520972-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513586-39-00",
            "title": "A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Prostate Cancer",
            "member_states": "Austria; Sweden; Spain; France; Netherlands; Germany; Belgium; Finland; Hungary; Poland; Italy",
            "decision_date": "12/11/2025",
            "enrolled": "253",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513586-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520977-37-00",
            "title": "Intubation Conditions in Morbidly Obese Patients with Rapid Sequence Induction: A Comparative Study of Rocuronium Dosing based on Ideal vs. Real Body Weight",
            "phase": "Phase IV",
            "lead_sponsor": "UZ Brussel",
            "conditions": "Obesity",
            "member_states": "Belgium",
            "decision_date": "12/11/2025",
            "enrolled": "182",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520977-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521441-24-00",
            "title": "A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Alentis Therapeutics AG",
            "conditions": "Advanced or Metastatic Solid Tumors",
            "member_states": "Spain; France; Netherlands; Italy",
            "decision_date": "12/11/2025",
            "enrolled": "77",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521441-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523861-58-00",
            "title": "A clinical study of MK-6050 in healthy people (MK-6050-001)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Hidradenitis suppurativa",
            "member_states": "Belgium",
            "decision_date": "12/11/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523861-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522402-21-00",
            "title": "A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers",
            "phase": "Phase I",
            "lead_sponsor": "Kupando GmbH",
            "conditions": "Advanced solid tumors (cutaneous melanoma, mucosal melanoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, or basal cell carcinoma)",
            "member_states": "Germany",
            "decision_date": "12/11/2025",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522402-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522336-14-00",
            "title": "A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension.",
            "phase": "Phase I",
            "lead_sponsor": "Bayer AG",
            "conditions": "Chronic Kidney Disease, Arterial hypertension",
            "member_states": "Germany",
            "decision_date": "12/11/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522336-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521737-91-00",
            "title": "A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Neoplasm malignant with KRAS G12C mutation",
            "member_states": "Norway; Spain; Sweden; Italy; Denmark; France; Poland; Germany; Greece",
            "decision_date": "12/11/2025",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521737-91-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521325-33-00",
            "title": "A 26-Week (with 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients with Symptomatic Coronary Artery Disease with Left Ventricular Dysfunction at Risk for Incomplete Revascularization",
            "phase": "Phase II",
            "lead_sponsor": "Xylocor Therapeutics Inc.",
            "conditions": "Chronic angina and left ventricular dysfunction due to coronary artery disease that is considered high risk for incomplete revascularization via coronary artery bypass grafting",
            "member_states": "Netherlands; Germany; Hungary; Poland",
            "decision_date": "11/11/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521325-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523301-15-00",
            "title": "A first-in-human study to learn about how safe BAY\u202f3620122 is, how much of it gets absorbed in the blood, and how it affects the body of healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Bayer AG",
            "conditions": "Vasodilatory shock",
            "member_states": "Germany",
            "decision_date": "11/11/2025",
            "enrolled": "190",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523301-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521843-19-00",
            "title": "Efficacy of Tuvusertib in Recurrent IDH mutant Astrocytoma with ATRX mutation, a phase II prospective trial.",
            "phase": "Phase II",
            "lead_sponsor": "Grupo Espanol De Investigacion En Neurooncologia",
            "conditions": "IDH1/2-mutated, ATRX-mutated and p53-mutated astrocytoma",
            "member_states": "Spain",
            "decision_date": "11/11/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521843-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521784-12-00",
            "title": "Remimazolam versus propofol for deep sedation during Endoscopic Ultrasound (EUS) procedures. A randomized controlled trial.",
            "phase": "Phase IV",
            "lead_sponsor": "Ospedale San Raffaele S.r.l.",
            "conditions": "Gastric and pancreatic cancer",
            "member_states": "Italy",
            "decision_date": "11/11/2025",
            "enrolled": "332",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521784-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517979-20-00",
            "title": "A Phase I/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, and pharmacokinetics of BNT323 in combination with BNT327 in participants with advanced breast cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "BioNTech SE",
            "conditions": "Advanced Breast Cancer\nMetastatic Breast Cancer",
            "member_states": "Italy; Spain; France",
            "decision_date": "11/11/2025",
            "enrolled": "95",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517979-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-510926-19-00",
            "title": "RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Myelofibrosis",
            "member_states": "Netherlands",
            "decision_date": "11/11/2025",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-510926-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523083-21-00",
            "title": "A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor",
            "phase": "Phase III",
            "lead_sponsor": "Relay Therapeutics Inc.",
            "conditions": "PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer",
            "member_states": "Hungary; Spain; Italy; Belgium; Netherlands; Austria; Germany; Greece; Czechia; Denmark; Poland; Bulgaria; Portugal; France; Ireland; Romania",
            "decision_date": "11/11/2025",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523083-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515107-19-00",
            "title": "ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Lille",
            "conditions": "Patients (male or female) \u226518 years old with Detrusor overactivity (DO) in multiple sclerosis (MS) or spinal cord injured (SCI).",
            "member_states": "France",
            "decision_date": "10/11/2025",
            "enrolled": "526",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515107-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520132-15-00",
            "title": "The effect of music on perioperative anxiety and pain of patients undergoing retrobulbar anaesthesia",
            "phase": "Phase III",
            "lead_sponsor": "Medical University Of Graz",
            "conditions": "Patients undergoing vitrectomy and/or cataract surgery",
            "member_states": "Austria",
            "decision_date": "10/11/2025",
            "enrolled": "240",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520132-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520545-74-00",
            "title": "Venetoclax as treatment of acute graft-versus-host disease in patients after allogeneic hematopoietic stem cell transplantation in a Phase-II dose escalation pilot study.",
            "phase": "Phase II",
            "lead_sponsor": "Medical University Of Vienna",
            "conditions": "Acute graft-versus-host disease of the skin",
            "member_states": "Austria",
            "decision_date": "10/11/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520545-74-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521242-26-00",
            "title": "Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase II",
            "lead_sponsor": "Spyre Therapeutics Inc.",
            "conditions": "Moderately to Severely Active Ulcerative Colitis",
            "member_states": "Belgium; Hungary; Lithuania; Netherlands; Croatia; Czechia; Bulgaria; Romania; Spain; France; Austria; Italy; Greece; Poland; Germany; Slovakia",
            "decision_date": "10/11/2025",
            "enrolled": "238",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521242-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522560-32-01",
            "title": "A prospective, randomized, controlled clinical pilot trial investigating the partial down-titration of guideline-directed medical therapy in patients with heart failure in remission",
            "phase": "Phase IV",
            "lead_sponsor": "Ziekenhuis Oost Limburg",
            "conditions": "Heart failure in remission",
            "member_states": "Belgium",
            "decision_date": "10/11/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522560-32-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517136-21-00",
            "title": "A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Renal Cell Carcinoma",
            "member_states": "Greece; Germany; France; Italy; Croatia; Denmark; Czechia; Austria; Belgium; Ireland; Spain; Poland",
            "decision_date": "10/11/2025",
            "enrolled": "398",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517136-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521391-58-00",
            "title": "A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 in Adult Participants with Moderate or Severe Asthma (the POLARIS trial)",
            "phase": "Phase II",
            "lead_sponsor": "Windward Bio AG",
            "conditions": "Asthma",
            "member_states": "Germany; France; Sweden; Bulgaria; Spain",
            "decision_date": "10/11/2025",
            "enrolled": "202",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521391-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522962-58-00",
            "title": "SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions",
            "phase": "Phase II",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Renal cell carcinom",
            "member_states": "Netherlands",
            "decision_date": "10/11/2025",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522962-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523736-39-00",
            "title": "Comparative Bioavailability of Levonorgestrel 52 mg Intrauterine System versus Mirena\u00ae in Healthy Pre-Menopausal, Non-Pregnant Female Participants.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Leon Farma S.A.",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "10/11/2025",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523736-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522862-58-00",
            "title": "A Phase 3, Multi-center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",
            "phase": "Phase III",
            "lead_sponsor": "BeOne Medicines AG",
            "conditions": "Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma",
            "member_states": "Spain; France; Austria; Italy; Poland; Czechia",
            "decision_date": "10/11/2025",
            "enrolled": "63",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522862-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522755-26-01",
            "title": "A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-001 in Patients with Osteoarthritis of the Knee",
            "phase": "Phase II",
            "lead_sponsor": "Latigo Biotherapeutics Inc.",
            "conditions": "Osteoarthritis of the knee",
            "member_states": "Denmark",
            "decision_date": "10/11/2025",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522755-26-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522766-78-00",
            "title": "A study investigating the safety, absorption, and elimination of RO7795081, a\nnew compound that may potentially be used in the treatment of type 2 diabetes and weight control",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Not Applicable",
            "member_states": "Netherlands",
            "decision_date": "07/11/2025",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522766-78-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522320-27-00",
            "title": "A trial to evaluate the absolute bioavailability of cenerimod in healthy male participants",
            "phase": "Phase I",
            "lead_sponsor": "Viatris Innovation GmbH",
            "conditions": "Not applicable - healthy volunteer trial",
            "member_states": "Netherlands",
            "decision_date": "07/11/2025",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522320-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521215-39-00",
            "title": "A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization",
            "phase": "Phase III",
            "lead_sponsor": "Neurocrine Biosciences Inc.",
            "conditions": "Schizophrenia",
            "member_states": "Hungary; Romania; Bulgaria",
            "decision_date": "07/11/2025",
            "enrolled": "139",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521215-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522203-23-00",
            "title": "A Phase 1/2a, First-in-human, Open label Study of BMS-986517 as Monotherapy in Adult Participants with Advanced Solid Tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Denmark; Spain",
            "decision_date": "07/11/2025",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522203-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522323-10-00",
            "title": "Prevention and Treatment of Episodic migraine by Cabergoline Therapy (PROTECT)\nA randomized, placebo-controlled, double-blind, investigator-initiated trial",
            "phase": "Phase III",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Migraine",
            "member_states": "Denmark",
            "decision_date": "07/11/2025",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522323-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521510-25-00",
            "title": "A phase 2 randomized, double blind, placebo-controlled study to evaluate the safety and efficacy of topical AT-004 1% in the participants with acne vulgaris.",
            "phase": "Phase II",
            "lead_sponsor": "Arctic Therapeutics hf.",
            "conditions": "Acne vulgaris",
            "member_states": "Denmark",
            "decision_date": "07/11/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521510-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522778-34-00",
            "title": "The use of intranasal dexmedetomidine for pediatric sedation in non-invasive radiological procedures (CTMS 004321)\nAssessing the efficacy and safety profile of intranasal dexmedetomidine for procedural sedation in radiological procedures in children with a prospective exploratory interventional monocentric study in a tertiary center in Antwerp (Belgium)",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Ziekenhuis Antwerpen",
            "conditions": "Sedation in healthy children",
            "member_states": "Belgium",
            "decision_date": "07/11/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522778-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519511-33-00",
            "title": "A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Montpellier",
            "conditions": "Patients will be included with a stable but active disease (as defined Diagnosis of systemic \nsclerosis according to ACR/EULAR classification by EUSTAR \u22652.5) or to patients with a \nworsening disease despite low dose steroids and at least 2 immunosuppressive treatment \nincluding DMARDs (methotrexate, azathioprine, mycophenolate mofetil) and/or a biological \nDMARD (rituximab or tocilizumab) for at least 6 months.",
            "member_states": "France",
            "decision_date": "07/11/2025",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519511-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512577-27-00",
            "title": "A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY Kids)",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Chronic kidney disease in paediatric patients",
            "member_states": "Spain; Germany; Portugal; Netherlands; Belgium; Poland; Italy; France; Sweden; Hungary",
            "decision_date": "06/11/2025",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512577-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522347-18-00",
            "title": "A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress",
            "phase": "Phase II",
            "lead_sponsor": "Seaport Therapeutics Inc.",
            "conditions": "Major Depressive Disorder (MDD), with or without Anxious Distress",
            "member_states": "Bulgaria; Czechia; Germany; Poland; Hungary; Slovakia; Romania",
            "decision_date": "06/11/2025",
            "enrolled": "250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522347-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519208-29-00",
            "title": "IFCT-2402 LAG-MAPS A non-comparative phase IIR trial assessing fianlimab plus cemiplimab plus pemetrexed-platinum chemotherapy or cemiplimab plus pemetrexed-platinum chemotherapy for treatment-naive Pleural Mesothelioma (PM) patients",
            "phase": "Phase II",
            "lead_sponsor": "Intergroupe Francophone De Cancerologie Thoracique",
            "conditions": "Pleural mesothelioma",
            "member_states": "France",
            "decision_date": "06/11/2025",
            "enrolled": "126",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519208-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522059-24-00",
            "title": "Nitraattien vaikutus matalapaineglaukoomassa",
            "phase": "Phase IV",
            "lead_sponsor": "University Of Helsinki",
            "conditions": "Normal tension glaucoma",
            "member_states": "Finland",
            "decision_date": "06/11/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522059-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521276-59-00",
            "title": "STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease",
            "phase": "Phase III",
            "lead_sponsor": "University Of Cologne",
            "conditions": "Autosomal dominant polycystic kidney disease (ADPKD)",
            "member_states": "Netherlands; Austria; Spain; Germany",
            "decision_date": "06/11/2025",
            "enrolled": "420",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521276-59-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518674-14-00",
            "title": "An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene",
            "phase": "Phase III",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Monogenic obesity",
            "member_states": "Germany; Spain",
            "decision_date": "06/11/2025",
            "enrolled": "3",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518674-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521199-80-00",
            "title": "Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial",
            "phase": "Phase II",
            "lead_sponsor": "French Innovative Leukemia Organization",
            "conditions": "Patients with previously untreated symptomatic chronic lymphocytic leukemia.",
            "member_states": "France",
            "decision_date": "05/11/2025",
            "enrolled": "82",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521199-80-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521904-23-00",
            "title": "An Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HR-positive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy",
            "member_states": "Spain; France; Italy",
            "decision_date": "05/11/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521904-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518437-28-00",
            "title": "Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "Sickle cell disease",
            "member_states": "France",
            "decision_date": "05/11/2025",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518437-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521330-29-00",
            "title": "Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial",
            "phase": "Phase II",
            "lead_sponsor": "Ostfold Hospital Trust",
            "conditions": "Major Depression Disorder (MDD)",
            "member_states": "Norway",
            "decision_date": "05/11/2025",
            "enrolled": "230",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521330-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522432-14-00",
            "title": "A study in healthy people to test whether BI 764198 influences the amount of metformin in the body",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "05/11/2025",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522432-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522451-25-00",
            "title": "PROBHE: Prehabilitation with Botulinum Toxin A in complex hernia: an Italian prospective study on predictive scores of myofascial release.",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Socio Sanitaria Territoriale Ovest Milanese",
            "conditions": "Large hernia width, chronically retracted lateral abdominal wall muscles, and irreducible visceral content in the hernia",
            "member_states": "Italy",
            "decision_date": "04/11/2025",
            "enrolled": "1",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522451-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523300-77-00",
            "title": "Bioequivalence of Testosterone Transdermal Gel in Healthy Female Participants.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Leon Farma S.A.",
            "conditions": "No medical conditions.",
            "member_states": "Portugal",
            "decision_date": "04/11/2025",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523300-77-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514874-36-01",
            "title": "Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (with 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety (EXACT-2 Trial)",
            "phase": "Phase II",
            "lead_sponsor": "Xylocor Therapeutics Inc.",
            "conditions": "Refractory angina due to obstructive coronary artery disease",
            "member_states": "Belgium; Poland; Hungary; Netherlands; Germany",
            "decision_date": "04/11/2025",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514874-36-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521692-31-00",
            "title": "A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults with Chronic Primary Immune Thrombocytopenia",
            "phase": "Phase III",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Chronic Primary Immune Thrombocytopenia",
            "member_states": "Bulgaria; Spain; Netherlands; Italy; Poland; Greece; Germany; France; Czechia; Croatia; Norway; Sweden",
            "decision_date": "04/11/2025",
            "enrolled": "109",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521692-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522427-10-00",
            "title": "A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study",
            "phase": "Phase II",
            "lead_sponsor": "Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL",
            "conditions": "Germ Cell Tumors refractory to salvage chemotherapy",
            "member_states": "Spain",
            "decision_date": "04/11/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522427-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523948-12-00",
            "title": "Bioequivalence of Cinnarizine/Dimenhydrinate 20 mg/40 mg Tablets in Healthy Participants Under Fed Conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Hennig Arzneimittel GmbH & Co. KG",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "04/11/2025",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523948-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521567-12-00",
            "title": "Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)",
            "phase": "Phase II",
            "lead_sponsor": "Laboratoires Thea",
            "conditions": "Vernal Keratoconjunctivitis (VKC)",
            "member_states": "Spain; Italy; Bulgaria; France; Greece",
            "decision_date": "04/11/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521567-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517963-21-00",
            "title": "Dehydroepiandrosterone (DHEA) as augmentation of standard antidepressants in treatment-resistant depression: a randomized controlled trial (DARE-Trial) - A multicenter, randomized, double-blind, placebo-controlled trial with group sequential design",
            "phase": "Phase III",
            "lead_sponsor": "Charite Universitaetsmedizin Berlin K\u00f6R",
            "conditions": "Treatment Resistant Depression (TRD)",
            "member_states": "Germany",
            "decision_date": "04/11/2025",
            "enrolled": "320",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517963-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519404-27-00",
            "title": "EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)",
            "phase": "Phase III",
            "lead_sponsor": "Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi",
            "conditions": "\u200b\u200bIDH-mutant grade 2 or 3 astrocytoma\u200b",
            "member_states": "Germany; France; Italy; Austria; Netherlands; Spain; Czechia; Belgium",
            "decision_date": "04/11/2025",
            "enrolled": "247",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519404-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522395-92-00",
            "title": "ENGIC 06 (PRODIGE 114) \u2013 FFCD 2401 \u2013 FRUQUITAS \nRandomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus trifluridine/tipiracil alone for metastatic oeso-gastric adenocarcinoma.",
            "phase": "Phase III",
            "lead_sponsor": "Fondation Franc.Cancerologie Digestive",
            "conditions": "metastatic oeso-gastric adenocarcinoma",
            "member_states": "France; Germany; Spain",
            "decision_date": "04/11/2025",
            "enrolled": "324",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522395-92-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522194-11-00",
            "title": "Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial",
            "phase": "Phase III",
            "lead_sponsor": "Fondazione Penta Ets",
            "conditions": "Respiratory Syncytial Virus (RSV)",
            "member_states": "Belgium; Netherlands",
            "decision_date": "04/11/2025",
            "enrolled": "400",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522194-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521529-34-00",
            "title": "A multicenter, phase 3, randomized, placebo-controlled, triple-blind crossover study of candesartan for prevention of chronic cluster headache (Chronic CandClus2)",
            "phase": "Phase III",
            "lead_sponsor": "Helse Bergen HF, St. Olavs Hospital HF",
            "conditions": "chronic cluster headache",
            "member_states": "Norway; Denmark",
            "decision_date": "04/11/2025",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521529-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521470-34-00",
            "title": "A phase 3 randomized, placebo-controlled, triple blind parallel-group study of candesartan in adults with episodic cluster headache (Episodic CandClus2)",
            "phase": "Phase III",
            "lead_sponsor": "Helse Bergen HF, St. Olavs Hospital HF",
            "conditions": "episodic cluster headache",
            "member_states": "Denmark; Norway",
            "decision_date": "04/11/2025",
            "enrolled": "83",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521470-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518008-33-00",
            "title": "A Phase III, Multicenter, Randomized, Double blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer\u2019s Disease (MCI to Mild Dementia due to AD)",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Early Symptomatic Alzheimer\u2019s Disease (MCI to Mild Dementia due to AD)",
            "member_states": "Poland; France; Germany; Netherlands; Spain; Italy; Denmark",
            "decision_date": "04/11/2025",
            "enrolled": "247",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518008-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518006-40-00",
            "title": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer\u2019s Disease (MCI to Mild Dementia Due to AD)",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Early Symptomatic Alzheimer\u2019s Disease (MCI to Mild Dementia Due to AD)",
            "member_states": "Spain; Poland; Italy; Denmark; France; Germany",
            "decision_date": "04/11/2025",
            "enrolled": "265",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518006-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520623-24-00",
            "title": "(22931) A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors.",
            "phase": "Phase I/II",
            "lead_sponsor": "Bayer AG",
            "conditions": "MTAP-deleted Solid Tumors",
            "member_states": "Belgium; Sweden; Denmark; Italy; Spain; Netherlands; Czechia",
            "decision_date": "04/11/2025",
            "enrolled": "195",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520623-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521012-18-00",
            "title": "A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)",
            "phase": "Phase III",
            "lead_sponsor": "Avidity Biosciences Inc.",
            "conditions": "Facioscapulohumeral Muscular Dystrophy (FSHD)",
            "member_states": "Italy; France; Germany; Spain; Denmark; Netherlands",
            "decision_date": "04/11/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521012-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521293-34-00",
            "title": "A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa",
            "phase": "Phase II",
            "lead_sponsor": "Almirall S.A.",
            "conditions": "Moderate-to-severe hidradenitis suppurativa",
            "member_states": "Germany; Italy; Ireland; Poland; Spain; France",
            "decision_date": "03/11/2025",
            "enrolled": "128",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521293-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521581-10-00",
            "title": "A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)",
            "phase": "Phase I/II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Neoplasms, Prostate",
            "member_states": "France; Spain",
            "decision_date": "03/11/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521581-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522517-35-00",
            "title": "A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors \n(5-STAR 1-01)",
            "phase": "Phase I/II",
            "lead_sponsor": "Tubulis GmbH",
            "conditions": "Patients with advanced/metastatic tumors with head and neck squamous cell carcinomas (HNSCC), non-small-cell lung cancer (NSCLC)",
            "member_states": "France; Spain; Romania",
            "decision_date": "03/11/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522517-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522826-11-00",
            "title": "Longitudinal study with positron emission tomography using [18F]PI-2620 in primary tauopathies. Proof-of-concept study",
            "phase": "Phase I/II",
            "lead_sponsor": "ZRO Imaging AB",
            "conditions": "Corticobasal syndrome (CBS), Progressive supranuclear palsy (PSP), Behavioral variant frontotemporal dementia (bvFTD).",
            "member_states": "Spain",
            "decision_date": "03/11/2025",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522826-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519493-39-00",
            "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator\u2019s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gu\u00e9rin (BCG)",
            "phase": "Phase III",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "High-risk Non-muscle-invasive Bladder\nCancer with Susceptible FGFR Alterations",
            "member_states": "France; Germany; Spain; Netherlands; Italy; Belgium; Greece",
            "decision_date": "03/11/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519493-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523152-31-00",
            "title": "Is magnesium sulfate an alternative with an analgesic and safety profile equivalent to dexmedetomidine as an adjuvant to ropivacaine in erector block in mastectomy?",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana",
            "conditions": "Breast cancer",
            "member_states": "Spain",
            "decision_date": "03/11/2025",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523152-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522002-20-00",
            "title": "A trial to learn how safe AZD4063 is, how it moves throughout the body over time, and how it affects the levels of PLN mRNA in adults with dilated cardiomyopathy because of an R14del mutation in the PLN gene",
            "phase": "Phase I",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "PLN R14del Dilated Cardiomyopathy",
            "member_states": "Netherlands",
            "decision_date": "03/11/2025",
            "enrolled": "23",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522002-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522669-32-00",
            "title": "A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 versus Investigator's Choice in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "phase": "Phase III",
            "lead_sponsor": "Dizal Pharmaceutical Co. Ltd.",
            "conditions": "Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "member_states": "Italy; Poland",
            "decision_date": "03/11/2025",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522669-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517238-16-00",
            "title": "A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia",
            "phase": "Phase III",
            "lead_sponsor": "Biomarin Pharmaceutical Inc.",
            "conditions": "Hypochondroplasia",
            "member_states": "France; Spain; Italy; Germany",
            "decision_date": "03/11/2025",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517238-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519554-37-00",
            "title": "A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants with Phenylketonuria",
            "phase": "Phase III",
            "lead_sponsor": "Otsuka Pharmaceutical Development & Commercialization Inc.",
            "conditions": "Phenylketonuria",
            "member_states": "Czechia; Italy; Spain; Netherlands; Poland; France; Germany",
            "decision_date": "03/11/2025",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519554-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519745-30-01",
            "title": "A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects with Immune Thrombocytopenia (ITP)",
            "phase": "Phase I/II",
            "lead_sponsor": "Climb Bio Inc.",
            "conditions": "Immune Thrombocytopenia (ITP)",
            "member_states": "Greece; Spain; Bulgaria",
            "decision_date": "03/11/2025",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519745-30-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522422-13-00",
            "title": "Comparison of Prefilled syringe and Autoinjector presentations of FYB202",
            "phase": "Phase I",
            "lead_sponsor": "Fresenius Kabi SwissBioSim GmbH",
            "conditions": "Chronic inflammatory diseases",
            "member_states": "Poland",
            "decision_date": "03/11/2025",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522422-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522719-40-00",
            "title": "GAIN-CTNNB1: A Phase I/II open-label trial to evaluate the safety, tolerability, and preliminary efficacy of a single intracerebroventricular administration of an AAV9-based gene replacement therapy in paediatric patients with CTNNB1 syndrome",
            "phase": "Phase I/II",
            "lead_sponsor": "Fundacija CTNNB1 Ustanova Za Raziskave Na Podrocju Genske Terapije",
            "conditions": "CTNNB1 syndrome",
            "member_states": "Slovenia",
            "decision_date": "03/11/2025",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522719-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522482-30-00",
            "title": "Double-blind, Placebo-Controlled, Randomized Exploratory Trial: Topical VDA-1102 Ointment in Rapidly Proliferating Actinic Keratosis",
            "phase": "Phase II",
            "lead_sponsor": "Vidac Pharma Ltd.",
            "conditions": "Actinic keratosis",
            "member_states": "Germany",
            "decision_date": "03/11/2025",
            "enrolled": "39",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522482-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521711-39-00",
            "title": "A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)",
            "phase": "Phase III",
            "lead_sponsor": "Acadia Pharmaceuticals Inc.",
            "conditions": "Lewy body Dementia psychosis (LBDP)",
            "member_states": "Czechia; Italy; France; Bulgaria",
            "decision_date": "03/11/2025",
            "enrolled": "49",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521711-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520555-89-00",
            "title": "A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Metastatic castration-resistant prostate cancer (mCRPC)",
            "member_states": "Austria; Netherlands; Portugal; Spain; Belgium; Greece; France; Italy; Germany",
            "decision_date": "03/11/2025",
            "enrolled": "297",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520555-89-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520197-36-00",
            "title": "A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors.",
            "phase": "Phase I/II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Neoplasms",
            "member_states": "Estonia; Czechia; Spain; Romania; Italy; Denmark; Belgium; Greece",
            "decision_date": "03/11/2025",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520197-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517753-27-01",
            "title": "A multicenter, randomized clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE)",
            "phase": "Phase III",
            "lead_sponsor": "Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher",
            "conditions": "moderate or severe activity of systemic lupus erythematosus (SLE)",
            "member_states": "Poland",
            "decision_date": "31/10/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517753-27-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523009-14-00",
            "title": "A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Bronchiectasis with chronic pseudomonas aeruginosa colonization",
            "member_states": "Netherlands; Italy; Greece; Denmark; Belgium; Spain; France; Germany",
            "decision_date": "31/10/2025",
            "enrolled": "112",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523009-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521624-30-00",
            "title": "A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Atopic Dermatitis (COMPASS 2-AD)",
            "phase": "Phase II",
            "lead_sponsor": "Bluefin Biomedicine Inc.",
            "conditions": "Atopic dermatitis",
            "member_states": "Poland; Bulgaria; Germany; Czechia; Spain",
            "decision_date": "31/10/2025",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521624-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522930-29-00",
            "title": "A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Otsuka Pharmaceutical Development & Commercialization Inc.",
            "conditions": "Incomplete Response - Major Depressive Disorder (IR-MDD)",
            "member_states": "Netherlands",
            "decision_date": "31/10/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522930-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522455-26-00",
            "title": "A Phase 1b/2a Open-Label Dose-Finding Followed by Randomized, Double-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TGD001 in Patients with Acute Ischemic Stroke",
            "phase": "Phase I/II",
            "lead_sponsor": "TargED Biopharmaceuticals B.V.",
            "conditions": "Acute Ischemic Stroke",
            "member_states": "Poland; Germany; Spain",
            "decision_date": "31/10/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522455-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522358-38-02",
            "title": "Post-operative analgesia and spinal block duration following total hip arthroplasties -  comparison of single-shot intrathecal ropivacaine, and bupivacaine: a randomized, double blinded controlled study",
            "phase": "Phase IV",
            "lead_sponsor": "Turku University Hospital",
            "conditions": "Hip osteoarthrosis and postoperative pain",
            "member_states": "Finland",
            "decision_date": "31/10/2025",
            "enrolled": "162",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522358-38-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520385-57-01",
            "title": "A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus",
            "phase": "Phase I",
            "lead_sponsor": "Climb Bio Inc.",
            "conditions": "Systemic Lupus Erythematosus",
            "member_states": "Romania; Bulgaria; Greece; Spain",
            "decision_date": "31/10/2025",
            "enrolled": "11",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520385-57-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522437-65-00",
            "title": "A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status (SPACE-T) [without IMPD-Q]",
            "phase": "Phase II",
            "lead_sponsor": "AIO-Studien gGmbH",
            "conditions": "small-cell lung cancer",
            "member_states": "Germany",
            "decision_date": "31/10/2025",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522437-65-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518011-19-01",
            "title": "DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMIDS) USING SYSTEMS APPROACHES",
            "phase": "Phase II",
            "lead_sponsor": "Cardiff University",
            "conditions": "Psoriatic Arthritis, Rheumatoid Arthritis",
            "member_states": "Spain",
            "decision_date": "30/10/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518011-19-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516625-31-00",
            "title": "Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.",
            "phase": "Phase I",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "Advanced Solid Tumor",
            "member_states": "Spain; France",
            "decision_date": "30/10/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516625-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521163-12-01",
            "title": "The use of [68Ga]Ga-FAPI PET/MRI in assessing disease activity in patients with Graves\u2019 orbitopathy",
            "phase": "Phase I/II",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Graves' Orbitopathy",
            "member_states": "Netherlands",
            "decision_date": "30/10/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521163-12-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521059-21-00",
            "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Radiographic axial spondyloarthritis (as known as ankylosing spondylitis)",
            "member_states": "Netherlands; Germany; Poland",
            "decision_date": "30/10/2025",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521059-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521317-50-00",
            "title": "Efficacy of Ursodeoxycholic Acid versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy: A Multicenter, Controlled, Randomized, Open Trial",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Montpellier",
            "conditions": "Cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs)",
            "member_states": "France",
            "decision_date": "30/10/2025",
            "enrolled": "94",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521317-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520846-31-00",
            "title": "Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series",
            "phase": "Phase III",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Tuberous Sclerosis Complex (TSC), Sanfilippo syndrome, Fragile X syndrome (FXS)",
            "member_states": "Netherlands",
            "decision_date": "30/10/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520846-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521457-16-00",
            "title": "LIVER AKI: A randomized, open-label trial to evaluate the efficacy of intravenous human albumin administration versus saline solution (NaCl 0.9%) in patients with decompensated cirrhosis and AKI 1B or grater.",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "descompensated hepatic cirrosis",
            "member_states": "Spain",
            "decision_date": "29/10/2025",
            "enrolled": "114",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521457-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521039-35-00",
            "title": "Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire De Tours",
            "conditions": "Impact on delirium of the use of  DEXmedetomidine as first-line sedation in PEDIAtric intensive care:",
            "member_states": "France",
            "decision_date": "29/10/2025",
            "enrolled": "266",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521039-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521644-37-00",
            "title": "DEPECA-1 \u2013 DEfeating PEnile CAncer 1 \u2013 A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma",
            "phase": "Phase II",
            "lead_sponsor": "Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH",
            "conditions": "locally advanced or metastatic penile squamous cell carcinoma",
            "member_states": "Germany",
            "decision_date": "29/10/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521644-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521230-29-00",
            "title": "A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma",
            "phase": "Phase III",
            "lead_sponsor": "LETI Pharma S.L.U.",
            "conditions": "Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae",
            "member_states": "Spain; Portugal",
            "decision_date": "29/10/2025",
            "enrolled": "410",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521230-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519531-41-00",
            "title": "Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Overweight and obesity",
            "member_states": "Czechia; Romania; Croatia; Slovakia; Hungary",
            "decision_date": "29/10/2025",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519531-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521710-25-00",
            "title": "A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults with Lewy Body Dementia Psychosis (LBDP)",
            "phase": "Phase II",
            "lead_sponsor": "Acadia Pharmaceuticals Inc.",
            "conditions": "Lewy Body Dementia Psychosis (LBDP)",
            "member_states": "Bulgaria; Czechia; Italy; France",
            "decision_date": "29/10/2025",
            "enrolled": "77",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521710-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521144-38-00",
            "title": "The CAROLYN Trial: Lisocabtagene Maraleucel   as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients",
            "phase": "Phase II",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Primary Central Nervous System Lymphoma",
            "member_states": "France; Germany",
            "decision_date": "29/10/2025",
            "enrolled": "31",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521144-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522127-95-00",
            "title": "NEOREM/NEO-1 - NEOREM : Neo-adjuvant Adaptive Master Trial for Localized Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / NEO-1 : Neo-adjuvant intratumoral Anti-CTLA4 + Anti-PD1 treatment in patients with localized melanoma",
            "phase": "Phase II",
            "lead_sponsor": "Unicancer",
            "conditions": "NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have\nmedical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.",
            "member_states": "France",
            "decision_date": "28/10/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522127-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522376-82-00",
            "title": "Intralymphatic Allergen Immunotherapy (ILIT) in grass pollen allergy: a randomized controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "University Of Foggia",
            "conditions": "allergic diseases (allergic rhinosinusitis, allergic asthma, allergy to Hymenoptera venoms)",
            "member_states": "Italy",
            "decision_date": "28/10/2025",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522376-82-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517498-25-00",
            "title": "A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients with Antibody-Mediated Rejection after Kidney Transplantation",
            "phase": "Phase II",
            "lead_sponsor": "Alexion Pharmaceuticals Inc.",
            "conditions": "Antibody-Mediated Rejection after Kidney Transplantation",
            "member_states": "Spain",
            "decision_date": "28/10/2025",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517498-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520208-25-00",
            "title": "An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with Still\u2019s disease",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Still\u2019s disease",
            "member_states": "Italy; Netherlands; Spain; France; Germany",
            "decision_date": "28/10/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520208-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514693-47-01",
            "title": "Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE",
            "phase": "Phase III",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "EGFR mutated locally advanced or metastatic non-small cell lung cancer",
            "member_states": "Netherlands; Belgium",
            "decision_date": "28/10/2025",
            "enrolled": "283",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514693-47-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521780-12-00",
            "title": "Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.",
            "phase": "Phase III",
            "lead_sponsor": "Andrea Di Marco",
            "conditions": "Non-ischemic cardiomyopathy",
            "member_states": "Spain",
            "decision_date": "28/10/2025",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521780-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-504282-23-00",
            "title": "European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatment of faecal incontinence (FI) in women with obstetric anal sphincter injury.",
            "phase": "Phase I",
            "lead_sponsor": "University College London",
            "conditions": "Faecal incontinence",
            "member_states": "France; Spain; Austria; Denmark",
            "decision_date": "28/10/2025",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-504282-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521707-48-00",
            "title": "AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "KRAS Altered Advanced or Metastatic Solid Tumors",
            "member_states": "France; Netherlands; Germany; Denmark; Spain; Italy; Belgium",
            "decision_date": "28/10/2025",
            "enrolled": "135",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521707-48-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520888-41-00",
            "title": "PROlonged versus Single dose in PEnicillin oral Challenge Testing double-blind parallel randomized placebo cOntrolled\n\ntRial \u2013 PROSPECTOR-2 Study",
            "phase": "Phase IV",
            "lead_sponsor": "Gentofte Hospital, Austin Health",
            "conditions": "Penicillin allergy",
            "member_states": "Belgium; Denmark",
            "decision_date": "28/10/2025",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520888-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517614-14-00",
            "title": "A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
            "phase": "Phase II",
            "lead_sponsor": "Immunovant Sciences GmbH",
            "conditions": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
            "member_states": "Austria; Hungary; Slovenia; Greece; Denmark; Ireland; Finland; Estonia; Spain; Slovakia; Netherlands; Poland; Norway; Italy; Portugal; Belgium; Germany; Romania; Bulgaria",
            "decision_date": "28/10/2025",
            "enrolled": "79",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517614-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523015-11-00",
            "title": "Bisoprolol for pericarditis -Phase III randomized controlled clinical trial in patients with acute or recurrent pericarditis",
            "phase": "Phase III",
            "lead_sponsor": "Azienda Sanitaria Universitaria Friuli Centrale",
            "conditions": "Pericarditis",
            "member_states": "Italy",
            "decision_date": "27/10/2025",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523015-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519820-26-00",
            "title": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer\u2019s Disease Psychosis",
            "phase": "Phase II",
            "lead_sponsor": "Maplight Therapeutics Inc.",
            "conditions": "Hallucinations and Delusions Associated with Alzheimer\u2019s Disease Psychosis",
            "member_states": "France; Czechia; Slovakia; Hungary; Portugal; Romania; Bulgaria; Italy; Poland",
            "decision_date": "27/10/2025",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519820-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-524021-41-00",
            "title": "A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX\u00ae LP.8.1 against SARS-CoV-2 variants.",
            "phase": "Phase IV",
            "lead_sponsor": "Hipra Scientific S.L.",
            "conditions": "COVID-19",
            "member_states": "Spain",
            "decision_date": "27/10/2025",
            "enrolled": "68",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-524021-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521745-25-00",
            "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Rheumatoid Arthritis",
            "member_states": "Poland; Spain; Germany",
            "decision_date": "27/10/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521745-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-507525-42-00",
            "title": "A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator\u2019s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer",
            "phase": "Phase III",
            "lead_sponsor": "BioNTech SE",
            "conditions": "Endometrial cancer",
            "member_states": "Denmark; Poland; Italy; Finland; Czechia; Sweden; Greece; Belgium; Norway; Hungary; Germany; Austria; France; Spain; Netherlands",
            "decision_date": "27/10/2025",
            "enrolled": "225",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-507525-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522946-37-00",
            "title": "A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Participants with Familial Adenomatous Polyposis",
            "phase": "Phase III",
            "lead_sponsor": "Biodexa Limited, Rapamycin Holdings Inc.",
            "conditions": "Familial adenomatous polyposis (FAP)",
            "member_states": "Denmark; Spain; Germany; Netherlands; Italy",
            "decision_date": "27/10/2025",
            "enrolled": "82",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522946-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516034-35-00",
            "title": "A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fasting condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "major depressive illness",
            "member_states": "Romania",
            "decision_date": "27/10/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516034-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516035-27-00",
            "title": "A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fed condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "major depressive illness",
            "member_states": "Romania",
            "decision_date": "27/10/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516035-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522097-36-00",
            "title": "A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Inc.",
            "conditions": "alopecia areata",
            "member_states": "Romania",
            "decision_date": "27/10/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522097-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521981-90-00",
            "title": "A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer",
            "phase": "Phase I",
            "lead_sponsor": "Xencor Inc.",
            "conditions": "Advanced Solid Tumors",
            "member_states": "Spain; France; Belgium; Denmark",
            "decision_date": "27/10/2025",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521981-90-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523254-14-00",
            "title": "Research into the safety of a new agent (AX-5006) in people with and without Parkinson's disease.",
            "phase": "Phase I",
            "lead_sponsor": "Vertero Therapeutics Inc.",
            "conditions": "Parkinson's disease",
            "member_states": "Netherlands",
            "decision_date": "27/10/2025",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523254-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521735-36-00",
            "title": "A single-arm, multicenter, open-label, Phase I/II trial of Allo-QuadCAR01-T, an allogeneic CAR-T-cell therapy targeting CD19 and CD20, for the treatment of relapsed or refractory B-cell malignancies",
            "phase": "Phase I/II",
            "lead_sponsor": "Avencell Therapeutics Inc.",
            "conditions": "Relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) or chronic lymphocytic leukaemia (CLL)",
            "member_states": "Germany",
            "decision_date": "27/10/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521735-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522111-42-02",
            "title": "Long-term muscle synthetic effects of intradialytic parenteral nutrition in chronic hemodialysis patients",
            "phase": "Phase IV",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "muscle protein turnover\nhemodialysis",
            "member_states": "Netherlands",
            "decision_date": "27/10/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522111-42-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522345-21-00",
            "title": "Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi\u00ae, and US licensed Skyrizi\u00ae in Healthy Adult Participants",
            "phase": "Phase I",
            "lead_sponsor": "Chong Kun Dang Pharmaceutical Corp.",
            "conditions": "Moderately to severely active Crohn\u2019s disease, Moderately to severely active ulcerative colitis, Active psoriatic arthritis, Moderate-to-severe plaque psoriasis",
            "member_states": "Poland",
            "decision_date": "26/10/2025",
            "enrolled": "213",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522345-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520731-17-02",
            "title": "68Ga-FAPI PET/CT imaging to assess pulmonary artery and right ventricle remodeling\nSoFAPI study",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional Et Universitaire De Brest",
            "conditions": "Pulmonary arterial hypertension (PAH)",
            "member_states": "France",
            "decision_date": "24/10/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520731-17-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520308-24-00",
            "title": "BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.",
            "member_states": "France",
            "decision_date": "24/10/2025",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520308-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515679-36-01",
            "title": "CAT-VHL - Exploring the role of Carbonic Anhydrase IX as diagnostic and Theranostic target in Von-Hippel Lindau disease",
            "phase": "Phase II",
            "lead_sponsor": "Ospedale San Raffaele S.r.l.",
            "conditions": "Von-Hippel Lindau (VHL) Disease",
            "member_states": "Italy",
            "decision_date": "24/10/2025",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515679-36-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521677-14-00",
            "title": "Randomized Multicentric Proof-of-Concept Phase 2 Trial Doravirine in the Early Outpatient Management of \nWest Nile Virus Infection in Patients at Risk of Progression - DORICO Trial",
            "phase": "Phase II",
            "lead_sponsor": "Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia",
            "conditions": "West Nile Virus Infection",
            "member_states": "Italy",
            "decision_date": "24/10/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521677-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522189-60-00",
            "title": "Cityview: PET-Based Imaging to Evaluate the Distribution of Radiolabeled CIT-013 in Patients with Inflammatory Mediated Immune Disease",
            "phase": "Phase II",
            "lead_sponsor": "Citryll B.V.",
            "conditions": "Inflammatory mediated immune diseases",
            "member_states": "Netherlands",
            "decision_date": "24/10/2025",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522189-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519382-22-00",
            "title": "A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Healthy Participants and Participants with type 2 diabetes",
            "member_states": "Germany",
            "decision_date": "24/10/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519382-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521511-40-00",
            "title": "A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion.",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "metastatic non-small cell lung cancer",
            "member_states": "Greece; Czechia; France; Sweden; Romania; Belgium; Austria; Bulgaria; Italy; Netherlands; Denmark; Germany; Poland; Hungary; Spain",
            "decision_date": "24/10/2025",
            "enrolled": "201",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521511-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522525-34-00",
            "title": "Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial",
            "phase": "Phase IV",
            "lead_sponsor": "Santiago Dexeus Font Fundacio Privada",
            "conditions": "Infertility",
            "member_states": "Spain",
            "decision_date": "24/10/2025",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522525-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521398-15-00",
            "title": "A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Immune system diseases",
            "member_states": "Netherlands; Spain; France; Belgium; Sweden; Germany; Poland; Italy",
            "decision_date": "24/10/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521398-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520200-26-00",
            "title": "LUSPARA - A basket phase II clinical trial evaluating Luspatercept in patients affected with rare inherited anemias",
            "phase": "Phase II",
            "lead_sponsor": "Eurobloodnet Association",
            "conditions": "Inherited anemias",
            "member_states": "Italy; France",
            "decision_date": "24/10/2025",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520200-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521909-40-00",
            "title": "ALTER : A Phase 2, Multicenter, Randomized, Open-label trial assessing sacituzumab-govitecan and trastuzumab-deruxtecan combinaison in an ALTERnating regimen for patients with metastatic or locally advanced Her2-low triple-negative breast Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Unicancer",
            "conditions": "Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.",
            "member_states": "France",
            "decision_date": "23/10/2025",
            "enrolled": "260",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521909-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520468-16-00",
            "title": "Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor",
            "phase": "Phase II",
            "lead_sponsor": "Genmab A/S",
            "conditions": "Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)",
            "member_states": "France; Spain; Netherlands; Germany",
            "decision_date": "23/10/2025",
            "enrolled": "129",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520468-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516544-26-00",
            "title": "Local tenecteplase applicatiOn subsequent to endovasCular recanalization in Anterior circuLation stroke - the LOCAL trial",
            "phase": "Phase II",
            "lead_sponsor": "Universitaetsklinikum Heidelberg A\u00f6R",
            "conditions": "acute ischemic stroke",
            "member_states": "Germany",
            "decision_date": "23/10/2025",
            "enrolled": "380",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516544-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520206-19-00",
            "title": "A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout",
            "phase": "Phase III",
            "lead_sponsor": "Crystalys Therapeutics Inc.",
            "conditions": "Hyperuricemia associated with gout.",
            "member_states": "Spain; Poland",
            "decision_date": "23/10/2025",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520206-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519913-76-00",
            "title": "An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer",
            "phase": "Phase II",
            "lead_sponsor": "Queen Mary University Of London",
            "conditions": "PDL1-negative metastatic triple-negative breast cancer",
            "member_states": "Spain; Germany",
            "decision_date": "23/10/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519913-76-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521802-17-00",
            "title": "RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.",
            "phase": "Phase III",
            "lead_sponsor": "Farmalider S.A.",
            "conditions": "Erosive/inflammatory osteoarthritis of the hands",
            "member_states": "Spain; Italy; Portugal",
            "decision_date": "23/10/2025",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521802-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521107-42-00",
            "title": "A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer\u2019s Disease.",
            "phase": "Phase II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Alzheimer's Disease",
            "member_states": "Sweden; Norway; Italy; France; Spain; Finland; Netherlands; Germany",
            "decision_date": "23/10/2025",
            "enrolled": "143",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521107-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517710-15-00",
            "title": "Preoperative use of Romiplostim in thrombocytopenic patients undergoing cardiac surgery. A Phase 3, multicenter randomized double-blinded controlled against placebo study",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "thrombocytopenic patients undergoing cardiac surgery",
            "member_states": "France",
            "decision_date": "22/10/2025",
            "enrolled": "136",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517710-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513676-18-00",
            "title": "A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)",
            "phase": "Phase III",
            "lead_sponsor": "Eidos Therapeutics Inc.",
            "conditions": "Transthyretin Amyloidosis",
            "member_states": "Germany; Portugal; Netherlands; France; Spain; Italy; Ireland; Belgium; Sweden; Denmark; Greece",
            "decision_date": "22/10/2025",
            "enrolled": "117",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513676-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523391-22-01",
            "title": "The Role of Beta-Blockade During Cardiac CT in Patients with Atrial Fibrillation",
            "phase": "Phase IV",
            "lead_sponsor": "Semmelweis University",
            "conditions": "Atrial fibrillation, Coronary artery disease",
            "member_states": "Hungary",
            "decision_date": "22/10/2025",
            "enrolled": "136",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523391-22-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519131-42-02",
            "title": "F-puff_SE_2024",
            "phase": "Phase IV",
            "lead_sponsor": "Semmelweis University",
            "conditions": "PAIN MANAGEMENT",
            "member_states": "Hungary",
            "decision_date": "22/10/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519131-42-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517653-27-00",
            "title": "A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Astellas Pharma Global Development Inc.",
            "conditions": "Prostate Cancer",
            "member_states": "Italy; Poland; Spain; France; Germany",
            "decision_date": "22/10/2025",
            "enrolled": "89",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517653-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521402-18-00",
            "title": "Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants",
            "phase": "Phase I",
            "lead_sponsor": "Springworks Therapeutics Inc.",
            "conditions": "Desmoid tumor",
            "member_states": "Netherlands",
            "decision_date": "22/10/2025",
            "enrolled": "16",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521402-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521559-22-00",
            "title": "Pre- and post-treatment evaluation of lung function with Xenon-gas enhanced Dual-Energy CT-imaging in patients undergoing radiotherapy",
            "phase": "Phase III",
            "lead_sponsor": "UZ Brussel",
            "conditions": "Radiation-induced lung injury (radiation fibrosis, radiation pneumonitis), Lung and breast cancer",
            "member_states": "Belgium",
            "decision_date": "22/10/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521559-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519700-28-01",
            "title": "The HIt HArd and hiT early in multiple sclerosis trial \u2013 HiHat trial",
            "phase": "Phase II",
            "lead_sponsor": "Region Uppsala",
            "conditions": "Patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration.",
            "member_states": "Sweden",
            "decision_date": "22/10/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519700-28-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521352-38-00",
            "title": "STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema",
            "phase": "Phase III",
            "lead_sponsor": "Adarx Pharmaceuticals Inc.",
            "conditions": "Hereditary Angioedema",
            "member_states": "Belgium; Poland; Italy; Czechia; Hungary; Spain; Germany; Croatia; France; Bulgaria; Austria",
            "decision_date": "22/10/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521352-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520612-34-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate\nthe Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with\nAlzheimer\u2019s Disease (ADAGIO-2)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Agitation Associated with\nAlzheimer\u2019s Disease",
            "member_states": "Poland; Hungary; Italy; France; Czechia",
            "decision_date": "22/10/2025",
            "enrolled": "92",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520612-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514401-54-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia",
            "phase": "Phase III",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Chronic Primary Immune Thrombocytopenia",
            "member_states": "Poland; Spain; Bulgaria; Italy; Netherlands; Croatia; Germany; Sweden; Greece; Czechia; Norway; France",
            "decision_date": "22/10/2025",
            "enrolled": "103",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514401-54-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522839-33-00",
            "title": "The \"MAGNEFFICIENT\" Prospective Trial: Preoperative Administration of MAGNesium for EFFICIENT Parathyroids after Thyroidectomy",
            "phase": "Phase III",
            "lead_sponsor": "Henry Dunant Hospital Center",
            "conditions": "Postoperative Hypoparathyroidism after thyroid surgery.",
            "member_states": "Greece",
            "decision_date": "22/10/2025",
            "enrolled": "500",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522839-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521755-23-00",
            "title": "Prevention of RSV infection in infants by administering nirsevimab to infants, with or without maternal RSV vaccination: a randomised controlled trial in France as part of the Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Annecy Genevois",
            "conditions": "Respiratory syncytial virus infection, Bronchiolitis, Respiratory tract infection",
            "member_states": "France",
            "decision_date": "21/10/2025",
            "enrolled": "2000",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521755-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519709-37-00",
            "title": "A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria with Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Paroxysmal nocturnal hemoglobinuria (PNH)",
            "member_states": "Poland; Italy; Spain",
            "decision_date": "21/10/2025",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519709-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520688-42-00",
            "title": "A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)",
            "phase": "Phase II",
            "lead_sponsor": "Phenonet Inc.",
            "conditions": "Amyotrophic Lateral Sclerosis (ALS)",
            "member_states": "Germany; Czechia; Poland; Spain",
            "decision_date": "21/10/2025",
            "enrolled": "128",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520688-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520746-30-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer\u2019s Disease (MINDSET 1)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Mild to moderate Alzheimer\u2019s Disease",
            "member_states": "Germany; Croatia; Italy; Poland; Romania; Czechia; Greece; Spain; Netherlands",
            "decision_date": "21/10/2025",
            "enrolled": "240",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520746-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520918-64-00",
            "title": "A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS).                                   The AnifAPS trial.",
            "phase": "Phase II",
            "lead_sponsor": "National And Kapodistrian University Of Athens",
            "conditions": "Primary Antiphospholipid Syndrome (APS)",
            "member_states": "Greece",
            "decision_date": "21/10/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520918-64-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521730-28-00",
            "title": "A Phase 2, Multicenter, Randomized, Double blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants with Colorectal Cancer who have Cancer Cachexia (SAPPHIRE)",
            "phase": "Phase II",
            "lead_sponsor": "Ngm Biopharmaceuticals Inc.",
            "conditions": "Colorectal Cancer with Cancer Cachexia",
            "member_states": "Czechia; Slovakia; Poland; Hungary; Bulgaria",
            "decision_date": "21/10/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521730-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519994-20-00",
            "title": "CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer\u2019s Disease (ADAGIO-3)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Agitation Associated with Alzheimer\u2019s Disease",
            "member_states": "Croatia; Romania; France; Spain; Italy; Greece; Czechia; Bulgaria; Poland; Portugal; Hungary",
            "decision_date": "21/10/2025",
            "enrolled": "193",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519994-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520130-29-00",
            "title": "A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)",
            "phase": "Phase II",
            "lead_sponsor": "Scholar Rock Inc.",
            "conditions": "Spinal Muscular Atrophy",
            "member_states": "Belgium; France; Italy; Spain; Netherlands",
            "decision_date": "21/10/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520130-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522090-11-00",
            "title": "A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma",
            "phase": "Phase I/II",
            "lead_sponsor": "Celgene Corp.",
            "conditions": "Relapsed or Refractory Multiple Myeloma (RRMM)",
            "member_states": "Norway; Greece; Germany; Spain",
            "decision_date": "21/10/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522090-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521385-10-00",
            "title": "ENDO-67 project: Investigating ENDOcrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery",
            "phase": "Phase IV",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Breast cancer",
            "member_states": "Netherlands",
            "decision_date": "21/10/2025",
            "enrolled": "175",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521385-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520747-32-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer\u2019s Disease (MINDSET 2)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Mild to moderate Alzheimer\u2019s Disease",
            "member_states": "Germany; Netherlands; Portugal; France; Spain; Poland; Greece; Romania; Italy; Finland",
            "decision_date": "21/10/2025",
            "enrolled": "292",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520747-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518365-10-00",
            "title": "A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Previously Untreated Advanced or Metastatic Non-Squamous Non\u2212Small Cell Lung Cancer",
            "member_states": "Ireland; Greece; Hungary; Netherlands; France; Denmark; Germany; Poland; Italy; Portugal; Spain; Belgium",
            "decision_date": "21/10/2025",
            "enrolled": "282",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518365-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521564-35-00",
            "title": "Cangrelor in endovascular stroke treatment with emergent carotid artery stenting (CANCAS)",
            "phase": "Phase II",
            "lead_sponsor": "Medical University Of Graz",
            "conditions": "ischemic stroke with intracranial large artery occlusion of the anterior cerebral circulation",
            "member_states": "Austria",
            "decision_date": "20/10/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521564-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522710-22-00",
            "title": "MetAddon: Methadone as co-analgesic for patients with metastatic bone pain: a double-blind randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Universiteit Maastricht",
            "conditions": "Cancer, bone metastasis, pain",
            "member_states": "Netherlands",
            "decision_date": "20/10/2025",
            "enrolled": "166",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522710-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518824-56-00",
            "title": "Pregabalin or Baclofen in Spastic Motor Behavior Treatment After SCI (PoBSCI), Prospective, Double-Blind, Randomised Drug Study",
            "phase": "Phase III",
            "lead_sponsor": "Fakultni Nemocnice V Motole",
            "conditions": "Complete to incomplete (AIS A-C) sub-acute cervical or thoracic (NLI C4-T10) spinal cord injury (SCI) with severe spastic motor behaviour",
            "member_states": "Czechia",
            "decision_date": "20/10/2025",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518824-56-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520128-27-00",
            "title": "BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study",
            "phase": "Phase II",
            "lead_sponsor": "Association Gercor",
            "conditions": "colorectal adenocarcinoma",
            "member_states": "France",
            "decision_date": "20/10/2025",
            "enrolled": "162",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520128-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512261-14-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months",
            "phase": "Phase II",
            "lead_sponsor": "Biomarin Pharmaceutical Inc.",
            "conditions": "Hypochondroplasia",
            "member_states": "Germany; Italy; France",
            "decision_date": "20/10/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512261-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519798-20-00",
            "title": "Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment\u00a0after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)\u00a0Patients \u2013 IMMUNOSTAR Trial\u00a0 -\u00a0 GOIRC-02-2024",
            "phase": "Phase II",
            "lead_sponsor": "G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica",
            "conditions": "pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)",
            "member_states": "Italy",
            "decision_date": "20/10/2025",
            "enrolled": "270",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519798-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521697-34-00",
            "title": "A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 \u00b5g in 1-through 3-year-old Children with Peanut Allergy",
            "phase": "Phase III",
            "lead_sponsor": "Dbv Technologies",
            "conditions": "Peanut allergy",
            "member_states": "Spain; France; Netherlands; Ireland",
            "decision_date": "20/10/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521697-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522700-24-00",
            "title": "RANDOMISED CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF PLATELET-RICH PLASMA (PRP) INFILTRATION COMBINED WITH PHYSICAL EXERCISE IN CHRONIC OMALGIA",
            "phase": "Phase III",
            "lead_sponsor": "Asociacion Instituto De Investigacion Sanitaria Biobizkaia",
            "conditions": "CHRONIC OMALGIA",
            "member_states": "Spain",
            "decision_date": "20/10/2025",
            "enrolled": "86",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522700-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520955-10-00",
            "title": "PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial.",
            "phase": "Phase II",
            "lead_sponsor": "Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy",
            "conditions": "Multiple sclerosis",
            "member_states": "Poland",
            "decision_date": "20/10/2025",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520955-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520566-22-00",
            "title": "C4551002 - An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator\u2019s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer",
            "member_states": "Hungary; Bulgaria; Czechia; Slovakia; Netherlands; Spain; Greece; Finland; Belgium; Sweden; Poland; Germany; France; Italy",
            "decision_date": "20/10/2025",
            "enrolled": "153",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520566-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515169-33-00",
            "title": "Blomia tropicalis allergen extract. Determination of the vivo histamine equivalent prick test units",
            "phase": "Phase II",
            "lead_sponsor": "Inmunotek S.L.",
            "conditions": "Allergy to Blomia tropicalis",
            "member_states": "Spain",
            "decision_date": "20/10/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515169-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522001-38-00",
            "title": "A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics with Multiple Therapies in Participants with Active Crohn\u2019s Disease or Active Ulcerative Colitis (ASCEND-IBD)",
            "phase": "Phase II",
            "lead_sponsor": "Mirador Therapeutics Inc.",
            "conditions": "Crohn\u2019s Disease, Ulcerative Colitis",
            "member_states": "Poland; Bulgaria; Croatia; Germany; Belgium; Slovakia; Czechia; Italy",
            "decision_date": "20/10/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522001-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515979-35-00",
            "title": "A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis",
            "phase": "Phase III",
            "lead_sponsor": "Immunovant Sciences GmbH",
            "conditions": "Generalized Myasthenia Gravis",
            "member_states": "Czechia; Greece; Spain; Italy; Denmark; Germany; Romania; Poland; Hungary",
            "decision_date": "20/10/2025",
            "enrolled": "158",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515979-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519976-19-00",
            "title": "The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Asthma with type 2 inflammation characterized by an eosinophilic phenotype",
            "member_states": "Belgium; Spain; Italy; Greece; France; Germany",
            "decision_date": "20/10/2025",
            "enrolled": "55",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519976-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519960-42-00",
            "title": "EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "PIK3CA-Related Overgrowth Spectrum (PROS)",
            "member_states": "Italy; Netherlands; Belgium; Spain; Austria; Germany; France",
            "decision_date": "20/10/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519960-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520613-31-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer\u2019s Disease (ADAGIO-1)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Agitation Associated with Alzheimer\u2019s Disease",
            "member_states": "Portugal; Croatia; Bulgaria; Greece; Spain; Romania",
            "decision_date": "20/10/2025",
            "enrolled": "103",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520613-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520433-76-00",
            "title": "EFfIcacy and Tolerability of FIXed duration teclistamab and talquetamab FOR FRAIL patients with newly diagnosed multiple myeloma (2 cohort study) - the EMN 37 FITFIX FOR FRAIL trial",
            "phase": "Phase II",
            "lead_sponsor": "European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale",
            "conditions": "Newly Diagnosed Multiple Myeloma",
            "member_states": "Norway; Italy; Spain; Netherlands",
            "decision_date": "20/10/2025",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520433-76-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520587-18-00",
            "title": "RENAISSANCE 2:\nA Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures",
            "phase": "Phase II",
            "lead_sponsor": "Supernus Pharmaceuticals Inc.",
            "conditions": "Focal Onset Seizures",
            "member_states": "Poland; Hungary; Bulgaria",
            "decision_date": "20/10/2025",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520587-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519753-11-00",
            "title": "PRODIGE 104 \u2013 NEOPREDICT \nA multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.",
            "phase": "Phase II",
            "lead_sponsor": "Fondation Franc.Cancerologie Digestive",
            "conditions": "Resectable borderline pancreatic adenocarcinoma",
            "member_states": "France",
            "decision_date": "17/10/2025",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519753-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519871-24-00",
            "title": "IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician\u2019s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Breast cancer, Triple-negative breast cancer",
            "member_states": "France; Portugal; Romania; Greece; Italy; Spain; Sweden; Austria; Poland; Germany",
            "decision_date": "17/10/2025",
            "enrolled": "159",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519871-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519133-29-00",
            "title": "Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring",
            "phase": "Phase II",
            "lead_sponsor": "Fondation A De Rothschild",
            "conditions": "Focal epilepsy",
            "member_states": "France",
            "decision_date": "17/10/2025",
            "enrolled": "192",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519133-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517261-16-00",
            "title": "A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "BioNTech SE",
            "conditions": "Advanced solid tumors",
            "member_states": "Belgium; Germany; Spain; Italy",
            "decision_date": "17/10/2025",
            "enrolled": "329",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517261-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521920-31-00",
            "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease",
            "phase": "Phase II",
            "lead_sponsor": "Immunovant Sciences GmbH",
            "conditions": "Graves\u2019 Disease",
            "member_states": "Italy; Poland; Greece; Germany; Netherlands; Czechia; Spain; Latvia; Bulgaria",
            "decision_date": "17/10/2025",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521920-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522935-32-00",
            "title": "Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Dompe' Farmaceutici S.p.A.",
            "conditions": "interstitial cystitis/bladder pain syndrome",
            "member_states": "Netherlands",
            "decision_date": "17/10/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522935-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521849-25-00",
            "title": "A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)",
            "phase": "Phase II",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Chronic Graft-Versus-Host Disease",
            "member_states": "Spain; Belgium; Germany; Italy",
            "decision_date": "17/10/2025",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521849-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521947-19-00",
            "title": "A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Healthy, Hepatic Insufficiency",
            "member_states": "Slovakia; Hungary",
            "decision_date": "17/10/2025",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521947-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522133-66-00",
            "title": "Immunomodulatory therapy to restore ovarian function and improve fertility in women with autoimmune premature ovarian insufficiency \u2013 a double-blind, placebo-controlled, randomized study",
            "phase": "Phase III",
            "lead_sponsor": "Karolinska University Hospital",
            "conditions": "Autoimmune Premature Ovarian Insufficiency",
            "member_states": "Sweden",
            "decision_date": "17/10/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522133-66-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521452-30-01",
            "title": "EUROpean pragmatic multicenter randomized trial on platelet inhibition and/or lipid lowering treatment in Covert Brain Infarction (CBI)",
            "phase": "Phase III",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Covert brain infarction (asymptomatic brain infarctions)",
            "member_states": "Denmark; Sweden; Norway",
            "decision_date": "17/10/2025",
            "enrolled": "1402",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521452-30-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521408-24-00",
            "title": "Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease \u2013 prospective randomized controlled phase III trial",
            "phase": "Phase III",
            "lead_sponsor": "Medical University Of Lodz",
            "conditions": "Fabry disease",
            "member_states": "Poland",
            "decision_date": "17/10/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521408-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516232-10-00",
            "title": "Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study\nto determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nimes",
            "conditions": "Serious infections in critically ill patients treated with antibiotics",
            "member_states": "France",
            "decision_date": "17/10/2025",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516232-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519402-12-00",
            "title": "Efficacy of non operative treatment with amoxicillin/clavulanic acid versus surgical treatment in acute uncomplicated appendicitis in children: a prospective multicenter randomized controlled non-inferiority trial with cost utility analysis",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "uncomplicated appendicitis",
            "member_states": "France",
            "decision_date": "17/10/2025",
            "enrolled": "724",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519402-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513710-35-00",
            "title": "SERORL Effect of aspirin and folic acid  for sudden sensorineural hearing loss",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of \u226530 decibels affecting at least 3 consecutive frequencies:\n1.\tA history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. \n2.\tA unilateral sensorineural hearing loss demonstrable on a pure\u2010tone audiogram at the time of entry into the trial. \n3.\tNo other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment.\n4.\tNo history of fluctuating sensorineural hearing loss or otologic disease.",
            "member_states": "France",
            "decision_date": "17/10/2025",
            "enrolled": "142",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513710-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2022-502362-24-00",
            "title": "Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial, ADEM2 study",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nice",
            "conditions": "Erosive osteoarthritis",
            "member_states": "France",
            "decision_date": "17/10/2025",
            "enrolled": "170",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2022-502362-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522109-39-00",
            "title": "PROlonged Corticosteroid treatment or N-ACetylcysteine for severe alcoholic hepatitis (PROCORNAC)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Lille",
            "conditions": "Alcoholic hepatitis",
            "member_states": "France",
            "decision_date": "17/10/2025",
            "enrolled": "477",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522109-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523957-32-00",
            "title": "Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy. (SNAP)",
            "phase": "Phase IV",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Medically uncontrolled glaucoma that requires filtration surgery.",
            "member_states": "Denmark",
            "decision_date": "17/10/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523957-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521611-39-00",
            "title": "A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Clinical Efficacy of AGP100 in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia",
            "phase": "Phase II",
            "lead_sponsor": "Agiana Pharmaceuticals AS",
            "conditions": "Catecholaminergic Polymorphic Ventricular Tachycardia",
            "member_states": "Norway",
            "decision_date": "16/10/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521611-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519674-40-00",
            "title": "A Phase 1/2, Open-Label, Dose Finding Study to Investigate the Safety, Tolerability, and\nEfficacy of ALXN2350 Gene Therapy in Adult Participants with Symptomatic BAG3\nMutation-Associated Dilated Cardiomyopathy",
            "phase": "Phase I/II",
            "lead_sponsor": "Alexion Pharmaceuticals Inc.",
            "conditions": "BAG3 Mutation Associated Dilated Cardiomyopathy",
            "member_states": "Spain; Italy; Germany",
            "decision_date": "16/10/2025",
            "enrolled": "8",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519674-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523052-32-00",
            "title": "A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at steady state in participants with Type 1 Diabetes",
            "phase": "Phase I",
            "lead_sponsor": "Gan & Lee Pharmaceuticals USA Corp.",
            "conditions": "Type 1 diabetes Mellitus",
            "member_states": "Germany",
            "decision_date": "15/10/2025",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523052-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521302-17-00",
            "title": "PRODIGE 118 - PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma \nPhase II single arm study -mutlicenter",
            "phase": "Phase III",
            "lead_sponsor": "Fondation Franc.Cancerologie Digestive",
            "conditions": "Hihg risk of cholangiocarcinoma intra h\u00e9patic resectable",
            "member_states": "France",
            "decision_date": "15/10/2025",
            "enrolled": "49",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521302-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520375-27-00",
            "title": "A phase 2, two-part study to assess the safety, antiviral biomarker responses, and efficacy of inhaled SNG001 for the treatment of patients with a confirmed respiratory virus infection undergoing invasive mechanical ventilation",
            "phase": "Phase II",
            "lead_sponsor": "Synairgen Research Limited",
            "conditions": "Lower respiratory tract viral infections",
            "member_states": "Netherlands; France; Spain; Belgium",
            "decision_date": "15/10/2025",
            "enrolled": "134",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520375-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516943-14-01",
            "title": "Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystectomy patients: phase II trial (preSAVE trial)",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione IRCCS Istituto Nazionale Dei Tumori",
            "conditions": "Muscle-Invasive Bladder cancer",
            "member_states": "Italy",
            "decision_date": "15/10/2025",
            "enrolled": "62",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516943-14-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516906-47-00",
            "title": "A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. \nTROPION-Urothelial03 (TU03).",
            "phase": "Phase III",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "Locally Advanced or Metastatic Urothelial Carcinoma",
            "member_states": "Netherlands; Germany; Norway; Denmark; France; Austria; Italy; Spain; Belgium; Czechia; Greece",
            "decision_date": "15/10/2025",
            "enrolled": "343",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516906-47-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521535-36-00",
            "title": "A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors",
            "phase": "Phase I",
            "lead_sponsor": "Janssen Cilag International",
            "conditions": "Locally advanced, metastatic NSCLC, CRC, or HNSCC that has recurred or progressed after prior stand of care therapy",
            "member_states": "Spain",
            "decision_date": "15/10/2025",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521535-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522128-28-00",
            "title": "Study Investigating Tucatinib and Osimertinib Pharmacokinetics in Primary and Metastatic Brain Tumors: the STICK trial",
            "phase": "Phase I",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Breast cancer, Non small cell lung carcinoma, Glioblastoma",
            "member_states": "Netherlands",
            "decision_date": "15/10/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522128-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521052-35-00",
            "title": "A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer",
            "phase": "Phase I/II",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "Patients with HER2Positive Advanced Breast Cancer",
            "member_states": "Spain",
            "decision_date": "15/10/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521052-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523705-14-00",
            "title": "Bioequivalence clinical trial of two formulations of loperamide.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Normon S.A.",
            "conditions": "Healthy volunteers",
            "member_states": "Spain",
            "decision_date": "15/10/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523705-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521876-77-00",
            "title": "A PHASE 1 TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PD of AX-0810 IN HEALTHY PARTICIPANTS",
            "phase": "Phase I",
            "lead_sponsor": "ProQR Therapeutics VIII B.V.",
            "conditions": "Cholestatic liver disease",
            "member_states": "Netherlands",
            "decision_date": "14/10/2025",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521876-77-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515438-33-00",
            "title": "B7981027 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Alopecia areata",
            "member_states": "Spain; France; Czechia; Italy; Poland",
            "decision_date": "14/10/2025",
            "enrolled": "68",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515438-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519917-72-00",
            "title": "TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)",
            "phase": "Phase III",
            "lead_sponsor": "Alnylam Pharmaceuticals Inc.",
            "conditions": "Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)",
            "member_states": "France; Germany; Italy; Greece; Belgium; Portugal; Netherlands; Austria; Sweden; Denmark; Spain; Czechia; Hungary; Ireland; Romania; Norway; Poland; Slovakia",
            "decision_date": "14/10/2025",
            "enrolled": "742",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519917-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515439-31-00",
            "title": "B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Alopecia areata",
            "member_states": "Italy; France; Czechia; Poland; Spain",
            "decision_date": "14/10/2025",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515439-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522605-37-00",
            "title": "Early-stage clinical trial investigating the individual and combined effect of two drugs, senicapoc and perampanel, as part of the treatment for newly diagnosed glioblastoma, which is an aggressive brain tumor",
            "phase": "Phase I",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Glioblastoma",
            "member_states": "Denmark",
            "decision_date": "14/10/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522605-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520801-12-00",
            "title": "Inhibition of late sodium current (INa) to prevent coronary MICROvascular dysfunction in patients presenting with ST-Elevation myocardial infarction and multivessel disease: A multicenter, randomized, controlled and open label study (INaMICRON study)",
            "phase": "Phase II",
            "lead_sponsor": "Universita' Degli Studi Di Napoli Federico II",
            "conditions": "Acute myocardial infarction in patients presenting with STEMI and multivessel disease.",
            "member_states": "Italy",
            "decision_date": "13/10/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520801-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521808-22-01",
            "title": "Effect of perioperative intravenous infusion of lidocaine on the postoperative course and the immune response in patients undergoing surgery for colon cancer - the PILDI study",
            "phase": "Phase II",
            "lead_sponsor": "Institute Of Oncology Ljubljana",
            "conditions": "Colon cancer",
            "member_states": "Slovenia",
            "decision_date": "13/10/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521808-22-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522599-97-00",
            "title": "A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older",
            "phase": "Phase II",
            "lead_sponsor": "GlaxoSmithKline Biologicals",
            "conditions": "Influenza, Human",
            "member_states": "Belgium",
            "decision_date": "13/10/2025",
            "enrolled": "168",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522599-97-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521067-13-00",
            "title": "J2O-MC-EKBG: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event - MOVE-Lp(a)",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)",
            "member_states": "Italy; Poland; Germany; Austria; Romania; Spain; Czechia; France; Denmark; Greece; Hungary; Slovakia; Belgium; Netherlands",
            "decision_date": "13/10/2025",
            "enrolled": "3160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521067-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520364-34-00",
            "title": "Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with  acute myocardial infarction. A serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S, ECRI-trials B.V.",
            "conditions": "Acute myocardial infarction",
            "member_states": "Italy; Netherlands; Austria; Denmark; Spain",
            "decision_date": "13/10/2025",
            "enrolled": "249",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520364-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519832-17-00",
            "title": "Perineural incobotulinumtoxin-A for Complex Regional Pain Syndrome - An open-label feasibility study (PINCom)",
            "phase": "Phase II",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Complex Regional Pain Syndrome",
            "member_states": "Denmark",
            "decision_date": "13/10/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519832-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523325-18-00",
            "title": "The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adults patients.",
            "phase": "Phase I",
            "lead_sponsor": "Adamed Pharma S.A.",
            "conditions": "Bioequivalence study under fasting conditions",
            "member_states": "Czechia",
            "decision_date": "13/10/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523325-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521785-10-00",
            "title": "A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)",
            "phase": "Phase III",
            "lead_sponsor": "Telix Pharmaceuticals (Innovations) Pty Limited",
            "conditions": "Glioblastoma",
            "member_states": "Austria; Netherlands; Belgium; Denmark; France; Germany; Spain",
            "decision_date": "13/10/2025",
            "enrolled": "65",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521785-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521397-34-00",
            "title": "Colchicine to reduce microvascular complications in people with type 1 diabetes and high glycemic variability",
            "phase": "Phase III",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Type 1 Diabetes",
            "member_states": "Netherlands",
            "decision_date": "13/10/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521397-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522472-85-00",
            "title": "Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population",
            "phase": "Phase III",
            "lead_sponsor": "Humanitas Mirasole S.p.A.",
            "conditions": "Recurrent Metastatic Nasopharingeal Carcinoma",
            "member_states": "Italy",
            "decision_date": "13/10/2025",
            "enrolled": "49",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522472-85-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522306-21-00",
            "title": "Effectiveness of CITicoline (TRAUSAN) in preventing cognitive decline After DELirium in older adults with proximal hip fracture \u2013 The CITADEL randomized controlled trial",
            "phase": "Phase II",
            "lead_sponsor": "Universita Degli Studi Di Milano Bicocca",
            "conditions": "Cognitive profiles",
            "member_states": "Italy",
            "decision_date": "13/10/2025",
            "enrolled": "122",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522306-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521923-58-00",
            "title": "Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.\nThe INFINITE Study",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Toulouse",
            "conditions": "Intracerebral hemorrhage.",
            "member_states": "France",
            "decision_date": "10/10/2025",
            "enrolled": "117",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521923-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522574-36-00",
            "title": "A Study to Learn How Different Forms of The Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Primary and secondary hypertension, and heart failure",
            "member_states": "Belgium",
            "decision_date": "10/10/2025",
            "enrolled": "72",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522574-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521556-35-00",
            "title": "A first-in-human, randomized, double-blind, placebo-controlled, three-part study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of BP1.15205 after single and repeated oral ascending doses, including the BP1.15205 effect on cardiac repolarization, as well as an exploratory assessment of the food effect on the pharmacokinetics of BP1.15205 in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "Bioprojet Pharma",
            "conditions": "Narcolepsy",
            "member_states": "Belgium",
            "decision_date": "10/10/2025",
            "enrolled": "178",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521556-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519792-25-00",
            "title": "Elacestrant and exemestane for patients with pretreated HR+/HER2- metastatic breast cancer and [18F]-FES-avid lesions (COMBINE): a proof-of-concept phase 2 clinical trial",
            "phase": "Phase II",
            "lead_sponsor": "Istituto Europeo Di Oncologia S.r.l.",
            "conditions": "Metastatic hormone receptor-positive/HER2-negative breast cancer",
            "member_states": "Italy",
            "decision_date": "10/10/2025",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519792-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512905-18-00",
            "title": "Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.",
            "phase": "Phase I",
            "lead_sponsor": "Allysta Pharmaceuticals Inc.",
            "conditions": "NASH",
            "member_states": "Bulgaria",
            "decision_date": "10/10/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512905-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522694-11-00",
            "title": "Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT",
            "phase": "Phase IV",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Episodic expiratory wheezing",
            "member_states": "Netherlands",
            "decision_date": "09/10/2025",
            "enrolled": "285",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522694-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522915-40-00",
            "title": "A phase 1, Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt (EYP651) and Evaluation of Potential Drug-Drug Interactions.",
            "phase": "Phase I",
            "lead_sponsor": "ENYO Pharma",
            "conditions": "Healthy volunteers, Impaired renal function and suspected MASH",
            "member_states": "France",
            "decision_date": "09/10/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522915-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522446-51-00",
            "title": "Assessment of the safety and effects on the body of investigational products when used on psoriatic skin",
            "phase": "Phase I",
            "lead_sponsor": "Bacoba AG",
            "conditions": "Plaque psoriasis",
            "member_states": "Germany",
            "decision_date": "09/10/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522446-51-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520658-12-00",
            "title": "A double-blind, randomised, placebo-controlled, parallel group, Phase IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI 765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis",
            "phase": "Phase II",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "Idiopathic Pulmonary Fibrosis (IPF)",
            "member_states": "Germany; Italy; Spain; Belgium",
            "decision_date": "09/10/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520658-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522216-17-00",
            "title": "A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)",
            "phase": "Phase I",
            "lead_sponsor": "Sitryx Therapeutics Limited",
            "conditions": "Atopic Dermatitis",
            "member_states": "Germany; Bulgaria; Ireland; Denmark",
            "decision_date": "09/10/2025",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522216-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523808-75-00",
            "title": "Randomised, crossover bioequivalence clinical trial of memantine 20 mg capsules versus memantine 20 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Alter S.A.",
            "conditions": "Alzheimer\u2019s disease",
            "member_states": "Spain",
            "decision_date": "09/10/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523808-75-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-505349-26-00",
            "title": "Impact of low dose epinephrine in the management of out-of-hospital cardiac arrest on neurological outcome:  A multicenter randomized and double-blind trial (Low-EPI Study)",
            "phase": "Phase III",
            "lead_sponsor": "CHRU De Nancy",
            "conditions": "Out-of-hospital cardiac arrest.",
            "member_states": "France",
            "decision_date": "08/10/2025",
            "enrolled": "4336",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-505349-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522656-68-00",
            "title": "Influence of patient\u2019s morphological characteristics on pharmacokinetic and toxicity of trastuzumab-deruxtecan administered for metastatic breast cancers (TDXdose)",
            "phase": "Phase IV",
            "lead_sponsor": "Oncopole Claudius Regaud",
            "conditions": "Metastatic breast cancers",
            "member_states": "France",
            "decision_date": "08/10/2025",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522656-68-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519258-35-00",
            "title": "PRODIGE 111 \u2013 DOMZIGAST\nA randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.",
            "phase": "Phase II",
            "lead_sponsor": "Fondation Franc.Cancerologie Digestive",
            "conditions": "stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma",
            "member_states": "France",
            "decision_date": "08/10/2025",
            "enrolled": "95",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519258-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522108-26-00",
            "title": "PRODIGE 115 (FFCD 2406) ULYSSE : A phase II, open-label, non-comparative, randomized study of second-line doublet chemotherapy (FOLFOX or FOLFIRI) plus Fruquintinib versus doublet chemotherapy (FOLFOX or FOLFIRI) plus Bevacizumab in metastatic colorectal cancer",
            "phase": "Phase II",
            "lead_sponsor": "Fondation Franc.Cancerologie Digestive",
            "conditions": "m\u00e9tastatique colorectal cancer",
            "member_states": "France",
            "decision_date": "08/10/2025",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522108-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519779-24-00",
            "title": "GFM-VEXAS-MMB: A single-arm phase II with safety run-in multicenter study of momelotinib in patients with VEXAS syndrome with or without associated myelodysplastic syndrome",
            "phase": "Phase II",
            "lead_sponsor": "Groupe Francophone Des Myelodysplasies",
            "conditions": "VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC) syndrome, Myelodysplastic syndrome",
            "member_states": "France",
            "decision_date": "08/10/2025",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519779-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523384-37-00",
            "title": "Bioequivalence clinical trial of two formulations of linagliptin",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Normon S.A.",
            "conditions": "Healthy volunteers",
            "member_states": "Spain",
            "decision_date": "08/10/2025",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523384-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522971-27-00",
            "title": "Open-label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, study to assess the bioequivalence between the test product Betahistine dihydrochloride 24 mg tablets from Esperante Development BV and reference product Betaserc\u00ae 24 mg tablets.",
            "phase": "Phase I",
            "lead_sponsor": "Esperante Development B.V.",
            "conditions": "Bioequivalence study under fasting conditions",
            "member_states": "Czechia",
            "decision_date": "08/10/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522971-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522100-25-00",
            "title": "A clinical study of MK-4082 in healthy people (MK-4082-001)",
            "phase": "Phase I",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Weight management",
            "member_states": "Belgium",
            "decision_date": "08/10/2025",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522100-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520478-20-00",
            "title": "A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX).",
            "phase": "Phase III",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Thromboembolic disease",
            "member_states": "Bulgaria; Lithuania; Poland; Hungary; Latvia; Romania",
            "decision_date": "08/10/2025",
            "enrolled": "1087",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520478-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518438-94-00",
            "title": "C4921003 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched-Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948 in Adults with Heart Failure (BRANCH-HF)",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Heart failure",
            "member_states": "France; Spain; Bulgaria; Poland; Hungary; Czechia",
            "decision_date": "08/10/2025",
            "enrolled": "356",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518438-94-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520794-39-00",
            "title": "SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION",
            "phase": "Phase III",
            "lead_sponsor": "Universitaetsklinikum Schleswig-Holstein A\u00f6R",
            "conditions": "Arterial Hypertension",
            "member_states": "Germany; Slovenia; Spain; Austria; Portugal; Italy",
            "decision_date": "08/10/2025",
            "enrolled": "3540",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520794-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521277-14-00",
            "title": "A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)",
            "phase": "Phase II",
            "lead_sponsor": "Tyra Biosciences Inc.",
            "conditions": "Non-muscle invasive bladder cancer (NMIBC)",
            "member_states": "Italy; Spain; France",
            "decision_date": "08/10/2025",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521277-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522252-74-00",
            "title": "Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad\u00ae 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions",
            "phase": "Phase I",
            "lead_sponsor": "PharOS Pharmaceutical Oriented Servises Ltd., CCDRD Cooperative Clinical Drug Research and Development AG",
            "conditions": "No therapeutic indication in the current trial with healthy volunteers.",
            "member_states": "Bulgaria",
            "decision_date": "08/10/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522252-74-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-506296-97-00",
            "title": "A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Moderate to Severe Plaque Psoriasis",
            "member_states": "Germany; Romania; Italy; Belgium; Poland; Hungary; Spain",
            "decision_date": "08/10/2025",
            "enrolled": "145",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-506296-97-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519901-36-00",
            "title": "ETOP 27-23 ARCH \u2013 A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCLC who have not received prior adjuvant chemotherapy.",
            "phase": "Phase III",
            "lead_sponsor": "ETOP IBCSG Partners Foundation",
            "conditions": "Patients with resected stage IIA-IIIB non-small cell lung cancer (NSCLC) with PD-L1 expression \u22651%",
            "member_states": "France; Estonia; Spain; Austria; Italy; Germany; Ireland",
            "decision_date": "08/10/2025",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519901-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519530-24-00",
            "title": "Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity",
            "phase": "Phase III",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Overweight and obesity",
            "member_states": "Norway; France; Italy; Germany; Poland",
            "decision_date": "07/10/2025",
            "enrolled": "116",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519530-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521161-27-00",
            "title": "CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Children and adolescents with severe neurodevelopmental disorders",
            "member_states": "France",
            "decision_date": "07/10/2025",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521161-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518385-26-01",
            "title": "Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional Et Universitaire De Brest",
            "conditions": "Polymyalgia Rheumatica (PMR)",
            "member_states": "France",
            "decision_date": "07/10/2025",
            "enrolled": "140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518385-26-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522635-34-00",
            "title": "A Study to Evaluate the Effect of TRIV-509 on Skin Barrier Function in Patients with Atopic Dermatitis.",
            "phase": "Phase I",
            "lead_sponsor": "Triveni Bio Inc.",
            "conditions": "Atopic Dermatitis",
            "member_states": "Netherlands",
            "decision_date": "07/10/2025",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522635-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519465-22-01",
            "title": "Functional lung avoidance planning guided by lung perfusion PET/CT versus anatomical planning for lung stereotactic body radiotherapy: a double blinded, randomized, controlled trial",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Regional Et Universitaire De Brest",
            "conditions": "planned to be treated in the radiotherapy department of the participating centers with SBRT for primary or secondary lung tumors.",
            "member_states": "France",
            "decision_date": "07/10/2025",
            "enrolled": "418",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519465-22-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518288-37-00",
            "title": "Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis",
            "phase": "Phase I",
            "lead_sponsor": "Regeneron Pharmaceuticals Inc.",
            "conditions": "Lupus Nephritis",
            "member_states": "Spain; France; Germany",
            "decision_date": "07/10/2025",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518288-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522070-36-00",
            "title": "A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment",
            "phase": "Phase III",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "immune thrombocytopenia (ITP)",
            "member_states": "France; Spain; Italy; Germany; Czechia; Poland; Hungary; Austria; Norway",
            "decision_date": "07/10/2025",
            "enrolled": "43",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522070-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520940-14-00",
            "title": "TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial",
            "phase": "Phase IV",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Pyogenic liver abscess",
            "member_states": "France",
            "decision_date": "06/10/2025",
            "enrolled": "456",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520940-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519278-37-00",
            "title": "A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)",
            "phase": "Phase II",
            "lead_sponsor": "Celgene Corp.",
            "conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
            "member_states": "France; Spain; Portugal; Germany; Belgium; Poland; Italy; Denmark; Austria",
            "decision_date": "06/10/2025",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519278-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521640-38-00",
            "title": "Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.",
            "phase": "Phase III",
            "lead_sponsor": "Praxis Precision Medicines Inc.",
            "conditions": "Focal onset seizures or primary generalized tonic-clonic seizures.",
            "member_states": "Germany; Spain; Poland; Italy",
            "decision_date": "06/10/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521640-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521772-57-00",
            "title": "A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson\u2019s disease and motor fluctuations - ADIP study",
            "phase": "Phase III",
            "lead_sponsor": "Zambon Biotech S.A.",
            "conditions": "Motor fluctuations in advanced Parkinson\u2019s disease",
            "member_states": "Spain; Italy; Poland",
            "decision_date": "06/10/2025",
            "enrolled": "91",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521772-57-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521775-31-00",
            "title": "A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)",
            "phase": "Phase III",
            "lead_sponsor": "Taiho Oncology Inc.",
            "conditions": "Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations",
            "member_states": "Germany; Poland; Spain; France; Belgium; Italy; Greece; Romania; Netherlands",
            "decision_date": "06/10/2025",
            "enrolled": "141",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521775-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522004-24-00",
            "title": "A Prospective, Open-Label, Randomized, Interventional Study to Evaluate the Efficacy and Tolerability of Sucrosomial\u00ae Iron vs Ferric Maltol in Iron Deficient Women",
            "phase": "Phase III",
            "lead_sponsor": "Pharmanutra S.p.A.",
            "conditions": "iron deficient",
            "member_states": "Spain",
            "decision_date": "06/10/2025",
            "enrolled": "146",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522004-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519654-37-00",
            "title": "A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (FORTIFI-HN01).",
            "phase": "Phase III",
            "lead_sponsor": "Bicara Therapeutics Inc.",
            "conditions": "Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.",
            "member_states": "Belgium; Austria; Italy; Poland; Spain; Germany; Czechia; Ireland; Greece; France; Portugal",
            "decision_date": "06/10/2025",
            "enrolled": "216",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519654-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-510596-37-01",
            "title": "Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation.",
            "phase": "Phase III",
            "lead_sponsor": "Instituto Bernabeu S.L.",
            "conditions": "low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism",
            "member_states": "Spain",
            "decision_date": "06/10/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-510596-37-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522633-57-00",
            "title": "A Phase I, Open-label, Randomized, Active-Controlled, to Evaluate the Safety and Immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old Healthy Participants in Sweden.",
            "phase": "Phase I",
            "lead_sponsor": "International Vaccine Institute",
            "conditions": "Prevention of Cholera disease",
            "member_states": "Sweden",
            "decision_date": "06/10/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522633-57-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516794-70-00",
            "title": "A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-02)",
            "phase": "Phase II",
            "lead_sponsor": "CatalYm GmbH",
            "conditions": "Metastatic non-squamous non-small cell lung cancer",
            "member_states": "Spain; Italy; Germany; Poland; Romania",
            "decision_date": "06/10/2025",
            "enrolled": "103",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516794-70-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521684-12-00",
            "title": "A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on disease activity in patients with Hidradenitis Suppurativa (HS)",
            "phase": "Phase II",
            "lead_sponsor": "Citryll B.V.",
            "conditions": "Hidradenitis Suppurativa",
            "member_states": "Netherlands; Germany; Poland; Spain",
            "decision_date": "06/10/2025",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521684-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515658-26-00",
            "title": "A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination \nwith Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, \nas First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic \nHER2-overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer. (DESTINY-Lung06)",
            "phase": "Phase III",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer",
            "member_states": "France; Belgium; Germany; Portugal; Italy; Greece; Romania; Spain; Poland",
            "decision_date": "06/10/2025",
            "enrolled": "159",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515658-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-503447-33-00",
            "title": "Pivmecillinam as oral step-down treatment for Escherichia coli febrile urinary tract infection versus standard of care; a randomized controlled non-inferiority multicenter trial",
            "phase": "Phase II",
            "lead_sponsor": "Uppsala Universitet",
            "conditions": "febrile Urinary Tract Infection (fUTI)",
            "member_states": "Sweden; Norway",
            "decision_date": "06/10/2025",
            "enrolled": "560",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-503447-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522116-16-00",
            "title": "Phase IV multicenter immunogenicity and safety study of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults immunized with an H5N1/MF59 influenza vaccine, approximately 20 years before the trial, compared to H5 naive adult participants.",
            "phase": "Phase IV",
            "lead_sponsor": "University Of Antwerp",
            "conditions": "Avian Influenza",
            "member_states": "Italy; Belgium",
            "decision_date": "06/10/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522116-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521744-37-00",
            "title": "Multi-centre, double-blind, placebo-controlled, randomised trial to prove the efficacy and safety of Silexan\u00ae (WS\u00ae1265) in patients with a major depressive episode of mild to moderate severity",
            "phase": "Phase III",
            "lead_sponsor": "Dr. Willmar Schwabe GmbH & Co. KG",
            "conditions": "Mild to moderate major depressive disorder",
            "member_states": "Germany; Austria",
            "decision_date": "06/10/2025",
            "enrolled": "500",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521744-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517121-10-00",
            "title": "C4951063: An interventional efficacy and safety, Phase 3, double-blind, parallel group study to investigate intermittent prevention of Menstrual Migraine with Rimegepant compared with placebo in women participants 18 to 45 years of age",
            "phase": "Phase III",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Menstrual Migraine",
            "member_states": "Netherlands; Italy; Poland; Denmark; Germany; Spain",
            "decision_date": "06/10/2025",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517121-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516652-18-00",
            "title": "A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight",
            "member_states": "Slovakia; Denmark; Portugal; Czechia; Poland; Greece; Bulgaria; France; Spain; Sweden; Finland; Belgium; Romania; Germany; Hungary; Netherlands; Italy; Austria",
            "decision_date": "06/10/2025",
            "enrolled": "6002",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516652-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521315-39-00",
            "title": "EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)",
            "phase": "Phase I",
            "lead_sponsor": "Grey Wolf Therapeutics Limited",
            "conditions": "Axial spondyloarthritis",
            "member_states": "Belgium; Germany; Netherlands; Spain; Poland",
            "decision_date": "06/10/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521315-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520715-13-00",
            "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)",
            "phase": "Phase II",
            "lead_sponsor": "Rein Therapeutics Inc.",
            "conditions": "Idiopathic Pulmonary Fibrosis",
            "member_states": "Germany; Poland",
            "decision_date": "06/10/2025",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520715-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521147-21-00",
            "title": "A Phase 1b/2 Open-Label, Multicenter Study of RMC-9805 with or without RMC-6236, in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) \u2013 Subprotocol C",
            "phase": "Phase II",
            "lead_sponsor": "Revolution Medicines Inc.",
            "conditions": "Lung Cancer",
            "member_states": "Germany; Austria; France; Netherlands; Czechia; Greece; Italy; Spain; Denmark",
            "decision_date": "06/10/2025",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521147-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517140-65-00",
            "title": "A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma",
            "phase": "Phase I/II",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Multiple Myeloma (MM).",
            "member_states": "Belgium; Portugal; Sweden; Italy; France; Poland; Germany",
            "decision_date": "06/10/2025",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517140-65-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521209-42-00",
            "title": "A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial",
            "phase": "Phase IV",
            "lead_sponsor": "Fondazione GONO G.I.",
            "conditions": "advanced colorectal cancer with wild-type RAS and right primary tumour location (right-PTL)",
            "member_states": "Italy; Germany; Spain",
            "decision_date": "06/10/2025",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521209-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520610-58-00",
            "title": "A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to  Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "HIV-1 prevention",
            "member_states": "France",
            "decision_date": "03/10/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520610-58-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521086-28-00",
            "title": "Randomized clinical trial to assess the efficacy and safety of a strategy for primary prevention of cardiovascular disease in patients with inflammatory rheumatic diseases based on the use of carotid ultrasound.",
            "phase": "Phase IV",
            "lead_sponsor": "Instituto De Investigacion Marques De Valdecilla",
            "conditions": "CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoriatic arthritis or axial spondyloarthritis or systemic lupus erythematosus",
            "member_states": "Spain",
            "decision_date": "03/10/2025",
            "enrolled": "1250",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521086-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520690-39-00",
            "title": "A Phase IIb, Multicenter, Double-Blind, Placebo-Controlled Induction Study with an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients with Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase II",
            "lead_sponsor": "Genentech Inc.",
            "conditions": "Moderately to Severely Active Ulcerative Colitis (UC)",
            "member_states": "France; Italy; Czechia; Poland; Germany",
            "decision_date": "03/10/2025",
            "enrolled": "84",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520690-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516576-15-00",
            "title": "A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer\nTherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study",
            "phase": "Phase III",
            "lead_sponsor": "Centre Regional Lutte Contre Le Cancer",
            "conditions": "metastatic breast cancer",
            "member_states": "France",
            "decision_date": "03/10/2025",
            "enrolled": "224",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516576-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521088-10-00",
            "title": "A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton\u2019s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)",
            "phase": "Phase II",
            "lead_sponsor": "Nurix Therapeutics Inc.",
            "conditions": "Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",
            "member_states": "France; Italy; Hungary; Poland",
            "decision_date": "02/10/2025",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521088-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519479-24-00",
            "title": "Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA trial",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione GONO G.I.",
            "conditions": "metastatic colorectal cancer",
            "member_states": "Germany; France; Italy; Spain",
            "decision_date": "02/10/2025",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519479-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508930-33-00",
            "title": "CRYOBI study - A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious active cryoglobulinemia vasculitis refractory or intolerant to Rituximab",
            "phase": "Phase II",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab",
            "member_states": "France",
            "decision_date": "02/10/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508930-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522088-13-00",
            "title": "The DALBA-study\nIntroduction of the antibiotic dalbavancin in orthopaedic surgery \u2013 an evaluation of:\n\u2022\tHealth economic costs\n\u2022\tPatient-reported outcomes on quality of life\n\u2022\tLocal bone and soft tissue concentrations\n\u2022\tEffect on the gut microbiome\nA randomised controlled study of dalbavancin versus standard antibiotic treatment of Gram-positive periprosthetic joint infections.",
            "phase": "Phase IV",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Periprosthetic joint infection",
            "member_states": "Denmark",
            "decision_date": "02/10/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522088-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515201-26-00",
            "title": "A phase II randomized clinical trial of Tarlatamab as maintenance treatment after sequential chemo-radiotherapy vs sequential chemo-radiotherapy as standard treatment for limited stage SCLC patients not eligible for concurrent chemo-radiotherapy. MERLIN GECP 24/01",
            "phase": "Phase II",
            "lead_sponsor": "Fundacion GECP",
            "conditions": "Small cell lung cancer (SCLC)",
            "member_states": "Spain",
            "decision_date": "02/10/2025",
            "enrolled": "37",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515201-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521903-28-00",
            "title": "A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (allo HCT)",
            "phase": "Phase III",
            "lead_sponsor": "Symbio Pharmaceuticals Ltd.",
            "conditions": "Adenovirus viremia",
            "member_states": "Germany; Italy; France; Spain; Portugal",
            "decision_date": "02/10/2025",
            "enrolled": "87",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521903-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522169-31-00",
            "title": "AcS\u00e9 HER2_Widening treatment options among adult patients with HER2-overexpressing or mutant solid cancers",
            "phase": "Phase II",
            "lead_sponsor": "Unicancer",
            "conditions": "Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, colorectal, head & neck or sarcoma) or HER2 mutant non-small cell lung cancer.",
            "member_states": "France",
            "decision_date": "01/10/2025",
            "enrolled": "105",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522169-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522135-34-00",
            "title": "The effect of a superficial parasternal intercostal plane block in cardiac surgical patients undergoing conventional median sternotomy: a multicentric, double-blind, prospective, randomized controlled superiority trial.",
            "phase": "Phase III",
            "lead_sponsor": "UZ Leuven",
            "conditions": "Patients undergoing cardiac surgery through conventional median sternotomy access",
            "member_states": "Belgium",
            "decision_date": "01/10/2025",
            "enrolled": "136",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522135-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521278-32-00",
            "title": "A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)",
            "phase": "Phase II",
            "lead_sponsor": "Mediar Therapeutics Inc.",
            "conditions": "Idiopathic Pulmonary Fibrosis (IPF)",
            "member_states": "Croatia; Ireland; Netherlands; Spain; France; Belgium",
            "decision_date": "01/10/2025",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521278-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521658-40-00",
            "title": "A first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.",
            "phase": "Phase I",
            "lead_sponsor": "Egle Therapeutics",
            "conditions": "Atopic dermatitis",
            "member_states": "Germany; Bulgaria; Poland",
            "decision_date": "01/10/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521658-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522741-21-00",
            "title": "Heart rate control: Betablockers or Ivabradine therapy before cardiac computed tomography",
            "phase": "Phase IV",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "ischemic heart disease",
            "member_states": "Denmark",
            "decision_date": "01/10/2025",
            "enrolled": "350",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522741-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-511508-18-00",
            "title": "An open-label, Phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic graft versus host disease (cGVHD).",
            "phase": "Phase I/II",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Chronic graft versus host disease.",
            "member_states": "France; Italy; Belgium; Spain; Netherlands; Germany",
            "decision_date": "30/09/2025",
            "enrolled": "23",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-511508-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515903-21-00",
            "title": "Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)",
            "phase": "Phase I",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
            "member_states": "France; Germany; Spain; Greece; Hungary; Italy",
            "decision_date": "30/09/2025",
            "enrolled": "47",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515903-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521304-21-00",
            "title": "A single-arm, open-label, phase I/II clinical trial of autologous hematopoietic stem and progenitor cells (HSPCs) genetically modified with a lentiviral vector (LVV) encoding for the human programmed death-ligand 1 (hPD-L1) complementary deoxyribonucleic acid (cDNA) for the treatment of patients with type 1 diabetes (T1D) at recent onset and with residual \u03b2-cell function (Immunostem)",
            "phase": "Phase I/II",
            "lead_sponsor": "Altheia Science S.r.l.",
            "conditions": "Type 1 diabetes",
            "member_states": "Italy",
            "decision_date": "30/09/2025",
            "enrolled": "15",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521304-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519190-19-00",
            "title": "A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease",
            "phase": "Phase II",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Alzheimer\u2019s Disease",
            "member_states": "Spain; Belgium; Netherlands",
            "decision_date": "30/09/2025",
            "enrolled": "58",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519190-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517304-12-00",
            "title": "A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia",
            "phase": "Phase II",
            "lead_sponsor": "Pharmnovo AB",
            "conditions": "Mechanical allodynia",
            "member_states": "Spain; Czechia",
            "decision_date": "30/09/2025",
            "enrolled": "45",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517304-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522593-36-00",
            "title": "A phase IV study to investigate the immunogenicity of the Seqirus licensed MF59 adjuvanted zoonotic influenza vaccine (H5N8) in adults previously vaccinated in 2009 with the Matrix M adjuvanted virosomal influenza (H5N1) vaccine compared to H5 na\u00efve adults.",
            "phase": "Phase IV",
            "lead_sponsor": "Helse Bergen HF",
            "conditions": "Virus Diseases",
            "member_states": "Norway",
            "decision_date": "30/09/2025",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522593-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520384-14-00",
            "title": "A randomised, double-masked, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of oral BI 1815368 in participants with centre-involved diabetic macular edema for 48 weeks of treatment (THULITE)",
            "phase": "Phase II",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Centre-involved diabetic macular edema",
            "member_states": "Germany; Slovakia; Poland; Hungary; Czechia",
            "decision_date": "30/09/2025",
            "enrolled": "193",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520384-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521075-31-00",
            "title": "RANDOMIZED CONTROLLED STUDY COMPARING SUFENTANIL AND KETAMINE INTRANASALLY IN THE MANAGEMENT OF SEVERE ACUTE TRAUMA-RELATED PAIN IN CHILDREN",
            "phase": "Phase II",
            "lead_sponsor": "Fondation Lenval Nice",
            "conditions": "SEVERE ACUTE TRAUMA-RELATED PAIN",
            "member_states": "France",
            "decision_date": "30/09/2025",
            "enrolled": "116",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521075-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522290-11-00",
            "title": "IMAGINE 1",
            "phase": "Phase I",
            "lead_sponsor": "Karolinska University Hospital",
            "conditions": "Cholangiocarcinoma, pancreatic cancer, colo-rectal cancer",
            "member_states": "Sweden",
            "decision_date": "30/09/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522290-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517397-25-00",
            "title": "FT819 in B-cell Mediated Autoimmune Diseases",
            "phase": "Phase I",
            "lead_sponsor": "Fate Therapeutics Inc.",
            "conditions": "B-cell Mediated Autoimmune Diseases",
            "member_states": "France; Sweden; Germany",
            "decision_date": "30/09/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517397-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-504439-42-01",
            "title": "Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)",
            "phase": "Phase II",
            "lead_sponsor": "Hospital Universitario 12 De Octubre",
            "conditions": "alcohol dependence",
            "member_states": "Spain",
            "decision_date": "30/09/2025",
            "enrolled": "118",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-504439-42-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2022-501458-13-01",
            "title": "Pembro-FLASH - Phase II trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classic Hodgkin Lymphoma",
            "phase": "Phase II",
            "lead_sponsor": "University Of Cologne",
            "conditions": "Advanced Stage of Classic Hodgkin Lymphoma",
            "member_states": "Germany",
            "decision_date": "30/09/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2022-501458-13-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518210-81-00",
            "title": "A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Advanced Hepatocellular Carcinoma",
            "member_states": "Italy; Germany; France; Poland; Spain; Netherlands",
            "decision_date": "30/09/2025",
            "enrolled": "273",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518210-81-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519261-21-00",
            "title": "Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT)",
            "phase": "Phase II",
            "lead_sponsor": "Italian Sarcoma Group",
            "conditions": "Desmoplastic small round cell tumor",
            "member_states": "Spain; Italy",
            "decision_date": "30/09/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519261-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521268-37-00",
            "title": "A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease (AEOLUS)",
            "phase": "Phase IV",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Respiratory tract diseases",
            "member_states": "Netherlands; Hungary; France; Germany; Austria; Spain; Poland; Sweden; Italy; Denmark",
            "decision_date": "29/09/2025",
            "enrolled": "184",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521268-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520582-51-00",
            "title": "An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician\u2019s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Hormone receptor positive breast cancer",
            "member_states": "Greece; Poland; France; Italy; Spain; Hungary; Germany",
            "decision_date": "29/09/2025",
            "enrolled": "211",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520582-51-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521600-21-00",
            "title": "A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies",
            "phase": "Phase I",
            "lead_sponsor": "Beigene Ltd.",
            "conditions": "mature B-Cell malignancies",
            "member_states": "France; Italy",
            "decision_date": "29/09/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521600-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521916-20-00",
            "title": "A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Cancer",
            "member_states": "Spain; France",
            "decision_date": "29/09/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521916-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519671-26-00",
            "title": "A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial of Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in Participants with Advanced or Metastatic Non-small Cell Lung Cancer whose Tumors Express PD-L1 with Tumor Proportion Score \u226550% Without Actionable Genomic Alterations",
            "phase": "Phase I/II",
            "lead_sponsor": "Daiichi Sankyo Inc.",
            "conditions": "Advanced or Metastatic Non-Small Cell Lung Cancer",
            "member_states": "Spain; France; Italy",
            "decision_date": "29/09/2025",
            "enrolled": "21",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519671-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521627-78-00",
            "title": "Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)",
            "phase": "Phase III",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Neoplasms, Lung",
            "member_states": "Hungary; France; Portugal; Greece; Sweden; Ireland; Poland; Bulgaria; Romania; Finland; Italy; Germany; Spain",
            "decision_date": "29/09/2025",
            "enrolled": "210",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521627-78-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522023-10-00",
            "title": "Testosterone supplementation in patients in best supportive care: impact on quality of life.",
            "phase": "Phase II",
            "lead_sponsor": "Institut Jules Bordet",
            "conditions": "Androgen deficiency, palliative care",
            "member_states": "Belgium",
            "decision_date": "29/09/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522023-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520407-27-00",
            "title": "APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with \nErythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)",
            "phase": "Phase III",
            "lead_sponsor": "Disc Medicine Inc.",
            "conditions": "X-Linked Protoporphyria (XLP), Erythropoietic Protoporphyria (EPP)",
            "member_states": "Germany; Ireland; Spain; France; Norway; Netherlands; Sweden; Belgium; Italy",
            "decision_date": "29/09/2025",
            "enrolled": "71",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520407-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523419-12-00",
            "title": "Multiple-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Participants.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Leon Farma S.A.",
            "conditions": "No medical condition.",
            "member_states": "Portugal",
            "decision_date": "29/09/2025",
            "enrolled": "60",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523419-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519225-38-00",
            "title": "STOP-RIO: A randomized controlled non-inferiority trial to test the safety of discontinuation of riociguat after balloon pulmonary angioplasty in Chronic Thrombo-embolic Pulmonary Hypertension",
            "phase": "Phase III",
            "lead_sponsor": "Amsterdam UMC Stichting",
            "conditions": "Chronic thromboembolic pulmonary hypertension (CTEPH)",
            "member_states": "Netherlands",
            "decision_date": "29/09/2025",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519225-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520766-22-00",
            "title": "A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1",
            "phase": "Phase III",
            "lead_sponsor": "Avidity Biosciences Inc.",
            "conditions": "Myotonic Dystrophy Type 1",
            "member_states": "France; Denmark; Spain; Italy; Germany; Netherlands",
            "decision_date": "29/09/2025",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520766-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508804-39-00",
            "title": "A Phase 3b Extension Study to Evaluate the Long-Term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Ulcerative Colitis or Crohn\u2019s Disease",
            "member_states": "Spain; Ireland; Portugal; Poland; Belgium; Netherlands; Bulgaria; Romania; Italy; Denmark",
            "decision_date": "29/09/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508804-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516253-49-01",
            "title": "HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer",
            "phase": "Phase II",
            "lead_sponsor": "Institut Jules Bordet",
            "conditions": "advanced/metastatic HER2-positive breast carcinoma",
            "member_states": "Belgium; Netherlands",
            "decision_date": "29/09/2025",
            "enrolled": "109",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516253-49-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519495-83-00",
            "title": "A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of SAR444336 in participants with microscopic colitis in clinical remission with budesonide.",
            "phase": "Phase II",
            "lead_sponsor": "Sanofi-Aventis Recherche & Developpement",
            "conditions": "Digestive system diseases",
            "member_states": "Italy; Sweden; Germany; France; Poland; Denmark; Belgium; Hungary",
            "decision_date": "29/09/2025",
            "enrolled": "78",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519495-83-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521243-20-00",
            "title": "A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly",
            "phase": "Phase II",
            "lead_sponsor": "Alexion Pharmaceuticals Inc.",
            "conditions": "Acromegaly",
            "member_states": "Lithuania; Romania; Denmark; Italy; Hungary; Poland; Netherlands",
            "decision_date": "29/09/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521243-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521377-14-00",
            "title": "Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.",
            "phase": "Phase II",
            "lead_sponsor": "Acesion Pharma ApS",
            "conditions": "Atrial fibrillation",
            "member_states": "Hungary; Italy; Denmark; Bulgaria; Poland; Netherlands; Germany",
            "decision_date": "29/09/2025",
            "enrolled": "180",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521377-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518821-13-00",
            "title": "A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis",
            "phase": "Phase II",
            "lead_sponsor": "CSL Behring LLC",
            "conditions": "Non-cystic Fibrosis Bronchiectasis",
            "member_states": "Spain; Belgium; Germany; Greece; Denmark; Netherlands; Hungary; Italy; France; Poland",
            "decision_date": "26/09/2025",
            "enrolled": "226",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518821-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520294-13-00",
            "title": "CITY",
            "phase": "Phase I",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "Cutaneous T-cell lymphomas (CTCL)",
            "member_states": "Spain; France",
            "decision_date": "26/09/2025",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520294-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520627-25-00",
            "title": "A single centre parallel-group randomized control trial of Magnetic Resonance Assessment of Variations in Effects of anaesthesia on renaL perfusion in children",
            "phase": "Phase IV",
            "lead_sponsor": "Region Uppsala",
            "conditions": "Post-operative Acute Kidney Injury",
            "member_states": "Sweden",
            "decision_date": "26/09/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520627-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519537-29-00",
            "title": "A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS",
            "phase": "Phase I",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Acute Myeloid Leukemia and Myelodysplastic Syndrome",
            "member_states": "France; Spain",
            "decision_date": "26/09/2025",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519537-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522326-13-00",
            "title": "Obesity and Semaglutide in Type 1 Diabetes Therapy (OBES1TY): A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial",
            "phase": "Phase III",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Obesity defined by BMI equal to or higher than 30, Obesity defined by BMI equal to or higher than 27 and obesity-related diagnosis registered in the electronic patient journal such as: hypertension, hypercholesterolemia, dyslipidemia, micro albuminuria, ischemic heart disease, stroke, atherosclerosis or athrosis), Type 1 Diabetes",
            "member_states": "Denmark",
            "decision_date": "26/09/2025",
            "enrolled": "122",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522326-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517131-52-00",
            "title": "A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "phase": "Phase III",
            "lead_sponsor": "BeOne Medicines AG",
            "conditions": "Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "member_states": "France; Sweden; Czechia; Austria; Belgium; Germany; Denmark; Spain; Netherlands; Italy; Ireland; Poland",
            "decision_date": "26/09/2025",
            "enrolled": "285",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517131-52-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521249-25-00",
            "title": "A phase 1/2, open label, multicenter clinical trial investigating the safety, tolerability, pharmacokinetics, and antineoplastic activity of S095035 (MAT2A inhibitor) as a single agent and in combination in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP",
            "phase": "Phase I/II",
            "lead_sponsor": "Institut De Recherches Internationales Servier IRIS",
            "conditions": "MTAP-deleted advanced or metastatic solid tumors",
            "member_states": "Denmark; Italy; Germany; Spain; France",
            "decision_date": "26/09/2025",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521249-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514248-95-00",
            "title": "A 52 week, randomized, double-blind, double dummy multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 \u00b5g pMDI (fixed combination of extrafine Beclomethasone Dipropionate plus Formoterol Fumarate plus Glycopyrronium Bromide) to Seretide\u00ae Evohaler\u00ae 125/25 \u00b5g pMDI (fixed combination of fluticasone propionate / salmeterol xinafoate) in adolescent subjects with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long acting \u00df2 agonists.",
            "phase": "Phase III",
            "lead_sponsor": "Chiesi Farmaceutici S.p.A.",
            "conditions": "Uncontrolled Asthma",
            "member_states": "Italy; Germany; Spain",
            "decision_date": "26/09/2025",
            "enrolled": "147",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514248-95-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522148-42-00",
            "title": "A PHASE 1/1B, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF VVD-159642 AS A SINGLE AGENT AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS",
            "phase": "Phase I",
            "lead_sponsor": "Vividion Therapeutics Inc.",
            "conditions": "Advanced Solid Tumours",
            "member_states": "Spain",
            "decision_date": "26/09/2025",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522148-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520841-60-00",
            "title": "A multi-centre, single-arm study to demonstrate the efficacy of bone marrow allogeneic mesenchymal cells combined with biomaterial (combined ATMP) for bone healing in delayed union and non-union after long bone fractures (OrthoAlloUnion).",
            "phase": "Phase III",
            "lead_sponsor": "Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda",
            "conditions": "Delayed consolidation or non-union long bone fracture",
            "member_states": "Spain; Italy; France; Germany",
            "decision_date": "26/09/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520841-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522585-72-00",
            "title": "Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed moderate-to-severe ulcerative colitis: A 52-week, multicenter, open-label, randomized controlled trial",
            "phase": "Phase IV",
            "lead_sponsor": "Universitaetsklinikum Schleswig-Holstein A\u00f6R",
            "conditions": "ulcerative colitis",
            "member_states": "Germany",
            "decision_date": "26/09/2025",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522585-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522528-29-00",
            "title": "The effect of colchicine, on insulin sensitivity in individuals with type 1 diabetes and systemic low-grade inflammation (INS1GHT)",
            "phase": "Phase II",
            "lead_sponsor": "Gentofte Hospital",
            "conditions": "Type 1 diabetes",
            "member_states": "Denmark",
            "decision_date": "26/09/2025",
            "enrolled": "26",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522528-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523061-22-00",
            "title": "A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA)",
            "phase": "Phase II",
            "lead_sponsor": "Universitaet Leipzig",
            "conditions": "Granulomatous Polyangiitis, Systemic Lupus Erythematosus, Systemic Sclerosis",
            "member_states": "Germany",
            "decision_date": "26/09/2025",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523061-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522868-32-00",
            "title": "Changes in plaque characteristics after short-term statin therapy assessed with coronary CT",
            "phase": "Phase III",
            "lead_sponsor": "Semmelweis University",
            "conditions": "Coronary Artery Disease, Cardiology, Statin Therapy, Coronary Computed Tomography Angiography, Stable chest pain",
            "member_states": "Hungary",
            "decision_date": "26/09/2025",
            "enrolled": "140",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522868-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514152-32-00",
            "title": "A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL) and Small Lymphocytic Lymphoma (SLL)",
            "member_states": "France; Spain; Poland",
            "decision_date": "25/09/2025",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514152-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521578-32-00",
            "title": "A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Phase III Therapeutic Superiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Diclofenac + Orphenadrine + Paracetamol to Diclofenac (Cataflam\u00ae) and Orphenadrine + Paracetamol (Norgesic\u00ae) in Patients with Acute Severe Low Back Pain.",
            "phase": "Phase III",
            "lead_sponsor": "Verisfield Single Member S.A.",
            "conditions": "LOW BACK PAIN",
            "member_states": "Greece",
            "decision_date": "25/09/2025",
            "enrolled": "224",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521578-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522547-17-00",
            "title": "PK/PD of Cefadroxil in Staphylococcus Aureus Bacteremia, a preliminary study",
            "phase": "Phase II",
            "lead_sponsor": "UZ Brussel",
            "conditions": "staphylococcus aureus bacteremia",
            "member_states": "Belgium",
            "decision_date": "24/09/2025",
            "enrolled": "25",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522547-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521926-13-00",
            "title": "Pharmacokinetic study of the use of Nefopam 30 mg tablet in patients suffering from acute pain in rheumatology - NEFOPAIN kinetics",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire Rouen",
            "conditions": "Hospitalized patient with acute rheumatological pain, requiring nefopam if necessary",
            "member_states": "France",
            "decision_date": "24/09/2025",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521926-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521178-33-00",
            "title": "A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)",
            "phase": "Phase II",
            "lead_sponsor": "Aligos Therapeutics Inc.",
            "conditions": "Chronic Hepatitis B Virus Infection",
            "member_states": "Spain; Italy; Bulgaria; Romania; France",
            "decision_date": "24/09/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521178-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521519-37-00",
            "title": "A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN",
            "phase": "Phase II",
            "lead_sponsor": "Vera Therapeutics Inc.",
            "conditions": "IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders",
            "member_states": "Spain; Poland",
            "decision_date": "24/09/2025",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521519-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521188-11-00",
            "title": "EASi-PROTKT\u2122 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease",
            "phase": "Phase III",
            "lead_sponsor": "Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.",
            "conditions": "hypertension, cardiovascular disease, Type 2 diabetes",
            "member_states": "Lithuania; Netherlands; Ireland; Romania; France; Hungary; Finland; Latvia; Austria; Germany; Greece; Italy; Sweden; Denmark; Czechia; Belgium; Slovakia; Croatia; Spain; Norway; Bulgaria; Poland; Portugal",
            "decision_date": "24/09/2025",
            "enrolled": "4718",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521188-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521055-23-00",
            "title": "ARGX-113-2409: A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo- Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants from 12 Years to Less Than 18 Years of Age with Chronic ITP",
            "phase": "Phase III",
            "lead_sponsor": "Argenx",
            "conditions": "Chronic Idiopathic thrombocytopenic purpura",
            "member_states": "Lithuania; Romania; Hungary; France; Italy; Spain; Poland; Germany",
            "decision_date": "24/09/2025",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521055-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520029-35-01",
            "title": "TACTIC : MP0317, A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN, IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CARCINOMA\nA RANDOMIZED NON COMPARATIVE PROOF OF CONCEPT PHASE II STUDY",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire",
            "conditions": "ADVANCED BILIARY TRACT CARCINOMA",
            "member_states": "France",
            "decision_date": "24/09/2025",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520029-35-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520117-50-00",
            "title": "A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Inmagene LLC",
            "conditions": "Atopic Dermatitis",
            "member_states": "Czechia; Spain; Germany; Hungary; Poland",
            "decision_date": "24/09/2025",
            "enrolled": "177",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520117-50-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518785-28-00",
            "title": "A low-intervention prospective-retrospective study to evaluate the pharmacokinetics of elexacaftor/tezacaftor/ivacaftor combination in a Cystic Fibrosis population",
            "phase": "Phase IV",
            "lead_sponsor": "IRCCS Istituto Giannina Gaslini",
            "conditions": "Cystic Fibrosis",
            "member_states": "Italy",
            "decision_date": "24/09/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518785-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518206-40-00",
            "title": "Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)",
            "phase": "Phase III",
            "lead_sponsor": "Arrowhead Pharmaceuticals Inc.",
            "conditions": "Severe hypertriglyceridemia (SHTG)",
            "member_states": "Hungary; Bulgaria; Sweden; Austria; Norway; Belgium; Croatia; Czechia; Latvia; Lithuania; Spain; Slovakia",
            "decision_date": "23/09/2025",
            "enrolled": "243",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518206-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519655-28-00",
            "title": "OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women",
            "phase": "Phase III",
            "lead_sponsor": "Unicancer",
            "conditions": "Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: \na.\t1-3 lymph nodes involved AND any invasive tumour size. \nb.\tnode negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size \u2265 50mm.",
            "member_states": "Poland; France; Italy; Greece; Spain; Ireland; Belgium",
            "decision_date": "23/09/2025",
            "enrolled": "2270",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519655-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516234-35-00",
            "title": "A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell\nMalignancies",
            "phase": "Phase I/II",
            "lead_sponsor": "BeOne Medicines AG",
            "conditions": "Relapsed or Refractory B-Cell Malignancies",
            "member_states": "Italy; Germany; Poland",
            "decision_date": "23/09/2025",
            "enrolled": "99",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516234-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516411-24-00",
            "title": "A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA",
            "phase": "Phase III",
            "lead_sponsor": "Vanda Pharmaceuticals Netherlands B.V., Vanda Pharmaceuticals Inc.",
            "conditions": "Insomnia Disorder",
            "member_states": "Poland; Germany",
            "decision_date": "23/09/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516411-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519345-30-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)",
            "phase": "Phase III",
            "lead_sponsor": "Biogen Idec Research Limited",
            "conditions": "IgA nephropathy",
            "member_states": "Greece; Portugal; Spain; Croatia; Czechia; Belgium; Bulgaria; Germany; Italy; Poland; France",
            "decision_date": "23/09/2025",
            "enrolled": "208",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519345-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521372-62-00",
            "title": "Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning before Allogeneic Stem Cell Transplantation in AML, MDS/AML and higher risk MDS (Vestal)",
            "phase": "Phase II",
            "lead_sponsor": "Universitaetsklinikum Tuebingen A\u00f6R",
            "conditions": "Acute Myeloid Leukemia (AML), Myleodyplastic Neoplasm/Acute Myeloid Leukemia (MDS/AML) and higher risk MDS",
            "member_states": "Germany",
            "decision_date": "23/09/2025",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521372-62-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521565-27-00",
            "title": "A randomized, multicenter, multiple-dose, double-blind, placebo-controlled, parallel-group design, clinical endpoint bioequivalence study to evaluate the therapeutic equivalence and safety of fluticasone furoate and vilanterol inhalation powder 100 mcg/25 mcg (Sandoz) and BREO\u00ae ELLIPTA\u00ae (fluticasone furoate and vilanterol inhalation powder) 100 mcg/25 mcg (GlaxoSmithKline) in adult participants with asthma",
            "phase": "Phase III",
            "lead_sponsor": "Sandoz Private Limited",
            "conditions": "Asthma",
            "member_states": "Poland",
            "decision_date": "22/09/2025",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521565-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520490-38-00",
            "title": "A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A",
            "phase": "Phase I",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.",
            "member_states": "Poland; Spain; Austria; Italy; Germany; Belgium; France; Portugal; Sweden",
            "decision_date": "22/09/2025",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520490-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521555-23-00",
            "title": "Clindamycin as an alternative to vancomycin in patients undergoing aortic cardiac surgery with extracorporeal circulation (ECC): a prospective single-center pharmacokinetic study _ CLINDAPASS",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "Patients undergoing cardiac surgery with extracorporeal circulation (ECC)",
            "member_states": "France",
            "decision_date": "22/09/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521555-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519081-49-00",
            "title": "A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Moderate to severe atopic dermatitis",
            "member_states": "Czechia; Netherlands; Poland; Germany; Spain; Hungary; France; Italy; Slovakia",
            "decision_date": "22/09/2025",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519081-49-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519622-20-00",
            "title": "A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Advanced Solid Tumors Harboring RAS Mutation(S)",
            "member_states": "Germany; Netherlands; Spain; Denmark; France; Belgium",
            "decision_date": "22/09/2025",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519622-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517561-16-00",
            "title": "A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE) [without IMPD-Q]",
            "phase": "Phase II",
            "lead_sponsor": "AIO-Studien gGmbH",
            "conditions": "non-small cell lung cancer",
            "member_states": "Germany",
            "decision_date": "22/09/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517561-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522389-66-00",
            "title": "Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone)",
            "phase": "Phase I",
            "lead_sponsor": "Centre for Human Drug Research",
            "conditions": "(Chronic) pain",
            "member_states": "Netherlands",
            "decision_date": "22/09/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522389-66-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520473-40-00",
            "title": "A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO).",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)",
            "member_states": "Spain; Greece; Bulgaria; Germany; Denmark; Hungary; Italy; Poland",
            "decision_date": "22/09/2025",
            "enrolled": "307",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520473-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521681-10-00",
            "title": "A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant\nNon-Small Cell Lung Cancer (NSCLC) \u2013 Subprotocol D",
            "phase": "Phase II",
            "lead_sponsor": "Revolution Medicines Inc.",
            "conditions": "Lung Cancer",
            "member_states": "Germany; Greece; Netherlands; Czechia; France; Austria; Denmark; Spain; Italy",
            "decision_date": "22/09/2025",
            "enrolled": "91",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521681-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520629-19-00",
            "title": "An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)",
            "phase": "Phase I",
            "lead_sponsor": "Viiv Healthcare UK Limited",
            "conditions": "HIV Infections",
            "member_states": "Netherlands; Spain; Belgium; Denmark",
            "decision_date": "22/09/2025",
            "enrolled": "86",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520629-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512403-39-01",
            "title": "A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors previously treated with other therapies.",
            "phase": "Phase I",
            "lead_sponsor": "Abalos Therapeutics GmbH",
            "conditions": "Advanced Solid Tumors Who Are Beyond Standard of Care",
            "member_states": "Spain; Germany",
            "decision_date": "22/09/2025",
            "enrolled": "27",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512403-39-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520554-11-00",
            "title": "A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Cardiovascular Disease",
            "member_states": "Spain; Hungary; Portugal; Greece; Germany; Italy; Austria; Ireland; Romania; Slovakia; Netherlands; Czechia; Bulgaria; Denmark; France; Poland; Belgium",
            "decision_date": "22/09/2025",
            "enrolled": "3800",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520554-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521678-32-00",
            "title": "ADVANCE: A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy Clinical Trial Comparing Essentiale\u00ae Liquid vs. Capsules for MASLD/MASH, Alcoholic Liver Disease, and Chronic Viral Hepatitis B",
            "phase": "Phase III",
            "lead_sponsor": "Opella Healthcare Group S.A.S.",
            "conditions": "Chronic Viral Hepatitis B, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MASH, Metabolic Dysfunction-Associated Steatohepatitis, Alcoholic Liver Disease",
            "member_states": "Bulgaria; Germany; Poland",
            "decision_date": "22/09/2025",
            "enrolled": "486",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521678-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521405-40-01",
            "title": "Remifentanil versus rocuronium for optimizing video laryngoscopy assisted tracheal intubation in patients undergoing general anaesthesia - a multicentre randomised controlled trial\nThe ROCVIDEO trial",
            "phase": "Phase III",
            "lead_sponsor": "Nordsjaellands Hospital",
            "conditions": "Adult patients undergoing tracheal intubation using video laryngoscopy.",
            "member_states": "Denmark; Sweden",
            "decision_date": "22/09/2025",
            "enrolled": "3184",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521405-40-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521764-35-00",
            "title": "A prospective, multi-centre, randomised, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges with benzydamine hydrochloride and dichlorobenzyl alcohol in the symptomatic treatment of patients suffering from acute pharyngitis",
            "phase": "Phase III",
            "lead_sponsor": "MEDICE Arzneimittel Puetter GmbH & Co. KG",
            "conditions": "acute pharyngitis",
            "member_states": "Germany",
            "decision_date": "19/09/2025",
            "enrolled": "810",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521764-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521941-25-00",
            "title": "Ipilimumab and nivolumab plus temozolomide and capecitabine for patients with chemo-refractory pMMR, MGMT silenced metastatic colorectal cancer: The MAYA2 trial",
            "phase": "Phase II",
            "lead_sponsor": "Odense University Hospital",
            "conditions": "Colorectal cancer",
            "member_states": "Denmark",
            "decision_date": "19/09/2025",
            "enrolled": "165",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521941-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521095-66-00",
            "title": "A study in healthy men to find out how different doses of BI 3009947 are tolerated and how different formulations or food influence how BI 3009947 is taken up into the blood",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "19/09/2025",
            "enrolled": "68",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521095-66-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521502-18-00",
            "title": "A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function",
            "phase": "Phase I",
            "lead_sponsor": "Otsuka Pharmaceutical Development & Commercialization Inc.",
            "conditions": "Tuberculosis",
            "member_states": "Bulgaria",
            "decision_date": "19/09/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521502-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518156-24-00",
            "title": "INCB018424-316: A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to < 18 Years Old) With Moderate Atopic Dermatitis",
            "phase": "Phase III",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Atopic Dermatitis",
            "member_states": "France; Germany; Spain; Belgium; Italy; Hungary; Poland",
            "decision_date": "18/09/2025",
            "enrolled": "111",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518156-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509432-25-00",
            "title": "STS-001: An explorative clinical study to assess the potential of intravenously administered sodium thiosulfate in subjects with primary Raynaud\u2019s phenomenon",
            "phase": "Phase II",
            "lead_sponsor": "Universitair Medisch Centrum Groningen",
            "conditions": "Raynaud\u2019s phenomenon",
            "member_states": "Netherlands",
            "decision_date": "18/09/2025",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509432-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520164-33-00",
            "title": "A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO\u00ae) vs Investigator Choice of Single-agent Chemotherapy as Third-line Treatment in Subjects with Advanced / Metastatic Non-Small Cell Lung Cancer (NSCLC)",
            "phase": "Phase III",
            "lead_sponsor": "Maia Biotechnology Inc.",
            "conditions": "Non-Small Cell Lung Cancer",
            "member_states": "Poland; Hungary; Romania; Spain; Portugal",
            "decision_date": "18/09/2025",
            "enrolled": "130",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520164-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521358-41-00",
            "title": "Phase II RAINSPOT: a multicentric open label trial of  Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gastro-esophageal adenocarcinoma",
            "phase": "Phase II",
            "lead_sponsor": "UZ Leuven",
            "conditions": "CLDN18.2 positive gastro-esophageal adenocarcinoma",
            "member_states": "Belgium",
            "decision_date": "17/09/2025",
            "enrolled": "200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521358-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512106-26-02",
            "title": "A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects",
            "phase": "Phase I",
            "lead_sponsor": "Vandria S.A.",
            "conditions": "Cognitive impairment",
            "member_states": "France",
            "decision_date": "17/09/2025",
            "enrolled": "96",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512106-26-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520425-37-00",
            "title": "A Phase 1/2 Open-label, Multi-centre, Dose-exploration Trial to Evaluate the Safety and Preliminary Efficacy of VG801 via Subretinal Injection in Treatment of Patients with Biallelic ABCA4 Mutation-Associated Retinal Dystrophy.",
            "phase": "Phase I/II",
            "lead_sponsor": "VeonGen Therapeutics GmbH",
            "conditions": "Biallelic ABCA4 Mutation-Associated Retinal Dystrophy.",
            "member_states": "Germany",
            "decision_date": "17/09/2025",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520425-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521522-15-00",
            "title": "Standardized Dermatophagoides mix (D. pteronyssinus + D. farinae) in TBU/ml in liquid formulation for sublingual immunotherapy: Phase II, randomized dose determination clinical trial.",
            "phase": "Phase II",
            "lead_sponsor": "Asac Pharmaceutical Inmunology S.A., Advanced Outcomes Research S.L.",
            "conditions": "Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy",
            "member_states": "Spain",
            "decision_date": "17/09/2025",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521522-15-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522812-18-00",
            "title": "CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size",
            "phase": "Phase III",
            "lead_sponsor": "Hospital Clinico San Carlos",
            "conditions": "Endometriosis",
            "member_states": "Spain",
            "decision_date": "17/09/2025",
            "enrolled": "120",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522812-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520155-24-00",
            "title": "A Phase II, randomized, open-label, multi-center study of JSB462 in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Metastatic castration resistant prostate cancer (mCRPC)",
            "member_states": "Netherlands; Austria; Germany; Italy; France; Czechia; Spain",
            "decision_date": "17/09/2025",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520155-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517232-22-00",
            "title": "A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012).",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer",
            "member_states": "Poland; Spain; Netherlands; Italy; Finland; Romania; France; Germany; Hungary",
            "decision_date": "17/09/2025",
            "enrolled": "141",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517232-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519637-32-00",
            "title": "PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial",
            "phase": "Phase II",
            "lead_sponsor": "University Hospital Of Clermont-Ferrand",
            "conditions": "Head and Neck Cancer",
            "member_states": "France",
            "decision_date": "16/09/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519637-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519730-23-00",
            "title": "A Phase 2b, non-randomized, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted RSVPreF3 vaccine and the safety and immunogenicity following revaccination in lung and kidney transplant recipients (\u226518 years of age)",
            "phase": "Phase II",
            "lead_sponsor": "GlaxoSmithKline Biologicals",
            "conditions": "Respiratory Syncytial Virus Infections",
            "member_states": "Italy; Germany; Spain",
            "decision_date": "16/09/2025",
            "enrolled": "71",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519730-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522181-71-00",
            "title": "A Study to Investigate the Effect of RO7504109 on Immune Cells in Healthy Participants",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Not Applicable (N/A)",
            "member_states": "Netherlands",
            "decision_date": "16/09/2025",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522181-71-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521811-38-01",
            "title": "Phase II study evaluating the ability of a 5-HT4 receptor agonist, prucalopride (Resolor\u00a9), to accelerate the therapeutic efficacy of a selective serotonin reuptake inhibitor (SSRI) antidepressant: clinical proof-of-concept.",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Universitaire Grenoble Alpes",
            "conditions": "D\u00e9pression",
            "member_states": "France",
            "decision_date": "16/09/2025",
            "enrolled": "70",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521811-38-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520825-19-00",
            "title": "A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of  Mezagitamab (TAK-079) in Study Participants with Primary IgA Nephropathy in Combination with Stable Background Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as\nBerger's disease)",
            "member_states": "Spain; Czechia; Austria; Hungary; Germany; Norway; Slovenia; France; Sweden; Netherlands; Poland; Italy",
            "decision_date": "16/09/2025",
            "enrolled": "138",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520825-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514360-70-00",
            "title": "A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects with Low-Grade Upper Tract Urothelial Carcinoma (LG-UTUC)",
            "phase": "Phase I/II",
            "lead_sponsor": "Ferring Pharmaceuticals A/S",
            "conditions": "Low-grade upper track urothelial carcinoma (LG-UTUC)",
            "member_states": "Spain; France; Netherlands",
            "decision_date": "16/09/2025",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514360-70-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520541-72-00",
            "title": "NBI-1065845-MDD3027: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI 1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)",
            "phase": "Phase III",
            "lead_sponsor": "Neurocrine Biosciences Inc.",
            "conditions": "Major Depressive Disorder",
            "member_states": "Bulgaria; Estonia; Poland; Italy; Spain",
            "decision_date": "16/09/2025",
            "enrolled": "158",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520541-72-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522412-16-00",
            "title": "An Open Label Study to Assess the Effect of Patient Use and Robustness on Tiotropium Bromide Spray 2.5\u03bcg, Soft Mist Inhaler device",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Liconsa S.A.",
            "conditions": "Chronic obstructive pulmonary disease",
            "member_states": "Spain",
            "decision_date": "16/09/2025",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522412-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519010-31-00",
            "title": "A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma \u2013 NEO-CYT",
            "phase": "Phase I",
            "lead_sponsor": "Fondazione Melanoma Onlus",
            "conditions": "High-Risk, Surgically Resectable Melanoma",
            "member_states": "Italy",
            "decision_date": "15/09/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519010-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521987-37-00",
            "title": "A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants with Chronic Obstructive Pulmonary Disease and Hyperinflation (ORATOS)",
            "phase": "Phase IV",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Chronic Obstructive Pulmonary Disease",
            "member_states": "Germany",
            "decision_date": "15/09/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521987-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514110-12-00",
            "title": "A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects with Moderate-to-Severe Active Thyroid Eye Disease",
            "phase": "Phase I/II",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Thyroid Eye Disease",
            "member_states": "France; Spain; Italy; Poland; Germany; Greece",
            "decision_date": "15/09/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514110-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515215-21-00",
            "title": "A Single-arm, Open-label Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumors/Aggressive Fibromatosis (DT/AF)",
            "phase": "Phase IV",
            "lead_sponsor": "Springworks Therapeutics Inc.",
            "conditions": "DESMOID TUMOURS/AGGRESSIVE FIBROMATOSIS (DT/AF)",
            "member_states": "Netherlands; Italy; Spain; Belgium; Germany",
            "decision_date": "15/09/2025",
            "enrolled": "47",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515215-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521686-27-01",
            "title": "AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, placebo-controlled, double-blind clinical trial",
            "phase": "Phase II",
            "lead_sponsor": "Region Uppsala",
            "conditions": "Major Depression Disorder (MDD), Major Depression",
            "member_states": "Sweden",
            "decision_date": "15/09/2025",
            "enrolled": "105",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521686-27-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513155-32-00",
            "title": "Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria \u2013 a single-arm, open-label, phase II study (TAILOR-CSU)",
            "phase": "Phase II",
            "lead_sponsor": "Philipps-Universitaet Marburg",
            "conditions": "chronic spontaneous urticaria",
            "member_states": "Germany",
            "decision_date": "15/09/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513155-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521480-12-00",
            "title": "A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations",
            "phase": "Phase I",
            "lead_sponsor": "Atavistik Bio Inc.",
            "conditions": "Advanced solid tumors, Breast Cancer",
            "member_states": "Belgium; Italy; Spain; France",
            "decision_date": "15/09/2025",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521480-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522774-36-00",
            "title": "A Phase 1 Study of NDI-219216 in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair",
            "phase": "Phase I",
            "lead_sponsor": "Nimbus Wadjet Inc.",
            "conditions": "Advanced solid tumors",
            "member_states": "Spain; Portugal; France; Ireland",
            "decision_date": "15/09/2025",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522774-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519727-18-00",
            "title": "A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Metastatic Solid Tumor\nAdvanced Solid Tumor\nNon-small Cell Lung Cancer\nSMARCA4-Deficient Tumor",
            "member_states": "Spain; Germany; France",
            "decision_date": "15/09/2025",
            "enrolled": "112",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519727-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521468-36-00",
            "title": "Intraperitoneal irinotecan combined with systemic therapy for patients with gastric peritoneal metastases: A phase II, multicenter study",
            "phase": "Phase II",
            "lead_sponsor": "Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)",
            "conditions": "Gastric peritoneal metastases",
            "member_states": "Netherlands",
            "decision_date": "15/09/2025",
            "enrolled": "49",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521468-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522390-11-00",
            "title": "A phase 2a open-label study to assess the safety, tolerability, and dosing regimen of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) in patients with peripheral arterial occlusive disease and chronic limb-threatening ischemia undergoing endovascular revascularization (HEALING -study)",
            "phase": "Phase II",
            "lead_sponsor": "Aplagon Oy",
            "conditions": "Peripheral arterial occlusive disease (PAOD), Chronic limb-threatening ischemia (CLTI)",
            "member_states": "Finland",
            "decision_date": "15/09/2025",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522390-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509861-19-01",
            "title": "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "lead_sponsor": "Universitaet Muenster",
            "conditions": "Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL) grade 3B, High-grade B-cell lymphoma (HGBL)",
            "member_states": "Germany",
            "decision_date": "15/09/2025",
            "enrolled": "104",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509861-19-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517565-16-00",
            "title": "A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma - PERSEPHONE Trial",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione GONO Plus",
            "conditions": "Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma",
            "member_states": "Italy",
            "decision_date": "15/09/2025",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517565-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521205-41-00",
            "title": "A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma",
            "phase": "Phase II",
            "lead_sponsor": "Aalborg University Hospital",
            "conditions": "Diffuse large B-cell lymphoma NOS, follicular lymphoma Grade 3b, anaplastic large T-cell lymphoma (ALK positive), follicular lymphoma grade 1-3a, and T-cell lymphomas.",
            "member_states": "Denmark",
            "decision_date": "14/09/2025",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521205-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520499-24-00",
            "title": "A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo in adult participants with moderate to severe platysma prominence in Europe",
            "phase": "Phase III",
            "lead_sponsor": "Merz Aesthetics GmbH",
            "conditions": "Moderate to Severe Platysma Prominence",
            "member_states": "Germany; Poland; France; Spain",
            "decision_date": "12/09/2025",
            "enrolled": "300",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520499-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520538-49-00",
            "title": "ACUMEN: Phase I Dose Escalation and Cohort Expansion study to affirm the safety of pharmacological doses of a novel formulation of intravenous melatonin in babies with hypoxic-ischaemic encephalopathy (HIE) to augment therapeutic hypothermia (HT) treatment; to reduce the incidence and severity of disability in babies with moderate-severe HIE.",
            "phase": "Phase I",
            "lead_sponsor": "University College London",
            "conditions": "Moderate-Severe Hypoxic-Ischaemic Encephalopathy (HIE)",
            "member_states": "Ireland",
            "decision_date": "12/09/2025",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520538-49-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522379-26-00",
            "title": "Dose-finding exploratory study on Azithromycin on senescence in healthy volunteers",
            "phase": "Phase II",
            "lead_sponsor": "IRCCS Ospedale Policlinico San Martino",
            "conditions": "Cellular senescence and associated inflammatory status",
            "member_states": "Italy",
            "decision_date": "12/09/2025",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522379-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520792-67-00",
            "title": "A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC",
            "phase": "Phase III",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.",
            "member_states": "Netherlands",
            "decision_date": "12/09/2025",
            "enrolled": "500",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520792-67-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-509180-24-00",
            "title": "Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2\nMITO VULVA-01 study.",
            "phase": "Phase II",
            "lead_sponsor": "IRCCS Istituto Nazionale Tumori Fondazione Pascale",
            "conditions": "vulvar cancer",
            "member_states": "Italy",
            "decision_date": "12/09/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-509180-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520721-21-00",
            "title": "A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis.",
            "phase": "Phase II",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Rheumatoid Arthritis",
            "member_states": "Germany; Czechia; Hungary; Spain; Poland; Slovakia",
            "decision_date": "12/09/2025",
            "enrolled": "108",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520721-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519624-24-00",
            "title": "\"H3RAKLES\": Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer",
            "phase": "Phase II",
            "lead_sponsor": "Institut Curie",
            "conditions": "HER3-mutant and HER2-not amplified metastatic breast cancer",
            "member_states": "France",
            "decision_date": "11/09/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519624-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521267-13-01",
            "title": "An open-label, randomized clinical trial comparing Etacizin versus Propafenone in Atrial Fibrillation",
            "phase": "Phase IV",
            "lead_sponsor": "Olpha AS",
            "conditions": "Atrial fibrillation",
            "member_states": "Latvia",
            "decision_date": "11/09/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521267-13-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520676-26-00",
            "title": "Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations",
            "phase": "Phase II",
            "lead_sponsor": "Fondazione Ricerca Traslazionale",
            "conditions": "Non-small cell lung cancer (NSCLC)",
            "member_states": "Italy",
            "decision_date": "11/09/2025",
            "enrolled": "35",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520676-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518281-27-00",
            "title": "A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants with Advanced Solid Tumours",
            "phase": "Phase I/II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma",
            "member_states": "Germany",
            "decision_date": "11/09/2025",
            "enrolled": "17",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518281-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519188-17-00",
            "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers",
            "phase": "Phase I",
            "lead_sponsor": "Iambic Therapeutics Inc.",
            "conditions": "Relapsed/refractory malignancy with documented diagnosis of human epidermal growth factor receptor 2 (HER2) alterations",
            "member_states": "Spain; France; Ireland; Italy; Netherlands",
            "decision_date": "11/09/2025",
            "enrolled": "98",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519188-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522921-37-00",
            "title": "An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Gebro Pharma GmbH",
            "conditions": "inteneded for treatment of\n- active rheumatoid arthritis in adult patients,\n- polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate,\n- severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients,\n- mild-to-moderate Crohn\u2019s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.",
            "member_states": "Czechia",
            "decision_date": "11/09/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522921-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521260-35-00",
            "title": "Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)",
            "phase": "Phase IV",
            "lead_sponsor": "University Medical Center Hamburg-Eppendorf",
            "conditions": "acute ischemic stroke and atrial fibrillation (AF)",
            "member_states": "Spain; Germany; Netherlands",
            "decision_date": "11/09/2025",
            "enrolled": "1035",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521260-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520656-29-00",
            "title": "A study in healthy people to test whether BI 3000202 affects how 2 other medicines (rosuvastatin and digoxin) are taken up in the body",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "11/09/2025",
            "enrolled": "14",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520656-29-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522287-32-00",
            "title": "A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants",
            "phase": "Phase I",
            "lead_sponsor": "AlzeCure Pharma AB",
            "conditions": "Depression, Cognitive dysfunction, Alzheimer\u2019s disease",
            "member_states": "Sweden",
            "decision_date": "10/09/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522287-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522254-39-00",
            "title": "Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the comparative bioavailability of Test Product Dapagliflozin/metformin hydrochloride 5 mg/1000 mg film-coated tablets to Reference Product Xigduo 5 mg/1000 mg film-coated tablets in healthy adult male and female subjects under fed conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Laboratorios Cinfa S.A.",
            "conditions": "Bioavailability study in healthy volunteers under fed conditions.",
            "member_states": "Czechia",
            "decision_date": "10/09/2025",
            "enrolled": "32",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522254-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523137-25-00",
            "title": "Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "MEDITOP Gyogyszeripari Kft.",
            "conditions": "Comparative bioequivalence study in healthy volunteers under fasting conditions.",
            "member_states": "Czechia",
            "decision_date": "10/09/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523137-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519590-19-00",
            "title": "A randomized, open label, multicenter, Phase 2 study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo\u00ae in combination with mFOLFOX6 and bevacizumab versus standard of care for first-line treatment of non-MSI-H/dMMR, PD-L1 positive advanced colorectal cancer.",
            "phase": "Phase II",
            "lead_sponsor": "Ono Pharmaceutical Co. Ltd.",
            "conditions": "PD-L1 positive advanced colorectal cancer",
            "member_states": "Spain; France; Italy",
            "decision_date": "10/09/2025",
            "enrolled": "76",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519590-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515978-27-00",
            "title": "Vitamin D as add-on treatment option of pneumonia and sepsis in elderly subjects (TreatViD)",
            "phase": "Phase III",
            "lead_sponsor": "Azienda Ospedaliero-Universitaria Maggiore Della Carita",
            "conditions": "Sepsis, Pneumonia due to a presumed infection",
            "member_states": "Italy",
            "decision_date": "10/09/2025",
            "enrolled": "552",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515978-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519736-17-00",
            "title": "A phase 2, multi-center study consisting of a randomized, placebo-controlled period, followed by an open-label extension period to assess the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa",
            "phase": "Phase II",
            "lead_sponsor": "Zura Bio Inc.",
            "conditions": "Hidradenitis Suppurativa",
            "member_states": "Poland; Germany; Spain; Hungary",
            "decision_date": "10/09/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519736-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514327-42-00",
            "title": "Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin",
            "phase": "Phase II",
            "lead_sponsor": "Grupo Espanol De Tumores Neuroendocrinos",
            "conditions": "Advanced neuroendocrine carcinomas (NECs) of the digestive system or unknown primary origin.",
            "member_states": "Spain; France",
            "decision_date": "10/09/2025",
            "enrolled": "87",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514327-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522331-34-00",
            "title": "A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144",
            "phase": "Phase I",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "locally advanced or metastatic ER+/HER2- breast cancer",
            "member_states": "Belgium",
            "decision_date": "09/09/2025",
            "enrolled": "12",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522331-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521476-65-00",
            "title": "Optimising TREATment for severe Gram-Negative Bacterial infections.",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Para La Gestion De La Investigacion En Salud De Sevilla",
            "conditions": "Severe Gram-Negative Bacterial infections",
            "member_states": "Spain",
            "decision_date": "09/09/2025",
            "enrolled": "1200",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521476-65-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518012-39-00",
            "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)",
            "phase": "Phase I",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer",
            "member_states": "Spain",
            "decision_date": "09/09/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518012-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522235-34-00",
            "title": "Low Intervention, Open, Multicentric, Phase IV Exploratory Clinical Trial to evaluate new biomarkers for the diagnosis and treatment monitoring of tuberculosis",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz",
            "conditions": "Bacterial pneumonia patients, Pulmonary tuberculosis patients",
            "member_states": "Spain",
            "decision_date": "09/09/2025",
            "enrolled": "75",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522235-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520802-37-00",
            "title": "Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.",
            "phase": "Phase IV",
            "lead_sponsor": "Universita' Degli Studi Di Napoli Federico II",
            "conditions": "Type 2 diabetes mellitus",
            "member_states": "Italy",
            "decision_date": "09/09/2025",
            "enrolled": "80",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520802-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520488-42-00",
            "title": "A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)",
            "phase": "Phase II",
            "lead_sponsor": "Upstream Bio Inc.",
            "conditions": "Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)",
            "member_states": "Romania; Lithuania; Hungary; Spain; Bulgaria; Ireland; Germany; Latvia; Czechia; Poland; Slovakia",
            "decision_date": "09/09/2025",
            "enrolled": "287",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520488-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522506-20-00",
            "title": "Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial",
            "phase": "Phase IV",
            "lead_sponsor": "Region Hovedstaden",
            "conditions": "Depression",
            "member_states": "Denmark",
            "decision_date": "09/09/2025",
            "enrolled": "145",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522506-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522503-18-00",
            "title": "Semaglutide and Finerenone for Kidney and Vascular Protection in CKD",
            "phase": "Phase IV",
            "lead_sponsor": "Region Midtjylland",
            "conditions": "Chronic kidney disease",
            "member_states": "Denmark",
            "decision_date": "09/09/2025",
            "enrolled": "160",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522503-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519930-22-00",
            "title": "A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients with Systemic Lupus Erythematosus with or without Active Lupus Nephritis",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)",
            "member_states": "Italy",
            "decision_date": "09/09/2025",
            "enrolled": "5",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519930-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521115-40-00",
            "title": "Phase 2 Study of Zelenectide Pevedotin in Participants with Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Bicycletx Limited",
            "conditions": "Advanced or Metastatic Non-small Cell Lung Cancer",
            "member_states": "Italy; Spain; France; Germany",
            "decision_date": "09/09/2025",
            "enrolled": "28",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521115-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522278-35-00",
            "title": "A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older.",
            "phase": "Phase II",
            "lead_sponsor": "GlaxoSmithKline Biologicals",
            "conditions": "Influenza, Human",
            "member_states": "Belgium",
            "decision_date": "09/09/2025",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522278-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521533-85-00",
            "title": "A Randomized, Parallel, Open-Label, Phase 1/2a Study to Assess the Safety and Tolerability of Multiple Doses of the Bacteriophage Cocktail TP-122 (Component TP-122A), for the Treatment of Ventilator-Associated Pneumonia",
            "phase": "Phase I/II",
            "lead_sponsor": "Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.",
            "conditions": "Ventilator-Associated Pneumonia",
            "member_states": "Portugal; Netherlands",
            "decision_date": "09/09/2025",
            "enrolled": "38",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521533-85-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520694-39-00",
            "title": "GRACIE : Phase II study evaluating ivonescimab in combination with chemotherapy for first- and second-line treatment of advanced or metastatic gastric and gastroesophageal adenocarcinoma patients",
            "phase": "Phase II",
            "lead_sponsor": "Unicancer",
            "conditions": "Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)",
            "member_states": "France",
            "decision_date": "08/09/2025",
            "enrolled": "88",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520694-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520998-39-00",
            "title": "A Phase 3 Randomized, Controlled Study to Assess the Efficacy and Safety of NVD003 compared with Iliac Crest Bone Graft in Pediatric Participants Treated Surgically for Congenital Pseudarthrosis of the Tibia",
            "phase": "Phase III",
            "lead_sponsor": "Novadip Biosciences",
            "conditions": "Congenital pseudarthrosis of the tibia",
            "member_states": "France; Spain; Belgium",
            "decision_date": "08/09/2025",
            "enrolled": "4",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520998-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521717-67-00",
            "title": "Long-Term Follow-up of AvenCell-Sponsored CAR-T Cell Clinical Trials",
            "phase": "Phase I",
            "lead_sponsor": "Avencell Therapeutics Inc.",
            "conditions": "Acute myeloid leukemia",
            "member_states": "Germany",
            "decision_date": "08/09/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521717-67-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521251-24-00",
            "title": "Phase II randomized clinical trial for evaluating the safety and feasibility of fecal microbiota transplant (FMT) in stage II-III non-small cell lung cancer (NSCLC) patients, using immune checkpoint inhibitors (ICI) responders as donors. MIGRANT GECP 24/02",
            "phase": "Phase II",
            "lead_sponsor": "Fundacion GECP",
            "conditions": "Non-Small cell lung cancer (NSCLC)",
            "member_states": "Spain",
            "decision_date": "08/09/2025",
            "enrolled": "68",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521251-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518465-10-00",
            "title": "A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)",
            "phase": "Phase II",
            "lead_sponsor": "Vera Therapeutics Inc.",
            "conditions": "Multiple Autoimmune Glomerular Diseases",
            "member_states": "Germany; France; Italy; Spain; Poland; Belgium",
            "decision_date": "08/09/2025",
            "enrolled": "124",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518465-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522606-20-00",
            "title": "A\u00a0randomised, open label, three periods,\u00a0three-treatment\u00a0crossover study\u00a0to evaluate the\u00a0pharmacokinetics of\u00a0alendronic acid oral formulations after single\u00a0dose administration in healthy volunteers under fasted conditions: a pilot study",
            "phase": "Phase I",
            "lead_sponsor": "Faes Farma S.A.",
            "conditions": "Pharmacokinetic study in healthy volunteers under fasted conditions.",
            "member_states": "Czechia",
            "decision_date": "08/09/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522606-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522975-27-00",
            "title": "The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.",
            "phase": "Phase I",
            "lead_sponsor": "Adamed Pharma S.A.",
            "conditions": "Not applicable (submitted trial is a BE study in healthy subjects).",
            "member_states": "Czechia",
            "decision_date": "08/09/2025",
            "enrolled": "44",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522975-27-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517745-14-00",
            "title": "A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Spasticity in Participants with Multiple Sclerosis (BALANCE-MSS-1)",
            "phase": "Phase II",
            "lead_sponsor": "Celgene Corp.",
            "conditions": "Multiple Sclerosis Spasticity",
            "member_states": "Germany; Czechia; Poland",
            "decision_date": "08/09/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517745-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521096-31-00",
            "title": "An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study",
            "phase": "Phase III",
            "lead_sponsor": "Atea Pharmaceuticals Inc.",
            "conditions": "Chronic Hepatitis C Virus (HCV) Infection",
            "member_states": "Romania; France; Germany; Greece; Poland; Spain",
            "decision_date": "08/09/2025",
            "enrolled": "275",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521096-31-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516284-90-00",
            "title": "A prospective, controlled, randomized, double blind, 2-arms, parallel-group, multicentre, phase 3 study to investigate effectiveness of Actisoufre nasal spray in a pressurized container compared to placebo in female and male adult and paediatric population over 6 years old with acute rhinitis, rhinopharyngitis and rhinosinusitis not requiring antibiotic therapy.",
            "phase": "Phase III",
            "lead_sponsor": "Laboratoires Grimberg",
            "conditions": "rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy",
            "member_states": "Poland",
            "decision_date": "08/09/2025",
            "enrolled": "248",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516284-90-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521892-30-00",
            "title": "Comparing high and lOw-dose asPirin with dual anTIplatelet therapy for three Months using prasUgrel and aSpirin following Coronary Artery Bypass Grafting. (OPTIMUS-CABG trial).",
            "phase": "Phase III",
            "lead_sponsor": "Dolnoslaskie Centrum Chorob Serca Im. Prof. Zbigniewa Religi Medinet Sp. z o.o.",
            "conditions": "Primary isolated CABG patients with stable coronary artery disease (chronic coronary syndrome) planned for at least 2 grafts.",
            "member_states": "Poland",
            "decision_date": "08/09/2025",
            "enrolled": "1703",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521892-30-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522559-25-00",
            "title": "Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors",
            "phase": "Phase II",
            "lead_sponsor": "Rigshospitalet",
            "conditions": "Xerostomia due to readiotherapy for a head & neck cancer",
            "member_states": "Denmark",
            "decision_date": "08/09/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522559-25-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517524-18-00",
            "title": "Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy",
            "phase": "Phase III",
            "lead_sponsor": "ROXALL Medizin GmbH",
            "conditions": "Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (Bousquet et al., 2008)",
            "member_states": "Germany",
            "decision_date": "05/09/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517524-18-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520142-32-00",
            "title": "A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of brain disorders, like Alzheimer\u2019s disease and Parkinson\u2019s disease.",
            "phase": "Phase I",
            "lead_sponsor": "Nodthera Limited",
            "conditions": "Cryopyrin associated periodic syndrome",
            "member_states": "Netherlands",
            "decision_date": "05/09/2025",
            "enrolled": "53",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520142-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520322-11-00",
            "title": "A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants with Type 2 Diabetes Mellitus",
            "phase": "Phase II",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Type 2 Diabetes Mellitus (T2D)",
            "member_states": "Poland; Spain; Hungary",
            "decision_date": "05/09/2025",
            "enrolled": "74",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520322-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521810-24-00",
            "title": "Pilot study to explore the diagnostic value of gadopiclenol in pathological and radiological insights with multiparametric MRI enhancement in breast cancer.",
            "phase": "Phase IV",
            "lead_sponsor": "Fundacion Ribera Salud",
            "conditions": "Breast cancer",
            "member_states": "Spain",
            "decision_date": "05/09/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521810-24-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520068-32-00",
            "title": "EFFectiveness of once-weekly insulin ICodec versus once-daily basal Insulin analogues in an insulin-na\u00efve type 2 diabEtes population in real-world cliNical pracTice- The EFFICIENT pragmatic study",
            "phase": "Phase IV",
            "lead_sponsor": "Novo Nordisk A/S",
            "conditions": "Type 2 diabetes",
            "member_states": "Germany; Italy",
            "decision_date": "05/09/2025",
            "enrolled": "204",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520068-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521478-32-00",
            "title": "ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM",
            "phase": "Phase III",
            "lead_sponsor": "Assistance Publique Hopitaux De Paris",
            "conditions": "PEDIATRIC ACUTE MYOCARDITIS",
            "member_states": "France",
            "decision_date": "04/09/2025",
            "enrolled": "110",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521478-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521770-34-00",
            "title": "Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study",
            "phase": "Phase I",
            "lead_sponsor": "Radboud universitair medisch centrum Stichting",
            "conditions": "Chronic pulmonary aspergillosis",
            "member_states": "Netherlands",
            "decision_date": "04/09/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521770-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522368-34-00",
            "title": "A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer\u2019s disease and other neurological disorders",
            "phase": "Phase I",
            "lead_sponsor": "Muna Therapeutics ApS",
            "conditions": "Alzheimer\u2019s Disease",
            "member_states": "Netherlands",
            "decision_date": "04/09/2025",
            "enrolled": "123",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522368-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518344-20-00",
            "title": "The efficacy and safety of Intramuscular Methylprednisolone in patients with Hand OsteoArthritis: the IMHOA trial",
            "phase": "Phase III",
            "lead_sponsor": "Sint Maartenskliniek Stichting",
            "conditions": "Hand osteoarthritis",
            "member_states": "Netherlands",
            "decision_date": "04/09/2025",
            "enrolled": "212",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518344-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520219-42-00",
            "title": "adIVO \u2013 A phase II trial of ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma",
            "phase": "Phase III",
            "lead_sponsor": "Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH",
            "conditions": "ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma",
            "member_states": "Germany",
            "decision_date": "04/09/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520219-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518296-56-00",
            "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn\u2019s Disease",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Crohn\u2019s Disease",
            "member_states": "Spain; Austria; Lithuania; France; Belgium; Germany; Sweden; Czechia; Finland; Croatia; Latvia; Portugal; Netherlands; Italy; Denmark; Slovakia; Romania; Poland; Ireland; Hungary; Greece",
            "decision_date": "03/09/2025",
            "enrolled": "567",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518296-56-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518583-13-00",
            "title": "PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PETERPEN)",
            "phase": "Phase IV",
            "lead_sponsor": "Azienda Ospedaliero Universitaria Di Modena",
            "conditions": "Patients with bacteremia",
            "member_states": "Italy",
            "decision_date": "03/09/2025",
            "enrolled": "490",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518583-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519573-19-00",
            "title": "NEOSTART Study - NEOADJUVANT PEMBROLIZUMAB IN PATIENTS WITH HIGH RISK, STAGE IIB/IIC CUTANEOUS MELANOMA: A SINGLE ARM PROOF OF CONCEPT PHASE IIA STUDY",
            "phase": "Phase II",
            "lead_sponsor": "Centre Hospitalier Regional Universitaire",
            "conditions": "melanoma",
            "member_states": "France",
            "decision_date": "02/09/2025",
            "enrolled": "19",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519573-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515948-23-00",
            "title": "GCO-003 TARLANEC A randomized phase III trial study comparing tarlatamab with standard of care chemotherapy in patients with pre-treated advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas",
            "phase": "Phase III",
            "lead_sponsor": "Intergroupe Francophone De Cancerologie Thoracique",
            "conditions": "Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)",
            "member_states": "France",
            "decision_date": "02/09/2025",
            "enrolled": "129",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515948-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519650-36-00",
            "title": "Evaluation of the effect of adrenalized lidocaine with or without bicarbonate on early postoperative recovery in ambulatory hand and foot surgery with WALANT:\nA Single-centre prospective randomised double-blind non-inferiority study.",
            "phase": "Phase IV",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nimes",
            "conditions": "Hand Surgery, Foot surgery",
            "member_states": "France",
            "decision_date": "02/09/2025",
            "enrolled": "150",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519650-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522240-40-00",
            "title": "The POWER trial: A randomised, two-armed open label phase 3 clinical trial on personalised dose optimisation with adjuvant tamoxifen therapy after breast cancer to investigate the impact on discontinuation and efficacy compared to standard of care",
            "phase": "Phase III",
            "lead_sponsor": "Karolinska Institutet",
            "conditions": "Breast Cancer",
            "member_states": "Sweden",
            "decision_date": "02/09/2025",
            "enrolled": "1100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522240-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522325-35-00",
            "title": "A study in healthy people to compare how 2 different formulations of survodutide are taken up by the body",
            "phase": "Phase I",
            "lead_sponsor": "Boehringer Ingelheim International GmbH",
            "conditions": "Healthy volunteer trial",
            "member_states": "Germany",
            "decision_date": "02/09/2025",
            "enrolled": "100",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522325-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521835-35-00",
            "title": "Impact of Glucagon on Physical Capacity and Metabolism",
            "phase": "Phase II",
            "lead_sponsor": "Katholisches Klinikum Bochum gGmbH",
            "conditions": "Heart Failure with preserved Ejection Fraction (HFpEF) with or without concomitant Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)",
            "member_states": "Germany",
            "decision_date": "02/09/2025",
            "enrolled": "47",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521835-35-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521295-60-00",
            "title": "Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis",
            "phase": "Phase I",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Sporadic Amyotrophic Lateral Sclerosis",
            "member_states": "Belgium; Spain; Netherlands; Germany",
            "decision_date": "02/09/2025",
            "enrolled": "30",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521295-60-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520302-19-00",
            "title": "A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients with Moderate-to-Severe Atopic Dermatitis",
            "phase": "Phase II",
            "lead_sponsor": "Aclaris Therapeutics Inc.",
            "conditions": "Atopic dermatitis",
            "member_states": "Poland; Czechia; Germany",
            "decision_date": "02/09/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520302-19-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521497-34-00",
            "title": "Long-term follow-up of patients treated with GD2IL18CART",
            "phase": "Phase I",
            "lead_sponsor": "Universitaet Muenster",
            "conditions": "Neuroblastoma, Advanced breast cancer, Ewing sarcoma, Osteosarcoma",
            "member_states": "Germany",
            "decision_date": "02/09/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521497-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516805-22-00",
            "title": "A Phase III Long-Term\u202fExtension Trial with Optional Additional Doses\u202fof CYB003 to Assess the Safety and Long-term Efficacy in Participants with Major Depressive\u202fDisorder (EXTEND)",
            "phase": "Phase III",
            "lead_sponsor": "Cybin IRL Limited",
            "conditions": "Major Depressive Disorder",
            "member_states": "Greece; Poland; Ireland; Germany; Czechia",
            "decision_date": "02/09/2025",
            "enrolled": "131",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516805-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521694-14-00",
            "title": "REstoration with calcifediol of VItamin D deficiency in pulmonary Arterial Hypertension patients (REVIDAH study)",
            "phase": "Phase IV",
            "lead_sponsor": "Consorci Mar Parc De Salut De Barcelona",
            "conditions": "Patients with diagnosis of Pulmonary Arterial Hypertension of the following types according to 2022 ERS/ESC guidelines: idiopathic, hereditary, drug- and toxin-induced PAH or associated to connective tissues disease",
            "member_states": "Spain",
            "decision_date": "02/09/2025",
            "enrolled": "102",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521694-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516909-23-00",
            "title": "A Master Protocol for an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants with Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)",
            "phase": "Phase II",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Locally Advanced Resectable Gastroesophageal Adenocarcinoma",
            "member_states": "Italy; Spain",
            "decision_date": "01/09/2025",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516909-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519827-16-00",
            "title": "A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients",
            "phase": "Phase III",
            "lead_sponsor": "European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale",
            "conditions": "Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients",
            "member_states": "Norway; Denmark; Spain; Sweden; Austria; Netherlands; Greece; Germany; Italy; Belgium; Portugal; Estonia; Croatia; Ireland; Czechia; Finland",
            "decision_date": "01/09/2025",
            "enrolled": "713",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519827-16-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520050-38-00",
            "title": "A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)",
            "phase": "Phase III",
            "lead_sponsor": "Amgen Inc.",
            "conditions": "Extensive stage small cell lung cancer (ES-SCLC).                    Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly\nassociated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.",
            "member_states": "Portugal; Germany; Spain; Italy; Denmark; Netherlands; France; Austria; Greece; Belgium; Hungary; Poland; Romania",
            "decision_date": "01/09/2025",
            "enrolled": "156",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520050-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522106-20-00",
            "title": "A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.",
            "phase": "Phase I",
            "lead_sponsor": "Sun Pharmaceutical Industries Limited",
            "conditions": "ulcerative colitis",
            "member_states": "Romania",
            "decision_date": "01/09/2025",
            "enrolled": "112",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522106-20-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515682-34-00",
            "title": "A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin\u00ae injections for the prevention of chronic migraine (MINT-C)",
            "phase": "Phase III",
            "lead_sponsor": "Merz Therapeutics GmbH",
            "conditions": "Chronic migraine",
            "member_states": "Spain; Denmark; France; Germany; Slovakia; Austria; Italy; Poland; Czechia",
            "decision_date": "01/09/2025",
            "enrolled": "511",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515682-34-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517047-30-01",
            "title": "PSEUDOVAX \u2013 A CANCER VACCINE TARGETING MUTATED GNAS COMBINED WITH IMMUNE CHECKPOINT INHIBITION FOR PATIENTS WITH PSEUDOMYXOMA PERITONEI",
            "phase": "Phase I",
            "lead_sponsor": "Oslo University Hospital HF",
            "conditions": "Pseudomyxoma Peritonei",
            "member_states": "Norway",
            "decision_date": "01/09/2025",
            "enrolled": "10",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517047-30-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-512177-27-01",
            "title": "A phase 3, randomised, multi-center, open label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin therapy (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC)",
            "phase": "Phase III",
            "lead_sponsor": "Ferring Pharmaceuticals A/S",
            "conditions": "High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours",
            "member_states": "Spain; Denmark; Poland; Czechia; France",
            "decision_date": "01/09/2025",
            "enrolled": "141",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-512177-27-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515715-22-00",
            "title": "A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin\u00ae injections for the prevention of episodic migraine (MINT-E)",
            "phase": "Phase III",
            "lead_sponsor": "Merz Therapeutics GmbH",
            "conditions": "Episodic migraine",
            "member_states": "Italy; Austria; Poland; Germany; France; Spain; Slovakia; Denmark; Czechia",
            "decision_date": "01/09/2025",
            "enrolled": "657",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515715-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521872-69-00",
            "title": "OMTX705-006 Phase 1b",
            "phase": "Phase I",
            "lead_sponsor": "Oncomatryx Biopharma S.A.",
            "conditions": "Advanced/Metastatic Pancreatic Adenocarcinoma",
            "member_states": "Spain",
            "decision_date": "01/09/2025",
            "enrolled": "54",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521872-69-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520564-17-00",
            "title": "A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa",
            "phase": "Phase III",
            "lead_sponsor": "MoonLake Immunotherapeutics AG",
            "conditions": "Hidradenitis suppurativa (HS)",
            "member_states": "Norway; Hungary; Spain; France; Germany; Poland; Czechia; Slovakia; Bulgaria; Netherlands; Italy; Portugal; Belgium",
            "decision_date": "29/08/2025",
            "enrolled": "492",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520564-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-514695-41-00",
            "title": "A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Ulcerative Colitis",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Ulcerative Colitis",
            "member_states": "Sweden; Greece; Germany; Italy; Belgium; Spain",
            "decision_date": "29/08/2025",
            "enrolled": "34",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-514695-41-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516610-38-00",
            "title": "Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson\u2019s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD",
            "phase": "Phase III",
            "lead_sponsor": "Institut National De La Sante Et De La Recherche Medicale",
            "conditions": "Parkinson's disease, Prodromal phase of Parkinson's disease",
            "member_states": "France",
            "decision_date": "29/08/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516610-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518588-36-00",
            "title": "A Double-Blind, Randomized, Active Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma",
            "phase": "Phase III",
            "lead_sponsor": "Celltrion Inc.",
            "conditions": "Refractory or Relapsed Multiple Myeloma",
            "member_states": "Spain; Poland",
            "decision_date": "29/08/2025",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518588-36-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520616-33-00",
            "title": "A study comparing different RO7269162 capsules and investigating the effect of food on the uptake, breakdown, and elimination of RO7269162 in Healthy Participants",
            "phase": "Phase I",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Not Applicable",
            "member_states": "Netherlands",
            "decision_date": "29/08/2025",
            "enrolled": "48",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520616-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522071-28-00",
            "title": "Eficacy of epidural analgesia initiated with dural puncture epidural technic for labour with ultra-low concentration of levobupivacaine 0.0625% (walking epidural). Impact on anaesthetic and obstetric outcomes.",
            "phase": "Phase IV",
            "lead_sponsor": "Hospital Universitario La Paz",
            "conditions": "Pregnant women who enter in the delivery room and request epidural analgesia for labour",
            "member_states": "Spain",
            "decision_date": "29/08/2025",
            "enrolled": "534",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522071-28-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519932-17-00",
            "title": "Etude de bio\u00e9quivalence entre Circadin et Melatonin PILEJE LP 2 mg",
            "phase": "Phase I",
            "lead_sponsor": "Pileje",
            "conditions": "Primary insomnia characterized by poor quality of sleep",
            "member_states": "France",
            "decision_date": "28/08/2025",
            "enrolled": "24",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519932-17-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520195-94-00",
            "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "BP-I mania or mania with mixed features",
            "member_states": "Slovakia; Spain; Croatia; Sweden; Romania",
            "decision_date": "28/08/2025",
            "enrolled": "89",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520195-94-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519157-10-00",
            "title": "A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)",
            "phase": "Phase I",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Systemic Lupus Erythematosus, Sjogren's disease",
            "member_states": "Netherlands; France",
            "decision_date": "28/08/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519157-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-515900-38-00",
            "title": "BOB1-TCR therapy for treatment of relapsed or refractory B-cell malignancies - A Phase 1/2 clinical trial",
            "phase": "Phase I/II",
            "lead_sponsor": "Leids Universitair Medisch Centrum (LUMC)",
            "conditions": "B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-Hodgkin B-cell lymphoma",
            "member_states": "Netherlands",
            "decision_date": "28/08/2025",
            "enrolled": "22",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-515900-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518018-22-00",
            "title": "Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE)",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "staphylococcal endocarditis",
            "member_states": "France",
            "decision_date": "28/08/2025",
            "enrolled": "422",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518018-22-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-523054-14-00",
            "title": "Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Pharma Start LLC",
            "conditions": "not applicable (submitted trial is bioavailability)",
            "member_states": "Czechia",
            "decision_date": "28/08/2025",
            "enrolled": "42",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-523054-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521040-37-00",
            "title": "Diagnostic HER2DX-guided trEatment For patIeNts wIth early-sTage HER2-positIVE breast cancer",
            "phase": "Phase III",
            "lead_sponsor": "Fundacio De Recerca Clinic Barcelona-Institut D\u2019Investigacions Biomediques August Pi I Sunyer",
            "conditions": "HER2-positive early breast cancer",
            "member_states": "Germany; Ireland; France; Spain",
            "decision_date": "28/08/2025",
            "enrolled": "224",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521040-37-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517031-51-00",
            "title": "A Phase I-IIa Trial on the Safety and Preliminary Effectiveness of Intramyocardial Injection of Cardiac Atrial Stem Cells for the Treatment of Advanced Ischemic Heart Failure in Subjects with Ischemic Left Ventricular Dysfunction and Chronic Myocardial Infarction.",
            "phase": "Phase I/II",
            "lead_sponsor": "CASC8",
            "conditions": "Heart Failure",
            "member_states": "Belgium",
            "decision_date": "27/08/2025",
            "enrolled": "20",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517031-51-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522126-13-00",
            "title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients with Chronic Inducible Urticaria (Part B)",
            "phase": "Phase I",
            "lead_sponsor": "Granular Therapeutics Limited",
            "conditions": "Cold Induced Urticaria",
            "member_states": "Germany",
            "decision_date": "27/08/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522126-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519993-38-00",
            "title": "NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma",
            "phase": "Phase I",
            "lead_sponsor": "Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH",
            "conditions": "resectable esophagogastric adenocarcinoma",
            "member_states": "Germany",
            "decision_date": "27/08/2025",
            "enrolled": "18",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519993-38-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520672-26-00",
            "title": "A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors",
            "phase": "Phase I/II",
            "lead_sponsor": "Glaxosmithkline Research & Development Limited",
            "conditions": "Gastrointestinal Neoplasms",
            "member_states": "Belgium; Italy; Norway; Finland; Poland; Netherlands; Germany; Spain; France; Sweden",
            "decision_date": "27/08/2025",
            "enrolled": "176",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520672-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520714-63-00",
            "title": "A Phase III b randomized open-label trial on metformin for cancer prevention in adolescents and adults with Li-Fraumeni syndrome (LFS)",
            "phase": "Phase III",
            "lead_sponsor": "Medizinische Hochschule Hannover",
            "conditions": "Li-Fraumeni syndrome",
            "member_states": "Germany",
            "decision_date": "27/08/2025",
            "enrolled": "330",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520714-63-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521673-14-00",
            "title": "An Open-label Multicenter Rollover Study to Provide Continued Treatment to Participants Previously Enrolled in a RVU120 Clinical Study",
            "phase": "Phase II",
            "lead_sponsor": "Ryvu Therapeutics S.A.",
            "conditions": "Relapsed / Refractory Metastatic or Advanced Solid Tumors, Myelofibrosis, Relapsed or Refractory High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with or without NPM1 Mutation",
            "member_states": "Spain; Poland; France; Italy",
            "decision_date": "27/08/2025",
            "enrolled": "29",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521673-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520190-12-00",
            "title": "A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer",
            "member_states": "France; Sweden; Poland; Spain; Finland; Portugal; Belgium; Czechia; Germany; Greece; Hungary; Italy; Romania; Norway",
            "decision_date": "27/08/2025",
            "enrolled": "598",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520190-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522136-14-00",
            "title": "Antibiotic Treatment Trial in Acute Coronary Syndrome",
            "phase": "Phase III",
            "lead_sponsor": "TAYS Sydaenkeskus Oy",
            "conditions": "non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), coronary artery disease",
            "member_states": "Finland",
            "decision_date": "27/08/2025",
            "enrolled": "1070",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522136-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520031-33-00",
            "title": "A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria",
            "phase": "Phase II",
            "lead_sponsor": "Blueprint Medicines Corp.",
            "conditions": "Chronic Inducible Urticaria and Chronic Spontaneous Urticaria",
            "member_states": "Germany; Denmark; Spain; Italy",
            "decision_date": "27/08/2025",
            "enrolled": "57",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520031-33-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520259-26-00",
            "title": "A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder (BALSAM-3)",
            "phase": "Phase III",
            "lead_sponsor": "Bristol-Myers Squibb Services Unlimited Company",
            "conditions": "Mania or Mania with Mixed Features in Bipolar-I Disorder",
            "member_states": "Hungary; Romania; Poland; Sweden; Croatia; Spain; Slovakia; Bulgaria; Italy; France; Denmark",
            "decision_date": "26/08/2025",
            "enrolled": "153",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520259-26-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-519883-42-00",
            "title": "A Randomized, Double-Blind, Multicenter, Pharmacokinetic Equivalence Clinical Trial of QL2107 (Keytruda\u00ae Biosimilar Candidate) in Comparison with Keytruda\u00ae (Pembrolizumab) for Adjuvant Therapy to Demonstrate Pharmacokinetic Similarity in Subjects with Resected Non-Small Cell Lung Cancer.",
            "phase": "Phase III",
            "lead_sponsor": "Qilu Pharmaceutical Co. Ltd.",
            "conditions": "Non-small cell lung cancer",
            "member_states": "Poland; Spain; Romania; Hungary; Greece",
            "decision_date": "26/08/2025",
            "enrolled": "52",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-519883-42-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-522562-70-00",
            "title": "A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.",
            "phase": "Phase I",
            "lead_sponsor": "Tarchominskie Zaklady Farmaceutyczne Polfa S.A.",
            "conditions": "infection",
            "member_states": "Czechia",
            "decision_date": "26/08/2025",
            "enrolled": "56",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-522562-70-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521221-32-00",
            "title": "Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Immunitybio Inc.",
            "conditions": "Advanced or Metastatic Non-Small Cell Lung Cancer",
            "member_states": "Germany; Hungary; Spain; Poland; Greece; Belgium; France; Italy; Romania",
            "decision_date": "26/08/2025",
            "enrolled": "206",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521221-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508995-12-01",
            "title": "LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu FAP 2286 in Participants with an Advanced Solid Tumor",
            "phase": "Phase II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Metastatic Breast Carcinoma (BC), Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)",
            "member_states": "Italy; Spain; Belgium; France",
            "decision_date": "26/08/2025",
            "enrolled": "36",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508995-12-01",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521223-78-00",
            "title": "A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer",
            "phase": "Phase II",
            "lead_sponsor": "Immunitybio Inc.",
            "conditions": "Non-Muscle Invasive Bladder Cancer",
            "member_states": "Germany",
            "decision_date": "26/08/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521223-78-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517866-40-00",
            "title": "C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma",
            "phase": "Phase II",
            "lead_sponsor": "Pfizer Inc.",
            "conditions": "Moderate-to-severe Asthma",
            "member_states": "Belgium; Hungary; Spain; Bulgaria; Italy; Poland; Czechia",
            "decision_date": "26/08/2025",
            "enrolled": "90",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517866-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520098-12-00",
            "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus",
            "phase": "Phase II",
            "lead_sponsor": "Ventus Therapeutics U.S. Inc.",
            "conditions": "Cutaneous Lupus Erythematosus",
            "member_states": "Poland; Czechia; France; Bulgaria; Spain; Hungary",
            "decision_date": "26/08/2025",
            "enrolled": "13",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520098-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520107-12-00",
            "title": "A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib",
            "phase": "Phase III",
            "lead_sponsor": "Incyte Corp.",
            "conditions": "Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo",
            "member_states": "Italy; France; Greece; Germany; Denmark; Netherlands; Austria; Spain; Poland; Belgium; Czechia; Hungary; Bulgaria",
            "decision_date": "26/08/2025",
            "enrolled": "863",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520107-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520210-21-00",
            "title": "I6T-MC-AMCE: A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Crohn\u2019s Disease and Obesity or Overweight",
            "phase": "Phase III",
            "lead_sponsor": "Eli Lilly & Co.",
            "conditions": "Crohn\u2019s Disease, Obesity or Overweight",
            "member_states": "Denmark; Hungary; Greece; Germany; Austria; Italy; Belgium; Netherlands; Spain; Czechia; Bulgaria; France; Poland; Romania; Slovakia",
            "decision_date": "26/08/2025",
            "enrolled": "171",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520210-21-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-517133-40-00",
            "title": "Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB)",
            "phase": "Phase III",
            "lead_sponsor": "GPOH gGmbH",
            "conditions": "newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified medulloblastoma",
            "member_states": "France; Denmark; Germany; Belgium; Netherlands",
            "decision_date": "26/08/2025",
            "enrolled": "46",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-517133-40-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520519-14-00",
            "title": "A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event",
            "phase": "Phase III",
            "lead_sponsor": "AstraZeneca AB",
            "conditions": "Atherosclerotic Cardiovascular Disease",
            "member_states": "Greece; Hungary; Poland; Germany; Slovakia; Denmark; Bulgaria; Spain; Italy; Sweden; France; Romania; Czechia",
            "decision_date": "26/08/2025",
            "enrolled": "3531",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520519-14-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-521577-13-00",
            "title": "A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)",
            "phase": "Phase I",
            "lead_sponsor": "Universitair Ziekenhuis Gent",
            "conditions": "metastatic non-small-cell lung cancer",
            "member_states": "Belgium",
            "decision_date": "25/08/2025",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-521577-13-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518586-10-00",
            "title": "A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer",
            "phase": "Phase III",
            "lead_sponsor": "AbbVie Deutschland GmbH & Co. KG",
            "conditions": "Non-Squamous Non-Small Cell Lung Cancer",
            "member_states": "Italy; Belgium; Spain; Portugal",
            "decision_date": "25/08/2025",
            "enrolled": "50",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518586-10-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-518420-80-00",
            "title": "A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen\u00d7CD3\u2013Directed Bispecific Antibody Therapy",
            "phase": "Phase III",
            "lead_sponsor": "Takeda Development Center Americas Inc.",
            "conditions": "Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy",
            "member_states": "Hungary; Germany; Greece; Netherlands; Austria; Poland; Italy; Czechia; Spain; Denmark; Romania; Norway",
            "decision_date": "25/08/2025",
            "enrolled": "172",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-518420-80-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-513613-12-00",
            "title": "A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of LTP001 in healthy adult participants (Part A) and to evaluate the efficacy and safety of LTP001 for the treatment of participants with pulmonary arterial hypertension (Part B)",
            "phase": "Phase I/II",
            "lead_sponsor": "Novartis Pharma AG",
            "conditions": "Part A: Healthy volunteers (Part A is not applicable to the EU; for information only)\nPart B: pulmonary arterial hypertension",
            "member_states": "Portugal; Latvia; Czechia; Italy; Belgium; Germany; France; Romania; Spain; Poland; Greece; Netherlands",
            "decision_date": "25/08/2025",
            "enrolled": "89",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-513613-12-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-516924-32-00",
            "title": "A phase IIIb, Multicenter, Single-Arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration",
            "phase": "Phase III",
            "lead_sponsor": "F. Hoffmann-La Roche AG",
            "conditions": "Neovascular Age-Related Macular Degeneration (nAMD)",
            "member_states": "Italy; Germany; France; Spain; Czechia; Austria; Denmark; Greece; Poland",
            "decision_date": "22/08/2025",
            "enrolled": "164",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-516924-32-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2023-508015-23-00",
            "title": "A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse 022/ENGOT ov84/GOG-3103)",
            "phase": "Phase III",
            "lead_sponsor": "Merck Sharp & Dohme LLC",
            "conditions": "Ovarian cancer recurrent",
            "member_states": "Spain; Austria; Belgium; Czechia; Denmark; Finland; France; Greece; Hungary; Ireland; Italy; Poland; Portugal; Romania",
            "decision_date": "22/08/2025",
            "enrolled": "252",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2023-508015-23-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2025-520754-11-00",
            "title": "Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment",
            "phase": "Phase I",
            "lead_sponsor": "Bial R&D Investments S.A.",
            "conditions": "Parkinson's disease",
            "member_states": "Hungary",
            "decision_date": "22/08/2025",
            "enrolled": "40",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2025-520754-11-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520205-39-00",
            "title": "Efficacy of early continuous infusion of hypertonic saline solution on the neurological outcome at 6 months in traumatic brain injured patients. A single-blinded, multicenter, randomized, controlled clinical trial with blinded evaluation of the primary outcome.",
            "phase": "Phase III",
            "lead_sponsor": "Centre Hospitalier Universitaire De Nantes",
            "conditions": "Traumatic brain injury",
            "member_states": "France",
            "decision_date": "22/08/2025",
            "enrolled": "760",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520205-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520105-39-00",
            "title": "A dosimetry trial of uPAR targeted radioligand therapy in patients with glioblastoma",
            "phase": "Phase I",
            "lead_sponsor": "Curasight A/S",
            "conditions": "Glioblastoma",
            "member_states": "Denmark",
            "decision_date": "22/08/2025",
            "enrolled": "6",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520105-39-00",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        },
        {
            "ct_number": "2024-520317-49-02",
            "title": "Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients with multi-quadrant peritonitis undergoing abdominal surgery: A randomized placebo-controlled trial (TRIPLE)",
            "phase": "Phase II",
            "lead_sponsor": "Region Sjaelland, Reponex Pharmaceuticals A/S",
            "conditions": "peritonitis",
            "member_states": "Denmark",
            "decision_date": "22/08/2025",
            "enrolled": "64",
            "registry_url": "https://euclinicaltrials.eu/ctis-public/#/view/2024-520317-49-02",
            "source_url": "https://priyalifescience.com/clinical-trials-europe",
            "retrieved_at": "2026-09-17T15:07:09+00:00"
        }
    ]
}